,text,drug1,drug2,ddi,type,label,smile1,smile2,pos1,pos2
0,Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUG2 or DRUGOTHER or the combination of DRUG2 and DRUGOTHER. ,abacavir,lamivudine,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,3,12
1,Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUGOTHER or DRUG2 or the combination of DRUGOTHER and DRUG2. ,abacavir,zidovudine,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],3,14
2,Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUG2 or DRUGOTHER or the combination of DRUG2 and DRUGOTHER. ,abacavir,lamivudine,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,3,12
3,Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUGOTHER or DRUG2 or the combination of DRUGOTHER and DRUG2. ,abacavir,zidovudine,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],3,14
4,Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,lamivudine,zidovudine,FALSE,Neg,0,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],12,14
5,Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUGOTHER or the combination of DRUG1 and DRUGOTHER. ,lamivudine,lamivudine,FALSE,Neg,0,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,12,-1
6,Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,lamivudine,zidovudine,FALSE,Neg,0,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],12,14
7,Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG2 or DRUG1 or the combination of DRUG2 and DRUG1. ,zidovudine,lamivudine,FALSE,Neg,0,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,14,12
8,Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUGOTHER or DRUG1 or the combination of DRUGOTHER and DRUG1. ,zidovudine,zidovudine,FALSE,Neg,0,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],14,-1
9,Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,lamivudine,zidovudine,FALSE,Neg,0,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],12,14
10,No clinically significant changes to DRUG1 or DRUG2 pharmacokinetics were observed following concomitant administration of DRUGOTHER. ,lamivudine,zidovudine,FALSE,Neg,0,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],5,7
11,No clinically significant changes to DRUG1 or DRUGOTHER pharmacokinetics were observed following concomitant administration of DRUG2. ,lamivudine,abacavir,FALSE,Neg,0,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,5,15
12,No clinically significant changes to DRUGOTHER or DRUG1 pharmacokinetics were observed following concomitant administration of DRUG2. ,zidovudine,abacavir,FALSE,Neg,0,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,7,15
13,DRUG1 has no effect on the pharmacokinetic properties of DRUG2. ,Abacavir,ethanol,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,CCO,0,9
14,DRUG1 decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of DRUGOTHER has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,Ethanol,abacavir,TRUE,mechanism,4,CCO,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,0,5
15,DRUG1 decreases the elimination of DRUGOTHER causing an increase in overall exposure . The addition of DRUG2 has no clinically significant effect on the pharmacokinetic properties of DRUGOTHER. ,Ethanol,methadone,FALSE,Neg,0,CCO,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,0,16
16,DRUG1 decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of DRUGOTHER has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,Ethanol,abacavir,FALSE,Neg,0,CCO,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,0,5
17,DRUGOTHER decreases the elimination of DRUG1 causing an increase in overall exposure . The addition of DRUG2 has no clinically significant effect on the pharmacokinetic properties of DRUG1. ,abacavir,methadone,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,5,16
18,DRUGOTHER decreases the elimination of DRUG1 causing an increase in overall exposure . The addition of DRUGOTHER has no clinically significant effect on the pharmacokinetic properties of DRUG1. ,abacavir,abacavir,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,5,-1
19,DRUGOTHER decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of DRUG1 has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,methadone,abacavir,FALSE,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,16,5
20,"In a study of 11 HIV-infected patients receiving DRUG1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUG2 twice daily (twice the currently recommended dose), oral DRUG1 clearance increased 22% (90% CI 6% to 42%). ",methadone,ZIAGEN,TRUE,mechanism,4,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,8,20
21,"In a study of 11 HIV-infected patients receiving DRUG1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUGOTHER twice daily (twice the currently recommended dose), oral DRUG1 clearance increased 22% (90% CI 6% to 42%). ",methadone,methadone,FALSE,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,8,-1
22,"In a study of 11 HIV-infected patients receiving DRUG2-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUG1 twice daily (twice the currently recommended dose), oral DRUG2 clearance increased 22% (90% CI 6% to 42%). ",ZIAGEN,methadone,FALSE,Neg,0,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,20,8
23,DRUG1: Concomitant DRUG2 administration decreased the mean AUC of total DRUGOTHER approximately 55%. ,Cholestyramine,cholestyramine,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,0,2
24,DRUG1: Concomitant DRUGOTHER administration decreased the mean AUC of total DRUG2 approximately 55%. ,Cholestyramine,ezetimibe,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,0,10
25,DRUGOTHER: Concomitant DRUG1 administration decreased the mean AUC of total DRUG2 approximately 55%. ,cholestyramine,ezetimibe,TRUE,mechanism,4,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,2,10
26,The incremental LDL-C reduction due to adding DRUG1 to DRUG2 may be reduced by this interaction. ,ezetimibe,cholestyramine,TRUE,effect,2,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,7,9
27,"DRUG1: In a pharmacokinetic study, concomitant DRUG2 administration increased total DRUGOTHER concentrations approximately 1.5-fold. ",Fenofibrate,fenofibrate,FALSE,Neg,0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,0,6
28,"DRUG1: In a pharmacokinetic study, concomitant DRUGOTHER administration increased total DRUG2 concentrations approximately 1.5-fold. ",Fenofibrate,ezetimibe,FALSE,Neg,0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,0,10
29,"DRUGOTHER: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.5-fold. ",fenofibrate,ezetimibe,TRUE,mechanism,4,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,6,10
30,"DRUG1: In a pharmacokinetic study, concomitant DRUG2 administration increased total DRUGOTHER concentrations approximately 1.7-fold. ",Gemfibrozil,gemfibrozil,FALSE,Neg,0,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,0,6
31,"DRUG1: In a pharmacokinetic study, concomitant DRUGOTHER administration increased total DRUG2 concentrations approximately 1.7-fold. ",Gemfibrozil,ezetimibe,FALSE,Neg,0,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,0,10
32,"DRUGOTHER: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.7-fold. ",gemfibrozil,ezetimibe,FALSE,Neg,0,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,6,10
33,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ezetimibe,atorvastatin,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,9,13
34,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ezetimibe,simvastatin,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,9,14
35,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",ezetimibe,pravastatin,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,9,15
36,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",ezetimibe,lovastatin,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,9,16
37,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",ezetimibe,fluvastatin,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,9,18
38,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",atorvastatin,simvastatin,FALSE,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,13,14
39,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",atorvastatin,pravastatin,FALSE,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,13,15
40,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",atorvastatin,lovastatin,FALSE,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,13,16
41,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",atorvastatin,fluvastatin,FALSE,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,13,18
42,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",simvastatin,pravastatin,FALSE,Neg,0,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,14,15
43,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",simvastatin,lovastatin,FALSE,Neg,0,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,14,16
44,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",simvastatin,fluvastatin,FALSE,Neg,0,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,14,18
45,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",pravastatin,lovastatin,FALSE,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,15,16
46,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",pravastatin,fluvastatin,FALSE,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,15,18
47,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",lovastatin,fluvastatin,FALSE,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,16,18
48,"DRUG1: The total DRUG2 level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUGOTHER. ",Cyclosporine,ezetimibe,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,0,3
49,"DRUG1: The total DRUGOTHER level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG2. ",Cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,16
50,"DRUGOTHER: The total DRUG1 level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG2. ",ezetimibe,cyclosporine,TRUE,mechanism,4,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,3,16
51,Patients who take both DRUG1 and DRUG2 should be carefully monitored. ,ezetimibe,cyclosporine,TRUE,advise,1,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,4,6
52,"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with DRUG1 was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",ezetimibe,ezetimibe,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,11,-1
53,A 104-week dietary carcinogenicity study with DRUG1 was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ,ezetimibe,ezetimibe,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,6,-1
54,"In oral (gavage) fertility studies of DRUG1 conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",ezetimibe,ezetimibe,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,6,-1
55,"In rabbits treated with DRUG1, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",ezetimibe,ezetimibe,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,4,-1
56,Multiple dose studies of DRUG1 given in combination with DRUGOTHER (DRUGOTHER) in rats and rabbits during organogenesis result in higher DRUG1 and statin exposures. ,ezetimibe,ezetimibe,FALSE,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,4,-1
57,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Cyclosporine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,11,12
58,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Rifampin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,11,13
59,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Theophylline,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,11,14
60,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Terfenadine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,11,15
61,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Cisapride,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,11,16
62,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Astemizole,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,11,17
63,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Rifabutin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,11,18
64,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Tacrolimus,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,11,19
65,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Phenytoin,DIFLUCAN,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,11,34
66,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Phenytoin,hypoglycemic agents,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,11,37
67,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Rifampin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,12,13
68,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Theophylline,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,14
69,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Terfenadine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,12,15
70,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Cisapride,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,12,16
71,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Astemizole,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,12,17
72,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Rifabutin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,12,18
73,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Tacrolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,12,19
74,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Cyclosporine,DIFLUCAN,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,12,34
75,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Cyclosporine,hypoglycemic agents,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,12,37
76,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifampin,Theophylline,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,13,14
77,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifampin,Terfenadine,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,13,15
78,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifampin,Cisapride,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,13,16
79,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifampin,Astemizole,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,13,17
80,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifampin,Rifabutin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,13,18
81,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifampin,Tacrolimus,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,13,19
82,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Rifampin,DIFLUCAN,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,13,34
83,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Rifampin,hypoglycemic agents,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,13,37
84,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Terfenadine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,14,15
85,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Cisapride,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,14,16
86,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Astemizole,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,14,17
87,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Rifabutin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,14,18
88,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Tacrolimus,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,14,19
89,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Theophylline,DIFLUCAN,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,14,34
90,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Theophylline,hypoglycemic agents,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,14,37
91,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Terfenadine,Cisapride,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,15,16
92,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Terfenadine,Astemizole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,15,17
93,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Terfenadine,Rifabutin,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,15,18
94,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Terfenadine,Tacrolimus,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,15,19
95,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Terfenadine,DIFLUCAN,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,15,34
96,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Terfenadine,hypoglycemic agents,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,15,37
97,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cisapride,Astemizole,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,16,17
98,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cisapride,Rifabutin,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,16,18
99,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cisapride,Tacrolimus,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,16,19
100,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Cisapride,DIFLUCAN,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,16,34
101,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Cisapride,hypoglycemic agents,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,16,37
102,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Astemizole,Rifabutin,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,17,18
103,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Astemizole,Tacrolimus,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,17,19
104,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Astemizole,DIFLUCAN,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,17,34
105,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Astemizole,hypoglycemic agents,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,17,37
106,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifabutin,Tacrolimus,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,18,19
107,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Rifabutin,DIFLUCAN,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,18,34
108,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Rifabutin,hypoglycemic agents,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,18,37
109,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Tacrolimus,DIFLUCAN,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,19,34
110,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Tacrolimus,hypoglycemic agents,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,19,37
111,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG1 with oral DRUG2; ",DIFLUCAN,hypoglycemic agents,TRUE,effect,2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,34,37
112,one fatality has been reported from hypoglycemia in association with combined DRUG1 and DRUG2 use. ,DIFLUCAN,glyburide,TRUE,effect,2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,11,13
113,"DRUG1 reduces the metabolism of DRUG2, DRUGOTHER, and DRUGOTHER and increases the plasma concentration of these agents. ",DIFLUCAN,tolbutamide,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,0,5
114,"DRUG1 reduces the metabolism of DRUGOTHER, DRUG2, and DRUGOTHER and increases the plasma concentration of these agents. ",DIFLUCAN,glyburide,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,0,6
115,"DRUG1 reduces the metabolism of DRUGOTHER, DRUGOTHER, and DRUG2 and increases the plasma concentration of these agents. ",DIFLUCAN,glipizide,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,0,8
116,"DRUGOTHER reduces the metabolism of DRUG1, DRUG2, and DRUGOTHER and increases the plasma concentration of these agents. ",tolbutamide,glyburide,FALSE,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,5,6
117,"DRUGOTHER reduces the metabolism of DRUG1, DRUGOTHER, and DRUG2 and increases the plasma concentration of these agents. ",tolbutamide,glipizide,FALSE,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,5,8
118,"DRUGOTHER reduces the metabolism of DRUGOTHER, DRUG1, and DRUG2 and increases the plasma concentration of these agents. ",glyburide,glipizide,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,8
119,"When DRUG1 is used concomitantly with these or other DRUG2 oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the DRUG2 should be adjusted as necessary. ",DIFLUCAN,sulfonylurea,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C(=O)(N)N=S(=O)=O.C(=O)(N)N=S(=O)=O,1,9
120,"In post-marketing experience, as with other DRUG1, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUG2 concurrently with DRUGOTHER. ",azole antifungals,fluconazole,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,6,29
121,"In post-marketing experience, as with other DRUG1, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUGOTHER concurrently with DRUG2. ",azole antifungals,warfarin,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,32
122,"In post-marketing experience, as with other DRUGOTHER, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUG1 concurrently with DRUG2. ",fluconazole,warfarin,TRUE,effect,2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,29,32
123,DRUG1: DRUG2 increases the plasma concentrations of DRUGOTHER. ,Phenytoin,DIFLUCAN,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,1
124,DRUG1: DRUGOTHER increases the plasma concentrations of DRUG2. ,Phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
125,DRUGOTHER: DRUG1 increases the plasma concentrations of DRUG2. ,DIFLUCAN,phenytoin,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,7
126,Careful monitoring of DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,phenytoin,DIFLUCAN,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,3,8
127,Careful monitoring of DRUG1 concentrations in patients receiving DRUGOTHER and DRUG1 is recommended. ,phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,-1
128,Careful monitoring of DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,DIFLUCAN,phenytoin,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,3
129,DRUG1: DRUG2 may significantly increase DRUGOTHER levels in renal transplant patients with or without renal impairment. ,Cyclosporine,DIFLUCAN,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,1
130,DRUG1: DRUGOTHER may significantly increase DRUG2 levels in renal transplant patients with or without renal impairment. ,Cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,5
131,DRUGOTHER: DRUG1 may significantly increase DRUG2 levels in renal transplant patients with or without renal impairment. ,DIFLUCAN,cyclosporine,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1,5
132,Careful monitoring of DRUG1 concentrations and serum creatinine is recommended in patients receiving DRUG2 and DRUG1. ,cyclosporine,DIFLUCAN,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,3,13
133,Careful monitoring of DRUG1 concentrations and serum creatinine is recommended in patients receiving DRUGOTHER and DRUG1. ,cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,3,-1
134,Careful monitoring of DRUG2 concentrations and serum creatinine is recommended in patients receiving DRUG1 and DRUG2. ,DIFLUCAN,cyclosporine,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,13,3
135,DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUGOTHER. ,Rifampin,Rifampin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,0,-1
136,DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUG2. ,Rifampin,DIFLUCAN,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,8
137,DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUG2. ,Rifampin,DIFLUCAN,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,8
138,"Depending on clinical circumstances, consideration should be given to increasing the dose of DRUG1 when it is administered with DRUG2. ",DIFLUCAN,rifampin,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,13,19
139,DRUG1: DRUG2 increases the serum concentrations of DRUGOTHER. ,Theophylline,DIFLUCAN,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,1
140,DRUG1: DRUGOTHER increases the serum concentrations of DRUG2. ,Theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,7
141,DRUGOTHER: DRUG1 increases the serum concentrations of DRUG2. ,DIFLUCAN,theophylline,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,7
142,Careful monitoring of serum DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,theophylline,DIFLUCAN,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,4,9
143,Careful monitoring of serum DRUG1 concentrations in patients receiving DRUGOTHER and DRUG1 is recommended. ,theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,4,-1
144,Careful monitoring of serum DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,DIFLUCAN,theophylline,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,4
145,"DRUG1: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving DRUG2 in conjunction with DRUGOTHER, interaction studies have been performed. ",Terfenadine,azole antifungals,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,OC(=O)CCCCCCCCC=C,0,19
146,"DRUG1: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving DRUGOTHER in conjunction with DRUG2, interaction studies have been performed. ",Terfenadine,terfenadine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,0,23
147,"DRUGOTHER: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving DRUG1 in conjunction with DRUG2, interaction studies have been performed. ",azole antifungals,terfenadine,TRUE,effect,2,OC(=O)CCCCCCCCC=C,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,19,23
148,Another study at a 400-mg and 800-mg daily dose of DRUG1 demonstrated that DRUG2 taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUGOTHER when taken concomitantly. ,fluconazole,DIFLUCAN,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,10,13
149,Another study at a 400-mg and 800-mg daily dose of DRUG1 demonstrated that DRUGOTHER taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUG2 when taken concomitantly. ,fluconazole,terfenadine,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,10,29
150,Another study at a 400-mg and 800-mg daily dose of DRUGOTHER demonstrated that DRUG1 taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUG2 when taken concomitantly. ,DIFLUCAN,terfenadine,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,13,29
151,The combined use of DRUG1 at doses of 400 mg or greater with DRUG2 is contraindicated. ,fluconazole,terfenadine,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,4,13
152,The coadministration of DRUG1 at doses lower than 400 mg/day with DRUG2 should be carefully monitored. ,fluconazole,terfenadine,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,3,11
153,"DRUG1: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUG2 and DRUGOTHER were coadministered. ",Cisapride,fluconazole,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,16
154,"DRUG1: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUGOTHER and DRUG2 were coadministered. ",Cisapride,cisapride,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,0,18
155,"DRUGOTHER: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUG1 and DRUG2 were coadministered. ",fluconazole,cisapride,TRUE,effect,2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,16,18
156,A controlled study found that concomitant DRUG1 200 mg once daily and DRUG2 20 mg four times a day yielded a significant increase in DRUG2 plasma levels and prolongation of QTc interval.,fluconazole,cisapride,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,6,12
157,A controlled study found that concomitant DRUG1 200 mg once daily and DRUG2 20 mg four times a day yielded a significant increase in DRUG2 plasma levels and prolongation of QTc interval.,fluconazole,cisapride,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,6,12
158,A controlled study found that concomitant DRUGOTHER 200 mg once daily and DRUG1 20 mg four times a day yielded a significant increase in DRUG1 plasma levels and prolongation of QTc interval.,cisapride,cisapride,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,12,-1
159,The combined use of DRUG1 with DRUG2 is contraindicated. ,fluconazole,cisapride,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,4,6
160,DRUG1: The use of DRUG2 in patients concurrently taking DRUGOTHER or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,Astemizole,fluconazole,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,4
161,DRUG1: The use of DRUGOTHER in patients concurrently taking DRUG2 or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,Astemizole,astemizole,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,0,9
162,DRUGOTHER: The use of DRUG1 in patients concurrently taking DRUG2 or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,fluconazole,astemizole,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,4,9
163,DRUG1: There have been reports of uveitis in patients to whom DRUG2 and DRUGOTHER were coadministered. ,Rifabutin,fluconazole,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,11
164,DRUG1: There have been reports of uveitis in patients to whom DRUGOTHER and DRUG2 were coadministered. ,Rifabutin,rifabutin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,0,13
165,DRUGOTHER: There have been reports of uveitis in patients to whom DRUG1 and DRUG2 were coadministered. ,fluconazole,rifabutin,TRUE,effect,2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,11,13
166,Patients receiving DRUG1 and DRUG2 concomitantly should be carefully monitored. ,rifabutin,fluconazole,TRUE,advise,1,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,2,4
167,DRUG1: There have been reports of nephrotoxicity in patients to whom DRUG2 and DRUGOTHER were coadministered. ,Tacrolimus,fluconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,11
168,DRUG1: There have been reports of nephrotoxicity in patients to whom DRUGOTHER and DRUG2 were coadministered. ,Tacrolimus,tacrolimus,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,0,13
169,DRUGOTHER: There have been reports of nephrotoxicity in patients to whom DRUG1 and DRUG2 were coadministered. ,fluconazole,tacrolimus,TRUE,effect,2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,11,13
170,Patients receiving DRUG1 and DRUG2 concomitantly should be carefully monitored. ,tacrolimus,fluconazole,TRUE,advise,1,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,2,4
171,"DRUGOTHER: Following oral administration of DRUG1, DRUG2 resulted in substantial increases in DRUG1 concentrations and psychomotor effects. ",midazolam,fluconazole,TRUE,mechanism,4,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5,6
172,"DRUGOTHER: Following oral administration of DRUG1, DRUGOTHER resulted in substantial increases in DRUG1 concentrations and psychomotor effects. ",midazolam,midazolam,FALSE,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,5,-1
173,"DRUGOTHER: Following oral administration of DRUG2, DRUG1 resulted in substantial increases in DRUG2 concentrations and psychomotor effects. ",fluconazole,midazolam,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,6,5
174,This effect on DRUG1 appears to be more pronounced following oral administration of DRUG2 than with DRUG2 administered intravenously. ,midazolam,fluconazole,TRUE,effect,2,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,3,13
175,This effect on DRUG1 appears to be more pronounced following oral administration of DRUG2 than with DRUG2 administered intravenously. ,midazolam,fluconazole,FALSE,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,3,13
176,This effect on DRUGOTHER appears to be more pronounced following oral administration of DRUG1 than with DRUG1 administered intravenously. ,fluconazole,fluconazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,13,-1
177,"If short-acting DRUG2s, which are metabolized by the cytochrome P450 system, are concomitantly administered with DRUG1, consideration should be given to decreasing the DRUG2 dosage, and the patients should be appropriately monitored. ",fluconazole,benzodiazepine,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC=C2C(=C1)C=CC=NN2,15,2
178,DRUG1 tablets coadministered with DRUG2- and DRUGOTHER-containing oral DRUGOTHER produced an overall mean increase in DRUG2 and DRUGOTHER levels; ,Fluconazole,ethinyl estradiol,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,0,4
179,DRUG1 tablets coadministered with DRUGOTHER- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in DRUGOTHER and DRUG2 levels; ,Fluconazole,levonorgestrel,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,0,6
180,DRUG1 tablets coadministered with DRUGOTHER- and DRUGOTHER-containing oral DRUG2 produced an overall mean increase in DRUGOTHER and DRUGOTHER levels; ,Fluconazole,contraceptives,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,0,8
181,DRUG1 tablets coadministered with DRUG2- and DRUGOTHER-containing oral DRUGOTHER produced an overall mean increase in DRUG2 and DRUGOTHER levels; ,Fluconazole,ethinyl estradiol,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,0,4
182,DRUG1 tablets coadministered with DRUGOTHER- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in DRUGOTHER and DRUG2 levels; ,Fluconazole,levonorgestrel,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,0,6
183,DRUGOTHER tablets coadministered with DRUG1- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in DRUG1 and DRUG2 levels; ,ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,4,6
184,DRUGOTHER tablets coadministered with DRUG1- and DRUGOTHER-containing oral DRUG2 produced an overall mean increase in DRUG1 and DRUGOTHER levels; ,ethinyl estradiol,contraceptives,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,4,8
185,DRUGOTHER tablets coadministered with DRUG1- and DRUGOTHER-containing oral DRUGOTHER produced an overall mean increase in DRUG1 and DRUGOTHER levels; ,ethinyl estradiol,ethinyl estradiol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,4,-1
186,DRUGOTHER tablets coadministered with DRUG1- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in DRUG1 and DRUG2 levels; ,ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,4,6
187,DRUGOTHER tablets coadministered with DRUGOTHER- and DRUG1-containing oral DRUG2 produced an overall mean increase in DRUGOTHER and DRUG1 levels; ,levonorgestrel,contraceptives,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,6,8
188,DRUGOTHER tablets coadministered with DRUG2- and DRUG1-containing oral DRUGOTHER produced an overall mean increase in DRUG2 and DRUG1 levels; ,levonorgestrel,ethinyl estradiol,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,6,4
189,DRUGOTHER tablets coadministered with DRUGOTHER- and DRUG1-containing oral DRUGOTHER produced an overall mean increase in DRUGOTHER and DRUG1 levels; ,levonorgestrel,levonorgestrel,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,6,-1
190,DRUGOTHER tablets coadministered with DRUG2- and DRUGOTHER-containing oral DRUG1 produced an overall mean increase in DRUG2 and DRUGOTHER levels; ,contraceptives,ethinyl estradiol,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,8,4
191,DRUGOTHER tablets coadministered with DRUGOTHER- and DRUG2-containing oral DRUG1 produced an overall mean increase in DRUGOTHER and DRUG2 levels; ,contraceptives,levonorgestrel,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,8,6
192,DRUGOTHER tablets coadministered with DRUG1- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in DRUG1 and DRUG2 levels; ,ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,4,6
193,"however, in some patients there were decreases up to 47% and 33% of DRUG1 and DRUG2 levels. ",ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,13,15
194,The data presently available indicate that the decreases in some individual DRUG1 and DRUG2 AUC values with DRUGOTHER treatment are likely the result of random variation. ,ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,11,13
195,The data presently available indicate that the decreases in some individual DRUG1 and DRUGOTHER AUC values with DRUG2 treatment are likely the result of random variation. ,ethinyl estradiol,fluconazole,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,11,17
196,The data presently available indicate that the decreases in some individual DRUGOTHER and DRUG1 AUC values with DRUG2 treatment are likely the result of random variation. ,levonorgestrel,fluconazole,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,13,17
197,"While there is evidence that DRUG1 can inhibit the metabolism of DRUG2 and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of DRUG2 or DRUGOTHER metabolism. ",fluconazole,ethinyl estradiol,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,5,11
198,"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUG2, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUG2 metabolism. ",fluconazole,levonorgestrel,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,5,13
199,"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUGOTHER metabolism. ",fluconazole,fluconazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5,-1
200,"While there is evidence that DRUG1 can inhibit the metabolism of DRUG2 and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of DRUG2 or DRUGOTHER metabolism. ",fluconazole,ethinyl estradiol,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,5,11
201,"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUG2, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUG2 metabolism. ",fluconazole,levonorgestrel,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,5,13
202,"While there is evidence that DRUGOTHER can inhibit the metabolism of DRUG1 and DRUG2, there is no evidence that DRUGOTHER is a net inducer of DRUG1 or DRUG2 metabolism. ",ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,11,13
203,"While there is evidence that DRUG2 can inhibit the metabolism of DRUG1 and DRUGOTHER, there is no evidence that DRUG2 is a net inducer of DRUG1 or DRUGOTHER metabolism. ",ethinyl estradiol,fluconazole,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,11,5
204,"While there is evidence that DRUGOTHER can inhibit the metabolism of DRUG1 and DRUGOTHER, there is no evidence that DRUGOTHER is a net inducer of DRUG1 or DRUGOTHER metabolism. ",ethinyl estradiol,ethinyl estradiol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,11,-1
205,"While there is evidence that DRUGOTHER can inhibit the metabolism of DRUG1 and DRUG2, there is no evidence that DRUGOTHER is a net inducer of DRUG1 or DRUG2 metabolism. ",ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,11,13
206,"While there is evidence that DRUG2 can inhibit the metabolism of DRUGOTHER and DRUG1, there is no evidence that DRUG2 is a net inducer of DRUGOTHER or DRUG1 metabolism. ",levonorgestrel,fluconazole,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,13,5
207,"While there is evidence that DRUGOTHER can inhibit the metabolism of DRUG2 and DRUG1, there is no evidence that DRUGOTHER is a net inducer of DRUG2 or DRUG1 metabolism. ",levonorgestrel,ethinyl estradiol,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,13,11
208,"While there is evidence that DRUGOTHER can inhibit the metabolism of DRUGOTHER and DRUG1, there is no evidence that DRUGOTHER is a net inducer of DRUGOTHER or DRUG1 metabolism. ",levonorgestrel,levonorgestrel,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,13,-1
209,"While there is evidence that DRUG1 can inhibit the metabolism of DRUG2 and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of DRUG2 or DRUGOTHER metabolism. ",fluconazole,ethinyl estradiol,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,5,11
210,"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUG2, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUG2 metabolism. ",fluconazole,levonorgestrel,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,5,13
211,"While there is evidence that DRUGOTHER can inhibit the metabolism of DRUG1 and DRUG2, there is no evidence that DRUGOTHER is a net inducer of DRUG1 or DRUG2 metabolism. ",ethinyl estradiol,levonorgestrel,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,11,13
212,"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",mazindol,isocarboxazid,TRUE,advise,1,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,3,13
213,"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",mazindol,Marplan,TRUE,advise,1,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,3,14
214,"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",mazindol,tranylcypromine,TRUE,advise,1,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1[C@H]([C@@H]1N)C2=CC=CC=C2,3,15
215,"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",mazindol,Parnate,TRUE,advise,1,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1[C@H]([C@@H]1N)C2=CC=CC=C2,3,16
216,"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",mazindol,phenelzine,TRUE,advise,1,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1=CC=C(C=C1)CCNN,3,18
217,"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",mazindol,Nardil,TRUE,advise,1,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1=CC=C(C=C1)CCNN,3,19
218,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",isocarboxazid,Marplan,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,13,14
219,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",isocarboxazid,tranylcypromine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1[C@H]([C@@H]1N)C2=CC=CC=C2,13,15
220,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",isocarboxazid,Parnate,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1[C@H]([C@@H]1N)C2=CC=CC=C2,13,16
221,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",isocarboxazid,phenelzine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1=CC=C(C=C1)CCNN,13,18
222,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",isocarboxazid,Nardil,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1=CC=C(C=C1)CCNN,13,19
223,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",Marplan,tranylcypromine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1[C@H]([C@@H]1N)C2=CC=CC=C2,14,15
224,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",Marplan,Parnate,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1[C@H]([C@@H]1N)C2=CC=CC=C2,14,16
225,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",Marplan,phenelzine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1=CC=C(C=C1)CCNN,14,18
226,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",Marplan,Nardil,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1=CC=C(C=C1)CCNN,14,19
227,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",tranylcypromine,Parnate,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C1[C@H]([C@@H]1N)C2=CC=CC=C2,15,16
228,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",tranylcypromine,phenelzine,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C1=CC=C(C=C1)CCNN,15,18
229,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",tranylcypromine,Nardil,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C1=CC=C(C=C1)CCNN,15,19
230,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUG2 (DRUGOTHER) in the last 14 days. ",Parnate,phenelzine,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C1=CC=C(C=C1)CCNN,16,18
231,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUGOTHER (DRUG2) in the last 14 days. ",Parnate,Nardil,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C1=CC=C(C=C1)CCNN,16,19
232,"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG1 (DRUG2) in the last 14 days. ",phenelzine,Nardil,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,C1=CC=C(C=C1)CCNN,18,19
233,Changes in DRUG1 and other diabetes drug therapies may be necessary during treatment with DRUG2.,insulin,mazindol,TRUE,advise,1,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,2,14
234,DRUG1 may reduce the effects of DRUG2 (DRUGOTHER). ,Mazindol,guanethidine,TRUE,effect,2,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1CCCN(CCC1)CCN=C(N)N,0,6
235,DRUG1 may reduce the effects of DRUGOTHER (DRUG2). ,Mazindol,Ismelin,TRUE,effect,2,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1CCCN(CCC1)CCN=C(N)N,0,7
236,DRUGOTHER may reduce the effects of DRUG1 (DRUG2). ,guanethidine,Ismelin,FALSE,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C1CCCN(CCC1)CCN=C(N)N,6,7
237,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,amitriptyline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,12,15
238,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Elavil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,12,16
239,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,amoxapine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,12,17
240,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Asendin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,12,18
241,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,doxepin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,12,19
242,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Sinequan,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,12,20
243,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,nortriptyline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,12,21
244,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Pamelor,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,12,22
245,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,imipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,12,23
246,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Tofranil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,12,24
247,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,clomipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,12,25
248,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Anafranil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,12,26
249,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,protriptyline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,12,27
250,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Vivactil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,12,28
251,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",tricyclic antidepressant,desipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,12,30
252,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",tricyclic antidepressant,Norpramin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,12,31
253,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Elavil,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,15,16
254,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,amoxapine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,15,17
255,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Asendin,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,15,18
256,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,doxepin,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,15,19
257,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Sinequan,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,15,20
258,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,nortriptyline,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,15,21
259,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Pamelor,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,15,22
260,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,imipramine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,23
261,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Tofranil,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,24
262,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,clomipramine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,15,25
263,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Anafranil,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,15,26
264,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,protriptyline,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,15,27
265,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Vivactil,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,15,28
266,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",amitriptyline,desipramine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,30
267,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",amitriptyline,Norpramin,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,15,31
268,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,amoxapine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,16,17
269,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,Asendin,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,16,18
270,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,doxepin,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,16,19
271,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,Sinequan,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,16,20
272,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,nortriptyline,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,16,21
273,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,Pamelor,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,16,22
274,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,imipramine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,16,23
275,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,Tofranil,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,16,24
276,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,clomipramine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,16,25
277,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,Anafranil,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,16,26
278,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,protriptyline,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,16,27
279,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",Elavil,Vivactil,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,16,28
280,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",Elavil,desipramine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,16,30
281,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",Elavil,Norpramin,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,16,31
282,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,Asendin,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,17,18
283,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,doxepin,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,17,19
284,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,Sinequan,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,17,20
285,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,nortriptyline,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,17,21
286,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,Pamelor,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,17,22
287,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,imipramine,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,17,23
288,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,Tofranil,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,17,24
289,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,clomipramine,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,17,25
290,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,Anafranil,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,17,26
291,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,protriptyline,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,17,27
292,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",amoxapine,Vivactil,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,17,28
293,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",amoxapine,desipramine,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,17,30
294,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",amoxapine,Norpramin,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,17,31
295,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,doxepin,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,18,19
296,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,Sinequan,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,18,20
297,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,nortriptyline,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,18,21
298,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,Pamelor,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,18,22
299,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,imipramine,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,18,23
300,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,Tofranil,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,18,24
301,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,clomipramine,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,18,25
302,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,Anafranil,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,18,26
303,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,protriptyline,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,18,27
304,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",Asendin,Vivactil,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,18,28
305,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",Asendin,desipramine,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,18,30
306,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",Asendin,Norpramin,FALSE,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,18,31
307,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Sinequan,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,19,20
308,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,nortriptyline,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,19,21
309,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Pamelor,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,19,22
310,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,imipramine,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,19,23
311,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Tofranil,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,19,24
312,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,clomipramine,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,19,25
313,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Anafranil,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,19,26
314,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,protriptyline,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,19,27
315,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",doxepin,Vivactil,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,19,28
316,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",doxepin,desipramine,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,19,30
317,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",doxepin,Norpramin,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,19,31
318,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,nortriptyline,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,20,21
319,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,Pamelor,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,20,22
320,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,imipramine,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,20,23
321,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,Tofranil,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,20,24
322,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,clomipramine,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,20,25
323,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,Anafranil,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,20,26
324,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,protriptyline,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,20,27
325,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",Sinequan,Vivactil,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,20,28
326,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",Sinequan,desipramine,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,20,30
327,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",Sinequan,Norpramin,FALSE,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,20,31
328,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",nortriptyline,Pamelor,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,21,22
329,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",nortriptyline,imipramine,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,21,23
330,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",nortriptyline,Tofranil,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,21,24
331,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",nortriptyline,clomipramine,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,21,25
332,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",nortriptyline,Anafranil,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,21,26
333,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",nortriptyline,protriptyline,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,21,27
334,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",nortriptyline,Vivactil,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,21,28
335,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",nortriptyline,desipramine,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,21,30
336,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",nortriptyline,Norpramin,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,21,31
337,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Pamelor,imipramine,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,22,23
338,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Pamelor,Tofranil,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,22,24
339,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Pamelor,clomipramine,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,22,25
340,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Pamelor,Anafranil,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,22,26
341,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Pamelor,protriptyline,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,22,27
342,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",Pamelor,Vivactil,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,22,28
343,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",Pamelor,desipramine,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,22,30
344,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",Pamelor,Norpramin,FALSE,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,22,31
345,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",imipramine,Tofranil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,23,24
346,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",imipramine,clomipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,23,25
347,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",imipramine,Anafranil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,23,26
348,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",imipramine,protriptyline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,23,27
349,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",imipramine,Vivactil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,23,28
350,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",imipramine,desipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,23,30
351,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",imipramine,Norpramin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,23,31
352,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Tofranil,clomipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,24,25
353,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Tofranil,Anafranil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,24,26
354,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Tofranil,protriptyline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,24,27
355,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",Tofranil,Vivactil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,24,28
356,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",Tofranil,desipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,24,30
357,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",Tofranil,Norpramin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,24,31
358,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",clomipramine,Anafranil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,25,26
359,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",clomipramine,protriptyline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,25,27
360,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",clomipramine,Vivactil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,25,28
361,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",clomipramine,desipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,25,30
362,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",clomipramine,Norpramin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,25,31
363,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Anafranil,protriptyline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,26,27
364,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",Anafranil,Vivactil,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,26,28
365,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",Anafranil,desipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,26,30
366,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",Anafranil,Norpramin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,26,31
367,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), or DRUGOTHER (DRUGOTHER). ",protriptyline,Vivactil,FALSE,Neg,0,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,27,28
368,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUG2 (DRUGOTHER). ",protriptyline,desipramine,FALSE,Neg,0,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,27,30
369,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUGOTHER (DRUG2). ",protriptyline,Norpramin,FALSE,Neg,0,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,27,31
370,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUG2 (DRUGOTHER). ",Vivactil,desipramine,FALSE,Neg,0,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,28,30
371,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUGOTHER (DRUG2). ",Vivactil,Norpramin,FALSE,Neg,0,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,28,31
372,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG1 (DRUG2). ",desipramine,Norpramin,FALSE,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,30,31
373,Preliminary evidence suggests that DRUG1 inhibits DRUG2 metabolism and may result in an increase in plasma concentrations of DRUG2.,cimetidine,mebendazole,TRUE,mechanism,4,CC1=C(N=CN1)CSCCNC(=NC)NC#N,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,4,6
374,Preliminary evidence suggests that DRUG1 inhibits DRUG2 metabolism and may result in an increase in plasma concentrations of DRUG2.,cimetidine,mebendazole,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,4,6
375,Preliminary evidence suggests that DRUGOTHER inhibits DRUG1 metabolism and may result in an increase in plasma concentrations of DRUG1.,mebendazole,mebendazole,FALSE,Neg,0,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,6,-1
376,Patients receiving DRUG1 and DRUG2 generally should not be treated with DRUGOTHER.  ,antibiotics,sulfonamides,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,2,4
377,"The action of DRUG1 may be potentiated by anesthesia, other DRUG2 and DRUGOTHER.",Mecamylamine,antihypertensive drugs,TRUE,effect,2,CC1(C2CCC(C2)C1(C)NC)C,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,3,10
378,"The action of DRUG1 may be potentiated by anesthesia, other DRUGOTHER and DRUG2.",Mecamylamine,alcohol,TRUE,effect,2,CC1(C2CCC(C2)C1(C)NC)C,CCO,3,12
379,"The action of DRUGOTHER may be potentiated by anesthesia, other DRUG1 and DRUG2.",antihypertensive drugs,alcohol,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCO,10,12
380,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUG1 or DRUG2 to warrant dosage adjustment when DRUGOTHER is administered with these drugs. ,zidovudine,rifabutin,FALSE,Neg,0,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,13,15
381,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUG1 or DRUGOTHER to warrant dosage adjustment when DRUG2 is administered with these drugs. ,zidovudine,megestrol acetate,FALSE,Neg,0,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,13,21
382,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUGOTHER or DRUG1 to warrant dosage adjustment when DRUG2 is administered with these drugs. ,rifabutin,megestrol acetate,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,15,21
383,A pharmacokinetic study demonstrated that coadministration of DRUG1 and DRUG2 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG2. ,megestrol acetate,indinavir,TRUE,mechanism,4,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,7,9
384,A pharmacokinetic study demonstrated that coadministration of DRUG1 and DRUG2 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG2. ,megestrol acetate,indinavir,FALSE,Neg,0,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,7,9
385,A pharmacokinetic study demonstrated that coadministration of DRUGOTHER and DRUG1 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG1. ,indinavir,indinavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,9,-1
386,Administration of a higher dose of DRUG1 should be considered when coadministering with DRUG2. ,indinavir,megestrol acetate,TRUE,advise,1,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,6,13
387,"The effects of DRUG1, DRUG2 or DRUGOTHER on the pharmacokinetics of DRUGOTHER were not studied.",indinavir,zidovudine,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],3,4
388,"The effects of DRUG1, DRUGOTHER or DRUG2 on the pharmacokinetics of DRUGOTHER were not studied.",indinavir,rifabutin,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,3,6
389,"The effects of DRUG1, DRUGOTHER or DRUGOTHER on the pharmacokinetics of DRUG2 were not studied.",indinavir,megestrol acetate,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,3,11
390,"The effects of DRUGOTHER, DRUG1 or DRUG2 on the pharmacokinetics of DRUGOTHER were not studied.",zidovudine,rifabutin,FALSE,Neg,0,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,4,6
391,"The effects of DRUGOTHER, DRUG1 or DRUGOTHER on the pharmacokinetics of DRUG2 were not studied.",zidovudine,megestrol acetate,FALSE,Neg,0,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,4,11
392,"The effects of DRUGOTHER, DRUGOTHER or DRUG1 on the pharmacokinetics of DRUG2 were not studied.",rifabutin,megestrol acetate,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,6,11
393,"DRUG1 may interact with the following drugs: DRUG2 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,aspirin,TRUE,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)OC1=CC=CC=C1C(=O)O,0,7
394,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
395,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG2 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,fluvoxamine,TRUE,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,0,15
396,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
397,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
398,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,fluoxetine,TRUE,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,29
399,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,progestin,TRUE,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,0,36
400,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
401,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,progestin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,0,36
402,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",Melatonin,corticosteroids,TRUE,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,66
403,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
404,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",Melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,66
405,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",Melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,66
406,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
407,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUG2 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,fluvoxamine,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,7,15
408,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
409,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
410,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,fluoxetine,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,7,29
411,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,progestin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,7,36
412,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
413,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,progestin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,7,36
414,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",aspirin,corticosteroids,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,66
415,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
416,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",aspirin,corticosteroids,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,66
417,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",aspirin,corticosteroids,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,66
418,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUG2 (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluvoxamine,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,13,15
419,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
420,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
421,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluoxetine,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,13,29
422,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
423,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
424,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
425,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
426,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
427,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
428,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
429,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
430,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
431,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,fluoxetine,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,15,29
432,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,progestin,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,15,36
433,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
434,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,progestin,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,15,36
435,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",fluvoxamine,corticosteroids,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,15,66
436,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
437,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",fluvoxamine,corticosteroids,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,15,66
438,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",fluvoxamine,corticosteroids,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,15,66
439,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
440,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluoxetine,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,13,29
441,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
442,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
443,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
444,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
445,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
446,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
447,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
448,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluoxetine,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,13,29
449,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
450,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
451,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
452,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
453,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
454,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
455,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
456,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluoxetine,progestin,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,29,36
457,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluoxetine,melatonin,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,29,13
458,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluoxetine,progestin,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,29,36
459,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",fluoxetine,corticosteroids,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,29,66
460,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluoxetine,melatonin,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,29,13
461,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",fluoxetine,corticosteroids,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,29,66
462,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",fluoxetine,corticosteroids,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,29,66
463,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",progestin,melatonin,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,36,13
464,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",progestin,progestin,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,36,-1
465,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",progestin,corticosteroids,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,36,66
466,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",progestin,melatonin,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,36,13
467,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",progestin,corticosteroids,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,36,66
468,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",progestin,corticosteroids,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,36,66
469,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,TRUE,effect,2,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
470,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
471,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
472,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
473,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
474,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",progestin,corticosteroids,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,36,66
475,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",progestin,melatonin,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,36,13
476,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",progestin,corticosteroids,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,36,66
477,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",progestin,corticosteroids,FALSE,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,36,66
478,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUG2 and DRUG1 may interfere with the efficacy of the DRUG1).",corticosteroids,melatonin,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,66,13
479,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUGOTHER and DRUG1 may interfere with the efficacy of the DRUG1).",corticosteroids,corticosteroids,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,66,-1
480,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUGOTHER and DRUG1 may interfere with the efficacy of the DRUG1).",corticosteroids,corticosteroids,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,66,-1
481,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,TRUE,effect,2,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
482,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,FALSE,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
483,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUGOTHER and DRUG1 may interfere with the efficacy of the DRUG1).",corticosteroids,corticosteroids,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,66,-1
484,DRUG1: Concomitant administration of DRUG2 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUGOTHER. ,Aspirin,aspirin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)OC1=CC=CC=C1C(=O)O,0,4
485,DRUG1: Concomitant administration of DRUGOTHER (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,Aspirin,meloxicam,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,21
486,DRUGOTHER: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,aspirin,meloxicam,TRUE,mechanism,4,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,4,21
487,"however, as with other DRUGOTHER, concomitant administration of DRUG1 and DRUG2 is not generally recommended because of the potential for increased adverse effects. ",meloxicam,aspirin,TRUE,advise,1,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)OC1=CC=CC=C1C(=O)O,8,10
488,"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",aspirin,MOBIC,TRUE,effect,2,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,4,6
489,"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",aspirin,MOBIC,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,4,6
490,"Concomitant administration of low-dose DRUGOTHER with DRUG1 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG1 alone. ",MOBIC,MOBIC,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,6,-1
491,DRUG1 is not a substitute for DRUG2 for cardiovascular prophylaxis. ,MOBIC,aspirin,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)OC1=CC=CC=C1C(=O)O,0,6
492,DRUG1: Pretreatment for four days with DRUG2 significantly increased the clearance of DRUGOTHER by 50%. ,Cholestyramine,cholestyramine,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,0,6
493,DRUG1: Pretreatment for four days with DRUGOTHER significantly increased the clearance of DRUG2 by 50%. ,Cholestyramine,meloxicam,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,12
494,DRUGOTHER: Pretreatment for four days with DRUG1 significantly increased the clearance of DRUG2 by 50%. ,cholestyramine,meloxicam,TRUE,mechanism,4,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,6,12
495,DRUG1: Concomitant administration of 200 mg DRUG2 QID did not alter the single-dose pharmacokinetics of 30 mg DRUGOTHER. ,Cimetidine,cimetidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,0,6
496,DRUG1: Concomitant administration of 200 mg DRUGOTHER QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,Cimetidine,meloxicam,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,17
497,DRUGOTHER: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,cimetidine,meloxicam,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,6,17
498,DRUG1: DRUG2 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUGOTHER after b-acetylDRUGOTHER administration for 7 days at clinical doses. ,Digoxin,Meloxicam,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,1
499,DRUG1: DRUGOTHER 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG2 after b-acetylDRUG2 administration for 7 days at clinical doses. ,Digoxin,digoxin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,17
500,DRUGOTHER: DRUG1 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG2 after b-acetylDRUG2 administration for 7 days at clinical doses. ,Meloxicam,digoxin,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,1,17
501,In vitro testing found no protein binding drug interaction between DRUG1 and DRUG2. ,digoxin,meloxicam,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,10,12
502,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients. ",Furosemide,furosemide,FALSE,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,18
503,Studies with DRUG1 agents and DRUG2 have not demonstrated a reduction in natriuretic effect. ,furosemide,meloxicam,FALSE,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,2,5
504,DRUG1: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of DRUG2. ,Furosemide,meloxicam,FALSE,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,15
505,"Nevertheless, during concomitant therapy with DRUG1 and DRUG2, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",furosemide,MOBIC,TRUE,advise,1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,5,7
506,DRUG1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG2 on the pharmacokinetics of DRUGOTHER taken once weekly. ,Methotrexate,meloxicam,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,16
507,DRUG1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUGOTHER on the pharmacokinetics of DRUG2 taken once weekly. ,Methotrexate,methotrexate,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,21
508,DRUGOTHER: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG1 on the pharmacokinetics of DRUG2 taken once weekly. ,meloxicam,methotrexate,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,16,21
509,DRUG1 did not have a significant effect on the pharmacokinetics of single doses of DRUG2. ,Meloxicam,methotrexate,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,14
510,"In vitro, DRUG1 did not displace DRUG2 from its human serum binding sites. ",methotrexate,meloxicam,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,2,6
511,"DRUG1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing DRUG2 therapy in patients receiving DRUGOTHER or similar agents, since these patients are at an increased risk of bleeding. ",Warfarin,MOBIC,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,16
512,"DRUG1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing DRUGOTHER therapy in patients receiving DRUG2 or similar agents, since these patients are at an increased risk of bleeding. ",Warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,21
513,"DRUGOTHER: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing DRUG1 therapy in patients receiving DRUG2 or similar agents, since these patients are at an increased risk of bleeding. ",MOBIC,warfarin,TRUE,advise,1,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,16,21
514,The effect of DRUG1 on the anticoagulant effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,meloxicam,warfarin,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,9
515,The effect of DRUG1 on the anticoagulant effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,meloxicam,warfarin,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,9
516,The effect of DRUGOTHER on the anticoagulant effect of DRUG1 was studied in a group of healthy subjects receiving daily doses of DRUG1 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,9,-1
517,"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average anticoagulant effect of DRUG2 as determined by prothrombin time. ",meloxicam,warfarin,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,7
518,"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average anticoagulant effect of DRUG2 as determined by prothrombin time. ",meloxicam,warfarin,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,7
519,"In these subjects, DRUGOTHER did not alter DRUG1 pharmacokinetics and the average anticoagulant effect of DRUG1 as determined by prothrombin time. ",warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,7,-1
520,Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,TRUE,advise,1,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,8
521,Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,FALSE,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,8
522,Caution should be used when administering DRUGOTHER with DRUG1 since patients on DRUG1 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,-1
523,DRUG INTERACTIONS  There are no known drug/drug interactions with oral DRUG1  Vaccinations with DRUGOTHER are not recommended in immunocompromised individuals  DRUG2 together with high-dose intravenous DRUGOTHER has caused deaths in children due to haemorrhagic enterocolitis.  ,ALKERAN,Nalidixic acid,FALSE,Neg,0,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,11,23
524,DRUG INTERACTIONS  There are no known drug/drug interactions with oral DRUG1  Vaccinations with DRUGOTHER are not recommended in immunocompromised individuals  DRUGOTHER together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,ALKERAN,melphalan,FALSE,Neg,0,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,11,28
525,DRUG INTERACTIONS  There are no known drug/drug interactions with oral DRUGOTHER  Vaccinations with DRUGOTHER are not recommended in immunocompromised individuals  DRUG1 together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,Nalidixic acid,melphalan,TRUE,effect,2,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,23,28
526,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous DRUG1 and who subsequently received DRUG2 to prevent graft-versus-host disease,melphalan,cyclosporin,TRUE,effect,2,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,17,22
527,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,quinidine,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,12,15
528,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,antihistamines,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,NCCC1=CNC=N1,12,16
529,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,phenothiazines,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,N1C2=CC=CC=C2SC2=CC=CC=C12,12,19
530,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,benzodiazepines,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,N1N=CC=CC2=CC=CC=C12,12,20
531,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,MAO inhibitors,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CN(CC#C)CC1=CC=CC=C1,12,21
532,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,narcotic analgesics,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,12,22
533,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,meperidine,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,12,24
534,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,nitrates,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,[N+](=O)([O-])[O-],12,25
535,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,nitrites,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,N(=O)[O-],12,27
536,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,sympathomimetic agents,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,12,28
537,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",amantadine,tricyclic antidepressants,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,12,29
538,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,antihistamines,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,NCCC1=CNC=N1,15,16
539,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,phenothiazines,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,N1C2=CC=CC=C2SC2=CC=CC=C12,15,19
540,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,benzodiazepines,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,N1N=CC=CC2=CC=CC=C12,15,20
541,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,MAO inhibitors,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN(CC#C)CC1=CC=CC=C1,15,21
542,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,narcotic analgesics,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,15,22
543,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,meperidine,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,15,24
544,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,nitrates,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,[N+](=O)([O-])[O-],15,25
545,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,nitrites,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,N(=O)[O-],15,27
546,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,sympathomimetic agents,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,15,28
547,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",quinidine,tricyclic antidepressants,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,15,29
548,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,phenothiazines,FALSE,Neg,0,NCCC1=CNC=N1,N1C2=CC=CC=C2SC2=CC=CC=C12,16,19
549,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,benzodiazepines,FALSE,Neg,0,NCCC1=CNC=N1,N1N=CC=CC2=CC=CC=C12,16,20
550,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,MAO inhibitors,FALSE,Neg,0,NCCC1=CNC=N1,CN(CC#C)CC1=CC=CC=C1,16,21
551,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,narcotic analgesics,FALSE,Neg,0,NCCC1=CNC=N1,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,16,22
552,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,meperidine,FALSE,Neg,0,NCCC1=CNC=N1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,16,24
553,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,nitrates,FALSE,Neg,0,NCCC1=CNC=N1,[N+](=O)([O-])[O-],16,25
554,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,nitrites,FALSE,Neg,0,NCCC1=CNC=N1,N(=O)[O-],16,27
555,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,sympathomimetic agents,FALSE,Neg,0,NCCC1=CNC=N1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,16,28
556,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",antihistamines,tricyclic antidepressants,FALSE,Neg,0,NCCC1=CNC=N1,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,16,29
557,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,benzodiazepines,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,N1N=CC=CC2=CC=CC=C12,19,20
558,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,MAO inhibitors,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CN(CC#C)CC1=CC=CC=C1,19,21
559,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,narcotic analgesics,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,19,22
560,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,meperidine,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,19,24
561,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,nitrates,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,[N+](=O)([O-])[O-],19,25
562,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,nitrites,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,N(=O)[O-],19,27
563,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,sympathomimetic agents,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,19,28
564,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",phenothiazines,tricyclic antidepressants,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,19,29
565,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",benzodiazepines,MAO inhibitors,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,CN(CC#C)CC1=CC=CC=C1,20,21
566,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",benzodiazepines,narcotic analgesics,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,20,22
567,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",benzodiazepines,meperidine,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,20,24
568,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",benzodiazepines,nitrates,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,[N+](=O)([O-])[O-],20,25
569,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",benzodiazepines,nitrites,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,N(=O)[O-],20,27
570,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",benzodiazepines,sympathomimetic agents,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,20,28
571,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",benzodiazepines,tricyclic antidepressants,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,20,29
572,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUG2 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",MAO inhibitors,narcotic analgesics,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,21,22
573,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",MAO inhibitors,meperidine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,21,24
574,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",MAO inhibitors,nitrates,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,[N+](=O)([O-])[O-],21,25
575,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",MAO inhibitors,nitrites,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,N(=O)[O-],21,27
576,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",MAO inhibitors,sympathomimetic agents,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,21,28
577,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",MAO inhibitors,tricyclic antidepressants,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,21,29
578,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",narcotic analgesics,meperidine,FALSE,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,22,24
579,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",narcotic analgesics,nitrates,FALSE,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,[N+](=O)([O-])[O-],22,25
580,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",narcotic analgesics,nitrites,FALSE,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,N(=O)[O-],22,27
581,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",narcotic analgesics,sympathomimetic agents,FALSE,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,22,28
582,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",narcotic analgesics,tricyclic antidepressants,FALSE,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,22,29
583,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",meperidine,nitrates,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,[N+](=O)([O-])[O-],24,25
584,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",meperidine,nitrites,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,N(=O)[O-],24,27
585,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",meperidine,sympathomimetic agents,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,24,28
586,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",meperidine,tricyclic antidepressants,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,24,29
587,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1 and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",nitrates,nitrites,FALSE,Neg,0,[N+](=O)([O-])[O-],N(=O)[O-],25,27
588,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1 and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",nitrates,sympathomimetic agents,FALSE,Neg,0,[N+](=O)([O-])[O-],CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,25,28
589,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1 and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",nitrates,tricyclic antidepressants,FALSE,Neg,0,[N+](=O)([O-])[O-],CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,25,29
590,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG1, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",nitrites,sympathomimetic agents,FALSE,Neg,0,N(=O)[O-],CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,27,28
591,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG1, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",nitrites,tricyclic antidepressants,FALSE,Neg,0,N(=O)[O-],CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,27,29
592,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUG1, DRUG2, and other drugs having anticholinergic activity. ",sympathomimetic agents,tricyclic antidepressants,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,28,29
593,"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",MEPERIDINE,ALCOHOL,TRUE,advise,1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCO,4,36
594,Some DRUG1 may interact with DRUG2. ,anticonvulsants,Mephenytoin,TRUE,int,3,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,1,5
595,"Those DRUG1 include DRUG2, DRUGOTHER, and DRUGOTHER. ",anticonvulsants,divalproex sodium,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+],1,3
596,"Those DRUG1 include DRUGOTHER, DRUG2, and DRUGOTHER. ",anticonvulsants,valproic acid,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCCC(CCC)C(=O)O,1,4
597,"Those DRUG1 include DRUGOTHER, DRUGOTHER, and DRUG2. ",anticonvulsants,phenobarbital,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,1,6
598,"Those DRUGOTHER include DRUG1, DRUG2, and DRUGOTHER. ",divalproex sodium,valproic acid,FALSE,Neg,0,CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+],CCCC(CCC)C(=O)O,3,4
599,"Those DRUGOTHER include DRUG1, DRUGOTHER, and DRUG2. ",divalproex sodium,phenobarbital,FALSE,Neg,0,CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+],CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,3,6
600,"Those DRUGOTHER include DRUGOTHER, DRUG1, and DRUG2. ",valproic acid,phenobarbital,FALSE,Neg,0,CCCC(CCC)C(=O)O,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,4,6
601,"DRUG1 may also affect the effects of other drugs, which include some DRUGOTHER, DRUG2, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG1 may interact with other drugs that are not listed here.",Mephenytoin,warfarin,TRUE,effect,2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,13
602,"DRUG1 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG2 and DRUGOTHER Please note that DRUG1 may interact with other drugs that are not listed here.",Mephenytoin,furosemide,TRUE,effect,2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,21
603,"DRUG1 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG2 Please note that DRUG1 may interact with other drugs that are not listed here.",Mephenytoin,theophylline,TRUE,effect,2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,23
604,"DRUG1 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG1 may interact with other drugs that are not listed here.",Mephenytoin,Mephenytoin,FALSE,Neg,0,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,0,-1
605,"DRUGOTHER may also affect the effects of other drugs, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUG2 and DRUGOTHER Please note that DRUGOTHER may interact with other drugs that are not listed here.",warfarin,furosemide,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,13,21
606,"DRUGOTHER may also affect the effects of other drugs, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG2 Please note that DRUGOTHER may interact with other drugs that are not listed here.",warfarin,theophylline,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,13,23
607,"DRUG2 may also affect the effects of other drugs, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG2 may interact with other drugs that are not listed here.",warfarin,Mephenytoin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,13,0
608,"DRUGOTHER may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG1 and DRUG2 Please note that DRUGOTHER may interact with other drugs that are not listed here.",furosemide,theophylline,FALSE,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,21,23
609,"DRUG2 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG1 and DRUGOTHER Please note that DRUG2 may interact with other drugs that are not listed here.",furosemide,Mephenytoin,FALSE,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,21,0
610,"DRUG2 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG1 Please note that DRUG2 may interact with other drugs that are not listed here.",theophylline,Mephenytoin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,23,0
611,"DRUG1 can interact with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",Mequitazine,TCA,TRUE,int,3,C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53,C(=O)(C(Cl)(Cl)Cl)O,0,6
612,"DRUG1 can interact with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",Mequitazine,alcohol,TRUE,int,3,C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53,CCO,0,9
613,"DRUGOTHER can interact with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",TCA,alcohol,FALSE,Neg,0,C(=O)(C(Cl)(Cl)Cl)O,CCO,6,9
614,DRUG1 competes with DRUG2 for active tubular secretion and thus inhibits the renal excretion of DRUG2. ,Probenecid,meropenem,TRUE,mechanism,4,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,0,3
615,DRUG1 competes with DRUG2 for active tubular secretion and thus inhibits the renal excretion of DRUG2. ,Probenecid,meropenem,FALSE,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,0,3
616,DRUGOTHER competes with DRUG1 for active tubular secretion and thus inhibits the renal excretion of DRUG1. ,meropenem,meropenem,FALSE,Neg,0,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,3,-1
617,"Therefore, the coadministration of DRUG1 with DRUG2 is not recommended. ",probenecid,meropenem,TRUE,advise,1,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,4,6
618,There is evidence that DRUG1 may reduce serum levels of DRUG2 to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUGOTHER).,meropenem,valproic acid,TRUE,mechanism,4,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,CCCC(CCC)C(=O)O,4,10
619,There is evidence that DRUG1 may reduce serum levels of DRUGOTHER to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUG2).,meropenem,valproate,FALSE,Neg,0,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,CCCC(CCC)C(=O)O,4,27
620,There is evidence that DRUGOTHER may reduce serum levels of DRUG1 to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUG2).,valproic acid,valproate,FALSE,Neg,0,CCCC(CCC)C(=O)O,CCCC(CCC)C(=O)O,10,27
621,"DRUG1 should be used with caution in digitalized patients, since the combination of DRUG2 and DRUGOTHER may cause ectopic arrhythmias. ",ARAMINE,digitalis,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0,13
622,DRUG1 or DRUG2 may potentiate the action of DRUGOTHER. ,Monoamine oxidase inhibitors,tricyclic antidepressants,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,0,2
623,"DRUG1 may enhance the effects of DRUG2, DRUGOTHER and other DRUGOTHER.",SKELAXIN,alcohol,TRUE,effect,2,CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C,CCO,0,6
624,"DRUG1 may enhance the effects of DRUGOTHER, DRUGOTHER and other DRUG2.",SKELAXIN,CNS depressants,TRUE,effect,2,CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,10
625,"DRUGOTHER may enhance the effects of DRUG1, DRUGOTHER and other DRUG2.",alcohol,CNS depressants,FALSE,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,10
626,"Caution is advised for patients receiving high-dose DRUG1 and DRUG2 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUGOTHER.",aspirin,methazolamide,TRUE,advise,1,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,7,9
627,"Caution is advised for patients receiving high-dose DRUG1 and DRUGOTHER concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUGOTHER.",aspirin,aspirin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)OC1=CC=CC=C1C(=O)O,7,-1
628,"Caution is advised for patients receiving high-dose DRUG1 and DRUGOTHER concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUG2.",aspirin,carbonic anhydrase inhibitors,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,OCC(O)CO,7,28
629,"Caution is advised for patients receiving high-dose DRUG2 and DRUG1 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG2 and DRUGOTHER.",methazolamide,aspirin,FALSE,Neg,0,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,CC(=O)OC1=CC=CC=C1C(=O)O,9,7
630,"Caution is advised for patients receiving high-dose DRUGOTHER and DRUG1 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUGOTHER and DRUG2.",methazolamide,carbonic anhydrase inhibitors,FALSE,Neg,0,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,OCC(O)CO,9,28
631,"Caution is advised for patients receiving high-dose DRUG1 and DRUGOTHER concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUG2.",aspirin,carbonic anhydrase inhibitors,TRUE,effect,2,CC(=O)OC1=CC=CC=C1C(=O)O,OCC(O)CO,7,28
632,DRUG1: Serum digitalis levels may be increased when hyperthyroid patients on a stable DRUG2 regimen become euthyroid; ,Digitalis glycosides,digitalis glycoside,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,13
633,DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUGOTHER regimen become euthyroid; ,Theophylline,Theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,-1
634,DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG2 regimen become euthyroid; ,Theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,11
635,DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG2 regimen become euthyroid; ,Theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,11
636,"Dosages of concomitantly administered DRUG1 should be reduced by approximately half, because DRUG2 amplifies the therapeutic actions and side-effects of DRUG1. ",opioids,levomepromazine,TRUE,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,4,12
637,"Dosages of concomitantly administered DRUG1 should be reduced by approximately half, because DRUGOTHER amplifies the therapeutic actions and side-effects of DRUG1. ",opioids,opioids,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,4,-1
638,"Dosages of concomitantly administered DRUG2 should be reduced by approximately half, because DRUG1 amplifies the therapeutic actions and side-effects of DRUG2. ",levomepromazine,opioids,TRUE,effect,2,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,12,4
639,Combination with DRUG1 (DRUG2) is associated with increased risk of seizures. ,tramadol,Ultram,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,2,3
640,Additive sedative effects and confusional states may emerge if DRUG1 is given with DRUG2 or DRUGOTHER. ,levomepromazine,benzodiazepines,TRUE,effect,2,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,N1N=CC=CC2=CC=CC=C12,9,13
641,"Exert particular caution in combining DRUG1 with other DRUGOTHER (DRUG2 and DRUGOTHER): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,tricyclic antidepressants,TRUE,advise,1,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,5,9
642,DRUG1 and/or stimulantes of the DRUG2/DRUGOTHER type may counteract the specific actions of DRUGOTHER. ,Caffeine,ephedrine,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,0,5
643,DRUG1 and/or stimulantes of the DRUGOTHER/DRUG2 type may counteract the specific actions of DRUGOTHER. ,Caffeine,amphetamine,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(CC1=CC=CC=C1)N,0,5
644,DRUG1 and/or stimulantes of the DRUGOTHER/DRUGOTHER type may counteract the specific actions of DRUG2. ,Caffeine,levomepromazine,TRUE,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,0,13
645,DRUGOTHER and/or stimulantes of the DRUG1/DRUG2 type may counteract the specific actions of DRUGOTHER. ,ephedrine,amphetamine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC(CC1=CC=CC=C1)N,5,5
646,DRUGOTHER and/or stimulantes of the DRUG1/DRUGOTHER type may counteract the specific actions of DRUG2. ,ephedrine,levomepromazine,TRUE,effect,2,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,5,13
647,DRUGOTHER and/or stimulantes of the DRUGOTHER/DRUG1 type may counteract the specific actions of DRUG2. ,amphetamine,levomepromazine,TRUE,effect,2,CC(CC1=CC=CC=C1)N,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,5,13
652,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUGOTHER and DRUGOTHER).",methsuximide,methsuximide,FALSE,Neg,0,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,2,-1
653,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and DRUGOTHER).",methsuximide,phenytoin,FALSE,Neg,0,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,27
654,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUGOTHER and DRUG2).",methsuximide,phenobarbital,FALSE,Neg,0,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,2,29
655,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and DRUGOTHER).",methsuximide,phenytoin,TRUE,mechanism,4,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,27
656,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUGOTHER and DRUG2).",methsuximide,phenobarbital,TRUE,mechanism,4,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,2,29
657,"Since DRUGOTHER (DRUGOTHER) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUG1 and DRUG2).",phenytoin,phenobarbital,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,27,29
658,DRUG1 may decrease arterial responsiveness to DRUG2. ,Thiazides,norepinephrine,TRUE,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC(=C(C=C1[C@H](CN)O)O)O,0,6
659,DRUG1 may add to or potentiate the action of other DRUG2. ,Thiazides,antihypertensive drugs,TRUE,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,10
660,"When DRUG1 is used with other DRUG2, potentiation of antihypertensive effect may occur. ",methyldopa,antihypertensive drugs,TRUE,effect,2,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,1,6
661,Patients may require reduced doses of DRUG1 when on DRUG2. ,anesthetics,methyldopa,TRUE,advise,1,CCOC(=O)C1=CC=C(N)C=C1,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,6,9
662,Several studies demonstrate a decrease in the bioavailability of DRUG1 when it is ingested with DRUG2 or DRUGOTHER. ,methyldopa,ferrous sulfate,TRUE,mechanism,4,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,[O-]S(=O)(=O)[O-].[Fe+2],9,15
663,Several studies demonstrate a decrease in the bioavailability of DRUG1 when it is ingested with DRUGOTHER or DRUG2. ,methyldopa,ferrous gluconate,TRUE,mechanism,4,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Fe+2],9,17
664,Several studies demonstrate a decrease in the bioavailability of DRUGOTHER when it is ingested with DRUG1 or DRUG2. ,ferrous sulfate,ferrous gluconate,FALSE,Neg,0,[O-]S(=O)(=O)[O-].[Fe+2],C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Fe+2],15,17
665,Coadministration of DRUG1 with DRUG2 or DRUGOTHER is not recommended. ,methyldopa,ferrous sulfate,TRUE,advise,1,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,[O-]S(=O)(=O)[O-].[Fe+2],2,4
666,Coadministration of DRUG1 with DRUGOTHER or DRUG2 is not recommended. ,methyldopa,ferrous gluconate,TRUE,advise,1,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Fe+2],2,6
667,Coadministration of DRUGOTHER with DRUG1 or DRUG2 is not recommended. ,ferrous sulfate,ferrous gluconate,FALSE,Neg,0,[O-]S(=O)(=O)[O-].[Fe+2],C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Fe+2],4,6
668,"DRUG1 does not interfere with measurement of DRUG2 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG2 to DRUGOTHER. ",Methyldopa,VMA,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,COC1=C(C=CC(=C1)C(C(=O)O)O)O,0,7
669,"DRUG1 does not interfere with measurement of DRUGOTHER (DRUG2), a test for pheochromocytoma, by those methods which convert DRUGOTHER to DRUGOTHER. ",Methyldopa,vanillylmandelic acid,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,COC1=C(C=CC(=C1)C(C(=O)O)O)O,0,8
670,"DRUG1 does not interfere with measurement of DRUG2 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG2 to DRUGOTHER. ",Methyldopa,VMA,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,COC1=C(C=CC(=C1)C(C(=O)O)O)O,0,7
671,"DRUG1 does not interfere with measurement of DRUGOTHER (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUGOTHER to DRUG2. ",Methyldopa,vanillin,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,COC1=C(C=CC(=C1)C=O)O,0,20
672,"DRUGOTHER does not interfere with measurement of DRUG1 (DRUG2), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUGOTHER. ",VMA,vanillylmandelic acid,FALSE,Neg,0,COC1=C(C=CC(=C1)C(C(=O)O)O)O,COC1=C(C=CC(=C1)C(C(=O)O)O)O,7,8
673,"DRUGOTHER does not interfere with measurement of DRUG1 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUGOTHER. ",VMA,VMA,FALSE,Neg,0,COC1=C(C=CC(=C1)C(C(=O)O)O)O,COC1=C(C=CC(=C1)C(C(=O)O)O)O,7,-1
674,"DRUGOTHER does not interfere with measurement of DRUG1 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUG2. ",VMA,vanillin,FALSE,Neg,0,COC1=C(C=CC(=C1)C(C(=O)O)O)O,COC1=C(C=CC(=C1)C=O)O,7,20
675,"DRUGOTHER does not interfere with measurement of DRUG2 (DRUG1), a test for pheochromocytoma, by those methods which convert DRUG2 to DRUGOTHER. ",vanillylmandelic acid,VMA,FALSE,Neg,0,COC1=C(C=CC(=C1)C(C(=O)O)O)O,COC1=C(C=CC(=C1)C(C(=O)O)O)O,8,7
676,"DRUGOTHER does not interfere with measurement of DRUGOTHER (DRUG1), a test for pheochromocytoma, by those methods which convert DRUGOTHER to DRUG2. ",vanillylmandelic acid,vanillin,FALSE,Neg,0,COC1=C(C=CC(=C1)C(C(=O)O)O)O,COC1=C(C=CC(=C1)C=O)O,8,20
677,"DRUGOTHER does not interfere with measurement of DRUG1 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUG2. ",VMA,vanillin,FALSE,Neg,0,COC1=C(C=CC(=C1)C(C(=O)O)O)O,COC1=C(C=CC(=C1)C=O)O,7,20
678,"CYP 3A4 Inhibitors (e.g. DRUGOTHER and DRUGOTHER) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER (e.g. DRUG1 and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",dihydroergotamine,ergotamine,FALSE,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,25,27
679,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,erythromycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,11,13
680,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,troleandomycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,11,14
681,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,clarithromycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,11,15
682,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,ritonavir,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,21
683,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,indinavir,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,11,22
684,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,nelfinavir,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,11,23
685,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,delavirdine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,11,24
686,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,azole antifungals,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,OC(=O)CCCCCCCCC=C,11,26
687,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,ketoconazole,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,28
688,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",macrolide antibiotics,itraconazole,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,11,29
689,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",macrolide antibiotics,voriconazole,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,11,30
690,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,troleandomycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,13,14
691,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,clarithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,13,15
692,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,ritonavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,13,21
693,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,indinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,13,22
694,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,nelfinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,13,23
695,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,delavirdine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,13,24
696,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,azole antifungals,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,OC(=O)CCCCCCCCC=C,13,26
697,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",erythromycin,ketoconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,13,28
698,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",erythromycin,itraconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,13,29
699,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",erythromycin,voriconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,13,30
700,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",troleandomycin,clarithromycin,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,14,15
701,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",troleandomycin,ritonavir,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,14,21
702,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",troleandomycin,indinavir,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,14,22
703,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",troleandomycin,nelfinavir,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,14,23
704,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",troleandomycin,delavirdine,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,14,24
705,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",troleandomycin,azole antifungals,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,OC(=O)CCCCCCCCC=C,14,26
706,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",troleandomycin,ketoconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,14,28
707,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",troleandomycin,itraconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,14,29
708,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",troleandomycin,voriconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,14,30
709,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",clarithromycin,ritonavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,15,21
710,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",clarithromycin,indinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,15,22
711,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",clarithromycin,nelfinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,15,23
712,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",clarithromycin,delavirdine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,15,24
713,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",clarithromycin,azole antifungals,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,OC(=O)CCCCCCCCC=C,15,26
714,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",clarithromycin,ketoconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,15,28
715,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",clarithromycin,itraconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,15,29
716,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",clarithromycin,voriconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,15,30
717,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,indinavir,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,21,22
718,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,nelfinavir,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,21,23
719,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,delavirdine,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,21,24
720,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,azole antifungals,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,OC(=O)CCCCCCCCC=C,21,26
721,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",ritonavir,ketoconazole,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,21,28
722,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",ritonavir,itraconazole,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,21,29
723,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",ritonavir,voriconazole,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,21,30
724,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",indinavir,nelfinavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,22,23
725,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",indinavir,delavirdine,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,22,24
726,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",indinavir,azole antifungals,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,OC(=O)CCCCCCCCC=C,22,26
727,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",indinavir,ketoconazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,22,28
728,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",indinavir,itraconazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,22,29
729,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",indinavir,voriconazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,22,30
730,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",nelfinavir,delavirdine,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,23,24
731,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",nelfinavir,azole antifungals,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,OC(=O)CCCCCCCCC=C,23,26
732,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",nelfinavir,ketoconazole,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,23,28
733,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",nelfinavir,itraconazole,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,23,29
734,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",nelfinavir,voriconazole,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,23,30
735,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",delavirdine,azole antifungals,FALSE,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,OC(=O)CCCCCCCCC=C,24,26
736,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",delavirdine,ketoconazole,FALSE,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,24,28
737,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",delavirdine,itraconazole,FALSE,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,24,29
738,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",delavirdine,voriconazole,FALSE,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,24,30
739,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",azole antifungals,ketoconazole,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,26,28
740,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",azole antifungals,itraconazole,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,26,29
741,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",azole antifungals,voriconazole,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,26,30
742,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER). ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,28,29
743,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2). ",ketoconazole,voriconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,28,30
744,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2). ",itraconazole,voriconazole,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,29,30
745,"Less potent inhibitors include DRUG1, DRUG2, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",saquinavir,nefazodone,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,4,5
746,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUG2, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",saquinavir,fluconazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,4,6
747,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",saquinavir,fluoxetine,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,4,9
748,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",saquinavir,fluvoxamine,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,4,10
749,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",saquinavir,zileuton,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,4,11
750,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",saquinavir,clotrimazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,4,13
751,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUG2, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",nefazodone,fluconazole,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5,6
752,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",nefazodone,fluoxetine,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,5,9
753,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",nefazodone,fluvoxamine,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,5,10
754,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",nefazodone,zileuton,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,5,11
755,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",nefazodone,clotrimazole,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,5,13
756,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",fluconazole,fluoxetine,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,6,9
757,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",fluconazole,fluvoxamine,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,6,10
758,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",fluconazole,zileuton,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,6,11
759,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",fluconazole,clotrimazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,6,13
760,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",fluoxetine,fluvoxamine,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,9,10
761,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",fluoxetine,zileuton,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,9,11
762,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",fluoxetine,clotrimazole,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,9,13
763,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",fluvoxamine,zileuton,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,10,11
764,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",fluvoxamine,clotrimazole,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,10,13
765,"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",zileuton,clotrimazole,FALSE,Neg,0,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,11,13
766,Caution should be exercised when DRUG1    (DRUG2) is used concurrently with other DRUGOTHER or DRUGOTHER.,Methergine,methylergonovine maleate,FALSE,Neg,0,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=C\C(=O)O)\C(=O)O,5,9
767,Caution should be exercised when DRUG1    (DRUGOTHER) is used concurrently with other DRUGOTHER or DRUG2.,Methergine,ergot alkaloids,TRUE,advise,1,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,5,17
768,Caution should be exercised when DRUGOTHER    (DRUG1) is used concurrently with other DRUGOTHER or DRUG2.,methylergonovine maleate,ergot alkaloids,FALSE,Neg,0,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=C\C(=O)O)\C(=O)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,9,17
769,DRUG1 may decrease the hypotensive effect of DRUG2. ,Ritalin,guanethidine,TRUE,effect,2,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,C1CCCN(CCC1)CCN=C(N)N,0,7
770,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",Ritalin,anticonvulsants,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,6,13
771,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",Ritalin,phenobarbital,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,6,14
772,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",Ritalin,diphenylhydantoin,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,15
773,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",Ritalin,primidone,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,6,16
774,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",Ritalin,phenylbutazone,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,6,17
775,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",Ritalin,imipramine,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,6,20
776,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",Ritalin,clomipramine,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,6,21
777,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",Ritalin,desipramine,TRUE,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,6,22
778,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",anticonvulsants,phenobarbital,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,13,14
779,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",anticonvulsants,diphenylhydantoin,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,15
780,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",anticonvulsants,primidone,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,13,16
781,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",anticonvulsants,phenylbutazone,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,13,17
782,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",anticonvulsants,imipramine,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,13,20
783,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",anticonvulsants,clomipramine,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,13,21
784,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",anticonvulsants,desipramine,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,13,22
785,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",phenobarbital,diphenylhydantoin,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,15
786,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",phenobarbital,primidone,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,14,16
787,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",phenobarbital,phenylbutazone,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,14,17
788,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",phenobarbital,imipramine,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,14,20
789,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",phenobarbital,clomipramine,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,14,21
790,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",phenobarbital,desipramine,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,14,22
791,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",diphenylhydantoin,primidone,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,15,16
792,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",diphenylhydantoin,phenylbutazone,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,15,17
793,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",diphenylhydantoin,imipramine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,20
794,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",diphenylhydantoin,clomipramine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,15,21
795,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",diphenylhydantoin,desipramine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,22
796,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",primidone,phenylbutazone,FALSE,Neg,0,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,16,17
797,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",primidone,imipramine,FALSE,Neg,0,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,16,20
798,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",primidone,clomipramine,FALSE,Neg,0,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,16,21
799,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",primidone,desipramine,FALSE,Neg,0,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,16,22
800,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",phenylbutazone,imipramine,FALSE,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,17,20
801,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",phenylbutazone,clomipramine,FALSE,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,17,21
802,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",phenylbutazone,desipramine,FALSE,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,17,22
803,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG1, DRUG2, DRUGOTHER). ",imipramine,clomipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,20,21
804,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG1, DRUGOTHER, DRUG2). ",imipramine,desipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,20,22
805,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG1, DRUG2). ",clomipramine,desipramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,21,22
806,The safety of using DRUG1 in combination with DRUG2 or other centrally acting DRUGOTHER has not been systemically evaluated.    ,methylphenidate,clonidine,FALSE,Neg,0,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,4,8
807,Mutual inhibition of metabolism occurs with concurrent use of DRUG1 and DRUG2; ,cyclosporin,methylprednisolone,TRUE,mechanism,4,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,9,11
808,convulsions have been reported with concurrent use of DRUG1 and DRUG2. ,methylprednisolone,cyclosporin,TRUE,effect,2,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,8,10
809,"Drugs that induce hepatic enzymes such as DRUG1, DRUG2, and DRUGOTHER may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",phenobarbital,phenytoin,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
810,"Drugs that induce hepatic enzymes such as DRUG1, DRUGOTHER, and DRUG2 may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",phenobarbital,rifampin,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,7,10
811,"Drugs that induce hepatic enzymes such as DRUG1, DRUGOTHER, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",phenobarbital,methylprednisolone,TRUE,mechanism,4,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,7,16
812,"Drugs that induce hepatic enzymes such as DRUG1, DRUGOTHER, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",phenobarbital,methylprednisolone,TRUE,advise,1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,7,16
813,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUG2 may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",phenytoin,rifampin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
814,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",phenytoin,methylprednisolone,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,8,16
815,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",phenytoin,methylprednisolone,TRUE,advise,1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,8,16
816,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER, and DRUG1 may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",rifampin,methylprednisolone,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,10,16
817,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER, and DRUG1 may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",rifampin,methylprednisolone,TRUE,advise,1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,10,16
818,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER, and DRUGOTHER may increase the clearance of DRUG1 and may require increased in DRUG1 dose to achieve the desired response. ",methylprednisolone,methylprednisolone,FALSE,Neg,0,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,16,-1
819,Drugs such as DRUG1 and DRUG2 may inhibit the metabolism of DRUGOTHER and thus decrease its clearance. ,troleandomycin,ketoconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,3,5
820,Drugs such as DRUG1 and DRUGOTHER may inhibit the metabolism of DRUG2 and thus decrease its clearance. ,troleandomycin,methylprednisolone,TRUE,mechanism,4,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,3,11
821,Drugs such as DRUGOTHER and DRUG1 may inhibit the metabolism of DRUG2 and thus decrease its clearance. ,ketoconazole,methylprednisolone,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,5,11
822,DRUG1 may increase the clearance of chronic high dose DRUG2. ,Methylprednisolone,aspirin,TRUE,mechanism,4,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,CC(=O)OC1=CC=CC=C1C(=O)O,0,9
823,This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUGOTHER is withdrawn. ,salicylate,salicylate,FALSE,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],C1=CC=C(C(=C1)C(=O)O)[O-],5,-1
824,This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,salicylate,methylprednisolone,FALSE,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,5,16
825,This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,salicylate,methylprednisolone,TRUE,effect,2,C1=CC=C(C(=C1)C(=O)O)[O-],C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,5,16
826,DRUG1 should be used cautiously in conjunction with DRUG2 in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,TRUE,advise,1,CC(=O)OC1=CC=CC=C1C(=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,8
827,There are reports of enhanced as well as diminished effects of DRUG1 when given concurrently with DRUG2. ,anticoagulant,corticosteroids,TRUE,effect,2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,11,16
829,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,MAO inhibitors,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,CN(CC#C)CC1=CC=CC=C1,0,7
830,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,phenelzine,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,C1=CC=C(C=C1)CCNN,0,9
831,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,linezolid,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,0,10
832,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,tranylcypromine,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,C1[C@H]([C@@H]1N)C2=CC=CC=C2,0,11
833,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,isocarboxazid,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,0,12
834,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,selegiline,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,C[C@H](CC1=CC=CC=C1)N(C)CC#C,0,13
835,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,furazolidone,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],0,14
836,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,quinidine,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,0,15
837,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,amantadine,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,C1C2CC3CC1CC(C2)(C3)N,0,16
838,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,antihistamines,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,NCCC1=CNC=N1,0,17
839,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,diphenhydramine,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,0,19
840,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,anticholinergics,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,C[N+](C)(C)CCO,0,21
841,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,potassium chloride,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,[Cl-].[K+],0,22
842,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,kaolin,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,0,27
843,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,pectin,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,0,27
844,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,phenothiazines,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,N1C2=CC=CC=C2SC2=CC=CC=C12,0,28
845,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",Methscopolamine,chlorpromazine,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,0,30
846,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",Methscopolamine,promethazine,TRUE,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,0,31
847,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,MAO inhibitors,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(CC#C)CC1=CC=CC=C1,4,7
848,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,phenelzine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1=CC=C(C=C1)CCNN,4,9
849,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,linezolid,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,4,10
850,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,tranylcypromine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1[C@H]([C@@H]1N)C2=CC=CC=C2,4,11
851,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,isocarboxazid,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,4,12
852,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,selegiline,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C[C@H](CC1=CC=CC=C1)N(C)CC#C,4,13
853,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,furazolidone,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],4,14
854,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,quinidine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,4,15
855,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,amantadine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1C2CC3CC1CC(C2)(C3)N,4,16
856,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,antihistamines,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC=N1,4,17
857,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,diphenhydramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,4,19
858,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,anticholinergics,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C[N+](C)(C)CCO,4,21
859,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,potassium chloride,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,[Cl-].[K+],4,22
860,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,kaolin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,4,27
861,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,pectin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,4,27
862,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,phenothiazines,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,N1C2=CC=CC=C2SC2=CC=CC=C12,4,28
863,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",antidepressants,chlorpromazine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,4,30
864,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",antidepressants,promethazine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,4,31
865,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,phenelzine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,C1=CC=C(C=C1)CCNN,7,9
866,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,linezolid,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,7,10
867,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,tranylcypromine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,C1[C@H]([C@@H]1N)C2=CC=CC=C2,7,11
868,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,isocarboxazid,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,7,12
869,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,selegiline,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,C[C@H](CC1=CC=CC=C1)N(C)CC#C,7,13
870,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,furazolidone,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],7,14
871,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,quinidine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,7,15
872,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,amantadine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,C1C2CC3CC1CC(C2)(C3)N,7,16
873,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,antihistamines,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,NCCC1=CNC=N1,7,17
874,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,diphenhydramine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,7,19
875,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,anticholinergics,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,C[N+](C)(C)CCO,7,21
876,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,potassium chloride,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,[Cl-].[K+],7,22
877,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,kaolin,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,7,27
878,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,pectin,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,7,27
879,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,phenothiazines,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,N1C2=CC=CC=C2SC2=CC=CC=C12,7,28
880,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",MAO inhibitors,chlorpromazine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,7,30
881,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",MAO inhibitors,promethazine,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,7,31
882,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,linezolid,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,9,10
883,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,tranylcypromine,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,C1[C@H]([C@@H]1N)C2=CC=CC=C2,9,11
884,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,isocarboxazid,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,9,12
885,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,selegiline,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,C[C@H](CC1=CC=CC=C1)N(C)CC#C,9,13
886,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,furazolidone,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],9,14
887,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,quinidine,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,9,15
888,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,amantadine,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,C1C2CC3CC1CC(C2)(C3)N,9,16
889,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,antihistamines,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,NCCC1=CNC=N1,9,17
890,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,diphenhydramine,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,9,19
891,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,anticholinergics,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,C[N+](C)(C)CCO,9,21
892,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,potassium chloride,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,[Cl-].[K+],9,22
893,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,kaolin,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,9,27
894,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,pectin,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,9,27
895,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,phenothiazines,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,N1C2=CC=CC=C2SC2=CC=CC=C12,9,28
896,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",phenelzine,chlorpromazine,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,9,30
897,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",phenelzine,promethazine,FALSE,Neg,0,C1=CC=C(C=C1)CCNN,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,9,31
898,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,tranylcypromine,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C1[C@H]([C@@H]1N)C2=CC=CC=C2,10,11
899,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,isocarboxazid,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,10,12
900,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,selegiline,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C[C@H](CC1=CC=CC=C1)N(C)CC#C,10,13
901,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,furazolidone,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],10,14
902,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,quinidine,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,10,15
903,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,amantadine,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C1C2CC3CC1CC(C2)(C3)N,10,16
904,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,antihistamines,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,NCCC1=CNC=N1,10,17
905,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,diphenhydramine,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,10,19
906,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,anticholinergics,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C[N+](C)(C)CCO,10,21
907,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,potassium chloride,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,[Cl-].[K+],10,22
908,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,kaolin,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,10,27
909,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,pectin,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,10,27
910,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",linezolid,phenothiazines,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,N1C2=CC=CC=C2SC2=CC=CC=C12,10,28
911,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",linezolid,chlorpromazine,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,10,30
912,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",linezolid,promethazine,FALSE,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,10,31
913,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,isocarboxazid,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,11,12
914,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,selegiline,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C[C@H](CC1=CC=CC=C1)N(C)CC#C,11,13
915,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,furazolidone,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],11,14
916,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,quinidine,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,11,15
917,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,amantadine,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C1C2CC3CC1CC(C2)(C3)N,11,16
918,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,antihistamines,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,NCCC1=CNC=N1,11,17
919,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,diphenhydramine,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,11,19
920,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,anticholinergics,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,C[N+](C)(C)CCO,11,21
921,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,potassium chloride,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,[Cl-].[K+],11,22
922,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,kaolin,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,11,27
923,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,pectin,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,11,27
924,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",tranylcypromine,phenothiazines,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,N1C2=CC=CC=C2SC2=CC=CC=C12,11,28
925,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",tranylcypromine,chlorpromazine,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,11,30
926,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",tranylcypromine,promethazine,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,11,31
927,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,selegiline,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C[C@H](CC1=CC=CC=C1)N(C)CC#C,12,13
928,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,furazolidone,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],12,14
929,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,quinidine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,12,15
930,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,amantadine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C1C2CC3CC1CC(C2)(C3)N,12,16
931,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,antihistamines,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,NCCC1=CNC=N1,12,17
932,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,diphenhydramine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,12,19
933,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,anticholinergics,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,C[N+](C)(C)CCO,12,21
934,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,potassium chloride,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,[Cl-].[K+],12,22
935,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,kaolin,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,12,27
936,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,pectin,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,12,27
937,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",isocarboxazid,phenothiazines,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,N1C2=CC=CC=C2SC2=CC=CC=C12,12,28
938,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",isocarboxazid,chlorpromazine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,12,30
939,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",isocarboxazid,promethazine,FALSE,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,12,31
940,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,furazolidone,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],13,14
941,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,quinidine,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,13,15
942,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,amantadine,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C1C2CC3CC1CC(C2)(C3)N,13,16
943,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,antihistamines,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,NCCC1=CNC=N1,13,17
944,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,diphenhydramine,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,13,19
945,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,anticholinergics,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C[N+](C)(C)CCO,13,21
946,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,potassium chloride,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,[Cl-].[K+],13,22
947,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,kaolin,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,13,27
948,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",selegiline,pectin,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,13,27
949,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",selegiline,phenothiazines,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,N1C2=CC=CC=C2SC2=CC=CC=C12,13,28
950,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",selegiline,chlorpromazine,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,13,30
951,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",selegiline,promethazine,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,13,31
952,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,quinidine,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,14,15
953,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,amantadine,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],C1C2CC3CC1CC(C2)(C3)N,14,16
954,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,antihistamines,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],NCCC1=CNC=N1,14,17
955,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,diphenhydramine,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,14,19
956,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,anticholinergics,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],C[N+](C)(C)CCO,14,21
957,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,potassium chloride,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],[Cl-].[K+],14,22
958,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,kaolin,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,14,27
959,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,pectin,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,14,27
960,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",furazolidone,phenothiazines,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],N1C2=CC=CC=C2SC2=CC=CC=C12,14,28
961,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",furazolidone,chlorpromazine,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,14,30
962,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",furazolidone,promethazine,FALSE,Neg,0,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,14,31
963,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",quinidine,amantadine,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C1C2CC3CC1CC(C2)(C3)N,15,16
964,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",quinidine,antihistamines,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,NCCC1=CNC=N1,15,17
965,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",quinidine,diphenhydramine,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,15,19
966,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",quinidine,anticholinergics,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C[N+](C)(C)CCO,15,21
967,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",quinidine,potassium chloride,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,[Cl-].[K+],15,22
968,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",quinidine,kaolin,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,15,27
969,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",quinidine,pectin,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,15,27
970,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",quinidine,phenothiazines,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,N1C2=CC=CC=C2SC2=CC=CC=C12,15,28
971,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",quinidine,chlorpromazine,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,15,30
972,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",quinidine,promethazine,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,15,31
973,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",amantadine,antihistamines,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,NCCC1=CNC=N1,16,17
974,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",amantadine,diphenhydramine,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,16,19
975,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",amantadine,anticholinergics,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,C[N+](C)(C)CCO,16,21
976,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",amantadine,potassium chloride,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,[Cl-].[K+],16,22
977,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",amantadine,kaolin,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,16,27
978,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",amantadine,pectin,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,16,27
979,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",amantadine,phenothiazines,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,N1C2=CC=CC=C2SC2=CC=CC=C12,16,28
980,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",amantadine,chlorpromazine,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,16,30
981,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",amantadine,promethazine,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,16,31
982,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antihistamines,diphenhydramine,FALSE,Neg,0,NCCC1=CNC=N1,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,17,19
983,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antihistamines,anticholinergics,FALSE,Neg,0,NCCC1=CNC=N1,C[N+](C)(C)CCO,17,21
984,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antihistamines,potassium chloride,FALSE,Neg,0,NCCC1=CNC=N1,[Cl-].[K+],17,22
985,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antihistamines,kaolin,FALSE,Neg,0,NCCC1=CNC=N1,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,17,27
986,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antihistamines,pectin,FALSE,Neg,0,NCCC1=CNC=N1,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,17,27
987,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",antihistamines,phenothiazines,FALSE,Neg,0,NCCC1=CNC=N1,N1C2=CC=CC=C2SC2=CC=CC=C12,17,28
988,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",antihistamines,chlorpromazine,FALSE,Neg,0,NCCC1=CNC=N1,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,17,30
989,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",antihistamines,promethazine,FALSE,Neg,0,NCCC1=CNC=N1,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,17,31
990,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",diphenhydramine,anticholinergics,FALSE,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,C[N+](C)(C)CCO,19,21
991,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",diphenhydramine,potassium chloride,FALSE,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,[Cl-].[K+],19,22
992,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",diphenhydramine,kaolin,FALSE,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,19,27
993,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",diphenhydramine,pectin,FALSE,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,19,27
994,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",diphenhydramine,phenothiazines,FALSE,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,N1C2=CC=CC=C2SC2=CC=CC=C12,19,28
995,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",diphenhydramine,chlorpromazine,FALSE,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,19,30
996,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",diphenhydramine,promethazine,FALSE,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,19,31
997,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",anticholinergics,potassium chloride,FALSE,Neg,0,C[N+](C)(C)CCO,[Cl-].[K+],21,22
998,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",anticholinergics,kaolin,FALSE,Neg,0,C[N+](C)(C)CCO,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,21,27
999,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",anticholinergics,pectin,FALSE,Neg,0,C[N+](C)(C)CCO,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,21,27
1000,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",anticholinergics,phenothiazines,FALSE,Neg,0,C[N+](C)(C)CCO,N1C2=CC=CC=C2SC2=CC=CC=C12,21,28
1001,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",anticholinergics,chlorpromazine,FALSE,Neg,0,C[N+](C)(C)CCO,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,21,30
1002,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",anticholinergics,promethazine,FALSE,Neg,0,C[N+](C)(C)CCO,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,21,31
1003,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG1 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",potassium chloride,kaolin,FALSE,Neg,0,[Cl-].[K+],O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,22,27
1004,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG1 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",potassium chloride,pectin,FALSE,Neg,0,[Cl-].[K+],[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,22,27
1005,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG1 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",potassium chloride,phenothiazines,FALSE,Neg,0,[Cl-].[K+],N1C2=CC=CC=C2SC2=CC=CC=C12,22,28
1006,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG1 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",potassium chloride,chlorpromazine,FALSE,Neg,0,[Cl-].[K+],CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,22,30
1007,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG1 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",potassium chloride,promethazine,FALSE,Neg,0,[Cl-].[K+],CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,22,31
1008,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",kaolin,pectin,FALSE,Neg,0,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,27,27
1009,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",kaolin,phenothiazines,FALSE,Neg,0,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,N1C2=CC=CC=C2SC2=CC=CC=C12,27,28
1010,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",kaolin,chlorpromazine,FALSE,Neg,0,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,27,30
1011,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",kaolin,promethazine,FALSE,Neg,0,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,27,31
1012,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG1), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",pectin,phenothiazines,FALSE,Neg,0,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,N1C2=CC=CC=C2SC2=CC=CC=C12,27,28
1013,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG1), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",pectin,chlorpromazine,FALSE,Neg,0,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,27,30
1014,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG1), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",pectin,promethazine,FALSE,Neg,0,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,27,31
1015,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG1 (e.g., DRUG2, DRUGOTHER).",phenothiazines,chlorpromazine,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,28,30
1016,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG1 (e.g., DRUGOTHER, DRUG2).",phenothiazines,promethazine,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,28,31
1017,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG1, DRUG2).",chlorpromazine,promethazine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,30,31
1018,Concurrent use of DRUG1 and other DRUGOTHER may increase the CNS depressant effects of DRUG2 or these other medications.,alcohol,methyprylon,TRUE,effect,2,CCO,CCC1(C(=O)C(CNC1=O)C)CC,3,14
1019,DRUG1 may reverse the analgesic activity of DRUG2. ,Methysergide,narcotic analgesics,TRUE,effect,2,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,0,7
1020,"Concurrent use with DRUGOTHER including DRUG1, DRUG2, and DRUGOTHER (e.g. smoking) may result in enhanced vasoconstriction.",ergot alkaloids,sumatriptan,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,5,6
1021,"Concurrent use with DRUGOTHER including DRUG1, DRUGOTHER, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",ergot alkaloids,nicotine,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1CCC[C@H]1C2=CN=CC=C2,5,8
1022,"Concurrent use with DRUGOTHER including DRUGOTHER, DRUG1, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",sumatriptan,nicotine,FALSE,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CN1CCC[C@H]1C2=CN=CC=C2,6,8
1023,The effects of DRUG1 on gastrointestinal motility are antagonized by DRUGOTHER and DRUG2. ,metoclopramide,narcotic analgesics,TRUE,effect,2,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,3,12
1024,"Additive sedative effects can occur when DRUG1 is given with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",metoclopramide,alcohol,TRUE,effect,2,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCO,6,10
1025,"Additive sedative effects can occur when DRUG1 is given with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",metoclopramide,tranquilizers,TRUE,effect,2,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,6,15
1026,"Additive sedative effects can occur when DRUGOTHER is given with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",alcohol,tranquilizers,FALSE,Neg,0,CCO,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,10,15
1027,"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUG2, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",digoxin,metoclopramide,TRUE,mechanism,4,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,10,12
1028,"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",digoxin,acetaminophen,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(=O)NC1=CC=C(C=C1)O,10,30
1029,"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",digoxin,tetracycline,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,10,31
1030,"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER). ",digoxin,levodopa,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,10,32
1031,"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER). ",digoxin,ethanol,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCO,10,33
1032,"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2). ",digoxin,cyclosporine,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,10,34
1033,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",metoclopramide,acetaminophen,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CC(=O)NC1=CC=C(C=C1)O,12,30
1034,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",metoclopramide,tetracycline,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,12,31
1035,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER). ",metoclopramide,levodopa,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,12,32
1036,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER). ",metoclopramide,ethanol,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCO,12,33
1037,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2). ",metoclopramide,cyclosporine,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,12,34
1038,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",acetaminophen,tetracycline,FALSE,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,30,31
1039,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER). ",acetaminophen,levodopa,FALSE,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,30,32
1040,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER). ",acetaminophen,ethanol,FALSE,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CCO,30,33
1041,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2). ",acetaminophen,cyclosporine,FALSE,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,30,34
1042,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER). ",tetracycline,levodopa,FALSE,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,31,32
1043,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER). ",tetracycline,ethanol,FALSE,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCO,31,33
1044,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2). ",tetracycline,cyclosporine,FALSE,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,31,34
1045,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER). ",levodopa,ethanol,FALSE,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,CCO,32,33
1046,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2). ",levodopa,cyclosporine,FALSE,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,32,34
1047,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2). ",ethanol,cyclosporine,FALSE,Neg,0,CCO,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,33,34
1048,"Because the action of DRUG1 will influence the delivery of food to the intestines and thus the rate of absorption, DRUG2 dosage or timing of dosage may require adjustment.",metoclopramide,insulin,TRUE,advise,1,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,4,20
1049,DRUG1: DRUG2 and probably other DRUGOTHER given concomitantly with DRUGOTHER can cause unusually large or prolonged losses of fluid and electrolytes. ,Diuretics,Furosemide,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,1
1050,DRUG1: DRUGOTHER and probably other DRUGOTHER given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,Diuretics,metolazone,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,0,9
1051,DRUGOTHER: DRUG1 and probably other DRUGOTHER given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,Furosemide,metolazone,TRUE,effect,2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,1,9
1052,"Other DRUG1: When DRUG2 Tablets are used with other DRUGOTHER, care must be taken, especially during initial therapy. ",Antihypertensives,MYKROX,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,1,3
1053,"Other DRUG1: When DRUGOTHER Tablets are used with other DRUG2, care must be taken, especially during initial therapy. ",Antihypertensives,antihypertensive drugs,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,1,9
1054,"Other DRUGOTHER: When DRUG1 Tablets are used with other DRUG2, care must be taken, especially during initial therapy. ",MYKROX,antihypertensive drugs,TRUE,advise,1,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,3,9
1055,"DRUG1, DRUGOTHER, and DRUGOTHER: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with DRUG2 therapy. ",Alcohol,metolazone,FALSE,Neg,0,CCO,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,0,22
1056,DRUG1 or DRUG2: May increase the risk of hypokalemia and increase salt and water retention. ,Corticosteroids,ACTH,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,0,2
1057,"DRUGOTHER: DRUG1 may decrease arterial responsiveness to DRUG2, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",Metolazone,norepinephrine,TRUE,effect,2,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,C1=CC(=C(C=C1[C@H](CN)O)O)O,1,7
1058,DRUG1: Efficacy may be decreased due to urinary alkalizing effect of DRUG2. ,Methenamine,metolazone,TRUE,effect,2,C1N2CN3CN1CN(C2)C3,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,0,11
1059,"Oral DRUG1 has been reported to potentiate the anticoagulant effect of DRUG2 and DRUGOTHER, resulting in a prolongation of prothrombin time. ",metronidazole,coumarin,TRUE,effect,2,CC1=NC=C(N1CCO)[N+](=O)[O-],C1=CC=C2C(=C1)C=CC(=O)O2,1,11
1060,"Oral DRUG1 has been reported to potentiate the anticoagulant effect of DRUGOTHER and DRUG2, resulting in a prolongation of prothrombin time. ",metronidazole,warfarin,TRUE,effect,2,CC1=NC=C(N1CCO)[N+](=O)[O-],CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,1,13
1061,"Oral DRUGOTHER has been reported to potentiate the anticoagulant effect of DRUG1 and DRUG2, resulting in a prolongation of prothrombin time. ",coumarin,warfarin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC(=O)O2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,11,13
1062,"Drug interactions should be kept in mind when DRUG1 (DRUG2 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical DRUG2 administration because of low absorption.    ",METROGEL,metronidazole,FALSE,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CC1=NC=C(N1CCO)[N+](=O)[O-],8,9
1063,"Drug interactions should be kept in mind when DRUG1 (DRUG2 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical DRUG2 administration because of low absorption.    ",METROGEL,metronidazole,FALSE,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CC1=NC=C(N1CCO)[N+](=O)[O-],8,9
1064,"Drug interactions should be kept in mind when DRUGOTHER (DRUG1 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical DRUG1 administration because of low absorption.    ",metronidazole,metronidazole,FALSE,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CC1=NC=C(N1CCO)[N+](=O)[O-],9,-1
1065,The metabolism of DRUG1 is accelerated by DRUG2; ,Metopirone,phenytoin,TRUE,mechanism,4,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,7
1066,DRUG1 inhibits the glucuronidation of DRUG2 and could possibly potentiate DRUG2 toxicity.,Metopirone,acetaminophen,TRUE,mechanism,4,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(=O)NC1=CC=C(C=C1)O,0,5
1067,DRUG1 inhibits the glucuronidation of DRUG2 and could possibly potentiate DRUG2 toxicity.,Metopirone,acetaminophen,TRUE,effect,2,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(=O)NC1=CC=C(C=C1)O,0,5
1068,DRUGOTHER inhibits the glucuronidation of DRUG1 and could possibly potentiate DRUG1 toxicity.,acetaminophen,acetaminophen,FALSE,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CC(=O)NC1=CC=C(C=C1)O,5,-1
1069,Caution should be observed in administering DRUG1 to patients receiving DRUG2 or DRUGOTHER because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,phenothiazines,TRUE,advise,1,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,N1C2=CC=CC=C2SC2=CC=CC=C12,6,10
1070,Caution should be observed in administering DRUG1 to patients receiving DRUGOTHER or DRUG2 because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,haloperidol,TRUE,advise,1,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,6,12
1071,Caution should be observed in administering DRUGOTHER to patients receiving DRUG1 or DRUG2 because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,phenothiazines,haloperidol,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,10,12
1072,Concurrent use of DRUG1 with DRUG2 or other DRUGOTHER can increase their sedative effects.,DEMSER,alcohol,TRUE,effect,2,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,CCO,3,5
1073,Concurrent use of DRUG1 with DRUGOTHER or other DRUG2 can increase their sedative effects.,DEMSER,CNS depressants,TRUE,effect,2,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,8
1074,Concurrent use of DRUGOTHER with DRUG1 or other DRUG2 can increase their sedative effects.,alcohol,CNS depressants,FALSE,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,8
1075,"Since DRUG1 is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter DRUG2 plasma concentrations. ",MEXITIL,mexiletine,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,1,27
1076,"In a formal, single-dose interaction study (n = 6 males) the clearance of DRUG1 was decreased by 38% following the coadministration of DRUG2, an inhibitor of CYP1A2. ",mexiletine,fluvoxamine,TRUE,mechanism,4,CC1=C(C(=CC=C1)C)OCC(C)N,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,13,22
1077,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of DRUG1 did not alter the kinetics of DRUG2 in the poor CYP2D6 metabolizer group. ",propafenone,mexiletine,FALSE,Neg,0,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CC1=C(C(=CC=C1)C)OCC(C)N,18,25
1078,"In this crossover steady state study, the pharmacokinetics of DRUG1 were unaffected in either phenotype by the coadministration of DRUG2. ",propafenone,mexiletine,FALSE,Neg,0,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CC1=C(C(=CC=C1)C)OCC(C)N,9,19
1079,"Addition of DRUG1 to DRUG2 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than DRUG2 alone. ",mexiletine,propafenone,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,2,4
1080,"Addition of DRUG1 to DRUG2 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than DRUG2 alone. ",mexiletine,propafenone,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,2,4
1081,"Addition of DRUGOTHER to DRUG1 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than DRUG1 alone. ",propafenone,propafenone,FALSE,Neg,0,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,4,-1
1082,"When concomitant administration of either of these two drugs with DRUG1 is initiated, the dose of DRUG1 should be slowly titrated to desired effect. ",mexiletine,mexiletine,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,10,-1
1083,"A variety of DRUGOTHER such as DRUG1 or DRUG2 were also added, sometimes with improved control of ventricular ectopy. ",quinidine,propranolol,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,6,8
1084,"When DRUG1 or other hepatic enzyme inducers such as DRUG2 and DRUGOTHER have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",phenytoin,rifampin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,1,9
1085,"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUG2 have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",phenytoin,phenobarbital,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,1,11
1086,"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",phenytoin,Mexitil,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C(=CC=C1)C)OCC(C)N,1,17
1087,"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",phenytoin,Mexitil,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C(=CC=C1)C)OCC(C)N,1,17
1088,"When DRUGOTHER or other hepatic enzyme inducers such as DRUG1 and DRUG2 have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",rifampin,phenobarbital,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,9,11
1089,"When DRUGOTHER or other hepatic enzyme inducers such as DRUG1 and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",rifampin,Mexitil,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=C(C(=CC=C1)C)OCC(C)N,9,17
1090,"When DRUGOTHER or other hepatic enzyme inducers such as DRUG1 and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",rifampin,Mexitil,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=C(C(=CC=C1)C)OCC(C)N,9,17
1091,"When DRUGOTHER or other hepatic enzyme inducers such as DRUGOTHER and DRUG1 have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",phenobarbital,Mexitil,TRUE,mechanism,4,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC1=C(C(=CC=C1)C)OCC(C)N,11,17
1092,"When DRUGOTHER or other hepatic enzyme inducers such as DRUGOTHER and DRUG1 have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",phenobarbital,Mexitil,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC1=C(C(=CC=C1)C)OCC(C)N,11,17
1093,"When DRUGOTHER or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG1   , lowered DRUG1    plasma levels have been reported. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,17,-1
1094,"In a formal study, DRUG1 were shown not to affect DRUG2    plasma concentrations. ",benzodiazepines,Mexitil,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,CC1=C(C(=CC=C1)C)OCC(C)N,4,10
1095,"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and DRUG2, DRUGOTHER, or DRUGOTHER. ",Mexitil,digoxin,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,11,16
1096,"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and DRUGOTHER, DRUG2, or DRUGOTHER. ",Mexitil,diuretics,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,11,17
1097,"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and DRUGOTHER, DRUGOTHER, or DRUG2. ",Mexitil,propranolol,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,11,19
1098,"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUGOTHER    and DRUG1, DRUG2, or DRUGOTHER. ",digoxin,diuretics,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,16,17
1099,"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUGOTHER    and DRUG1, DRUGOTHER, or DRUG2. ",digoxin,propranolol,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,16,19
1100,"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUGOTHER    and DRUGOTHER, DRUG1, or DRUG2. ",diuretics,propranolol,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,17,19
1101,"Concurrent administration of DRUG1 and DRUG2    has been reported to increase, decrease, or leave unchanged DRUG2    plasma levels; ",cimetidine,Mexitil,TRUE,mechanism,4,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(C(=CC=C1)C)OCC(C)N,3,5
1102,"Concurrent administration of DRUG1 and DRUG2    has been reported to increase, decrease, or leave unchanged DRUG2    plasma levels; ",cimetidine,Mexitil,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(C(=CC=C1)C)OCC(C)N,3,5
1103,"Concurrent administration of DRUGOTHER and DRUG1    has been reported to increase, decrease, or leave unchanged DRUG1    plasma levels; ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,5,-1
1104,"DRUG1    does not alter serum DRUG2 levels but DRUGOTHER, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",Mexitil,digoxin,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,8
1105,"DRUG1    does not alter serum DRUGOTHER levels but DRUGOTHER, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUGOTHER levels. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,0,-1
1106,"DRUG1    does not alter serum DRUG2 levels but DRUGOTHER, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",Mexitil,digoxin,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,8
1107,"DRUG2    does not alter serum DRUG1 levels but DRUGOTHER, when used to treat gastrointestinal symptoms due to DRUG2   , has been reported to lower serum DRUG1 levels. ",digoxin,Mexitil,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=C(C(=CC=C1)C)OCC(C)N,8,0
1108,"DRUGOTHER    does not alter serum DRUG1 levels but DRUGOTHER, when used to treat gastrointestinal symptoms due to DRUGOTHER   , has been reported to lower serum DRUG1 levels. ",digoxin,digoxin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,8,-1
1109,"DRUG1    does not alter serum DRUG2 levels but DRUGOTHER, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",Mexitil,digoxin,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,8
1110,Concurrent use of DRUG1    and DRUG2 may lead to increased plasma DRUG2 levels. ,Mexitil,theophylline,TRUE,mechanism,4,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,8
1111,Concurrent use of DRUG1    and DRUG2 may lead to increased plasma DRUG2 levels. ,Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,8
1112,Concurrent use of DRUGOTHER    and DRUG1 may lead to increased plasma DRUG1 levels. ,theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,-1
1113,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,20
1114,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1115,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1116,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1117,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1118,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1119,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1120,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
1121,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,TRUE,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
1122,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
1123,"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUG1 plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",Theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,42
1124,"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUG1 plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",Theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,42
1125,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
1126,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1127,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1128,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1129,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1130,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1131,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1132,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1133,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1134,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1135,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,TRUE,advise,1,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1136,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
1137,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Mexitil,FALSE,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CC1=C(C(=CC=C1)C)OCC(C)N,16,-1
1138,"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUGOTHER plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,42,-1
1139,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUGOTHER plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",theophylline,Mexitil,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,42,16
1140,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUGOTHER plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",theophylline,Mexitil,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,42,16
1141,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of DRUG1 was decreased 50% following the administration of DRUG2   .",caffeine,Mexitil,TRUE,mechanism,4,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=C(C(=CC=C1)C)OCC(C)N,15,23
1142,"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",Posicor,terfenadine,TRUE,mechanism,4,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,0,13
1143,"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",Posicor,astemizole,TRUE,mechanism,4,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,0,14
1144,"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",Posicor,cisapride,TRUE,mechanism,4,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,0,15
1145,"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",Posicor,cyclosporine,TRUE,mechanism,4,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,16
1146,"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",Posicor,tricyclic antidepressants,TRUE,mechanism,4,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,0,18
1147,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terfenadine,astemizole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,13,14
1148,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",terfenadine,cisapride,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,13,15
1149,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",terfenadine,cyclosporine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,13,16
1150,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",terfenadine,tricyclic antidepressants,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,13,18
1151,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",astemizole,cisapride,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,14,15
1152,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",astemizole,cyclosporine,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,14,16
1153,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",astemizole,tricyclic antidepressants,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,14,18
1154,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",cisapride,cyclosporine,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,15,16
1155,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",cisapride,tricyclic antidepressants,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,15,18
1156,"DRUGOTHER inhibits some of the liver's ability to metabolize some other drugs - DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",cyclosporine,tricyclic antidepressants,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,16,18
1166,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mycophenolate mofetil,cyclosporine,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,22,23
1167,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mycophenolate mofetil,tacrolimus,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,22,24
1168,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mycophenolate mofetil,prednisolone,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,22,25
1169,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mycophenolate mofetil,sirolimus,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,22,26
1170,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mycophenolate mofetil,nifedipine,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,22,27
1171,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",mycophenolate mofetil,fluconazole,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,22,28
1172,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",mycophenolate mofetil,ritonavir,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,22,29
1173,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",mycophenolate mofetil,rifampin,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,22,31
1174,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",cyclosporine,tacrolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,23,24
1175,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",cyclosporine,prednisolone,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,23,25
1176,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",cyclosporine,sirolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,23,26
1177,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",cyclosporine,nifedipine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,23,27
1178,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",cyclosporine,fluconazole,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,23,28
1179,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",cyclosporine,ritonavir,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,23,29
1180,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",cyclosporine,rifampin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,23,31
1181,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tacrolimus,prednisolone,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,24,25
1182,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tacrolimus,sirolimus,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,24,26
1183,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tacrolimus,nifedipine,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,24,27
1184,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",tacrolimus,fluconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,24,28
1185,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",tacrolimus,ritonavir,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,24,29
1186,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",tacrolimus,rifampin,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,24,31
1187,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisolone,sirolimus,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,25,26
1188,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisolone,nifedipine,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,25,27
1189,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",prednisolone,fluconazole,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,25,28
1190,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",prednisolone,ritonavir,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,25,29
1191,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",prednisolone,rifampin,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,25,31
1192,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",sirolimus,nifedipine,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,26,27
1193,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",sirolimus,fluconazole,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,26,28
1194,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",sirolimus,ritonavir,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,26,29
1195,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",sirolimus,rifampin,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,26,31
1196,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",nifedipine,fluconazole,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,27,28
1197,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",nifedipine,ritonavir,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,27,29
1198,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",nifedipine,rifampin,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,27,31
1199,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",fluconazole,ritonavir,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,28,29
1200,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",fluconazole,rifampin,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,28,31
1201,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",ritonavir,rifampin,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,29,31
1202,"There was no effect of a single dose or multiple doses of DRUG1 on DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",MYCAMINE,mycophenolate mofetil,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,12,14
1203,"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",MYCAMINE,cyclosporine,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,12,15
1204,"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",MYCAMINE,tacrolimus,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,12,16
1205,"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER pharmacokinetics. ",MYCAMINE,prednisolone,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,12,17
1206,"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 pharmacokinetics. ",MYCAMINE,fluconazole,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,12,19
1207,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",mycophenolate mofetil,cyclosporine,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,14,15
1208,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",mycophenolate mofetil,tacrolimus,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,14,16
1209,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER pharmacokinetics. ",mycophenolate mofetil,prednisolone,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,14,17
1210,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 pharmacokinetics. ",mycophenolate mofetil,fluconazole,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,14,19
1211,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",cyclosporine,tacrolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,15,16
1212,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER pharmacokinetics. ",cyclosporine,prednisolone,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,15,17
1213,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 pharmacokinetics. ",cyclosporine,fluconazole,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,15,19
1214,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER pharmacokinetics. ",tacrolimus,prednisolone,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,16,17
1215,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 pharmacokinetics. ",tacrolimus,fluconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,16,19
1216,"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 pharmacokinetics. ",prednisolone,fluconazole,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,17,19
1217,DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG2 compared with DRUGOTHER alone. ,Sirolimus,MYCAMINE,TRUE,mechanism,4,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,0,16
1218,DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUGOTHER compared with DRUG2 alone. ,Sirolimus,sirolimus,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,0,19
1219,DRUGOTHER AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG1 compared with DRUG2 alone. ,MYCAMINE,sirolimus,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,16,19
1220,"DRUG1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUG2 compared with DRUGOTHER alone. ",Nifedipine,MYCAMINE,TRUE,mechanism,4,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,0,16
1221,"DRUG1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUGOTHER compared with DRUG2 alone. ",Nifedipine,nifedipine,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,0,19
1222,"DRUGOTHER AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUG1 compared with DRUG2 alone. ",MYCAMINE,nifedipine,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,16,19
1223,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
1224,Patients receiving DRUG1 or DRUGOTHER in combination with DRUG2 should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,MYCAMINE,TRUE,advise,1,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,2,8
1225,Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,sirolimus,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,-1
1226,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
1227,Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,sirolimus,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,-1
1228,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
1229,Patients receiving DRUGOTHER or DRUG1 in combination with DRUG2 should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,nifedipine,MYCAMINE,TRUE,advise,1,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,4,8
1230,Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,nifedipine,sirolimus,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,4,2
1231,Patients receiving DRUGOTHER or DRUG1 in combination with DRUGOTHER should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,nifedipine,nifedipine,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,4,-1
1232,Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,nifedipine,sirolimus,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,4,2
1233,Patients receiving DRUGOTHER or DRUG1 in combination with DRUGOTHER should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,nifedipine,nifedipine,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,4,-1
1234,Patients receiving DRUG2 or DRUGOTHER in combination with DRUG1 should be monitored for DRUG2 or DRUGOTHER toxicity and DRUG2 or DRUGOTHER dosage should be reduced if necessary. ,MYCAMINE,sirolimus,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,8,2
1235,Patients receiving DRUGOTHER or DRUG2 in combination with DRUG1 should be monitored for DRUGOTHER or DRUG2 toxicity and DRUGOTHER or DRUG2 dosage should be reduced if necessary. ,MYCAMINE,nifedipine,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,8,4
1236,Patients receiving DRUG2 or DRUGOTHER in combination with DRUG1 should be monitored for DRUG2 or DRUGOTHER toxicity and DRUG2 or DRUGOTHER dosage should be reduced if necessary. ,MYCAMINE,sirolimus,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,8,2
1237,Patients receiving DRUGOTHER or DRUG2 in combination with DRUG1 should be monitored for DRUGOTHER or DRUG2 toxicity and DRUGOTHER or DRUG2 dosage should be reduced if necessary. ,MYCAMINE,nifedipine,FALSE,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,8,4
1238,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
1239,Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,sirolimus,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,-1
1240,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
1241,Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,nifedipine,sirolimus,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,4,2
1242,Patients receiving DRUGOTHER or DRUG1 in combination with DRUGOTHER should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,nifedipine,nifedipine,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,4,-1
1243,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
1244,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when DRUG1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2). ",midazolam,macrolide antibiotics,TRUE,advise,1,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,10,39
1245,"Drugs such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",erythromycin,diltiazem,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3,4
1246,"Drugs such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",erythromycin,verapamil,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,3,5
1247,"Drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",erythromycin,ketoconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,3,6
1248,"Drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",erythromycin,fluconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,3,7
1249,"Drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",erythromycin,itraconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,3,9
1250,"Drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",erythromycin,midazolam,TRUE,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,3,23
1251,"Drugs such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",diltiazem,verapamil,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,4,5
1252,"Drugs such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",diltiazem,ketoconazole,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,4,6
1253,"Drugs such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",diltiazem,fluconazole,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,4,7
1254,"Drugs such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",diltiazem,itraconazole,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,4,9
1255,"Drugs such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",diltiazem,midazolam,TRUE,mechanism,4,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,4,23
1256,"Drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",verapamil,ketoconazole,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,5,6
1257,"Drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",verapamil,fluconazole,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5,7
1258,"Drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",verapamil,itraconazole,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,5,9
1259,"Drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",verapamil,midazolam,TRUE,mechanism,4,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,5,23
1260,"Drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",ketoconazole,fluconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,6,7
1261,"Drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,6,9
1262,"Drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",ketoconazole,midazolam,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,6,23
1263,"Drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",fluconazole,itraconazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,9
1264,"Drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",fluconazole,midazolam,TRUE,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,7,23
1265,"Drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1 were shown to significantly increase the C max and AUC of orally administered DRUG2. ",itraconazole,midazolam,TRUE,mechanism,4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,9,23
1266,"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and DRUG2 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUGOTHER. ",ritonavir,nelfinavir,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,9,11
1267,"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and DRUGOTHER may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUG2. ",ritonavir,midazolam,TRUE,mechanism,4,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,9,29
1268,"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUGOTHER and DRUG1 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUG2. ",nelfinavir,midazolam,TRUE,mechanism,4,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,11,29
1269,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUG2, and DRUGOTHER, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",rifampin,carbamazepine,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,9,10
1270,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUGOTHER, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",rifampin,phenytoin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,12
1271,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUGOTHER, and DRUGOTHER, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",rifampin,midazolam,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,9,26
1272,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUG1, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",carbamazepine,phenytoin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,12
1273,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUG1, and DRUGOTHER, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",carbamazepine,midazolam,TRUE,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,10,26
1274,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUGOTHER, and DRUG1, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",phenytoin,midazolam,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,12,26
1275,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUG2 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",morphine,meperidine,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,21,22
1276,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",morphine,fentanyl,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,21,24
1277,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",morphine,propofol,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CC(C)C1=C(C(=CC=C1)C(C)C)O,21,25
1278,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",morphine,ketamine,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,21,26
1279,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",morphine,nitrous oxide,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,[N-]=[N+]=O,21,27
1280,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",morphine,secobarbital,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,21,28
1281,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",morphine,droperidol,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,21,30
1282,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",meperidine,fentanyl,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,22,24
1283,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",meperidine,propofol,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CC(C)C1=C(C(=CC=C1)C(C)C)O,22,25
1284,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",meperidine,ketamine,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,22,26
1285,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",meperidine,nitrous oxide,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,[N-]=[N+]=O,22,27
1286,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",meperidine,secobarbital,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,22,28
1287,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",meperidine,droperidol,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,22,30
1288,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",fentanyl,propofol,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC(C)C1=C(C(=CC=C1)C(C)C)O,24,25
1289,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",fentanyl,ketamine,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,24,26
1290,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",fentanyl,nitrous oxide,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,[N-]=[N+]=O,24,27
1291,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",fentanyl,secobarbital,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,24,28
1292,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",fentanyl,droperidol,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,24,30
1293,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",propofol,ketamine,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,25,26
1294,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",propofol,nitrous oxide,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,[N-]=[N+]=O,25,27
1295,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",propofol,secobarbital,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,25,28
1296,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",propofol,droperidol,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,25,30
1297,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER. ",ketamine,nitrous oxide,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,[N-]=[N+]=O,26,27
1298,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER. ",ketamine,secobarbital,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,26,28
1299,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2. ",ketamine,droperidol,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,26,30
1300,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER. ",nitrous oxide,secobarbital,FALSE,Neg,0,[N-]=[N+]=O,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,27,28
1301,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2. ",nitrous oxide,droperidol,FALSE,Neg,0,[N-]=[N+]=O,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,27,30
1302,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2. ",secobarbital,droperidol,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,28,30
1303,"No significant adverse interactions with common premedications (such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",atropine,scopolamine,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,9,10
1304,"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",atropine,glycopyrrolate,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],9,11
1305,"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",atropine,diazepam,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,9,12
1306,"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",atropine,hydroxyzine,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,9,13
1307,"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",atropine,anesthetics,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,9,19
1308,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",scopolamine,glycopyrrolate,FALSE,Neg,0,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],10,11
1309,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",scopolamine,diazepam,FALSE,Neg,0,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,10,12
1310,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",scopolamine,hydroxyzine,FALSE,Neg,0,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,10,13
1311,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",scopolamine,anesthetics,FALSE,Neg,0,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,CCOC(=O)C1=CC=C(N)C=C1,10,19
1312,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",glycopyrrolate,diazepam,FALSE,Neg,0,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,11,12
1313,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",glycopyrrolate,hydroxyzine,FALSE,Neg,0,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,11,13
1314,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",glycopyrrolate,anesthetics,FALSE,Neg,0,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],CCOC(=O)C1=CC=C(N)C=C1,11,19
1315,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",diazepam,hydroxyzine,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,12,13
1316,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",diazepam,anesthetics,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,12,19
1317,"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and other DRUGOTHER) or local DRUG2 have been observed.",hydroxyzine,anesthetics,FALSE,Neg,0,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,CCOC(=O)C1=CC=C(N)C=C1,13,19
1318,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,pseudoephedrine,FALSE,Neg,0,CNC[C@@H](C1=CC(=CC=C1)O)O,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,9,10
1319,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, pseudoDRUG2, DRUG2, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ephedrine,FALSE,Neg,0,CNC[C@@H](C1=CC(=CC=C1)O)O,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,9,10
1320,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,phenylpropanolamine,FALSE,Neg,0,CNC[C@@H](C1=CC(=CC=C1)O)O,C[C@@H]([C@@H](C1=CC=CC=C1)O)N,9,12
1321,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,dihydroergotamine,FALSE,Neg,0,CNC[C@@H](C1=CC(=CC=C1)O)O,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,9,14
1322,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,TRUE,effect,2,CNC[C@@H](C1=CC(=CC=C1)O)O,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,9,23
1323,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,FALSE,Neg,0,CNC[C@@H](C1=CC(=CC=C1)O)O,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,9,23
1324,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ephedrine,FALSE,Neg,0,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,10,11
1325,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,phenylpropanolamine,FALSE,Neg,0,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,C[C@@H]([C@@H](C1=CC=CC=C1)O)N,10,12
1326,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,dihydroergotamine,FALSE,Neg,0,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,10,14
1327,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,TRUE,effect,2,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,10,23
1328,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,FALSE,Neg,0,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,10,23
1329,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, pseudoDRUG1, DRUG1, DRUG2 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,phenylpropanolamine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,C[C@@H]([C@@H](C1=CC=CC=C1)O)N,10,12
1330,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, pseudoDRUG1, DRUG1, DRUGOTHER or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,dihydroergotamine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,10,14
1331,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, pseudoDRUG1, DRUG1, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,TRUE,effect,2,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,10,23
1332,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, pseudoDRUG1, DRUG1, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,10,23
1333,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,dihydroergotamine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)N,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,12,14
1334,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,TRUE,effect,2,C[C@@H]([C@@H](C1=CC=CC=C1)O)N,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,12,23
1335,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)N,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,12,23
1336,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG1) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,TRUE,effect,2,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,14,23
1337,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG1) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,FALSE,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,14,23
1338,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG1   . Therefore, caution should be used when DRUG1    is administered concomitantly with agents that cause vasoconstriction. ",ProAmatine,ProAmatine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,23,-1
1339,"DRUG1    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., DRUG2), with or without salt supplementation. ",ProAmatine,fludrocortisone acetate,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,0,16
1340,"DRUG1. DRUGOTHER, such as DRUG2, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,prazosin,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,0,4
1341,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUG2, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,terazosin,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,0,5
1342,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG2, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,doxazosin,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,0,7
1343,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,ProAmatine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,0,-1
1344,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,desglymidodrine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=CC(=C(C=C1)OC)C(CN)O,0,34
1345,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,metformin,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CN(C)C(=N)N=C(N)N,0,56
1346,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,cimetidine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CC1=C(N=CN1)CSCCNC(=NC)NC#N,0,57
1347,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,ranitidine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,0,58
1348,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,procainamide,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,0,59
1349,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",ProAmatine,triamterene,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,0,60
1350,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",ProAmatine,flecainide,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,0,61
1351,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",ProAmatine,quinidine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,0,63
1352,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUG2, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,terazosin,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,4,5
1353,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUG2, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,doxazosin,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,4,7
1354,"DRUG2. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,ProAmatine,TRUE,effect,2,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,4,0
1355,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,desglymidodrine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COC1=CC(=C(C=C1)OC)C(CN)O,4,34
1356,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,metformin,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,CN(C)C(=N)N=C(N)N,4,56
1357,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,cimetidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,CC1=C(N=CN1)CSCCNC(=NC)NC#N,4,57
1358,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,ranitidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,4,58
1359,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,procainamide,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,4,59
1360,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",prazosin,triamterene,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,4,60
1361,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",prazosin,flecainide,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,4,61
1362,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",prazosin,quinidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,4,63
1363,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUG2, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,doxazosin,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,5,7
1364,"DRUG2. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,ProAmatine,TRUE,effect,2,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,5,0
1365,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,desglymidodrine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=CC(=C(C=C1)OC)C(CN)O,5,34
1366,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,metformin,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CN(C)C(=N)N=C(N)N,5,56
1367,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,cimetidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CC1=C(N=CN1)CSCCNC(=NC)NC#N,5,57
1368,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,ranitidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,5,58
1369,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,procainamide,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,5,59
1370,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",terazosin,triamterene,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,5,60
1371,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",terazosin,flecainide,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,5,61
1372,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",terazosin,quinidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,5,63
1373,"DRUG2. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",doxazosin,ProAmatine,TRUE,effect,2,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,7,0
1374,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",doxazosin,desglymidodrine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COC1=CC(=C(C=C1)OC)C(CN)O,7,34
1375,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",doxazosin,metformin,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,CN(C)C(=N)N=C(N)N,7,56
1376,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",doxazosin,cimetidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,CC1=C(N=CN1)CSCCNC(=NC)NC#N,7,57
1377,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",doxazosin,ranitidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,7,58
1378,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",doxazosin,procainamide,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,7,59
1379,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",doxazosin,triamterene,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,7,60
1380,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",doxazosin,flecainide,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,7,61
1381,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",doxazosin,quinidine,FALSE,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,7,63
1382,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,desglymidodrine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=CC(=C(C=C1)OC)C(CN)O,0,34
1383,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,metformin,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CN(C)C(=N)N=C(N)N,0,56
1384,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,cimetidine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CC1=C(N=CN1)CSCCNC(=NC)NC#N,0,57
1385,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,ranitidine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,0,58
1386,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,procainamide,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,0,59
1387,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",ProAmatine,triamterene,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,0,60
1388,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",ProAmatine,flecainide,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,0,61
1389,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",ProAmatine,quinidine,FALSE,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,0,63
1390,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",desglymidodrine,metformin,TRUE,mechanism,4,COC1=CC(=C(C=C1)OC)C(CN)O,CN(C)C(=N)N=C(N)N,34,56
1391,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",desglymidodrine,cimetidine,TRUE,mechanism,4,COC1=CC(=C(C=C1)OC)C(CN)O,CC1=C(N=CN1)CSCCNC(=NC)NC#N,34,57
1392,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",desglymidodrine,ranitidine,TRUE,mechanism,4,COC1=CC(=C(C=C1)OC)C(CN)O,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,34,58
1393,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",desglymidodrine,procainamide,TRUE,mechanism,4,COC1=CC(=C(C=C1)OC)C(CN)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,34,59
1394,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",desglymidodrine,triamterene,TRUE,mechanism,4,COC1=CC(=C(C=C1)OC)C(CN)O,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,34,60
1395,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",desglymidodrine,flecainide,TRUE,mechanism,4,COC1=CC(=C(C=C1)OC)C(CN)O,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,34,61
1396,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",desglymidodrine,quinidine,TRUE,mechanism,4,COC1=CC(=C(C=C1)OC)C(CN)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,34,63
1397,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",metformin,cimetidine,FALSE,Neg,0,CN(C)C(=N)N=C(N)N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,56,57
1398,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",metformin,ranitidine,FALSE,Neg,0,CN(C)C(=N)N=C(N)N,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,56,58
1399,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",metformin,procainamide,FALSE,Neg,0,CN(C)C(=N)N=C(N)N,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,56,59
1400,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",metformin,triamterene,FALSE,Neg,0,CN(C)C(=N)N=C(N)N,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,56,60
1401,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",metformin,flecainide,FALSE,Neg,0,CN(C)C(=N)N=C(N)N,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,56,61
1402,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",metformin,quinidine,FALSE,Neg,0,CN(C)C(=N)N=C(N)N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,56,63
1403,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",cimetidine,ranitidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,57,58
1404,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",cimetidine,procainamide,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,57,59
1405,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",cimetidine,triamterene,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,57,60
1406,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",cimetidine,flecainide,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,57,61
1407,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",cimetidine,quinidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,57,63
1408,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ranitidine,procainamide,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,58,59
1409,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",ranitidine,triamterene,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,58,60
1410,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",ranitidine,flecainide,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,58,61
1411,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",ranitidine,quinidine,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,58,63
1412,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",procainamide,triamterene,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,59,60
1413,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",procainamide,flecainide,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,59,61
1414,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",procainamide,quinidine,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,59,63
1415,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",triamterene,flecainide,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,60,61
1416,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",triamterene,quinidine,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,60,63
1417,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",flecainide,quinidine,FALSE,Neg,0,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,61,63
1418,"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG2, DRUGOTHER, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",mifepristone,ketoconazole,FALSE,Neg,0,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7,29
1419,"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUG2, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",mifepristone,itraconazole,FALSE,Neg,0,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,30
1420,"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUGOTHER, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",mifepristone,erythromycin,FALSE,Neg,0,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,7,31
1421,"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUGOTHER, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",mifepristone,mifepristone,FALSE,Neg,0,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,7,-1
1422,"Although specific drug or food interactions with DRUGOTHER have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG1, DRUG2, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUGOTHER). ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,29,30
1423,"Although specific drug or food interactions with DRUGOTHER have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG1, DRUGOTHER, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUGOTHER). ",ketoconazole,erythromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,29,31
1424,"Although specific drug or food interactions with DRUG2 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG1, DRUGOTHER, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",ketoconazole,mifepristone,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,29,7
1425,"Although specific drug or food interactions with DRUGOTHER have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUG1, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUGOTHER). ",itraconazole,erythromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,30,31
1426,"Although specific drug or food interactions with DRUG2 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUG1, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",itraconazole,mifepristone,TRUE,mechanism,4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,30,7
1427,"Although specific drug or food interactions with DRUG2 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUGOTHER, DRUG1, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",erythromycin,mifepristone,TRUE,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,31,7
1428,"Furthermore, DRUG1, DRUG2, St. ",rifampin,dexamethasone,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,1,2
1429,"John   s Wort, and certain DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",anticonvulsants,phenytoin,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
1430,"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",anticonvulsants,phenobarbital,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,7,9
1431,"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",anticonvulsants,carbamazepine,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,7,10
1432,"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",anticonvulsants,mifepristone,TRUE,mechanism,4,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,7,13
1433,"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",anticonvulsants,mifepristone,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,7,13
1434,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",phenytoin,phenobarbital,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,8,9
1435,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,8,10
1436,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",phenytoin,mifepristone,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,8,13
1437,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",phenytoin,mifepristone,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,8,13
1438,"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUG1, DRUG2) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",phenobarbital,carbamazepine,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,9,10
1439,"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",phenobarbital,mifepristone,TRUE,mechanism,4,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,9,13
1440,"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",phenobarbital,mifepristone,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,9,13
1441,"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",carbamazepine,mifepristone,TRUE,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,10,13
1442,"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",carbamazepine,mifepristone,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,10,13
1443,"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) may induce DRUG1 metabolism (lowering serum levels of DRUG1). ",mifepristone,mifepristone,FALSE,Neg,0,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,13,-1
1444,"Because DRUG1 have been shown to depress plasma prothrombin activity, patients who are on DRUG2 therapy may require downward adjustment of their DRUG2 dosage. ",tetracyclines,anticoagulant,TRUE,advise,1,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,1,14
1445,"Because DRUG1 have been shown to depress plasma prothrombin activity, patients who are on DRUG2 therapy may require downward adjustment of their DRUG2 dosage. ",tetracyclines,anticoagulant,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,1,14
1446,"Because DRUGOTHER have been shown to depress plasma prothrombin activity, patients who are on DRUG1 therapy may require downward adjustment of their DRUG1 dosage. ",anticoagulant,anticoagulant,FALSE,Neg,0,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,14,-1
1447,"Since bacteriostatic drugs may interfere with the bactericidal action of DRUG1, it is advisable to avoid giving DRUGOTHER in conjunction with DRUG1. ",penicillin,penicillin,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,10,-1
1448,The concurrent use of DRUG1 and DRUG2 has been reported to result in fatal renal toxicity. ,tetracycline,methoxyflurane,TRUE,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC(C(Cl)Cl)(F)F,4,6
1449,Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.,tetracyclines,contraceptives,TRUE,effect,2,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,3,6
1450,Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.,tetracyclines,contraceptives,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,3,6
1451,Concurrent use of DRUGOTHER with oral DRUG1 may render oral DRUG1 less effective.,contraceptives,contraceptives,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,6,-1
1452,"Interaction with DRUG1: Although DRUG2 does not itself cause orthostatic hypotension, its administration to patients already receiving DRUGOTHER can result in profound orthostatic effects. ",Guanethidine,minoxidil,FALSE,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,2,4
1453,"Interaction with DRUG1: Although DRUGOTHER does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG2 can result in profound orthostatic effects. ",Guanethidine,guanethidine,FALSE,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C1CCCN(CCC1)CCN=C(N)N,2,17
1454,"Interaction with DRUGOTHER: Although DRUG1 does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG2 can result in profound orthostatic effects. ",minoxidil,guanethidine,TRUE,effect,2,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,C1CCCN(CCC1)CCN=C(N)N,4,17
1455,If at all possible DRUG1 should be discontinued well before DRUG2 is begun. ,guanethidine,minoxidil,TRUE,advise,1,C1CCCN(CCC1)CCN=C(N)N,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,4,10
1456,Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of DRUG1    (DRUG2) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. ,REMERON SolTab,mirtazapine,FALSE,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,9,13
1457,"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUGOTHER with most other drugs metabolized by these enzymes has not been formally studied. ",mirtazapine,mirtazapine,FALSE,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,7,-1
1458,"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUG2 with most other drugs metabolized by these enzymes has not been formally studied. ",mirtazapine,REMERON SolTab,FALSE,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,7,50
1459,"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUG2 with most other drugs metabolized by these enzymes has not been formally studied. ",mirtazapine,REMERON SolTab,FALSE,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,7,50
1460,DRUG1: Concomitant administration of DRUG2 (equivalent to 60 g) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 6 healthy male subjects. ,Alcohol,alcohol,FALSE,Neg,0,CCO,CCO,0,4
1461,DRUG1: Concomitant administration of DRUGOTHER (equivalent to 60 g) had a minimal effect on plasma levels of DRUG2 (15 mg) in 6 healthy male subjects. ,Alcohol,mirtazapine,FALSE,Neg,0,CCO,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,0,17
1462,DRUGOTHER: Concomitant administration of DRUG1 (equivalent to 60 g) had a minimal effect on plasma levels of DRUG2 (15 mg) in 6 healthy male subjects. ,alcohol,mirtazapine,TRUE,mechanism,4,CCO,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,4,17
1463,"However, the impairment of cognitive and motor skills produced by DRUG1    were shown to be additive with those produced by DRUG2. ",REMERON,alcohol,TRUE,effect,2,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CCO,10,23
1464,"Accordingly, patients should be advised to avoid DRUG1 while taking DRUG2. DRUGOTHER: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",alcohol,REMERON SolTab,TRUE,advise,1,CCO,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,7,10
1465,"Accordingly, patients should be advised to avoid DRUG1 while taking DRUGOTHER. DRUG2: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",alcohol,Diazepam,FALSE,Neg,0,CCO,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,7,11
1466,"Accordingly, patients should be advised to avoid DRUG1 while taking DRUGOTHER. DRUGOTHER: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",alcohol,diazepam,FALSE,Neg,0,CCO,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,7,15
1467,"Accordingly, patients should be advised to avoid DRUG1 while taking DRUGOTHER. DRUGOTHER: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",alcohol,mirtazapine,FALSE,Neg,0,CCO,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,7,26
1468,"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUG1. DRUG2: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",REMERON SolTab,Diazepam,FALSE,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,10,11
1469,"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUG1. DRUGOTHER: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",REMERON SolTab,diazepam,FALSE,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,10,15
1470,"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUG1. DRUGOTHER: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",REMERON SolTab,mirtazapine,FALSE,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,10,26
1471,"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER. DRUG1: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",Diazepam,diazepam,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,11,15
1472,"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER. DRUG1: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",Diazepam,mirtazapine,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,11,26
1473,"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER. DRUGOTHER: Concomitant administration of DRUG1 (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",diazepam,mirtazapine,TRUE,mechanism,4,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,15,26
1474,"However, the impairment of motor skills produced by DRUG1 has been shown to be additive with those caused by DRUG2. ",REMERON,diazepam,TRUE,effect,2,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,8,19
1475,"Accordingly, patients should be advised to avoid DRUG1 and other similar drugs while taking DRUG2.",diazepam,REMERON SolTab,TRUE,advise,1,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,7,14
1476,"DRUG1 has been reported to accelerate the metabolism of DRUG2 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG2. ",Mitotane,warfarin,TRUE,mechanism,4,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,9
1477,"DRUG1 has been reported to accelerate the metabolism of DRUG2 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG2. ",Mitotane,warfarin,FALSE,Neg,0,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,9
1478,"DRUGOTHER has been reported to accelerate the metabolism of DRUG1 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG1. ",warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,9,-1
1479,"Therefore, physicians should closely monitor patients for a change in DRUG1 dosage requirements when administering DRUG2 to patients on coumarin-type DRUG1s. ",anticoagulant,Mitotane,FALSE,Neg,0,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,10,15
1480,"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUGOTHER-facilitated tracheal intubation, the interaction between DRUG1 and DRUGOTHER has not been systematically studied. ",MIVACRON,MIVACRON,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],1,-1
1481,"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUG2-facilitated tracheal intubation, the interaction between DRUG1 and DRUG2 has not been systematically studied. ",MIVACRON,succinylcholine,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,12
1482,"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUG2-facilitated tracheal intubation, the interaction between DRUG1 and DRUG2 has not been systematically studied. ",MIVACRON,succinylcholine,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,12
1483,Evidence of spontaneous recovery from DRUG1 should be observed before the administration of DRUG2. ,succinylcholine,MIVACRON,TRUE,advise,1,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],5,13
1484,The use of DRUG1 before DRUG2 to attenuate some of the side effects of DRUG2 has not been studied. ,MIVACRON,succinylcholine,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,3,5
1485,The use of DRUG1 before DRUG2 to attenuate some of the side effects of DRUG2 has not been studied. ,MIVACRON,succinylcholine,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,3,5
1486,The use of DRUGOTHER before DRUG1 to attenuate some of the side effects of DRUG1 has not been studied. ,succinylcholine,succinylcholine,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,5,-1
1487,DRUG1 and DRUG2 (administered with DRUGOTHER/DRUGOTHER to achieve 1.25 M.C. ,Isoflurane,enflurane,FALSE,Neg,0,C(C(F)(F)F)(OC(F)F)Cl,C(C(OC(F)F)(F)F)(F)Cl,0,2
1488,DRUG1 and DRUGOTHER (administered with DRUG2/DRUGOTHER to achieve 1.25 M.C. ,Isoflurane,nitrous oxide,FALSE,Neg,0,C(C(F)(F)F)(OC(F)F)Cl,[N-]=[N+]=O,0,5
1489,DRUG1 and DRUGOTHER (administered with DRUGOTHER/DRUG2 to achieve 1.25 M.C. ,Isoflurane,oxygen,FALSE,Neg,0,C(C(F)(F)F)(OC(F)F)Cl,O=O,0,5
1490,DRUGOTHER and DRUG1 (administered with DRUG2/DRUGOTHER to achieve 1.25 M.C. ,enflurane,nitrous oxide,FALSE,Neg,0,C(C(OC(F)F)(F)F)(F)Cl,[N-]=[N+]=O,2,5
1491,DRUGOTHER and DRUG1 (administered with DRUGOTHER/DRUG2 to achieve 1.25 M.C. ,enflurane,oxygen,FALSE,Neg,0,C(C(OC(F)F)(F)F)(F)Cl,O=O,2,5
1492,DRUGOTHER and DRUGOTHER (administered with DRUG1/DRUG2 to achieve 1.25 M.C. ,nitrous oxide,oxygen,FALSE,Neg,0,[N-]=[N+]=O,O=O,5,5
1493,A greater potentiation of the neuromuscular blocking effects of DRUG1 may be expected with higher concentrations of DRUG2 or DRUGOTHER. ,MIVACRON,enflurane,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C(C(OC(F)F)(F)F)(F)Cl,9,17
1494,A greater potentiation of the neuromuscular blocking effects of DRUG1 may be expected with higher concentrations of DRUGOTHER or DRUG2. ,MIVACRON,isoflurane,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C(C(F)(F)F)(OC(F)F)Cl,9,19
1495,A greater potentiation of the neuromuscular blocking effects of DRUGOTHER may be expected with higher concentrations of DRUG1 or DRUG2. ,enflurane,isoflurane,FALSE,Neg,0,C(C(OC(F)F)(F)F)(F)Cl,C(C(F)(F)F)(OC(F)F)Cl,17,19
1496,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",MIVACRON,antibiotics,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,13,16
1497,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",MIVACRON,aminoglycosides,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],OC(=O)CCCCCCCC(O)=O,13,18
1498,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",MIVACRON,tetracyclines,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,13,19
1499,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",MIVACRON,lincomycin,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,13,22
1500,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",MIVACRON,clindamycin,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,13,23
1501,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",MIVACRON,colistin,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,13,24
1502,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",MIVACRON,sodium colistimethate,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],13,26
1503,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",MIVACRON,anesthetics,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],CCOC(=O)C1=CC=C(N)C=C1,13,31
1504,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",MIVACRON,procainamide,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,13,32
1505,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",MIVACRON,quinidine,TRUE,int,3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,13,34
1506,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",antibiotics,aminoglycosides,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,OC(=O)CCCCCCCC(O)=O,16,18
1507,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",antibiotics,tetracyclines,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,16,19
1508,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",antibiotics,lincomycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,16,22
1509,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",antibiotics,clindamycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,16,23
1510,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",antibiotics,colistin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,16,24
1511,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",antibiotics,sodium colistimethate,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],16,26
1512,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",antibiotics,anesthetics,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCOC(=O)C1=CC=C(N)C=C1,16,31
1513,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",antibiotics,procainamide,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,16,32
1514,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",antibiotics,quinidine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,16,34
1515,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",aminoglycosides,tetracyclines,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,18,19
1516,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",aminoglycosides,lincomycin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,18,22
1517,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",aminoglycosides,clindamycin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,18,23
1518,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",aminoglycosides,colistin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,18,24
1519,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",aminoglycosides,sodium colistimethate,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],18,26
1520,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",aminoglycosides,anesthetics,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCOC(=O)C1=CC=C(N)C=C1,18,31
1521,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",aminoglycosides,procainamide,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,18,32
1522,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",aminoglycosides,quinidine,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,18,34
1523,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tetracyclines,lincomycin,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,19,22
1524,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tetracyclines,clindamycin,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,19,23
1525,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tetracyclines,colistin,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,19,24
1526,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tetracyclines,sodium colistimethate,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],19,26
1527,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",tetracyclines,anesthetics,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,CCOC(=O)C1=CC=C(N)C=C1,19,31
1528,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",tetracyclines,procainamide,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,19,32
1529,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",tetracyclines,quinidine,FALSE,Neg,0,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,19,34
1530,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",lincomycin,clindamycin,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,22,23
1531,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",lincomycin,colistin,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,22,24
1532,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",lincomycin,sodium colistimethate,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],22,26
1533,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",lincomycin,anesthetics,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCOC(=O)C1=CC=C(N)C=C1,22,31
1534,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",lincomycin,procainamide,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,22,32
1535,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",lincomycin,quinidine,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,22,34
1536,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",clindamycin,colistin,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,23,24
1537,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",clindamycin,sodium colistimethate,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],23,26
1538,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",clindamycin,anesthetics,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCOC(=O)C1=CC=C(N)C=C1,23,31
1539,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",clindamycin,procainamide,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,23,32
1540,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",clindamycin,quinidine,FALSE,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,23,34
1541,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",colistin,sodium colistimethate,FALSE,Neg,0,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],24,26
1542,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",colistin,anesthetics,FALSE,Neg,0,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,CCOC(=O)C1=CC=C(N)C=C1,24,31
1543,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",colistin,procainamide,FALSE,Neg,0,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,24,32
1544,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",colistin,quinidine,FALSE,Neg,0,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,24,34
1545,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",sodium colistimethate,anesthetics,FALSE,Neg,0,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],CCOC(=O)C1=CC=C(N)C=C1,26,31
1546,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",sodium colistimethate,procainamide,FALSE,Neg,0,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,26,32
1547,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",sodium colistimethate,quinidine,FALSE,Neg,0,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,26,34
1548,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG1, DRUG2, and DRUGOTHER. ",anesthetics,procainamide,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,31,32
1549,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG1, DRUGOTHER, and DRUG2. ",anesthetics,quinidine,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,31,34
1550,"Other drugs which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG1, and DRUG2. ",procainamide,quinidine,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,32,34
1551,"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG2, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",MIVACRON,contraceptives,TRUE,effect,2,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,5,20
1552,"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG2, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",MIVACRON,glucocorticoids,TRUE,effect,2,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,5,21
1553,"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG2) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",MIVACRON,monoamine oxidase inhibitors,TRUE,effect,2,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],OC(=O)CCCCCCCC(O)=O,5,24
1554,"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",MIVACRON,phenytoin,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,50
1555,"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",MIVACRON,carbamazepine,FALSE,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,5,52
1556,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUG2, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",contraceptives,glucocorticoids,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,20,21
1557,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUG2) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",contraceptives,monoamine oxidase inhibitors,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,OC(=O)CCCCCCCC(O)=O,20,24
1558,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",contraceptives,phenytoin,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,50
1559,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",contraceptives,carbamazepine,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,20,52
1560,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUG2) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",glucocorticoids,monoamine oxidase inhibitors,FALSE,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,OC(=O)CCCCCCCC(O)=O,21,24
1561,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",glucocorticoids,phenytoin,FALSE,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,50
1562,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",glucocorticoids,carbamazepine,FALSE,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,21,52
1563,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG1) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",monoamine oxidase inhibitors,phenytoin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,50
1564,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG1) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",monoamine oxidase inhibitors,carbamazepine,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,24,52
1565,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG1 or DRUG2. ",phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,50,52
1566,"While the effects of chronic DRUG1 or DRUG2 therapy on the action of DRUGOTHER are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,5,7
1567,"While the effects of chronic DRUG1 or DRUGOTHER therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,MIVACRON,TRUE,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],5,13
1568,"While the effects of chronic DRUGOTHER or DRUG1 therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",carbamazepine,MIVACRON,TRUE,effect,2,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],7,13
1569,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG2 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,phenytoin,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,30
1570,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG2 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,carbamazepine,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,10,32
1571,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG2 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,antibiotics,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,10,35
1572,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,cisplatin,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,N.N.Cl[Pt]Cl,10,40
1573,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,edrophonium,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CC[N+](C)(C)C1=CC(=CC=C1)O,10,42
1574,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,neostigmine,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,10,44
1575,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,polymyxin B,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,10,46
1576,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,corticosteroids,anesthetics,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CCOC(=O)C1=CC=C(N)C=C1,10,51
1577,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,procaine,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,10,54
1578,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,corticosteroids,anesthetics,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CCOC(=O)C1=CC=C(N)C=C1,10,51
1579,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,corticosteroids,succinylcholine,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,10,59
1580,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUG2 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,30,32
1581,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUG2 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,antibiotics,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,30,35
1582,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,cisplatin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,N.N.Cl[Pt]Cl,30,40
1583,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,edrophonium,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[N+](C)(C)C1=CC(=CC=C1)O,30,42
1584,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,neostigmine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,30,44
1585,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,polymyxin B,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,30,46
1586,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,phenytoin,anesthetics,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,30,51
1587,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,procaine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,30,54
1588,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,phenytoin,anesthetics,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,30,51
1589,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,phenytoin,succinylcholine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,30,59
1590,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUG2 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,carbamazepine,antibiotics,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,32,35
1591,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,carbamazepine,cisplatin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,N.N.Cl[Pt]Cl,32,40
1592,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,carbamazepine,edrophonium,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC[N+](C)(C)C1=CC(=CC=C1)O,32,42
1593,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,carbamazepine,neostigmine,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,32,44
1594,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,carbamazepine,polymyxin B,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,32,46
1595,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,carbamazepine,anesthetics,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCOC(=O)C1=CC=C(N)C=C1,32,51
1596,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,carbamazepine,procaine,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,32,54
1597,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,carbamazepine,anesthetics,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCOC(=O)C1=CC=C(N)C=C1,32,51
1598,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,carbamazepine,succinylcholine,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,32,59
1599,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,antibiotics,cisplatin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,N.N.Cl[Pt]Cl,35,40
1600,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,antibiotics,edrophonium,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[N+](C)(C)C1=CC(=CC=C1)O,35,42
1601,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,antibiotics,neostigmine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,35,44
1602,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,antibiotics,polymyxin B,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,35,46
1603,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,antibiotics,anesthetics,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCOC(=O)C1=CC=C(N)C=C1,35,51
1604,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,antibiotics,procaine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,35,54
1605,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,antibiotics,anesthetics,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCOC(=O)C1=CC=C(N)C=C1,35,51
1606,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,antibiotics,succinylcholine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,35,59
1607,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUG2 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,cisplatin,edrophonium,FALSE,Neg,0,N.N.Cl[Pt]Cl,CC[N+](C)(C)C1=CC(=CC=C1)O,40,42
1608,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUG2 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,cisplatin,neostigmine,FALSE,Neg,0,N.N.Cl[Pt]Cl,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,40,44
1609,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,cisplatin,polymyxin B,FALSE,Neg,0,N.N.Cl[Pt]Cl,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,40,46
1610,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,cisplatin,anesthetics,FALSE,Neg,0,N.N.Cl[Pt]Cl,CCOC(=O)C1=CC=C(N)C=C1,40,51
1611,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,cisplatin,procaine,FALSE,Neg,0,N.N.Cl[Pt]Cl,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,40,54
1612,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,cisplatin,anesthetics,FALSE,Neg,0,N.N.Cl[Pt]Cl,CCOC(=O)C1=CC=C(N)C=C1,40,51
1613,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,cisplatin,succinylcholine,FALSE,Neg,0,N.N.Cl[Pt]Cl,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,40,59
1614,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUG2 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,edrophonium,neostigmine,FALSE,Neg,0,CC[N+](C)(C)C1=CC(=CC=C1)O,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,42,44
1615,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,edrophonium,polymyxin B,FALSE,Neg,0,CC[N+](C)(C)C1=CC(=CC=C1)O,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,42,46
1616,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,edrophonium,anesthetics,FALSE,Neg,0,CC[N+](C)(C)C1=CC(=CC=C1)O,CCOC(=O)C1=CC=C(N)C=C1,42,51
1617,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,edrophonium,procaine,FALSE,Neg,0,CC[N+](C)(C)C1=CC(=CC=C1)O,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,42,54
1618,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,edrophonium,anesthetics,FALSE,Neg,0,CC[N+](C)(C)C1=CC(=CC=C1)O,CCOC(=O)C1=CC=C(N)C=C1,42,51
1619,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,edrophonium,succinylcholine,FALSE,Neg,0,CC[N+](C)(C)C1=CC(=CC=C1)O,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,42,59
1620,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,neostigmine,polymyxin B,FALSE,Neg,0,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,44,46
1621,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,neostigmine,anesthetics,FALSE,Neg,0,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,CCOC(=O)C1=CC=C(N)C=C1,44,51
1622,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,neostigmine,procaine,FALSE,Neg,0,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,44,54
1623,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,neostigmine,anesthetics,FALSE,Neg,0,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,CCOC(=O)C1=CC=C(N)C=C1,44,51
1624,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,neostigmine,succinylcholine,FALSE,Neg,0,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,44,59
1625,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG1 or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,polymyxin B,anesthetics,FALSE,Neg,0,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,CCOC(=O)C1=CC=C(N)C=C1,46,51
1626,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG1 or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,polymyxin B,procaine,FALSE,Neg,0,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,46,54
1627,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG1 or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,polymyxin B,anesthetics,FALSE,Neg,0,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,CCOC(=O)C1=CC=C(N)C=C1,46,51
1628,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG1 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,polymyxin B,succinylcholine,FALSE,Neg,0,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,46,59
1629,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG1 such as DRUG2 - general DRUG1 - DRUGOTHER or other DRUGOTHER,anesthetics,procaine,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,51,54
1630,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUGOTHER or other DRUGOTHER,anesthetics,anesthetics,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCOC(=O)C1=CC=C(N)C=C1,51,-1
1631,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUG2 or other DRUGOTHER,anesthetics,succinylcholine,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,51,59
1632,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUG1 - general DRUG2 - DRUGOTHER or other DRUGOTHER,procaine,anesthetics,FALSE,Neg,0,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,CCOC(=O)C1=CC=C(N)C=C1,54,51
1633,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG1 - general DRUGOTHER - DRUG2 or other DRUGOTHER,procaine,succinylcholine,FALSE,Neg,0,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,54,59
1634,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUG2 or other DRUGOTHER,anesthetics,succinylcholine,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,51,59
1635,"The possibility of hypotensive effects with DRUG1    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with DRUG1   . If this is not possible, the starting dose of DRUGOTHER should be reduced.. ",UNIVASC,UNIVASC,FALSE,Neg,0,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,6,-1
1636,"Use of DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",spironolactone,triamterene,FALSE,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,3,4
1637,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",spironolactone,amiloride,FALSE,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,3,5
1638,"Use of DRUGOTHER (DRUGOTHER, DRUG1, DRUG2) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",triamterene,amiloride,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,4,5
1639,Oral DRUGOTHER: Interaction studies with DRUG1 failed to identify any clinically important effect on the serum concentrations of the DRUG2 or on its DRUG2 effect. ,warfarin,anticoagulant,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,5,19
1640,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with DRUG2, DRUGOTHER, or DRUGOTHER. ",UNIVASC,hydrochlorothiazide,FALSE,Neg,0,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,9,17
1641,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with DRUGOTHER, DRUG2, or DRUGOTHER. ",UNIVASC,digoxin,FALSE,Neg,0,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,9,18
1642,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with DRUGOTHER, DRUGOTHER, or DRUG2. ",UNIVASC,cimetidine,FALSE,Neg,0,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,CC1=C(N=CN1)CSCCNC(=NC)NC#N,9,20
1643,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUG1, DRUG2, or DRUGOTHER. ",hydrochlorothiazide,digoxin,FALSE,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,17,18
1644,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUG1, DRUGOTHER, or DRUG2. ",hydrochlorothiazide,cimetidine,FALSE,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,17,20
1645,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUGOTHER, DRUG1, or DRUG2. ",digoxin,cimetidine,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=C(N=CN1)CSCCNC(=NC)NC#N,18,20
1646,"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and cholesterol-lowering agents. ",UNIVASC,diuretics,FALSE,Neg,0,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,0,13
1647,"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER, and cholesterol-lowering agents. ",UNIVASC,digoxin,FALSE,Neg,0,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,15
1648,"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2, and cholesterol-lowering agents. ",UNIVASC,hypoglycemic agents,FALSE,Neg,0,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,0,17
1649,"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, oral DRUGOTHER, and cholesterol-lowering agents. ",diuretics,digoxin,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,13,15
1650,"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUG2, and cholesterol-lowering agents. ",diuretics,hypoglycemic agents,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,13,17
1651,"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUG2, and cholesterol-lowering agents. ",digoxin,hypoglycemic agents,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,15,17
1652,"However, DRUG1, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of DRUG2 during concomitant dosing.",ketoconazole,mometasone furoate,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C,1,14
1653,DRUG1 at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of DRUG2 (predominantly a cytochrome P450 1A2 substrate). ,Montelukast,theophylline,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,31
1654,- did not change the pharmacokinetic profile of DRUG1 (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of DRUG1 on prothrombin time or the INR (International Normalized Ratio). ,warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,-1
1655,"- did not change the plasma concentration profile of DRUG1 (a substrate of cytochrome P450 3A4) or DRUG2, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with DRUG1 60 mg twice daily. ",terfenadine,fexofenadine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,9,17
1656,"- did not change the plasma concentration profile of DRUG1 (a substrate of cytochrome P450 3A4) or DRUGOTHER, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with DRUG1 60 mg twice daily. ",terfenadine,terfenadine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,9,-1
1657,"- did not change the plasma concentration profile of DRUG2 (a substrate of cytochrome P450 3A4) or DRUG1, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with DRUG2 60 mg twice daily. ",fexofenadine,terfenadine,FALSE,Neg,0,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,17,9
1658,DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG2 containing DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg. ,Montelukast,contraceptive,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,0,30
1659,DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUGOTHER containing DRUG2 1 mg/ethinyl DRUGOTHER 35 mcg. ,Montelukast,norethindrone,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,0,32
1660,DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUGOTHER containing DRUGOTHER 1 mg/ethinyl DRUG2 35 mcg. ,Montelukast,estradiol,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,0,35
1661,DRUGOTHER at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG1 containing DRUG2 1 mg/ethinyl DRUGOTHER 35 mcg. ,contraceptive,norethindrone,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,30,32
1662,DRUGOTHER at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG1 containing DRUGOTHER 1 mg/ethinyl DRUG2 35 mcg. ,contraceptive,estradiol,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,30,35
1663,DRUGOTHER at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUGOTHER containing DRUG1 1 mg/ethinyl DRUG2 35 mcg. ,norethindrone,estradiol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,32,35
1664,"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",Phenobarbital,montelukast,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,0,9
1665,"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",Phenobarbital,montelukast,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,0,9
1666,"DRUGOTHER, which induces hepatic metabolism, decreased the AUC of DRUG1 approximately 40% following a single 10-mg dose of DRUG1. ",montelukast,montelukast,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,9,-1
1667,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUG2, are co-administered with DRUGOTHER. ",phenobarbital,rifampin,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,16,18
1668,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUGOTHER, are co-administered with DRUG2. ",phenobarbital,montelukast,TRUE,advise,1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,16,22
1669,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUGOTHER or DRUG1, are co-administered with DRUG2. ",rifampin,montelukast,TRUE,advise,1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,18,22
1670,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",montelukast,theophylline,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,22
1671,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",montelukast,prednisone,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,8,23
1672,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",montelukast,prednisolone,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,8,24
1673,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",montelukast,contraceptives,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,8,26
1674,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",montelukast,norethindrone,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,8,27
1675,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG2 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",montelukast,ethinyl estradiol,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,8,29
1676,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",montelukast,terfenadine,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,8,32
1677,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",montelukast,digoxin,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,8,33
1678,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",montelukast,warfarin,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,35
1679,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUG2, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,prednisone,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,22,23
1680,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUG2, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,prednisolone,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,22,24
1681,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,contraceptives,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,22,26
1682,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,norethindrone,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,22,27
1683,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG2 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,ethinyl estradiol,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,22,29
1684,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",theophylline,terfenadine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,22,32
1685,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",theophylline,digoxin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,22,33
1686,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",theophylline,warfarin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,22,35
1687,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG1, DRUG2, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisone,prednisolone,FALSE,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,23,24
1688,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisone,contraceptives,FALSE,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,23,26
1689,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisone,norethindrone,FALSE,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,23,27
1690,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG2 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisone,ethinyl estradiol,FALSE,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,23,29
1691,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",prednisone,terfenadine,FALSE,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,23,32
1692,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",prednisone,digoxin,FALSE,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,23,33
1693,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",prednisone,warfarin,FALSE,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,23,35
1694,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisolone,contraceptives,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,24,26
1695,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisolone,norethindrone,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,24,27
1696,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG2 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisolone,ethinyl estradiol,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,24,29
1697,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",prednisolone,terfenadine,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,24,32
1698,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",prednisolone,digoxin,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,24,33
1699,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",prednisolone,warfarin,FALSE,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,24,35
1700,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",contraceptives,norethindrone,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,26,27
1701,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/DRUG2 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",contraceptives,ethinyl estradiol,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,26,29
1702,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",contraceptives,terfenadine,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,26,32
1703,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",contraceptives,digoxin,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,26,33
1704,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",contraceptives,warfarin,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,26,35
1705,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/DRUG2 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",norethindrone,ethinyl estradiol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,27,29
1706,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",norethindrone,terfenadine,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,27,32
1707,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",norethindrone,digoxin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,27,33
1708,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",norethindrone,warfarin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,27,35
1709,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG1 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",ethinyl estradiol,terfenadine,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,29,32
1710,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG1 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",ethinyl estradiol,digoxin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,29,33
1711,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG1 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",ethinyl estradiol,warfarin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,29,35
1712,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG1, DRUG2, and DRUGOTHER. ",terfenadine,digoxin,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,32,33
1713,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG1, DRUGOTHER, and DRUG2. ",terfenadine,warfarin,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,32,35
1714,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG1, and DRUG2. ",digoxin,warfarin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,33,35
1715,"These medications included DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",thyroid hormones,non-steroidal anti-inflammatory agents,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,3,5
1716,"These medications included DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",thyroid hormones,benzodiazepines,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,N1N=CC=CC2=CC=CC=C12,3,6
1717,"These medications included DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",non-steroidal anti-inflammatory agents,benzodiazepines,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,N1N=CC=CC2=CC=CC=C12,5,6
1718,"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",Phenobarbital,montelukast,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,0,9
1719,"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",Phenobarbital,montelukast,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,0,9
1720,"DRUGOTHER, which induces hepatic metabolism, decreased the AUC of DRUG1 approximately 40% following a single 10-mg dose of DRUG1. ",montelukast,montelukast,FALSE,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,9,-1
1721,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUG2, are co-administered with DRUGOTHER.",phenobarbital,rifampin,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,16,18
1722,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUGOTHER, are co-administered with DRUG2.",phenobarbital,montelukast,TRUE,advise,1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,16,22
1723,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUGOTHER or DRUG1, are co-administered with DRUG2.",rifampin,montelukast,TRUE,advise,1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,18,22
1724,"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUG2 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",morphine,CNS depressants,TRUE,effect,2,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,16
1725,"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUGOTHER such as DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",morphine,alcohol,TRUE,effect,2,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCO,8,19
1726,"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUG1 such as DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",CNS depressants,alcohol,FALSE,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,16,19
1727,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",pentazocine,nalbuphine,FALSE,Neg,0,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,5,6
1728,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",pentazocine,butorphanol,FALSE,Neg,0,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,5,7
1729,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",pentazocine,buprenorphine,FALSE,Neg,0,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,5,9
1730,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",nalbuphine,butorphanol,FALSE,Neg,0,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,6,7
1731,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",nalbuphine,buprenorphine,FALSE,Neg,0,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,6,9
1732,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",butorphanol,buprenorphine,FALSE,Neg,0,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,7,9
1733,"DRUGOTHER: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUGOTHER containing DRUGOTHER (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",Myfortic,Myfortic,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,7,-1
1734,"DRUG1: When studied in stable renal transplant patients, DRUG2, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUGOTHER. ",Cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,8
1735,"DRUG1: When studied in stable renal transplant patients, DRUGOTHER, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUG2. ",Cyclosporine,Myfortic,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,0,19
1736,"DRUGOTHER: When studied in stable renal transplant patients, DRUG1, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUG2. ",cyclosporine,Myfortic,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,8,19
1737,DRUG1/DRUG2: may be taken with DRUGOTHER; ,Acyclovir,Ganciclovir,FALSE,Neg,0,C1=NC2=C(N1COCCO)N=C(NC2=O)N,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,0,0
1738,DRUG1/DRUGOTHER: may be taken with DRUG2; ,Acyclovir,Myfortic,FALSE,Neg,0,C1=NC2=C(N1COCCO)N=C(NC2=O)N,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,0,5
1739,DRUGOTHER/DRUG1: may be taken with DRUG2; ,Ganciclovir,Myfortic,FALSE,Neg,0,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,0,5
1740,"Both DRUG1/DRUG2 and DRUGOTHER concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",acyclovir,ganciclovir,FALSE,Neg,0,C1=NC2=C(N1COCCO)N=C(NC2=O)N,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,1,1
1741,"Both DRUG1/DRUGOTHER and DRUG2 concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",acyclovir,MPAG,FALSE,Neg,0,C1=NC2=C(N1COCCO)N=C(NC2=O)N,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O,1,3
1742,"Both DRUGOTHER/DRUG1 and DRUG2 concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",ganciclovir,MPAG,FALSE,Neg,0,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O,1,3
1743,"DRUG1/DRUG2: Given that DRUGOTHER and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUGOTHER. ",Azathioprine,Mycophenolate Mofetil,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,0,0
1744,"DRUG1/DRUGOTHER: Given that DRUG2 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUGOTHER. ",Azathioprine,azathioprine,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],0,3
1745,"DRUG1/DRUGOTHER: Given that DRUGOTHER and DRUG2 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUG2. ",Azathioprine,mycophenolate mofetil,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,0,5
1746,"DRUG1/DRUGOTHER: Given that DRUGOTHER and DRUGOTHER inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUGOTHER or DRUGOTHER. ",Azathioprine,Myfortic,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,0,13
1747,"DRUG1/DRUGOTHER: Given that DRUG2 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUGOTHER. ",Azathioprine,azathioprine,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],0,3
1748,"DRUG1/DRUGOTHER: Given that DRUGOTHER and DRUG2 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUG2. ",Azathioprine,mycophenolate mofetil,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,0,5
1749,"DRUGOTHER/DRUG1: Given that DRUG2 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUGOTHER. ",Mycophenolate Mofetil,azathioprine,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],0,3
1750,"DRUGOTHER/DRUG1: Given that DRUGOTHER and DRUG2 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUG2. ",Mycophenolate Mofetil,mycophenolate mofetil,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,0,5
1751,"DRUGOTHER/DRUG1: Given that DRUGOTHER and DRUGOTHER inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUGOTHER or DRUGOTHER. ",Mycophenolate Mofetil,Myfortic,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,0,13
1752,"DRUGOTHER/DRUG1: Given that DRUG2 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUGOTHER. ",Mycophenolate Mofetil,azathioprine,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],0,3
1753,"DRUGOTHER/DRUG1: Given that DRUGOTHER and DRUG2 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUG2. ",Mycophenolate Mofetil,mycophenolate mofetil,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,0,5
1754,"DRUGOTHER/DRUGOTHER: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUG2. ",azathioprine,mycophenolate mofetil,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,3,5
1755,"DRUGOTHER/DRUGOTHER: Given that DRUG1 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUG1 or DRUGOTHER. ",azathioprine,Myfortic,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,3,13
1756,"DRUGOTHER/DRUGOTHER: Given that DRUG1 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER. ",azathioprine,azathioprine,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],3,-1
1757,"DRUGOTHER/DRUGOTHER: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUG2. ",azathioprine,mycophenolate mofetil,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,3,5
1758,"DRUGOTHER/DRUGOTHER: Given that DRUGOTHER and DRUG1 inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUGOTHER or DRUG1. ",mycophenolate mofetil,Myfortic,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,5,13
1759,"DRUGOTHER/DRUGOTHER: Given that DRUG2 and DRUG1 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUG1. ",mycophenolate mofetil,azathioprine,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],5,3
1760,"DRUGOTHER/DRUGOTHER: Given that DRUGOTHER and DRUG1 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUG1. ",mycophenolate mofetil,mycophenolate mofetil,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,5,-1
1761,"DRUGOTHER/DRUGOTHER: Given that DRUG2 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUG1 not be administered concomitantly with DRUG2 or DRUGOTHER. ",Myfortic,azathioprine,TRUE,advise,1,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],13,3
1762,"DRUGOTHER/DRUGOTHER: Given that DRUGOTHER and DRUG2 inhibit purine metabolism, it is recommended that DRUG1 not be administered concomitantly with DRUGOTHER or DRUG2. ",Myfortic,mycophenolate mofetil,TRUE,advise,1,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,13,5
1763,"DRUGOTHER/DRUGOTHER: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUG2. ",azathioprine,mycophenolate mofetil,FALSE,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,3,5
1764,DRUG1 and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce DRUGOTHER exposure when coadministered with DRUG2. ,Cholestyramine,mycophenolate mofetil,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,0,19
1765,"Therefore, do not administer DRUG1 with DRUG2 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral DRUGOTHER, because of the potential to reduce the efficacy of DRUG1. ",Myfortic,cholestyramine,TRUE,advise,1,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,4,6
1766,"Therefore, do not administer DRUG1 with DRUGOTHER or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral DRUGOTHER, because of the potential to reduce the efficacy of DRUG1. ",Myfortic,Myfortic,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,4,-1
1767,"Therefore, do not administer DRUG2 with DRUG1 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral DRUGOTHER, because of the potential to reduce the efficacy of DRUG2. ",cholestyramine,Myfortic,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,6,4
1768,"Oral DRUGOTHER: Given the different metabolism of DRUG1 and oral DRUG2, no drug interaction between these two classes of drug is expected. ",Myfortic,contraceptives,FALSE,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,7,10
1769,"However, in a drug-drug interaction study, mean DRUG1 AUC was decreased by 15% when coadministered with DRUG2. ",levonorgesterol,mycophenolate mofetil,TRUE,mechanism,4,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)CC4=CC[C@H]3[C@@H]1CC[C@]2(C#C)O,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,7,16
1770,"Therefore, it is recommended that oral DRUG1 are co- administered with DRUG2 with caution and additional birth control methods be considered. ",contraceptives,Myfortic,TRUE,advise,1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,6,11
1771,"DRUGOTHER: During treatment with DRUG1, the use of DRUG2 should be avoided and patients should be advised that vaccinations may be less effective. ",Myfortic,live attenuated vaccines,TRUE,advise,1,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,CCN(CC)C(C)C(=O)C1=CC=CC=C1,4,8
1772,"Because DRUG1 is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of DRUG1. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,1,-1
1773,"DRUG1, DRUG2, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,Carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,0,1
1774,"DRUG1, DRUGOTHER, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,Rifampicin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,0,3
1775,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,13
1776,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,0,14
1777,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,rifampicin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,0,16
1778,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Phenytoin,ondansetron,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,0,20
1779,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Phenytoin,ondansetron,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,0,20
1780,"DRUGOTHER, DRUG1, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Carbamazepine,Rifampicin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,1,3
1781,"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Carbamazepine,phenytoin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,13
1782,"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Carbamazepine,carbamazepine,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1,14
1783,"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Carbamazepine,rifampicin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,1,16
1784,"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Carbamazepine,ondansetron,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,1,20
1785,"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Carbamazepine,ondansetron,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,1,20
1786,"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Rifampicin,phenytoin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,13
1787,"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Rifampicin,carbamazepine,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,3,14
1788,"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Rifampicin,rifampicin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,3,16
1789,"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Rifampicin,ondansetron,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,3,20
1790,"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Rifampicin,ondansetron,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,3,20
1791,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,13,14
1792,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",phenytoin,rifampicin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,13,16
1793,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",phenytoin,ondansetron,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,13,20
1794,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",phenytoin,ondansetron,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,13,20
1795,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUG1, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",carbamazepine,rifampicin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,14,16
1796,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUG1, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",carbamazepine,ondansetron,TRUE,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,14,20
1797,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUG1, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",carbamazepine,ondansetron,TRUE,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,14,20
1798,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",rifampicin,ondansetron,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,16,20
1799,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",rifampicin,ondansetron,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,16,20
1800,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG1 was significantly increased and DRUG1 blood concentrations were decreased. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,20,-1
1801,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUG2: Although no pharmacokinetic drug interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,Tramadol,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,11,20
1802,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,11,-1
1803,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,tramadol,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,11,29
1804,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,11,-1
1805,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,tramadol,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,11,29
1806,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,11,-1
1807,"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",Tramadol,ondansetron,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,20,11
1808,"However, on the basis of available data, no dosage adjustment for DRUGOTHER is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUGOTHER and DRUG2 has been observed, data from 2 small studies indicate that DRUGOTHER may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUGOTHER. ",Tramadol,tramadol,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,20,29
1809,"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",Tramadol,ondansetron,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,20,11
1810,"However, on the basis of available data, no dosage adjustment for DRUGOTHER is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUGOTHER and DRUG2 has been observed, data from 2 small studies indicate that DRUGOTHER may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUGOTHER. ",Tramadol,tramadol,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,20,29
1811,"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",Tramadol,ondansetron,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,20,11
1812,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,tramadol,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,11,29
1813,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,11,-1
1814,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,tramadol,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,11,29
1815,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,11,-1
1816,"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",tramadol,ondansetron,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,29,11
1817,"However, on the basis of available data, no dosage adjustment for DRUGOTHER is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUGOTHER and DRUG1 has been observed, data from 2 small studies indicate that DRUGOTHER may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUGOTHER. ",tramadol,tramadol,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,29,-1
1818,"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",tramadol,ondansetron,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,29,11
1819,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,tramadol,TRUE,effect,2,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,11,29
1820,"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",ondansetron,ondansetron,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,11,-1
1821,"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUGOTHER: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",tramadol,ondansetron,FALSE,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,29,11
1822,"In humans, DRUG1, DRUG2, and DRUGOTHER do not affect the pharmacokinetics of DRUGOTHER.  ",carmustine,etoposide,FALSE,Neg,0,C(CCl)NC(=O)N(CCCl)N=O,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,2,3
1823,"In humans, DRUG1, DRUGOTHER, and DRUG2 do not affect the pharmacokinetics of DRUGOTHER.  ",carmustine,cisplatin,FALSE,Neg,0,C(CCl)NC(=O)N(CCCl)N=O,N.N.Cl[Pt]Cl,2,5
1824,"In humans, DRUG1, DRUGOTHER, and DRUGOTHER do not affect the pharmacokinetics of DRUG2.  ",carmustine,ondansetron,FALSE,Neg,0,C(CCl)NC(=O)N(CCCl)N=O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,2,12
1825,"In humans, DRUGOTHER, DRUG1, and DRUG2 do not affect the pharmacokinetics of DRUGOTHER.  ",etoposide,cisplatin,FALSE,Neg,0,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,N.N.Cl[Pt]Cl,3,5
1826,"In humans, DRUGOTHER, DRUG1, and DRUGOTHER do not affect the pharmacokinetics of DRUG2.  ",etoposide,ondansetron,FALSE,Neg,0,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,3,12
1827,"In humans, DRUGOTHER, DRUGOTHER, and DRUG1 do not affect the pharmacokinetics of DRUG2.  ",cisplatin,ondansetron,FALSE,Neg,0,N.N.Cl[Pt]Cl,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,5,12
1828,DRUG1 did not increase blood levels of high-dose DRUG2.,ondansetron,methotrexate,FALSE,Neg,0,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,8
1829,Other DRUGOTHER should not be used concomitantly with DRUG1    (DRUG2 USP) because they may have additive effects. ,Alupent,metaproterenol sulfate,FALSE,Neg,0,CC(C)NCC(C1=CC(=CC(=C1)O)O)O,CC(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O,8,12
1830,"DRUGOTHER should be administered with caution to patients being treated with DRUG1 or DRUG2, since the action of DRUGOTHER on the vascular system may be potentiated.",monoamine oxidase inhibitors,tricyclic antidepressants,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,11,13
1831,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG2 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",Alcohol,XENICAL,FALSE,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,12
1832,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",Alcohol,alcohol,FALSE,Neg,0,CCO,CCO,0,17
1833,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",Alcohol,alcohol,FALSE,Neg,0,CCO,CCO,0,17
1834,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",Alcohol,orlistat,FALSE,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,32
1835,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",Alcohol,orlistat,FALSE,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,32
1836,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",XENICAL,alcohol,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCO,12,17
1837,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",XENICAL,alcohol,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCO,12,17
1838,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",XENICAL,orlistat,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,12,32
1839,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",XENICAL,orlistat,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,12,32
1840,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",alcohol,alcohol,FALSE,Neg,0,CCO,CCO,17,-1
1841,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,FALSE,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
1842,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,FALSE,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
1843,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,FALSE,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
1844,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,FALSE,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
1845,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG1 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG1. ",orlistat,orlistat,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,32,-1
1846,DRUG1: Preliminary data from a DRUG2 and DRUGOTHER drug interaction study indicate a reduction in DRUGOTHER plasma levels when DRUG2 was coadministered with DRUGOTHER. ,Cyclosporine,XENICAL,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,5
1847,DRUG1: Preliminary data from a DRUGOTHER and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUGOTHER was coadministered with DRUG2. ,Cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,7
1848,DRUG1: Preliminary data from a DRUGOTHER and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUGOTHER was coadministered with DRUG2. ,Cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,7
1849,DRUG1: Preliminary data from a DRUG2 and DRUGOTHER drug interaction study indicate a reduction in DRUGOTHER plasma levels when DRUG2 was coadministered with DRUGOTHER. ,Cyclosporine,XENICAL,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,5
1850,DRUG1: Preliminary data from a DRUGOTHER and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUGOTHER was coadministered with DRUG2. ,Cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,7
1851,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
1852,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
1853,DRUGOTHER: Preliminary data from a DRUG1 and DRUGOTHER drug interaction study indicate a reduction in DRUGOTHER plasma levels when DRUG1 was coadministered with DRUGOTHER. ,XENICAL,XENICAL,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,5,-1
1854,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
1855,DRUGOTHER: Preliminary data from a DRUGOTHER and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,7,-1
1856,DRUGOTHER: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,cyclosporine,XENICAL,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,7,5
1857,DRUGOTHER: Preliminary data from a DRUGOTHER and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,7,-1
1858,DRUGOTHER: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,cyclosporine,XENICAL,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,7,5
1859,DRUGOTHER: Preliminary data from a DRUGOTHER and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,7,-1
1860,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,TRUE,mechanism,4,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
1861,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUGOTHER. ",Digoxin,XENICAL,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
1862,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUGOTHER. ",Digoxin,XENICAL,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
1863,"DRUG1: In 12 normal-weight subjects receiving DRUGOTHER 120 mg three times a day for 6 days, DRUGOTHER did not alter the pharmacokinetics of a single dose of DRUG2. ",Digoxin,digoxin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,27
1864,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUGOTHER. ",XENICAL,XENICAL,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,6,-1
1865,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",XENICAL,digoxin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,6,27
1866,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",XENICAL,digoxin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,6,27
1867,DRUGOTHER and Analogues: A pharmacokinetic interaction study showed a 30% reduction in DRUG1 supplement absorption when concomitantly administered with DRUG2. ,beta-carotene,XENICAL,TRUE,mechanism,4,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\C)\C)/C)/C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,12,19
1868,DRUG1 inhibited absorption of a DRUG2 supplement by approximately 60%. ,XENICAL,vitamin E acetate,TRUE,mechanism,4,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OC(=O)C)C,0,5
1869,"The effect of DRUG1 on the absorption of supplemental DRUG2, DRUGOTHER, and nutritionally-derived DRUGOTHER is not known at this time. ",orlistat,vitamin D,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,OC(=O)CCCCCCCC(O)=O,3,9
1870,"The effect of DRUG1 on the absorption of supplemental DRUGOTHER, DRUG2, and nutritionally-derived DRUGOTHER is not known at this time. ",orlistat,vitamin A,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C,3,10
1871,"The effect of DRUG1 on the absorption of supplemental DRUGOTHER, DRUGOTHER, and nutritionally-derived DRUG2 is not known at this time. ",orlistat,vitamin K,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,3,13
1872,"The effect of DRUGOTHER on the absorption of supplemental DRUG1, DRUG2, and nutritionally-derived DRUGOTHER is not known at this time. ",vitamin D,vitamin A,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C,9,10
1873,"The effect of DRUGOTHER on the absorption of supplemental DRUG1, DRUGOTHER, and nutritionally-derived DRUG2 is not known at this time. ",vitamin D,vitamin K,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,9,13
1874,"The effect of DRUGOTHER on the absorption of supplemental DRUGOTHER, DRUG1, and nutritionally-derived DRUG2 is not known at this time. ",vitamin A,vitamin K,FALSE,Neg,0,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,10,13
1875,"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUGOTHER. ",Glyburide,orlistat,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
1876,"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUGOTHER. ",Glyburide,orlistat,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
1877,"DRUG1: In 12 normal-weight subjects receiving DRUGOTHER 80 mg three times a day for 5 days, DRUGOTHER did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG2. ",Glyburide,glyburide,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,0,27
1878,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUGOTHER. ",orlistat,orlistat,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,6,-1
1879,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG2. ",orlistat,glyburide,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,27
1880,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG2. ",orlistat,glyburide,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,27
1881,"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUGOTHER (extended-release tablets). ",Nifedipine,XENICAL,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,8
1882,"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUGOTHER (extended-release tablets). ",Nifedipine,XENICAL,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,8
1883,"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUGOTHER 120 mg three times a day for 6 days, DRUGOTHER did not alter the bioavailability of DRUG2 (extended-release tablets). ",Nifedipine,nifedipine,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,0,25
1884,"DRUGOTHER (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUGOTHER (extended-release tablets). ",XENICAL,XENICAL,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,8,-1
1885,"DRUGOTHER (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",XENICAL,nifedipine,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,8,25
1886,"DRUGOTHER (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",XENICAL,nifedipine,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,8,25
1887,"Oral DRUGOTHER: In 20 normal-weight female subjects, the treatment of DRUG1 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG2. ",XENICAL,contraceptives,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,10,30
1888,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUGOTHER. ",Phenytoin,XENICAL,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
1889,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUGOTHER. ",Phenytoin,XENICAL,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
1890,"DRUG1: In 12 normal-weight subjects receiving DRUGOTHER 120 mg three times a day for 7 days, DRUGOTHER did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",Phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,28
1891,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUGOTHER. ",XENICAL,XENICAL,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,6,-1
1892,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",XENICAL,phenytoin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,28
1893,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",XENICAL,phenytoin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,28
1894,"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUGOTHER. ",Pravastatin,XENICAL,FALSE,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,13
1895,"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUGOTHER. ",Pravastatin,XENICAL,FALSE,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,13
1896,"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUGOTHER 120 mg three times a day for 6 days, DRUGOTHER did not affect the pharmacokinetics of DRUG2. ",Pravastatin,pravastatin,FALSE,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,0,30
1897,"DRUGOTHER: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUGOTHER. ",XENICAL,XENICAL,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,13,-1
1898,"DRUGOTHER: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",XENICAL,pravastatin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,13,30
1899,"DRUGOTHER: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",XENICAL,pravastatin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,13,30
1900,"DRUG1: In 12 normal-weight subjects, administration of DRUG2 120 mg three times a day for 16 days did not result in any change in either DRUGOTHER pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",Warfarin,XENICAL,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,7
1901,"DRUG1: In 12 normal-weight subjects, administration of DRUGOTHER 120 mg three times a day for 16 days did not result in any change in either DRUG2 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",Warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,25
1902,"DRUGOTHER: In 12 normal-weight subjects, administration of DRUG1 120 mg three times a day for 16 days did not result in any change in either DRUG2 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",XENICAL,warfarin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,7,25
1903,"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with DRUG1 administration, vitamin K levels tended to decline in subjects taking DRUG1. ",XENICAL,XENICAL,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,13,-1
1904,"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,TRUE,mechanism,4,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,2,8
1905,"Therefore, as DRUG1 absorption may be decreased with DRUGOTHER, patients on chronic stable doses of DRUG2 who are prescribed DRUGOTHER should be monitored closely for changes in coagulation parameters.",vitamin K,warfarin,FALSE,Neg,0,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,2,15
1906,"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,FALSE,Neg,0,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,2,8
1907,"Therefore, as DRUGOTHER absorption may be decreased with DRUG1, patients on chronic stable doses of DRUG2 who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",XENICAL,warfarin,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,15
1908,"Therefore, as DRUGOTHER absorption may be decreased with DRUG1, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",XENICAL,XENICAL,FALSE,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,8,-1
1909,"Therefore, as DRUGOTHER absorption may be decreased with DRUG2, patients on chronic stable doses of DRUG1 who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",warfarin,XENICAL,TRUE,advise,1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,15,8
1910,"DRUG1, a bacteriostatic DRUGOTHER, may antagonize the bactericidal effect of DRUG2 and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,TRUE,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,0,10
1911,"DRUG1: A multidose study of DRUG2, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",Warfarin,oxandrolone,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,0,5
1912,"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG2, resulted in a mean increase in S-DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG2 half-life and AUC were also detected. ",Warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,20
1913,"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",Warfarin,S-warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)C[C@@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,27
1914,"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUG2 half-life and AUC were also detected. ",Warfarin,R-warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)C[C@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,44
1915,"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG2, resulted in a mean increase in S-DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG2 half-life and AUC were also detected. ",oxandrolone,warfarin,TRUE,mechanism,4,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,20
1916,"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",oxandrolone,S-warfarin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)C[C@@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,27
1917,"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUG2 half-life and AUC were also detected. ",oxandrolone,R-warfarin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)C[C@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,44
1918,"DRUGOTHER: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",warfarin,S-warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)C[C@@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,20,-1
1919,"DRUGOTHER: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",warfarin,R-warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)C[C@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,20,-1
1920,"DRUGOTHER: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUG2 half-life and AUC were also detected. ",S-warfarin,R-warfarin,FALSE,Neg,0,CC(=O)C[C@@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)C[C@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,27,44
1921,"A 5.5-fold decrease in the mean DRUG1 dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of DRUG1 dose), was necessary to maintain a target INR of 1.5. ",warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,-1
1922,"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,TRUE,advise,1,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,1,12
1923,"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,1,12
1924,"When DRUGOTHER therapy is initiated in a patient already receiving treatment with DRUG1, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG1 adjusted as necessary until a stable target INR or PT has been achieved. ",warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,12,-1
1925,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the DRUG1 dosage if indicated are recommended when the DRUG2 dose is changed or discontinued. ",warfarin,oxandrolone,TRUE,advise,1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,17,25
1926,Oral DRUG1 DRUG2 may inhibit the metabolism of oral DRUG1. ,hypoglycemic agents,Oxandrolone,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,1,2
1927,Oral DRUG1 DRUGOTHER may inhibit the metabolism of oral DRUG1. ,hypoglycemic agents,hypoglycemic agents,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,1,-1
1928,Oral DRUG2 DRUG1 may inhibit the metabolism of oral DRUG2. ,Oxandrolone,hypoglycemic agents,TRUE,mechanism,4,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,2,1
1929,"DRUGOTHER or DRUG1 In patients with edema, concomitant administration with DRUGOTHER or DRUG1 may increase the edema. ",ACTH,ACTH,FALSE,Neg,0,NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,2,-1
1930,"Mean DRUG1 plasma concentrations were approximately 2 fold higher when DRUG2 was administered with DRUGOTHER, a potent CYP3A4 inhibitor. ",oxybutynin chloride,DITROPAN XL,FALSE,Neg,0,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,1,10
1931,"Mean DRUG1 plasma concentrations were approximately 2 fold higher when DRUGOTHER was administered with DRUG2, a potent CYP3A4 inhibitor. ",oxybutynin chloride,ketoconazole,FALSE,Neg,0,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,1,14
1932,"Mean DRUGOTHER plasma concentrations were approximately 2 fold higher when DRUG1 was administered with DRUG2, a potent CYP3A4 inhibitor. ",DITROPAN XL,ketoconazole,TRUE,mechanism,4,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,10,14
1933,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUG2) or DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,miconazole,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,13,15
1934,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or DRUG2 (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,macrolide antibiotics,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,13,17
1935,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or DRUGOTHER (e.g., DRUG2 and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,erythromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,13,19
1936,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,clarithromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,13,21
1937,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,oxybutynin,TRUE,mechanism,4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,13,24
1938,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or DRUG2 (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,macrolide antibiotics,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,15,17
1939,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or DRUGOTHER (e.g., DRUG2 and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,erythromycin,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,15,19
1940,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or DRUGOTHER (e.g., DRUGOTHER and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,clarithromycin,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,15,21
1941,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,oxybutynin,TRUE,mechanism,4,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,15,24
1942,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or DRUG1 (e.g., DRUG2 and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,erythromycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,17,19
1943,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or DRUG1 (e.g., DRUGOTHER and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,clarithromycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,17,21
1944,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or DRUG1 (e.g., DRUGOTHER and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,oxybutynin,TRUE,mechanism,4,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,17,24
1945,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or DRUGOTHER (e.g., DRUG1 and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,clarithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,19,21
1946,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or DRUGOTHER (e.g., DRUG1 and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,oxybutynin,TRUE,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,19,24
1947,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER and DRUG1), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",clarithromycin,oxybutynin,TRUE,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,21,24
1948,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",antacid,antacid,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,3,-1
1949,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUG2, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",antacid,aluminum hydroxide,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,[OH-].[OH-].[OH-].[Al+3],3,9
1950,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUG2, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",antacid,magnesium hydroxide,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,[OH-].[OH-].[Mg+2],3,10
1951,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUGOTHER, and DRUG2) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",antacid,simethicone,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,3,12
1952,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or desethylDRUG2.    ",antacid,oxybutynin,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,3,20
1953,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",antacid,desethyloxybutynin,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,3,22
1954,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUG2, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",antacid,aluminum hydroxide,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,[OH-].[OH-].[OH-].[Al+3],3,9
1955,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUG2, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",antacid,magnesium hydroxide,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,[OH-].[OH-].[Mg+2],3,10
1956,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUGOTHER, and DRUG2) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",antacid,simethicone,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,3,12
1957,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or desethylDRUG2.    ",antacid,oxybutynin,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,3,20
1958,"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",antacid,desethyloxybutynin,FALSE,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,3,22
1959,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUG1, DRUG2, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",aluminum hydroxide,magnesium hydroxide,FALSE,Neg,0,[OH-].[OH-].[OH-].[Al+3],[OH-].[OH-].[Mg+2],9,10
1960,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUG1, DRUGOTHER, and DRUG2) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",aluminum hydroxide,simethicone,FALSE,Neg,0,[OH-].[OH-].[OH-].[Al+3],CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,9,12
1961,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUG1, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or desethylDRUG2.    ",aluminum hydroxide,oxybutynin,FALSE,Neg,0,[OH-].[OH-].[OH-].[Al+3],CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,9,20
1962,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUG1, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",aluminum hydroxide,desethyloxybutynin,FALSE,Neg,0,[OH-].[OH-].[OH-].[Al+3],CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,9,22
1963,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER, DRUG1, and DRUG2) did not significantly affect the exposure of DRUGOTHER or desethylDRUGOTHER.    ",magnesium hydroxide,simethicone,FALSE,Neg,0,[OH-].[OH-].[Mg+2],CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,10,12
1964,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER, DRUG1, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or desethylDRUG2.    ",magnesium hydroxide,oxybutynin,FALSE,Neg,0,[OH-].[OH-].[Mg+2],CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,10,20
1965,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER, DRUG1, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",magnesium hydroxide,desethyloxybutynin,FALSE,Neg,0,[OH-].[OH-].[Mg+2],CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,10,22
1966,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER, DRUGOTHER, and DRUG1) did not significantly affect the exposure of DRUG2 or desethylDRUG2.    ",simethicone,oxybutynin,FALSE,Neg,0,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,12,20
1967,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER, DRUGOTHER, and DRUG1) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",simethicone,desethyloxybutynin,FALSE,Neg,0,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,12,22
1968,"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER, DRUGOTHER, and DRUGOTHER) did not significantly affect the exposure of DRUG1 or desethylDRUG1.    ",oxybutynin,desethyloxybutynin,FALSE,Neg,0,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,20,-1
1969,The CNS depressant effects of DRUG1 may be additive with that of other DRUG2..,oxycodone hydrochloride,CNS depressants,TRUE,effect,2,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O.Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,13
1977,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUG2, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",tranquilizers,anesthetics,FALSE,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CCOC(=O)C1=CC=C(N)C=C1,9,11
1978,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUG2, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",tranquilizers,phenothiazines,FALSE,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,N1C2=CC=CC=C2SC2=CC=CC=C12,9,12
1979,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",tranquilizers,opioids,FALSE,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,9,14
1980,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",tranquilizers,tricyclic antidepressants,FALSE,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,9,15
1981,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive CNS depressant effects. ",tranquilizers,monoamine oxidase (MAO) inhibitors,FALSE,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,OC(=O)CCCCCCCC(O)=O,9,16
1982,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive CNS depressant effects. ",tranquilizers,alcohol,FALSE,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CCO,9,18
1983,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUG2, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",anesthetics,phenothiazines,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,N1C2=CC=CC=C2SC2=CC=CC=C12,11,12
1984,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",anesthetics,opioids,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,11,14
1985,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",anesthetics,tricyclic antidepressants,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,11,15
1986,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive CNS depressant effects. ",anesthetics,monoamine oxidase (MAO) inhibitors,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,OC(=O)CCCCCCCC(O)=O,11,16
1987,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive CNS depressant effects. ",anesthetics,alcohol,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCO,11,18
1988,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",phenothiazines,opioids,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,12,14
1989,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",phenothiazines,tricyclic antidepressants,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,12,15
1990,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive CNS depressant effects. ",phenothiazines,monoamine oxidase (MAO) inhibitors,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,OC(=O)CCCCCCCC(O)=O,12,16
1991,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive CNS depressant effects. ",phenothiazines,alcohol,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCO,12,18
1992,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER may produce additive CNS depressant effects. ",opioids,tricyclic antidepressants,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,14,15
1993,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive CNS depressant effects. ",opioids,monoamine oxidase (MAO) inhibitors,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,OC(=O)CCCCCCCC(O)=O,14,16
1994,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive CNS depressant effects. ",opioids,alcohol,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CCO,14,18
1995,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER may produce additive CNS depressant effects. ",tricyclic antidepressants,monoamine oxidase (MAO) inhibitors,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,OC(=O)CCCCCCCC(O)=O,15,16
1996,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 may produce additive CNS depressant effects. ",tricyclic antidepressants,alcohol,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CCO,15,18
1997,"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 may produce additive CNS depressant effects. ",monoamine oxidase (MAO) inhibitors,alcohol,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCO,16,18
1998,It has been reported that the incidence of bradycardia was increased when DRUG1 was combined with DRUG2 for induction of anesthesia. ,oxymorphone,propofol,TRUE,effect,2,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O,CC(C)C1=C(C(=CC=C1)C(C)C)O,12,16
1999,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of DRUG1 with DRUG2; ",cimetidine,opioid analgesics,TRUE,effect,2,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,16,18
2000,Potential for DRUG1    to Affect Other Drugs DRUG2 is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. ,INVEGA,Paliperidone,FALSE,Neg,0,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,2,10
2001,"Given the primary CNS effects of DRUG1, DRUG2    should be used with caution in combination with other DRUGOTHER and DRUGOTHER. ",paliperidone,INVEGA,FALSE,Neg,0,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,6,7
2002,"Given the primary CNS effects of DRUG1, DRUGOTHER    should be used with caution in combination with other DRUG2 and DRUGOTHER. ",paliperidone,centrally acting drugs,TRUE,advise,1,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,6,20
2003,"Given the primary CNS effects of DRUG1, DRUGOTHER    should be used with caution in combination with other DRUGOTHER and DRUG2. ",paliperidone,alcohol,TRUE,advise,1,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CCO,6,22
2004,"Given the primary CNS effects of DRUGOTHER, DRUG1    should be used with caution in combination with other DRUG2 and DRUGOTHER. ",INVEGA,centrally acting drugs,TRUE,advise,1,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,7,20
2005,"Given the primary CNS effects of DRUGOTHER, DRUG1    should be used with caution in combination with other DRUGOTHER and DRUG2. ",INVEGA,alcohol,TRUE,advise,1,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CCO,7,22
2006,"Given the primary CNS effects of DRUGOTHER, DRUGOTHER    should be used with caution in combination with other DRUG1 and DRUG2. ",centrally acting drugs,alcohol,FALSE,Neg,0,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,CCO,20,22
2007,DRUG1 may antagonize the effect of DRUG2 and other DRUGOTHER. ,Paliperidone,levodopa,TRUE,effect,2,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,0,6
2008,"Potential for Other Drugs to Affect DRUG1    DRUG2 is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. ",INVEGA,Paliperidone,FALSE,Neg,0,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,6,10
2033,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,cisapride,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,22,23
2034,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,antipyrine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=CC(=O)N(N1C)C2=CC=CC=C2,22,24
2035,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,caffeine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,22,25
2036,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,carbamazepine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,22,26
2037,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, desmethylDRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,diazepam,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,22,27
2038,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,desmethyldiazepam,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,22,32
2039,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,diclofenac,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,22,33
2040,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,naproxen,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,22,34
2041,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,piroxicam,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,22,35
2042,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,digoxin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,22,36
2043,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,ethanol,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCO,22,37
2044,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,glyburide,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,22,38
2045,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,contraceptive,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,22,41
2046,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,levonorgestrel,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,22,42
2047,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,ethinyl estradiol,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,22,42
2048,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,metoprolol,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,22,43
2049,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,nifedipine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,22,44
2050,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,phenytoin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,22,45
2051,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,warfarin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,22,46
2052,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,midazolam,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,22,47
2053,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",theophylline,clarithromycin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,22,48
2054,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",theophylline,metronidazole,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=NC=C(N1CCO)[N+](=O)[O-],22,49
2055,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",theophylline,amoxicillin,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,22,51
2056,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,antipyrine,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC1=CC(=O)N(N1C)C2=CC=CC=C2,23,24
2057,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,caffeine,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,23,25
2058,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,carbamazepine,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,23,26
2059,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, desmethylDRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,diazepam,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,23,27
2060,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,desmethyldiazepam,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,23,32
2061,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,diclofenac,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,23,33
2062,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,naproxen,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,23,34
2063,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,piroxicam,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,23,35
2064,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,digoxin,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,23,36
2065,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,ethanol,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CCO,23,37
2066,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,glyburide,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,23,38
2067,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,contraceptive,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,23,41
2068,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,levonorgestrel,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,23,42
2069,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,ethinyl estradiol,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,23,42
2070,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,metoprolol,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,23,43
2071,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,nifedipine,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,23,44
2072,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,phenytoin,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,45
2073,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,warfarin,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,23,46
2074,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,midazolam,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,23,47
2075,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",cisapride,clarithromycin,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,23,48
2076,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",cisapride,metronidazole,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC1=NC=C(N1CCO)[N+](=O)[O-],23,49
2077,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",cisapride,amoxicillin,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,23,51
2078,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,caffeine,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,24,25
2079,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,carbamazepine,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,24,26
2080,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, desmethylDRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,diazepam,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,24,27
2081,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,desmethyldiazepam,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,24,32
2082,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,diclofenac,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,24,33
2083,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,naproxen,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,24,34
2084,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,piroxicam,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,24,35
2085,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,digoxin,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,24,36
2086,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,ethanol,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CCO,24,37
2087,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,glyburide,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,24,38
2088,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,contraceptive,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,24,41
2089,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,levonorgestrel,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,24,42
2090,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,ethinyl estradiol,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,24,42
2091,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,metoprolol,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,24,43
2092,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,nifedipine,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,24,44
2093,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,phenytoin,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,45
2094,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,warfarin,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,24,46
2095,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,midazolam,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,24,47
2096,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",antipyrine,clarithromycin,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,24,48
2097,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",antipyrine,metronidazole,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC1=NC=C(N1CCO)[N+](=O)[O-],24,49
2098,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",antipyrine,amoxicillin,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,24,51
2099,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,carbamazepine,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,25,26
2100,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 (and its active metabolite, desmethylDRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,diazepam,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,25,27
2101,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,desmethyldiazepam,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,25,32
2102,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,diclofenac,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,25,33
2103,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,naproxen,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,25,34
2104,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,piroxicam,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,25,35
2105,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,digoxin,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,25,36
2106,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,ethanol,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCO,25,37
2107,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,glyburide,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,25,38
2108,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,contraceptive,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,25,41
2109,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,levonorgestrel,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,25,42
2110,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,ethinyl estradiol,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,25,42
2111,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,metoprolol,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,25,43
2112,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,nifedipine,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,25,44
2113,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,phenytoin,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,45
2114,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,warfarin,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,25,46
2115,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,midazolam,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,25,47
2116,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",caffeine,clarithromycin,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,25,48
2117,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",caffeine,metronidazole,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=NC=C(N1CCO)[N+](=O)[O-],25,49
2118,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",caffeine,amoxicillin,FALSE,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,25,51
2119,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 (and its active metabolite, desmethylDRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,diazepam,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,26,27
2120,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,desmethyldiazepam,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,26,32
2121,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,diclofenac,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,26,33
2122,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,naproxen,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,26,34
2123,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,piroxicam,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,26,35
2124,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,digoxin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,26,36
2125,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,ethanol,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCO,26,37
2126,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,glyburide,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,26,38
2127,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,contraceptive,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,26,41
2128,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,levonorgestrel,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,26,42
2129,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,ethinyl estradiol,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,26,42
2130,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,metoprolol,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,26,43
2131,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,nifedipine,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,26,44
2132,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,phenytoin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,26,45
2133,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,warfarin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,26,46
2134,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,midazolam,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,26,47
2135,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",carbamazepine,clarithromycin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,26,48
2136,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",carbamazepine,metronidazole,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1=NC=C(N1CCO)[N+](=O)[O-],26,49
2137,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",carbamazepine,amoxicillin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,26,51
2138,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,desmethyldiazepam,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,27,-1
2139,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,diclofenac,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,27,33
2140,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,naproxen,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,27,34
2141,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,piroxicam,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,27,35
2142,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,digoxin,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,27,36
2143,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,ethanol,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CCO,27,37
2144,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,glyburide,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,27,38
2145,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,contraceptive,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,27,41
2146,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,levonorgestrel,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,27,42
2147,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,ethinyl estradiol,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,27,42
2148,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,metoprolol,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,27,43
2149,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,nifedipine,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,27,44
2150,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,phenytoin,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,27,45
2151,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,warfarin,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,27,46
2152,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,midazolam,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,27,47
2153,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",diazepam,clarithromycin,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,27,48
2154,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",diazepam,metronidazole,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC1=NC=C(N1CCO)[N+](=O)[O-],27,49
2155,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",diazepam,amoxicillin,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,27,51
2156,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,diclofenac,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,32,33
2157,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,naproxen,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,32,34
2158,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,piroxicam,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,32,35
2159,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,digoxin,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,32,36
2160,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,ethanol,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CCO,32,37
2161,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,glyburide,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,32,38
2162,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,contraceptive,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,32,41
2163,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,levonorgestrel,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,32,42
2164,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,ethinyl estradiol,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,32,42
2165,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,metoprolol,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,32,43
2166,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,nifedipine,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,32,44
2167,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,phenytoin,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,32,45
2168,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,warfarin,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,32,46
2169,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,midazolam,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,32,47
2170,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,clarithromycin,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,32,48
2171,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",desmethyldiazepam,metronidazole,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC1=NC=C(N1CCO)[N+](=O)[O-],32,49
2172,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",desmethyldiazepam,amoxicillin,FALSE,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,32,51
2173,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,naproxen,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,33,34
2174,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,piroxicam,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,33,35
2175,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,digoxin,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,33,36
2176,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,ethanol,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CCO,33,37
2177,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,glyburide,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,33,38
2178,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,contraceptive,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,33,41
2179,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,levonorgestrel,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,33,42
2180,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,ethinyl estradiol,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,33,42
2181,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,metoprolol,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,33,43
2182,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,nifedipine,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,33,44
2183,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,phenytoin,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,33,45
2184,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,warfarin,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,33,46
2185,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,midazolam,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,33,47
2186,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",diclofenac,clarithromycin,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,33,48
2187,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",diclofenac,metronidazole,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC1=NC=C(N1CCO)[N+](=O)[O-],33,49
2188,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",diclofenac,amoxicillin,FALSE,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,33,51
2189,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,piroxicam,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,34,35
2190,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,digoxin,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,34,36
2191,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,ethanol,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CCO,34,37
2192,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,glyburide,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,34,38
2193,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,contraceptive,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,34,41
2194,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,levonorgestrel,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,34,42
2195,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,ethinyl estradiol,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,34,42
2196,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,metoprolol,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,34,43
2197,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,nifedipine,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,34,44
2198,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,phenytoin,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,34,45
2199,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,warfarin,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,34,46
2200,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,midazolam,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,34,47
2201,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",naproxen,clarithromycin,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,34,48
2202,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",naproxen,metronidazole,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC1=NC=C(N1CCO)[N+](=O)[O-],34,49
2203,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",naproxen,amoxicillin,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,34,51
2204,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,digoxin,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,35,36
2205,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,ethanol,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CCO,35,37
2206,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,glyburide,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,35,38
2207,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,contraceptive,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,35,41
2208,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,levonorgestrel,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,35,42
2209,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,ethinyl estradiol,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,35,42
2210,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,metoprolol,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,35,43
2211,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,nifedipine,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,35,44
2212,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,phenytoin,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,35,45
2213,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,warfarin,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,35,46
2214,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,midazolam,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,35,47
2215,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",piroxicam,clarithromycin,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,35,48
2216,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",piroxicam,metronidazole,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC1=NC=C(N1CCO)[N+](=O)[O-],35,49
2217,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",piroxicam,amoxicillin,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,35,51
2218,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,ethanol,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCO,36,37
2219,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,glyburide,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,36,38
2220,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,contraceptive,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,36,41
2221,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,levonorgestrel,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,36,42
2222,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,ethinyl estradiol,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,36,42
2223,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,metoprolol,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,36,43
2224,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,nifedipine,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,36,44
2225,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,phenytoin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,36,45
2226,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,warfarin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,36,46
2227,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,midazolam,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,36,47
2228,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",digoxin,clarithromycin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,36,48
2229,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",digoxin,metronidazole,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=NC=C(N1CCO)[N+](=O)[O-],36,49
2230,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",digoxin,amoxicillin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,36,51
2231,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,glyburide,FALSE,Neg,0,CCO,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,37,38
2232,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,contraceptive,FALSE,Neg,0,CCO,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,37,41
2233,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,levonorgestrel,FALSE,Neg,0,CCO,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,37,42
2234,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,ethinyl estradiol,FALSE,Neg,0,CCO,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,37,42
2235,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,metoprolol,FALSE,Neg,0,CCO,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,37,43
2236,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,nifedipine,FALSE,Neg,0,CCO,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,37,44
2237,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,phenytoin,FALSE,Neg,0,CCO,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,37,45
2238,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,warfarin,FALSE,Neg,0,CCO,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,37,46
2239,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,midazolam,FALSE,Neg,0,CCO,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,37,47
2240,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",ethanol,clarithromycin,FALSE,Neg,0,CCO,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,37,48
2241,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",ethanol,metronidazole,FALSE,Neg,0,CCO,CC1=NC=C(N1CCO)[N+](=O)[O-],37,49
2242,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",ethanol,amoxicillin,FALSE,Neg,0,CCO,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,37,51
2243,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,contraceptive,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,38,41
2244,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,levonorgestrel,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,38,42
2245,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,ethinyl estradiol,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,38,42
2246,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,metoprolol,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,38,43
2247,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,nifedipine,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,38,44
2248,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,phenytoin,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,38,45
2249,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,warfarin,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,38,46
2250,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,midazolam,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,38,47
2251,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",glyburide,clarithromycin,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,38,48
2252,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",glyburide,metronidazole,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC1=NC=C(N1CCO)[N+](=O)[O-],38,49
2253,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",glyburide,amoxicillin,FALSE,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,38,51
2254,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,levonorgestrel,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,41,42
2255,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,ethinyl estradiol,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,41,42
2256,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,metoprolol,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,41,43
2257,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,nifedipine,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,41,44
2258,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,phenytoin,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,41,45
2259,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,warfarin,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,41,46
2260,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,midazolam,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,41,47
2261,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",contraceptive,clarithromycin,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,41,48
2262,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",contraceptive,metronidazole,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC1=NC=C(N1CCO)[N+](=O)[O-],41,49
2263,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",contraceptive,amoxicillin,FALSE,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,41,51
2264,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,ethinyl estradiol,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,42,42
2265,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,metoprolol,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,42,43
2266,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,nifedipine,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,42,44
2267,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,phenytoin,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,42,45
2268,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,warfarin,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,42,46
2269,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,midazolam,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,42,47
2270,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,clarithromycin,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,42,48
2271,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",levonorgestrel,metronidazole,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC1=NC=C(N1CCO)[N+](=O)[O-],42,49
2272,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",levonorgestrel,amoxicillin,FALSE,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,42,51
2273,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethinyl estradiol,metoprolol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,42,43
2274,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethinyl estradiol,nifedipine,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,42,44
2275,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethinyl estradiol,phenytoin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,42,45
2276,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethinyl estradiol,warfarin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,42,46
2277,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethinyl estradiol,midazolam,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,42,47
2278,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",ethinyl estradiol,clarithromycin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,42,48
2279,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",ethinyl estradiol,metronidazole,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC1=NC=C(N1CCO)[N+](=O)[O-],42,49
2280,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",ethinyl estradiol,amoxicillin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,42,51
2281,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",metoprolol,nifedipine,FALSE,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,43,44
2282,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",metoprolol,phenytoin,FALSE,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,43,45
2283,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",metoprolol,warfarin,FALSE,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,43,46
2284,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",metoprolol,midazolam,FALSE,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,43,47
2285,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",metoprolol,clarithromycin,FALSE,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,43,48
2286,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",metoprolol,metronidazole,FALSE,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CC1=NC=C(N1CCO)[N+](=O)[O-],43,49
2287,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",metoprolol,amoxicillin,FALSE,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,43,51
2288,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",nifedipine,phenytoin,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,44,45
2289,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",nifedipine,warfarin,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,44,46
2290,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",nifedipine,midazolam,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,44,47
2291,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",nifedipine,clarithromycin,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,44,48
2292,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",nifedipine,metronidazole,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1=NC=C(N1CCO)[N+](=O)[O-],44,49
2293,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",nifedipine,amoxicillin,FALSE,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,44,51
2294,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",phenytoin,warfarin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,45,46
2295,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",phenytoin,midazolam,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,45,47
2296,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",phenytoin,clarithromycin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,45,48
2297,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",phenytoin,metronidazole,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=C(N1CCO)[N+](=O)[O-],45,49
2298,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",phenytoin,amoxicillin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,45,51
2299,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",warfarin,midazolam,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,46,47
2300,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",warfarin,clarithromycin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,46,48
2301,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",warfarin,metronidazole,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC1=NC=C(N1CCO)[N+](=O)[O-],46,49
2302,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",warfarin,amoxicillin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,46,51
2303,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",midazolam,clarithromycin,FALSE,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,47,48
2304,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",midazolam,metronidazole,FALSE,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CC1=NC=C(N1CCO)[N+](=O)[O-],47,49
2305,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",midazolam,amoxicillin,FALSE,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,47,51
2306,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",clarithromycin,metronidazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC1=NC=C(N1CCO)[N+](=O)[O-],48,49
2307,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",clarithromycin,amoxicillin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,48,51
2308,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",metronidazole,amoxicillin,FALSE,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,49,51
2309,"Therefore, when coadministered with DRUG1, adjustment of the dosage of DRUG1 or of such drugs may not be necessary. ",pantoprazole,pantoprazole,FALSE,Neg,0,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,4,-1
2310,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving DRUGOTHER, including DRUG1, and DRUG2 concomitantly. ",pantoprazole,warfarin,TRUE,effect,2,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,16,18
2311,"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, DRUG2, DRUGOTHER esters, and DRUGOTHER salts). ",pantoprazole,ketoconazole,TRUE,mechanism,4,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,29
2312,"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, DRUGOTHER, DRUG2 esters, and DRUGOTHER salts). ",pantoprazole,ampicillin,TRUE,mechanism,4,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,11,30
2313,"Because of profound and long lasting inhibition of gastric acid secretion, DRUGOTHER may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, DRUG1, DRUG2 esters, and DRUGOTHER salts). ",ketoconazole,ampicillin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,29,30
2314,"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (DRUG2) in patients receiving most DRUGOTHER, including DRUGOTHER. ",tetrahydrocannabinol,THC,FALSE,Neg,0,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,12,13
2315,"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (DRUGOTHER) in patients receiving most DRUGOTHER, including DRUG2. ",tetrahydrocannabinol,pantoprazole,FALSE,Neg,0,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,12,20
2316,"Laboratory Tests There have been reports of false-positive urine screening tests for DRUGOTHER (DRUG1) in patients receiving most DRUGOTHER, including DRUG2. ",THC,pantoprazole,FALSE,Neg,0,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,13,20
2317,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,paricalcitol,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,8,11
2318,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,paricalcitol,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,8,11
2319,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ketoconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8,-1
2320,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,paricalcitol,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,8,11
2321,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ketoconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8,-1
2322,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,atazanavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,8,54
2323,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,clarithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,8,55
2324,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,indinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,8,56
2325,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,8,57
2326,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nefazodone,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,58
2327,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nelfinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,8,59
2328,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ritonavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,60
2329,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",ketoconazole,saquinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,61
2330,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",ketoconazole,telithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,8,62
2331,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",ketoconazole,voriconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,8,64
2332,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,paricalcitol,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,11,-1
2333,"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ketoconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,8
2334,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,paricalcitol,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,11,-1
2335,"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ketoconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,8
2336,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,atazanavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,11,54
2337,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,clarithromycin,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,11,55
2338,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,indinavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,11,56
2339,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,itraconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,11,57
2340,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nefazodone,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,58
2341,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nelfinavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,11,59
2342,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ritonavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,60
2343,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",paricalcitol,saquinavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,61
2344,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",paricalcitol,telithromycin,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,62
2345,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",paricalcitol,voriconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,11,64
2346,"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ketoconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,8
2347,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,paricalcitol,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,11,-1
2348,"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ketoconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,8
2349,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,atazanavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,11,54
2350,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,clarithromycin,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,11,55
2351,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,indinavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,11,56
2352,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,itraconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,11,57
2353,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nefazodone,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,58
2354,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nelfinavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,11,59
2355,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ritonavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,60
2356,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",paricalcitol,saquinavir,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,61
2357,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",paricalcitol,telithromycin,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,62
2358,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",paricalcitol,voriconazole,FALSE,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,11,64
2359,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,paricalcitol,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,8,11
2360,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ketoconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8,-1
2361,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,atazanavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,8,54
2362,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,clarithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,8,55
2363,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,indinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,8,56
2364,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,8,57
2365,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nefazodone,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,58
2366,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nelfinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,8,59
2367,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ritonavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,60
2368,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",ketoconazole,saquinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,61
2369,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",ketoconazole,telithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,8,62
2370,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",ketoconazole,voriconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,8,64
2371,"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ketoconazole,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,8
2372,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,atazanavir,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,11,54
2373,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,clarithromycin,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,11,55
2374,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,indinavir,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,11,56
2375,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,itraconazole,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,11,57
2376,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nefazodone,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,58
2377,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nelfinavir,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,11,59
2378,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ritonavir,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,60
2379,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",paricalcitol,saquinavir,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,61
2380,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",paricalcitol,telithromycin,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,62
2381,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",paricalcitol,voriconazole,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,11,64
2382,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,atazanavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,8,54
2383,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,clarithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,8,55
2384,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,indinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,8,56
2385,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,8,57
2386,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nefazodone,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,58
2387,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nelfinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,8,59
2388,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ritonavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,60
2389,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",ketoconazole,saquinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,61
2390,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",ketoconazole,telithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,8,62
2391,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",ketoconazole,voriconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,8,64
2392,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,clarithromycin,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,54,55
2393,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,indinavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,54,56
2394,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,itraconazole,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,54,57
2395,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,nefazodone,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,54,58
2396,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,nelfinavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,54,59
2397,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,ritonavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,54,60
2398,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",atazanavir,saquinavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,54,61
2399,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",atazanavir,telithromycin,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,54,62
2400,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",atazanavir,voriconazole,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,54,64
2401,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",clarithromycin,indinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,55,56
2402,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",clarithromycin,itraconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,55,57
2403,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",clarithromycin,nefazodone,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,55,58
2404,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",clarithromycin,nelfinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,55,59
2405,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",clarithromycin,ritonavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,55,60
2406,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",clarithromycin,saquinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,55,61
2407,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",clarithromycin,telithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,55,62
2408,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",clarithromycin,voriconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,55,64
2409,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",indinavir,itraconazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,56,57
2410,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",indinavir,nefazodone,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,56,58
2411,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",indinavir,nelfinavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,56,59
2412,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",indinavir,ritonavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,56,60
2413,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",indinavir,saquinavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,56,61
2414,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",indinavir,telithromycin,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,56,62
2415,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",indinavir,voriconazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,56,64
2416,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",itraconazole,nefazodone,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,57,58
2417,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",itraconazole,nelfinavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,57,59
2418,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",itraconazole,ritonavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,57,60
2419,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",itraconazole,saquinavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,57,61
2420,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",itraconazole,telithromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,57,62
2421,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",itraconazole,voriconazole,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,57,64
2422,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",nefazodone,nelfinavir,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,58,59
2423,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",nefazodone,ritonavir,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,58,60
2424,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",nefazodone,saquinavir,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,58,61
2425,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",nefazodone,telithromycin,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,58,62
2426,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",nefazodone,voriconazole,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,58,64
2427,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",nelfinavir,ritonavir,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,59,60
2428,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",nelfinavir,saquinavir,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,59,61
2429,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",nelfinavir,telithromycin,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,59,62
2430,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",nelfinavir,voriconazole,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,59,64
2431,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER or DRUGOTHER. ",ritonavir,saquinavir,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,60,61
2432,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 or DRUGOTHER. ",ritonavir,telithromycin,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,60,62
2433,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2. ",ritonavir,voriconazole,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,60,64
2434,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 or DRUGOTHER. ",saquinavir,telithromycin,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,61,62
2435,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUG2. ",saquinavir,voriconazole,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,61,64
2436,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2. ",telithromycin,voriconazole,FALSE,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,62,64
2437,"Dose adjustment of DRUG1 Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as DRUG2. ",Zemplar,ketoconazole,TRUE,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,3,32
2438,"Drugs that impair intestinal absorption of DRUGOTHER, such as DRUG1, may interfere with the absorption of DRUG2 Capsules.",cholestyramine,Zemplar,TRUE,mechanism,4,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,9,16
2439,"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving DRUG1, treatment with DRUGOTHER once weekly for 4 weeks was associated with a mean increase of 16% in DRUG1 AUC; ",methadone,methadone,FALSE,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,12,-1
2440,"In clinical studies, patients on DRUG1 often needed higher serum DRUGOTHER concentrations to achieve appropriate IGF-I suppression compared with patients not receiving DRUG1. ",opioids,opioids,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,5,-1
2441,"Concomitant administration of substances that are also tubularly secreted (e.g., DRUG1) could potentially result in delayed clearance of DRUG2. ",probenecid,ALIMTA,TRUE,mechanism,4,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,10,18
2442,"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",ibuprofen,ALIMTA,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,1,9
2443,"Although DRUG1 (400 mg qid) can be administered with DRUGOTHER in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUGOTHER to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",ibuprofen,ibuprofen,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,1,-1
2444,"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",ibuprofen,ALIMTA,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,1,9
2445,"Although DRUG2 (400 mg qid) can be administered with DRUG1 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG2 concurrently with DRUG1 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",ALIMTA,ibuprofen,FALSE,Neg,0,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,9,1
2446,"Although DRUGOTHER (400 mg qid) can be administered with DRUG1 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUGOTHER concurrently with DRUG1 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",ALIMTA,ALIMTA,FALSE,Neg,0,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,9,-1
2447,"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",ibuprofen,ALIMTA,TRUE,advise,1,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,1,9
2448,"In the absence of data regarding potential interaction between DRUG1 and DRUGOTHER with longer half-lives, all patients taking these DRUGOTHER should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG1 administration. ",ALIMTA,ALIMTA,FALSE,Neg,0,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,9,-1
2449,The interaction of DRUG1 (DRUG2) with other drugs has not been studied in humans. ,CYLERT,pemoline,FALSE,Neg,0,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,3,4
2450,"Concurrent administration of DRUGOTHER (e.g., DRUG1, DRUG2) may diminish the bactericidal effects of DRUGOTHER by slowing the rate of bacterial growth. ",erythromycin,tetracycline,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,5,6
2451,"Concurrent administration of DRUGOTHER (e.g., DRUG1, DRUGOTHER) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",erythromycin,penicillins,TRUE,effect,2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,5,13
2452,"Concurrent administration of DRUGOTHER (e.g., DRUGOTHER, DRUG1) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",tetracycline,penicillins,TRUE,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,6,13
2453,DRUG1 blood levels may be prolonged by concurrent administration of DRUG2 which blocks the renal tubular secretion of DRUGOTHER. ,Penicillin,probenecid,TRUE,mechanism,4,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,0,10
2454,DRUG1 blood levels may be prolonged by concurrent administration of DRUGOTHER which blocks the renal tubular secretion of DRUG2. ,Penicillin,penicillins,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,18
2455,DRUGOTHER blood levels may be prolonged by concurrent administration of DRUG1 which blocks the renal tubular secretion of DRUG2. ,probenecid,penicillins,FALSE,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,10,18
2456,Displacement of DRUG1 from plasma protein binding sites will elevate the level of free DRUG1 in the serum.,penicillin,penicillin,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,2,-1
2457,"Usage with DRUG1: Due to the potential for increased CNS depressants effects, DRUG2 should be used with caution in patients who are currently receiving DRUGOTHER.",Alcohol,alcohol,FALSE,Neg,0,CCO,CCO,2,12
2458,"Usage with DRUG1: Due to the potential for increased CNS depressants effects, DRUGOTHER should be used with caution in patients who are currently receiving DRUG2.",Alcohol,pentazocine,FALSE,Neg,0,CCO,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,2,24
2459,"Usage with DRUGOTHER: Due to the potential for increased CNS depressants effects, DRUG1 should be used with caution in patients who are currently receiving DRUG2.",alcohol,pentazocine,TRUE,advise,1,CCO,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,12,24
2460,Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,TRENTAL,theophylline,TRUE,mechanism,4,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,5
2461,Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,TRENTAL,theophylline,FALSE,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,5
2462,Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,TRENTAL,theophylline,FALSE,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,5
2463,Concomitant administration of DRUGOTHER and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
2464,Concomitant administration of DRUGOTHER and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
2465,Concomitant administration of DRUGOTHER and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,theophylline,theophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
2466,"DRUG1 has been used concurrently with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",TRENTAL,antihypertensive drugs,FALSE,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,6
2467,"DRUG1 has been used concurrently with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",TRENTAL,digitalis,FALSE,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0,8
2468,"DRUG1 has been used concurrently with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",TRENTAL,diuretics,FALSE,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,0,9
2469,"DRUG1 has been used concurrently with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",TRENTAL,antidiabetic agents,FALSE,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,0,10
2470,"DRUGOTHER has been used concurrently with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",antihypertensive drugs,digitalis,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,6,8
2471,"DRUGOTHER has been used concurrently with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",antihypertensive drugs,diuretics,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,6,9
2472,"DRUGOTHER has been used concurrently with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",antihypertensive drugs,antidiabetic agents,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,6,10
2473,"DRUGOTHER has been used concurrently with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",digitalis,diuretics,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,8,9
2474,"DRUGOTHER has been used concurrently with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",digitalis,antidiabetic agents,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,8,10
2475,"DRUGOTHER has been used concurrently with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER, without observed problems. ",diuretics,antidiabetic agents,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,9,10
2476,"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER ) or DRUG2, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",phenothiazines,metoclopramide,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,5,10
2477,"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",phenothiazines,Permax,TRUE,advise,1,N1C2=CC=CC=C2SC2=CC=CC=C12,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,5,18
2478,"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUG1, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",metoclopramide,Permax,TRUE,advise,1,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,10,18
2479,"Because DRUG1 is approximately 90% bound to plasma proteins, caution should be exercised if DRUG1 is coadministered with other drugs known to affect protein binding.",pergolide mesylate,pergolide mesylate,FALSE,Neg,0,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,1,-1
2480,"DRUG1: Patients on DRUG2, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUGOTHER    Tablets therapy. ",Diuretics,diuretics,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,0,3
2481,"DRUG1: Patients on DRUGOTHER, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUG2    Tablets therapy. ",Diuretics,ACEON,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,0,21
2482,"DRUGOTHER: Patients on DRUG1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUG2    Tablets therapy. ",diuretics,ACEON,TRUE,effect,2,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,3,21
2483,The possibility of hypotensive effects can be minimized by either discontinuing the DRUG1 or increasing the salt intake prior to initiation of treatment with DRUG2. ,diuretic,perindopril,TRUE,effect,2,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,12,24
2484,"If DRUG1 cannot be interrupted, close medical supervision should be provided with the first dose of DRUG2    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",diuretics,ACEON,TRUE,advise,1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,1,16
2485,The rate and extent of DRUG1 absorption and elimination are not affected by concomitant DRUG2. ,perindopril,diuretics,FALSE,Neg,0,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,5,14
2486,"The bioavailability of DRUG1 was reduced by DRUG2, however, and this was associated with a decrease in plasma ACE inhibition. ",perindoprilat,diuretics,FALSE,Neg,0,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,3,7
2487,"Use of DRUGOTHER (DRUG1, DRUG2, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,amiloride,FALSE,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,3,4
2488,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUG2 and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,triamterene,FALSE,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,3,5
2489,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,indomethacin,FALSE,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,3,18
2490,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,heparin,FALSE,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,3,19
2491,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",spironolactone,cyclosporine,FALSE,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,3,20
2492,"Use of DRUGOTHER (DRUGOTHER, DRUG1, DRUG2 and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",amiloride,triamterene,FALSE,Neg,0,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,4,5
2493,"Use of DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",amiloride,indomethacin,FALSE,Neg,0,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,4,18
2494,"Use of DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",amiloride,heparin,FALSE,Neg,0,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,4,19
2495,"Use of DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",amiloride,cyclosporine,FALSE,Neg,0,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,4,20
2496,"Use of DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",triamterene,indomethacin,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,5,18
2497,"Use of DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",triamterene,heparin,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,5,19
2498,"Use of DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",triamterene,cyclosporine,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,20
2499,"Use of DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUG1, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",indomethacin,heparin,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,18,19
2500,"Use of DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUG1, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",indomethacin,cyclosporine,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,18,20
2501,"Use of DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG1, DRUG2 and others) can increase the risk of hyperkalemia. ",heparin,cyclosporine,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,19,20
2502,"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG2 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG2 on the plasma concentration of DRUGOTHER/DRUGOTHERat has not been excluded. ",Digoxin,digoxin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,11
2503,"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUG2    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUGOTHER/DRUGOTHERat has not been excluded. ",Digoxin,ACEON,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,0,16
2504,"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG2 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG2 on the plasma concentration of DRUGOTHER/DRUGOTHERat has not been excluded. ",Digoxin,digoxin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,11
2505,"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUG2/DRUG2at has not been excluded. ",Digoxin,perindopril,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,0,31
2506,"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",Digoxin,perindoprilat,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,0,31
2507,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUG2    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUGOTHERat has not been excluded. ",digoxin,ACEON,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,11,16
2508,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUGOTHERat has not been excluded. ",digoxin,digoxin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,11,-1
2509,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/DRUG2at has not been excluded. ",digoxin,perindopril,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,11,31
2510,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",digoxin,perindoprilat,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,11,31
2511,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUG2 concentrations when coadministered with DRUG1    Tablets, but an effect of DRUG2 on the plasma concentration of DRUGOTHER/DRUGOTHERat has not been excluded. ",ACEON,digoxin,FALSE,Neg,0,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,16,11
2512,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUG1    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUG2/DRUG2at has not been excluded. ",ACEON,perindopril,FALSE,Neg,0,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,16,31
2513,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUG1    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",ACEON,perindoprilat,FALSE,Neg,0,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,16,31
2514,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/DRUG2at has not been excluded. ",digoxin,perindopril,TRUE,mechanism,4,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,11,31
2515,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",digoxin,perindoprilat,TRUE,mechanism,4,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,11,31
2516,"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUG1/DRUG1at has not been excluded. ",perindopril,perindoprilat,FALSE,Neg,0,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,31,-1
2517,DRUG1: Animal data have suggested the possibility of interaction between DRUG2 and DRUGOTHER. ,Gentamicin,perindopril,FALSE,Neg,0,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,0,10
2518,DRUG1: Animal data have suggested the possibility of interaction between DRUGOTHER and DRUG2. ,Gentamicin,gentamicin,FALSE,Neg,0,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,0,12
2519,DRUGOTHER: Animal data have suggested the possibility of interaction between DRUG1 and DRUG2. ,perindopril,gentamicin,TRUE,int,3,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,10,12
2520,Food Interaction: Oral administration of DRUG1    Tablets with food does not significantly lower the rate or extent of DRUG2 absorption relative to the fasted state. ,ACEON,perindopril,FALSE,Neg,0,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,5,21
2521,"However, the extent of biotransformation of DRUG1 to the active metabolite, DRUG1at, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. ",perindopril,perindoprilat,FALSE,Neg,0,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,6,-1
2522,Concomitant use of DRUG1 with DRUG2 may result in an adverse drug interaction.,alcohol,phentermine hydrochloride,TRUE,int,3,CCO,CC(C)(CC1=CC=CC=C1)N.Cl,3,5
2523,"DRUGOTHER, particularly DRUG1, may cause serious cardiac arrhythmias during DRUG2 anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,TRUE,effect,2,C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N,C(C(F)(F)F)(Cl)Br,2,9
2524,DRUG1: The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUG2 (DRUGOTHER). ,MAO Inhibitors,monoamine oxidase inhibitors,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,OC(=O)CCCCCCCC(O)=O,0,12
2525,"DRUGOTHER, particularly DRUG1, may cause serious cardiac arrhythmias during DRUG2 anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,TRUE,effect,2,C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N,C(C(F)(F)F)(Cl)Br,2,9
2526,DRUG1 - The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUG2 (DRUGOTHER). ,MAO Inhibitors,monoamine oxidase inhibitors,FALSE,Neg,0,CN(CC#C)CC1=CC=CC=C1,OC(=O)CCCCCCCC(O)=O,0,13
2527,"These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., DRUG1, inhaled DRUG2). ",atropine,ipratropium,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,19,21
2528,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,conjugated estrogens,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],31,35
2529,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,hydroxychloroquine sulfate,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,31,36
2530,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,ibuprofen,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,31,37
2531,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,levothyroxine sodium,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],31,38
2532,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,medroxyprogesterone acetate,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,31,39
2533,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,methotrexate,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,31,40
2534,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,multivitamins,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,NC(=O)C1=CC=CN=C1,31,41
2535,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,naproxen,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,31,42
2536,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",acetylsalicylic acid,omeprazole,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,31,43
2537,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",acetylsalicylic acid,paracetamol,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NC1=CC=C(C=C1)O,31,44
2538,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",acetylsalicylic acid,prednisone,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,31,46
2539,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,hydroxychloroquine sulfate,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,35,36
2540,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,ibuprofen,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,35,37
2541,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,levothyroxine sodium,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],35,38
2542,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,medroxyprogesterone acetate,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,35,39
2543,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,methotrexate,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,35,40
2544,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,multivitamins,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],NC(=O)C1=CC=CN=C1,35,41
2545,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,naproxen,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,35,42
2546,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",conjugated estrogens,omeprazole,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,35,43
2547,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",conjugated estrogens,paracetamol,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],CC(=O)NC1=CC=C(C=C1)O,35,44
2548,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",conjugated estrogens,prednisone,FALSE,Neg,0,C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,35,46
2549,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydroxychloroquine sulfate,ibuprofen,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,36,37
2550,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydroxychloroquine sulfate,levothyroxine sodium,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],36,38
2551,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydroxychloroquine sulfate,medroxyprogesterone acetate,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,36,39
2552,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydroxychloroquine sulfate,methotrexate,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,36,40
2553,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydroxychloroquine sulfate,multivitamins,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,NC(=O)C1=CC=CN=C1,36,41
2554,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydroxychloroquine sulfate,naproxen,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,36,42
2555,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",hydroxychloroquine sulfate,omeprazole,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,36,43
2556,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",hydroxychloroquine sulfate,paracetamol,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,CC(=O)NC1=CC=C(C=C1)O,36,44
2557,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",hydroxychloroquine sulfate,prednisone,FALSE,Neg,0,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,36,46
2558,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ibuprofen,levothyroxine sodium,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],37,38
2559,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ibuprofen,medroxyprogesterone acetate,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,37,39
2560,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ibuprofen,methotrexate,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,37,40
2561,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ibuprofen,multivitamins,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,NC(=O)C1=CC=CN=C1,37,41
2562,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ibuprofen,naproxen,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,37,42
2563,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",ibuprofen,omeprazole,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,37,43
2564,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",ibuprofen,paracetamol,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(=O)NC1=CC=C(C=C1)O,37,44
2565,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",ibuprofen,prednisone,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,37,46
2566,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",levothyroxine sodium,medroxyprogesterone acetate,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,38,39
2567,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",levothyroxine sodium,methotrexate,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,38,40
2568,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",levothyroxine sodium,multivitamins,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],NC(=O)C1=CC=CN=C1,38,41
2569,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",levothyroxine sodium,naproxen,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,38,42
2570,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",levothyroxine sodium,omeprazole,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,38,43
2571,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",levothyroxine sodium,paracetamol,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],CC(=O)NC1=CC=C(C=C1)O,38,44
2572,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",levothyroxine sodium,prednisone,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,38,46
2573,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",medroxyprogesterone acetate,methotrexate,FALSE,Neg,0,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,39,40
2574,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",medroxyprogesterone acetate,multivitamins,FALSE,Neg,0,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,NC(=O)C1=CC=CN=C1,39,41
2575,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",medroxyprogesterone acetate,naproxen,FALSE,Neg,0,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,39,42
2576,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",medroxyprogesterone acetate,omeprazole,FALSE,Neg,0,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,39,43
2577,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",medroxyprogesterone acetate,paracetamol,FALSE,Neg,0,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)NC1=CC=C(C=C1)O,39,44
2578,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",medroxyprogesterone acetate,prednisone,FALSE,Neg,0,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,39,46
2579,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",methotrexate,multivitamins,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,NC(=O)C1=CC=CN=C1,40,41
2580,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",methotrexate,naproxen,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,40,42
2581,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",methotrexate,omeprazole,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,40,43
2582,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",methotrexate,paracetamol,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC(=O)NC1=CC=C(C=C1)O,40,44
2583,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",methotrexate,prednisone,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,40,46
2584,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",multivitamins,naproxen,FALSE,Neg,0,NC(=O)C1=CC=CN=C1,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,41,42
2585,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",multivitamins,omeprazole,FALSE,Neg,0,NC(=O)C1=CC=CN=C1,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,41,43
2586,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",multivitamins,paracetamol,FALSE,Neg,0,NC(=O)C1=CC=CN=C1,CC(=O)NC1=CC=C(C=C1)O,41,44
2587,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",multivitamins,prednisone,FALSE,Neg,0,NC(=O)C1=CC=CN=C1,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,41,46
2588,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",naproxen,omeprazole,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,42,43
2589,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",naproxen,paracetamol,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC(=O)NC1=CC=C(C=C1)O,42,44
2590,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2.",naproxen,prednisone,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,42,46
2591,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",omeprazole,paracetamol,FALSE,Neg,0,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,CC(=O)NC1=CC=C(C=C1)O,43,44
2592,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",omeprazole,prednisone,FALSE,Neg,0,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,43,46
2593,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2.",paracetamol,prednisone,FALSE,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,44,46
2594,"DRUG1 has been used with a variety of DRUG2, including DRUGOTHER, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",Pindolol,antihypertensive agents,FALSE,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,0,8
2595,"DRUG1 has been used with a variety of DRUGOTHER, including DRUG2, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",Pindolol,hydrochlorothiazide,FALSE,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,10
2596,"DRUG1 has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",Pindolol,hydralazine,FALSE,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,C1=CC=C2C(=C1)C=NN=C2NN,0,11
2597,"DRUG1 has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",Pindolol,guanethidine,FALSE,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,C1CCCN(CCC1)CCN=C(N)N,0,13
2598,"DRUGOTHER has been used with a variety of DRUG1, including DRUG2, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",antihypertensive agents,hydrochlorothiazide,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,8,10
2599,"DRUGOTHER has been used with a variety of DRUG1, including DRUGOTHER, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",antihypertensive agents,hydralazine,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C2C(=C1)C=NN=C2NN,8,11
2600,"DRUGOTHER has been used with a variety of DRUG1, including DRUGOTHER, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",antihypertensive agents,guanethidine,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1CCCN(CCC1)CCN=C(N)N,8,13
2601,"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUG1, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",hydrochlorothiazide,hydralazine,FALSE,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1=CC=C2C(=C1)C=NN=C2NN,10,11
2602,"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUG1, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",hydrochlorothiazide,guanethidine,FALSE,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1CCCN(CCC1)CCN=C(N)N,10,13
2603,"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUG1, and DRUG2 without unexpected adverse interactions. ",hydralazine,guanethidine,FALSE,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,C1CCCN(CCC1)CCN=C(N)N,11,13
2604,DRUG1 has been shown to increase serum DRUG2 levels when both drugs are co-administered. ,Pindolol,thioridazine,TRUE,mechanism,4,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,0,7
2605,"Although this has not occurred in in vitro studies with DRUGOTHER, interactions with DRUGOTHER have been reported with DRUG1 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG1 to patients on DRUGOTHER and other highly protein-bound drugs. ",FELDENE,FELDENE,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,18,-1
2606,"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . DRUGOTHER, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",piroxicam,FELDENE,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,3,14
2607,"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG2 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . DRUGOTHER, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",piroxicam,aspirin,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC(=O)OC1=CC=CC=C1C(=O)O,3,20
2608,"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . DRUGOTHER, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",piroxicam,piroxicam,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,3,-1
2609,"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . DRUG2, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",piroxicam,Nonsteroidal anti-inflammatory agents,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,3,36
2610,"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . DRUGOTHER, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",piroxicam,FELDENE,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,3,14
2611,"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUG2 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . DRUGOTHER, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",FELDENE,aspirin,TRUE,mechanism,4,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CC(=O)OC1=CC=CC=C1C(=O)O,14,20
2612,"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG2 plasma levels . DRUGOTHER, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",FELDENE,piroxicam,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,14,3
2613,"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . DRUG2, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",FELDENE,Nonsteroidal anti-inflammatory agents,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,14,36
2614,"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . DRUGOTHER, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",FELDENE,FELDENE,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,14,-1
2615,"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG2 plasma levels . DRUGOTHER, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",aspirin,piroxicam,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,20,3
2616,"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . DRUG2, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",aspirin,Nonsteroidal anti-inflammatory agents,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,20,36
2617,"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . DRUGOTHER, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",aspirin,FELDENE,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,20,14
2618,"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . DRUG2, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",piroxicam,Nonsteroidal anti-inflammatory agents,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,3,36
2619,"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . DRUGOTHER, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",piroxicam,FELDENE,FALSE,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,3,14
2620,"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . DRUG1, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",Nonsteroidal anti-inflammatory agents,FELDENE,FALSE,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,36,14
2621,"When DRUG1 and DRUG2 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG1 is used alone. ",atropine,pralidoxime,TRUE,effect,2,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,C[N+]1=CC=CC=C1/C=N/O,1,3
2622,"When DRUG1 and DRUGOTHER are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG1 is used alone. ",atropine,atropine,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,1,-1
2623,"When DRUG2 and DRUG1 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG2 is used alone. ",pralidoxime,atropine,FALSE,Neg,0,C[N+]1=CC=CC=C1/C=N/O,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,3,1
2624,This is especially true if the total dose of DRUG1 has been large and the administration of DRUG2 has been delayed. ,atropine,pralidoxime,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,C[N+]1=CC=CC=C1/C=N/O,9,17
2625,"DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",morphine,theophylline,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,1
2626,"DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",morphine,aminophylline,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,0,2
2627,"DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",morphine,succinylcholine,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,0,3
2628,"DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",morphine,reserpine,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,0,4
2629,"DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",theophylline,aminophylline,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,1,2
2630,"DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",theophylline,succinylcholine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,3
2631,"DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",theophylline,reserpine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,1,4
2632,"DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",aminophylline,succinylcholine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,2,3
2633,"DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",aminophylline,reserpine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,2,4
2634,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",succinylcholine,reserpine,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,3,4
2635,DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,Carbidopa,Levodopa,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,0,0
2636,DRUG1/DRUGOTHER: DRUG1/DRUGOTHER does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,Carbidopa,Carbidopa,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,0,-1
2637,DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,Carbidopa,Levodopa,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,0,0
2638,DRUG1/DRUGOTHER: DRUG1/DRUGOTHER does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,Carbidopa,pramipexole,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,8
2639,DRUG2/DRUG1: DRUG2/DRUG1 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,Levodopa,Carbidopa,FALSE,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,0,0
2640,DRUGOTHER/DRUG1: DRUGOTHER/DRUG1 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,Levodopa,Levodopa,FALSE,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,0,-1
2641,DRUGOTHER/DRUG1: DRUGOTHER/DRUG1 does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,Levodopa,pramipexole,FALSE,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,8
2642,DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,Carbidopa,Levodopa,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,0,0
2643,DRUG1/DRUGOTHER: DRUG1/DRUGOTHER does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,Carbidopa,pramipexole,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,8
2644,DRUGOTHER/DRUG1: DRUGOTHER/DRUG1 does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,Levodopa,pramipexole,FALSE,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,8
2645,"DRUG1: In healthy volunteers (N= 11), DRUG2 did not influence the pharmacokinetics of DRUGOTHER. ",Selegiline,selegiline,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C[C@H](CC1=CC=CC=C1)N(C)CC#C,0,6
2646,"DRUG1: In healthy volunteers (N= 11), DRUGOTHER did not influence the pharmacokinetics of DRUG2. ",Selegiline,pramipexole,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,13
2647,"DRUGOTHER: In healthy volunteers (N= 11), DRUG1 did not influence the pharmacokinetics of DRUG2. ",selegiline,pramipexole,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,6,13
2648,DRUG1: Population pharmacokinetic analysis suggests that DRUG2 is unlikely to alter the oral clearance of DRUGOTHER (N= 54). ,Amantadine,amantadine,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,C1C2CC3CC1CC(C2)(C3)N,0,6
2649,DRUG1: Population pharmacokinetic analysis suggests that DRUGOTHER is unlikely to alter the oral clearance of DRUG2 (N= 54). ,Amantadine,pramipexole,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,15
2650,DRUGOTHER: Population pharmacokinetic analysis suggests that DRUG1 is unlikely to alter the oral clearance of DRUG2 (N= 54). ,amantadine,pramipexole,FALSE,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,6,15
2651,"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUGOTHER AUC and a 40% increase in half-life (N= 12). ",Cimetidine,Cimetidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,0,-1
2652,"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUG2 AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,22
2653,"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUG2 AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,TRUE,mechanism,4,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,22
2654,"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUGOTHER pharmacokinetics (N= 12). ",Probenecid,Probenecid,FALSE,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,0,-1
2655,"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUG2 pharmacokinetics (N= 12). ",Probenecid,pramipexole,FALSE,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,20
2656,"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUG2 pharmacokinetics (N= 12). ",Probenecid,pramipexole,FALSE,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,0,20
2657,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,ranitidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,23,24
2658,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,diltiazem,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,23,25
2659,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,triamterene,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,23,26
2660,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,verapamil,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,23,27
2661,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,quinidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,23,28
2662,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,quinine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,23,30
2663,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",cimetidine,pramipexole,TRUE,mechanism,4,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,23,36
2664,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,cephalosporins,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,23,49
2665,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,penicillins,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,23,50
2666,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,indomethacin,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,23,51
2667,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,hydrochlorothiazide,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,23,52
2668,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,chlorpropamide,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,23,54
2669,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",cimetidine,pramipexole,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,23,36
2670,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,diltiazem,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,24,25
2671,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,triamterene,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,24,26
2672,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,verapamil,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,24,27
2673,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,quinidine,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,24,28
2674,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,quinine,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,24,30
2675,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",ranitidine,pramipexole,TRUE,mechanism,4,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,24,36
2676,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,cephalosporins,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,24,49
2677,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,penicillins,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,24,50
2678,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,indomethacin,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,24,51
2679,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,hydrochlorothiazide,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,24,52
2680,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,chlorpropamide,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,24,54
2681,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",ranitidine,pramipexole,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,24,36
2682,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,triamterene,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,25,26
2683,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,verapamil,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,25,27
2684,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,quinidine,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,25,28
2685,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,quinine,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,25,30
2686,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",diltiazem,pramipexole,TRUE,mechanism,4,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,25,36
2687,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,cephalosporins,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,25,49
2688,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,penicillins,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,25,50
2689,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,indomethacin,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,25,51
2690,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,hydrochlorothiazide,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,25,52
2691,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,chlorpropamide,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,25,54
2692,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",diltiazem,pramipexole,FALSE,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,25,36
2693,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,verapamil,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,26,27
2694,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,quinidine,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,26,28
2695,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,quinine,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,26,30
2696,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",triamterene,pramipexole,TRUE,mechanism,4,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,26,36
2697,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,cephalosporins,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,26,49
2698,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,penicillins,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,26,50
2699,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,indomethacin,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,26,51
2700,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,hydrochlorothiazide,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,26,52
2701,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,chlorpropamide,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,26,54
2702,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",triamterene,pramipexole,FALSE,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,26,36
2703,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,quinidine,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,27,28
2704,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,quinine,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,27,30
2705,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",verapamil,pramipexole,TRUE,mechanism,4,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,27,36
2706,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,cephalosporins,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,27,49
2707,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,penicillins,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,27,50
2708,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,indomethacin,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,27,51
2709,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,hydrochlorothiazide,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,27,52
2710,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,chlorpropamide,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,27,54
2711,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",verapamil,pramipexole,FALSE,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,27,36
2712,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinidine,quinine,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,28,30
2713,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",quinidine,pramipexole,TRUE,mechanism,4,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,28,36
2714,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinidine,cephalosporins,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,28,49
2715,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinidine,penicillins,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,28,50
2716,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinidine,indomethacin,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,28,51
2717,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinidine,hydrochlorothiazide,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,28,52
2718,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinidine,chlorpropamide,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,28,54
2719,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",quinidine,pramipexole,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,28,36
2720,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",quinine,pramipexole,TRUE,mechanism,4,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,30,36
2721,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinine,cephalosporins,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,30,49
2722,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinine,penicillins,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,30,50
2723,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinine,indomethacin,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,30,51
2724,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinine,hydrochlorothiazide,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,30,52
2725,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinine,chlorpropamide,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,30,54
2726,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",quinine,pramipexole,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,30,36
2733,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cephalosporins,penicillins,FALSE,Neg,0,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,49,50
2734,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cephalosporins,indomethacin,FALSE,Neg,0,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,49,51
2735,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cephalosporins,hydrochlorothiazide,FALSE,Neg,0,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,49,52
2736,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",cephalosporins,chlorpropamide,FALSE,Neg,0,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,49,54
2737,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",cephalosporins,pramipexole,TRUE,mechanism,4,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,49,36
2738,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",penicillins,indomethacin,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,50,51
2739,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",penicillins,hydrochlorothiazide,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,50,52
2740,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",penicillins,chlorpropamide,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,50,54
2741,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",penicillins,pramipexole,TRUE,mechanism,4,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,50,36
2742,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",indomethacin,hydrochlorothiazide,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,51,52
2743,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",indomethacin,chlorpropamide,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,51,54
2744,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",indomethacin,pramipexole,TRUE,mechanism,4,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,51,36
2745,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",hydrochlorothiazide,chlorpropamide,FALSE,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,52,54
2746,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",hydrochlorothiazide,pramipexole,TRUE,mechanism,4,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,52,36
2747,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) are likely to have little effect on the oral clearance of DRUG2. ",chlorpropamide,pramipexole,TRUE,mechanism,4,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,54,36
2748,CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect DRUG1 elimination because DRUG1 is not appreciably metabolized by these enzymes in vivo or in vitro. ,pramipexole,pramipexole,FALSE,Neg,0,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,13,-1
2749,"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUG2, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",pramipexole,dopamine antagonists,FALSE,Neg,0,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,NCCC1=CC(O)=C(O)C=C1,2,10
2750,"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",pramipexole,phenothiazines,FALSE,Neg,0,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,N1C2=CC=CC=C2SC2=CC=CC=C12,2,15
2751,"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",pramipexole,metoclopramide,FALSE,Neg,0,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,2,19
2752,"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",pramipexole,MIRAPEX,FALSE,Neg,0,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,2,25
2753,"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUG1, such as the DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",dopamine antagonists,phenothiazines,FALSE,Neg,0,NCCC1=CC(O)=C(O)C=C1,N1C2=CC=CC=C2SC2=CC=CC=C12,10,15
2754,"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUG1, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",dopamine antagonists,metoclopramide,FALSE,Neg,0,NCCC1=CC(O)=C(O)C=C1,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,10,19
2755,"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUG1, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",dopamine antagonists,MIRAPEX,TRUE,effect,2,NCCC1=CC(O)=C(O)C=C1,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,10,25
2756,"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",phenothiazines,metoclopramide,FALSE,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,15,19
2757,"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",phenothiazines,MIRAPEX,TRUE,effect,2,N1C2=CC=CC=C2SC2=CC=CC=C12,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,15,25
2758,"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG1, may diminish the effectiveness of DRUG2. ",metoclopramide,MIRAPEX,TRUE,effect,2,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,19,25
2759,"Due to its effects on gastric emptying, DRUGOTHER therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., DRUG1 such as DRUG2) and agents that slow the intestinal absorption of nutrients (e.g., DRUGOTHER). ",anticholinergic agents,atropine,FALSE,Neg,0,C[N+](C)(C)CCO,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,22,25
2760,"In clinical trials, the concomitant use of DRUG1 or DRUG2 did not alter the adverse event profile of DRUGOTHER. ",sulfonylureas,biguanides,FALSE,Neg,0,NC(N)=O,C(=NC(=N)N)(N)N,7,9
2761,"Mixing DRUGOTHER and DRUG1 The pharmacokinetic parameters of DRUGOTHER were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant DRUG2 immediately prior to injection. ",Insulin,human insulin,FALSE,Neg,0,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,3,22
2762,"Drugs that induce hepatic enzymes such as DRUG1, DRUG2 and DRUGOTHER may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",phenobarbital,phenytoin,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
2763,"Drugs that induce hepatic enzymes such as DRUG1, DRUGOTHER and DRUG2 may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",phenobarbital,rifampin,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,7,10
2764,"Drugs that induce hepatic enzymes such as DRUG1, DRUGOTHER and DRUGOTHER may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response. ",phenobarbital,corticosteroids,TRUE,mechanism,4,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,16
2765,"Drugs that induce hepatic enzymes such as DRUG1, DRUGOTHER and DRUGOTHER may increase the clearance of DRUG2s and may require increases in DRUG2 dose to achieve the desired response. ",phenobarbital,corticosteroid,TRUE,mechanism,4,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,16
2766,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUG2 may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",phenytoin,rifampin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
2767,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response. ",phenytoin,corticosteroids,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,8,16
2768,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUG2s and may require increases in DRUG2 dose to achieve the desired response. ",phenytoin,corticosteroid,TRUE,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,8,16
2769,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER and DRUG1 may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response. ",rifampin,corticosteroids,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,10,16
2770,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER and DRUG1 may increase the clearance of DRUG2s and may require increases in DRUG2 dose to achieve the desired response. ",rifampin,corticosteroid,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,10,16
2771,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER and DRUGOTHER may increase the clearance of DRUG1 and may require increases in DRUG2 dose to achieve the desired response. ",corticosteroids,corticosteroid,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,16,22
2772,Drugs such as DRUG1 and DRUG2 may inhibit the metabolism of DRUGOTHER and thus decrease their clearance. ,troleandomycin,ketoconazole,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,3,5
2773,Drugs such as DRUG1 and DRUGOTHER may inhibit the metabolism of DRUG2 and thus decrease their clearance. ,troleandomycin,corticosteroids,TRUE,mechanism,4,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,3,11
2774,Drugs such as DRUGOTHER and DRUG1 may inhibit the metabolism of DRUG2 and thus decrease their clearance. ,ketoconazole,corticosteroids,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,5,11
2775,DRUG1 may increase the clearance of chronic high dose DRUG2. ,Corticosteroids,aspirin,TRUE,mechanism,4,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CC(=O)OC1=CC=CC=C1C(=O)O,0,9
2776,This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUGOTHER is withdrawn. ,salicylate,salicylate,FALSE,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],C1=CC=C(C(=C1)C(=O)O)[O-],5,-1
2777,This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,salicylate,corticosteroid,FALSE,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,5,16
2778,This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,salicylate,corticosteroid,TRUE,effect,2,C1=CC=C(C(=C1)C(=O)O)[O-],[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,5,16
2779,DRUG1 should be used cautiously in conjunction with DRUG2 in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,TRUE,advise,1,CC(=O)OC1=CC=CC=C1C(=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,8
2780,DRUG1: Concurrent use of DRUG2 and DRUGOTHER may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUG2. ,Anticholinesterases,procaine hydrochloride,FALSE,Neg,0,C[N+](C)(C)CCO,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,0,4
2781,DRUG1: Concurrent use of DRUGOTHER and DRUG2 may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUGOTHER. ,Anticholinesterases,anticholinesterase agents,FALSE,Neg,0,C[N+](C)(C)CCO,C[N+](C)(C)CCO,0,6
2782,DRUG1: Concurrent use of DRUG2 and DRUGOTHER may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUG2. ,Anticholinesterases,procaine hydrochloride,FALSE,Neg,0,C[N+](C)(C)CCO,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,0,4
2783,DRUGOTHER: Concurrent use of DRUG1 and DRUG2 may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUG1. ,procaine hydrochloride,anticholinesterase agents,TRUE,effect,2,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,C[N+](C)(C)CCO,4,6
2784,DRUGOTHER: Concurrent use of DRUG1 and DRUGOTHER may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUG1. ,procaine hydrochloride,procaine hydrochloride,FALSE,Neg,0,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,4,-1
2785,DRUGOTHER: Concurrent use of DRUG2 and DRUG1 may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUG2. ,anticholinesterase agents,procaine hydrochloride,FALSE,Neg,0,C[N+](C)(C)CCO,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,6,4
2786,"DRUG1: DRUG1 may increase the diffusion rate of DRUGOTHER, resulting in a decreased time of onset, but an increase in systemic toxicity. ",Hyaluronidase,Hyaluronidase,FALSE,Neg,0,CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C.Br,CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C.Br,0,-1
2787,"DRUG1: DRUG1 may increase the diffusion rate of DRUG2, resulting in a decreased time of onset, but an increase in systemic toxicity. ",Hyaluronidase,procaine hydrochloride,FALSE,Neg,0,CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C.Br,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,0,8
2788,"DRUG1: DRUG1 may increase the diffusion rate of DRUG2, resulting in a decreased time of onset, but an increase in systemic toxicity. ",Hyaluronidase,procaine hydrochloride,TRUE,mechanism,4,CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C.Br,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,0,8
2789,DRUGOTHER (such as DRUG1): Concurrent use of DRUG2 and DRUGOTHER may result in prolongation or enhancement of the neuromuscular blockade. ,suxamethonium chloride,procaine hydrochloride,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,3,7
2790,DRUG1: Concurrent use of DRUG2 and DRUGOTHER may result in a reduction of the antibacterial action of the DRUGOTHER. ,Sulfonamides,procaine hydrochloride,FALSE,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,0,4
2791,DRUG1: Concurrent use of DRUGOTHER and DRUG2 may result in a reduction of the antibacterial action of the DRUGOTHER. ,Sulfonamides,sulfonamides,FALSE,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,0,6
2792,DRUGOTHER: Concurrent use of DRUG1 and DRUG2 may result in a reduction of the antibacterial action of the DRUGOTHER. ,procaine hydrochloride,sulfonamides,TRUE,effect,2,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,4,6
2793,DRUG1: Concurrent use of DRUG2 and DRUGOTHER may extend the plasma half-life of DRUGOTHER.,Acetazolamide,acetazolamide,FALSE,Neg,0,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,0,4
2794,DRUG1: Concurrent use of DRUGOTHER and DRUG2 may extend the plasma half-life of DRUGOTHER.,Acetazolamide,procaine hydrochloride,FALSE,Neg,0,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,0,6
2795,DRUG1: Concurrent use of DRUGOTHER and DRUG2 hydrochloride may extend the plasma half-life of DRUG2.,Acetazolamide,procaine,FALSE,Neg,0,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,0,6
2796,DRUGOTHER: Concurrent use of DRUG1 and DRUG2 may extend the plasma half-life of DRUGOTHER.,acetazolamide,procaine hydrochloride,TRUE,mechanism,4,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,4,6
2797,DRUGOTHER: Concurrent use of DRUG1 and DRUG2 hydrochloride may extend the plasma half-life of DRUG2.,acetazolamide,procaine,FALSE,Neg,0,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,4,6
2798,DRUGOTHER: Concurrent use of DRUGOTHER and DRUG1 may extend the plasma half-life of DRUG2.,procaine hydrochloride,procaine,FALSE,Neg,0,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,6,13
2799,"To minimize CNS depression and possible potentiation, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2 should be used with caution. ",antihistamines,phenothiazines,FALSE,Neg,0,NCCC1=CNC=N1,N1C2=CC=CC=C2SC2=CC=CC=C12,8,12
2800,"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUG2 drugs (e.g., DRUGOTHER, DRUGOTHER) and other drugs and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",Matulane,tricyclic antidepressant,TRUE,advise,1,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,1,9
2801,"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER drugs (e.g., DRUG2, DRUGOTHER) and other drugs and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",Matulane,amitriptyline HCl,TRUE,advise,1,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,1,12
2802,"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER, DRUG2) and other drugs and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",Matulane,imipramine HCl,TRUE,advise,1,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,1,13
2803,"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER, DRUGOTHER) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",Matulane,tyramine,TRUE,advise,1,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,C1=CC(=CC=C1CCN)O,1,22
2804,"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUG1 drugs (e.g., DRUG2, DRUGOTHER) and other drugs and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",tricyclic antidepressant,amitriptyline HCl,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,9,12
2805,"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUG1 drugs (e.g., DRUGOTHER, DRUG2) and other drugs and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",tricyclic antidepressant,imipramine HCl,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,9,13
2806,"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUG1 drugs (e.g., DRUGOTHER, DRUGOTHER) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",tricyclic antidepressant,tyramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1=CC(=CC=C1CCN)O,9,22
2807,"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER drugs (e.g., DRUG1, DRUG2) and other drugs and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",amitriptyline HCl,imipramine HCl,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,12,13
2808,"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER drugs (e.g., DRUG1, DRUGOTHER) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",amitriptyline HCl,tyramine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,C1=CC(=CC=C1CCN)O,12,22
2809,"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER, DRUG1) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",imipramine HCl,tyramine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,C1=CC(=CC=C1CCN)O,13,22
2810,Antihypertensive effects of DRUG1 and related compounds may be counteracted when DRUG2 are used concomitantly. ,guanethidine,phenothiazines,TRUE,effect,2,C1CCCN(CCC1)CCN=C(N)N,N1C2=CC=CC=C2SC2=CC=CC=C12,3,11
2811,Concomitant administration of DRUG1 with DRUG2 results in increased plasma levels of both drugs.,propranolol,phenothiazines,TRUE,mechanism,4,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,N1C2=CC=CC=C2SC2=CC=CC=C12,3,5
2812,"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG2, DRUGOTHER, and DRUGOTHER, etc.) ",DIPRIVAN,morphine,TRUE,effect,2,CC(C)C1=C(C(=CC=C1)C(C)C)O,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,5,22
2813,"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUG2, and DRUGOTHER, etc.) ",DIPRIVAN,meperidine,TRUE,effect,2,CC(C)C1=C(C(=CC=C1)C(C)C)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,5,23
2814,"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, and DRUG2, etc.) ",DIPRIVAN,fentanyl,TRUE,effect,2,CC(C)C1=C(C(=CC=C1)C(C)C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,5,25
2815,"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG1, DRUG2, and DRUGOTHER, etc.) ",morphine,meperidine,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,22,23
2816,"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG1, DRUGOTHER, and DRUG2, etc.) ",morphine,fentanyl,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,22,25
2817,"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUG1, and DRUG2, etc.) ",meperidine,fentanyl,FALSE,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,23,25
2818,"and combinations of DRUG1 and DRUGOTHER (eg, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.). ",opioids,benzodiazepines,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,N1N=CC=CC2=CC=CC=C12,3,7
2819,"and combinations of DRUG1 and DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, etc.). ",opioids,chloral hydrate,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,C(C(Cl)(Cl)Cl)(O)O,3,9
2820,"and combinations of DRUG1 and DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.). ",opioids,droperidol,FALSE,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,3,10
2821,"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, etc.). ",benzodiazepines,chloral hydrate,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,C(C(Cl)(Cl)Cl)(O)O,7,9
2822,"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, etc.). ",benzodiazepines,droperidol,FALSE,Neg,0,N1N=CC=CC2=CC=CC=C12,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,7,10
2823,"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, etc.). ",chloral hydrate,droperidol,FALSE,Neg,0,C(C(Cl)(Cl)Cl)(O)O,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,9,10
2824,"During maintenance of anesthesia or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental DRUGOTHER (eg, DRUG2 or DRUGOTHER). ",DIPRIVAN,nitrous oxide,TRUE,advise,1,CC(C)C1=C(C(=CC=C1)C(C)C)O,[N-]=[N+]=O,9,36
2825,"During maintenance of anesthesia or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental DRUGOTHER (eg, DRUGOTHER or DRUG2). ",DIPRIVAN,opioids,TRUE,advise,1,CC(C)C1=C(C(=CC=C1)C(C)C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,9,38
2826,"During maintenance of anesthesia or sedation, the rate of DRUGOTHER Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental DRUGOTHER (eg, DRUG1 or DRUG2). ",nitrous oxide,opioids,FALSE,Neg,0,[N-]=[N+]=O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,36,38
2827,"The concurrent administration of potent inhalational agents (eg, DRUG1, DRUG2, and DRUGOTHER) during maintenance with DRUGOTHER Injectable Emulsion has not been extensively evaluated. ",isoflurane,enflurane,FALSE,Neg,0,C(C(F)(F)F)(OC(F)F)Cl,C(C(OC(F)F)(F)F)(F)Cl,8,9
2828,"The concurrent administration of potent inhalational agents (eg, DRUG1, DRUGOTHER, and DRUG2) during maintenance with DRUGOTHER Injectable Emulsion has not been extensively evaluated. ",isoflurane,halothane,FALSE,Neg,0,C(C(F)(F)F)(OC(F)F)Cl,C(C(F)(F)F)(Cl)Br,8,11
2829,"The concurrent administration of potent inhalational agents (eg, DRUG1, DRUGOTHER, and DRUGOTHER) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",isoflurane,DIPRIVAN,FALSE,Neg,0,C(C(F)(F)F)(OC(F)F)Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,8,15
2830,"The concurrent administration of potent inhalational agents (eg, DRUGOTHER, DRUG1, and DRUG2) during maintenance with DRUGOTHER Injectable Emulsion has not been extensively evaluated. ",enflurane,halothane,FALSE,Neg,0,C(C(OC(F)F)(F)F)(F)Cl,C(C(F)(F)F)(Cl)Br,9,11
2831,"The concurrent administration of potent inhalational agents (eg, DRUGOTHER, DRUG1, and DRUGOTHER) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",enflurane,DIPRIVAN,FALSE,Neg,0,C(C(OC(F)F)(F)F)(F)Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,9,15
2832,"The concurrent administration of potent inhalational agents (eg, DRUGOTHER, DRUGOTHER, and DRUG1) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",halothane,DIPRIVAN,FALSE,Neg,0,C(C(F)(F)F)(Cl)Br,CC(C)C1=C(C(=CC=C1)C(C)C)O,11,15
2833,"DRUG1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUGOTHER (eg, DRUG2 and DRUGOTHER). ",DIPRIVAN,succinylcholine,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,0,23
2834,"The CNS-depressant effect of DRUG1 is additive with that of other DRUG2, including DRUGOTHER. ",propoxyphene,CNS depressants,TRUE,effect,2,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,11
2835,"The CNS-depressant effect of DRUG1 is additive with that of other DRUGOTHER, including DRUG2. ",propoxyphene,alcohol,TRUE,effect,2,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,CCO,4,13
2836,"The CNS-depressant effect of DRUGOTHER is additive with that of other DRUG1, including DRUG2. ",CNS depressants,alcohol,FALSE,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,11,13
2837,"Such occurrences have been reported when DRUG1 was administered to patients on DRUG2, DRUGOTHER, or DRUGOTHER-like drugs. ",propoxyphene,antidepressants,FALSE,Neg,0,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,6,12
2838,"Such occurrences have been reported when DRUG1 was administered to patients on DRUGOTHER, DRUG2, or DRUGOTHER-like drugs. ",propoxyphene,anticonvulsants,FALSE,Neg,0,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,6,13
2839,"Such occurrences have been reported when DRUG1 was administered to patients on DRUGOTHER, DRUGOTHER, or DRUG2-like drugs. ",propoxyphene,warfarin,FALSE,Neg,0,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,15
2840,"Such occurrences have been reported when DRUGOTHER was administered to patients on DRUG1, DRUG2, or DRUGOTHER-like drugs. ",antidepressants,anticonvulsants,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,12,13
2841,"Such occurrences have been reported when DRUGOTHER was administered to patients on DRUG1, DRUGOTHER, or DRUG2-like drugs. ",antidepressants,warfarin,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,12,15
2842,"Such occurrences have been reported when DRUGOTHER was administered to patients on DRUGOTHER, DRUG1, or DRUG2-like drugs. ",anticonvulsants,warfarin,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,13,15
2843,DRUG1 and DRUGOTHER increase the effects of DRUG2. ,MAO inhibitors,pseudoephedrine,TRUE,effect,2,CN(CC#C)CC1=CC=CC=C1,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,0,7
2844,"DRUGOTHER may reduce the antihypertensive effects of DRUG1, DRUG2, DRUGOTHER and DRUGOTHER.",methyldopa,mecamylamine,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,CC1(C2CCC(C2)C1(C)NC)C,7,8
2845,"DRUGOTHER may reduce the antihypertensive effects of DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER.",methyldopa,reserpine,FALSE,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,7,9
2846,"DRUGOTHER may reduce the antihypertensive effects of DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER.",mecamylamine,reserpine,FALSE,Neg,0,CC1(C2CCC(C2)C1(C)NC)C,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,8,9
2847,"DRUG1 may be used with DRUG2, DRUGOTHER and other DRUGOTHER, and with other DRUGOTHER. ",Pyrimethamine,sulfonamides,FALSE,Neg,0,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,0,5
2848,"DRUG1 may be used with DRUGOTHER, DRUG2 and other DRUGOTHER, and with other DRUGOTHER. ",Pyrimethamine,quinine,FALSE,Neg,0,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,0,6
2849,"DRUG1 may be used with DRUGOTHER, DRUGOTHER and other DRUGOTHER, and with other DRUG2. ",Pyrimethamine,antibiotics,FALSE,Neg,0,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,0,13
2850,"DRUGOTHER may be used with DRUG1, DRUG2 and other DRUGOTHER, and with other DRUGOTHER. ",sulfonamides,quinine,FALSE,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,5,6
2851,"DRUGOTHER may be used with DRUG1, DRUGOTHER and other DRUGOTHER, and with other DRUG2. ",sulfonamides,antibiotics,FALSE,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,5,13
2852,"DRUGOTHER may be used with DRUGOTHER, DRUG1 and other DRUGOTHER, and with other DRUG2. ",quinine,antibiotics,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,6,13
2853,DRUG1 (DRUG2) should be administered until normal hematopoiesis is restored. ,Folinic acid,leucovorin,FALSE,Neg,0,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,1
2854,Mild hepatotoxicity has been reported in some patients when DRUG1 and DRUG2 were administered concomitantly.,lorazepam,pyrimethamine,TRUE,effect,2,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,9,11
2855,DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUGOTHER and should not be coadministered with DRUGOTHER. ,Cholestyramine,Cholestyramine,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,0,-1
2856,DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUG2 and should not be coadministered with DRUGOTHER. ,Cholestyramine,raloxifene,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,0,13
2857,DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUGOTHER and should not be coadministered with DRUG2. ,Cholestyramine,EVISTA,FALSE,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,0,20
2858,DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUG2 and should not be coadministered with DRUGOTHER. ,Cholestyramine,raloxifene,TRUE,mechanism,4,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,0,13
2859,DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUGOTHER and should not be coadministered with DRUG2. ,Cholestyramine,EVISTA,TRUE,advise,1,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,0,20
2860,DRUGOTHER: DRUGOTHER causes a 60% reduction in the absorption and enterohepatic cycling of DRUG1 and should not be coadministered with DRUG2. ,raloxifene,EVISTA,FALSE,Neg,0,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,13,20
2861,DRUG1: The coadministration of DRUG2 and DRUGOTHER has not been assessed under chronic conditions. ,Warfarin,EVISTA,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,0,4
2862,DRUG1: The coadministration of DRUGOTHER and DRUG2 has not been assessed under chronic conditions. ,Warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,6
2863,DRUGOTHER: The coadministration of DRUG1 and DRUG2 has not been assessed under chronic conditions. ,EVISTA,warfarin,FALSE,Neg,0,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,4,6
2864,"If DRUG1 is given concurrently with DRUG2, prothrombin time should be monitored. ",EVISTA,warfarin,TRUE,advise,1,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,1,6
2865,"In vitro, DRUG1 did not affect the binding of DRUG2, DRUGOTHER, or DRUGOTHER. ",raloxifene,warfarin,FALSE,Neg,0,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,2,9
2866,"In vitro, DRUG1 did not affect the binding of DRUGOTHER, DRUG2, or DRUGOTHER. ",raloxifene,phenytoin,FALSE,Neg,0,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,10
2867,"In vitro, DRUG1 did not affect the binding of DRUGOTHER, DRUGOTHER, or DRUG2. ",raloxifene,tamoxifen,FALSE,Neg,0,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,2,12
2868,"In vitro, DRUGOTHER did not affect the binding of DRUG1, DRUG2, or DRUGOTHER. ",warfarin,phenytoin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,10
2869,"In vitro, DRUGOTHER did not affect the binding of DRUG1, DRUGOTHER, or DRUG2. ",warfarin,tamoxifen,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,9,12
2870,"In vitro, DRUGOTHER did not affect the binding of DRUGOTHER, DRUG1, or DRUG2. ",phenytoin,tamoxifen,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,10,12
2871,"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",EVISTA,clofibrate,TRUE,advise,1,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,5,15
2872,"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",EVISTA,indomethacin,TRUE,advise,1,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,5,16
2873,"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",EVISTA,naproxen,TRUE,advise,1,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,5,17
2874,"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",EVISTA,ibuprofen,TRUE,advise,1,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,5,18
2875,"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",EVISTA,diazepam,TRUE,advise,1,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,5,19
2876,"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",EVISTA,diazoxide,TRUE,advise,1,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,5,21
2877,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",clofibrate,indomethacin,FALSE,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,15,16
2878,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",clofibrate,naproxen,FALSE,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,15,17
2879,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",clofibrate,ibuprofen,FALSE,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,15,18
2880,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",clofibrate,diazepam,FALSE,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,15,19
2881,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",clofibrate,diazoxide,FALSE,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,15,21
2882,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",indomethacin,naproxen,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,16,17
2883,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",indomethacin,ibuprofen,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,16,18
2884,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",indomethacin,diazepam,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,16,19
2885,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",indomethacin,diazoxide,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,16,21
2886,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",naproxen,ibuprofen,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,17,18
2887,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",naproxen,diazepam,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,17,19
2888,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",naproxen,diazoxide,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,17,21
2889,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",ibuprofen,diazepam,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,18,19
2890,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",ibuprofen,diazoxide,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,18,21
2891,"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",diazepam,diazoxide,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,19,21
2892,"Coadministration of DRUG1 with DRUG2 resulted in increased plasma DRUGOTHER concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- DRUG2 plasma concentrations (31%). ",TRITEC,clarithromycin,TRUE,mechanism,4,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3],CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,2,4
2893,"Coadministration of DRUG1 with DRUGOTHER resulted in increased plasma DRUG2 concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- DRUGOTHER plasma concentrations (31%). ",TRITEC,ranitidine,FALSE,Neg,0,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3],CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,2,9
2894,"Coadministration of DRUGOTHER with DRUG1 resulted in increased plasma DRUG2 concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- DRUG1 plasma concentrations (31%). ",clarithromycin,ranitidine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,4,9
2895,Coadministration with DRUG1 results in a slight decrease in the rate of DRUG2 absorption that is clinically unimportant. ,aspirin,salicylate,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C1=CC=C(C(=C1)C(=O)O)[O-],2,12
2896,Coadministration with a high dose of DRUG1 (170 mEq) results in a 28% decrease in plasma concentrations of DRUG2 and may decrease plasma concentrations of bismuth from DRUGOTHER. ,antacid,ranitidine,TRUE,mechanism,4,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,6,18
2897,Coadministration with a high dose of DRUG1 (170 mEq) results in a 28% decrease in plasma concentrations of DRUGOTHER and may decrease plasma concentrations of bismuth from DRUG2. ,antacid,TRITEC,TRUE,mechanism,4,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3],6,27
2898,Coadministration with a high dose of DRUGOTHER (170 mEq) results in a 28% decrease in plasma concentrations of DRUG1 and may decrease plasma concentrations of bismuth from DRUG2. ,ranitidine,TRITEC,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3],18,27
2899,"For information on drug interactions associated with DRUG1, refer to the DRUG2     package insert.",ranitidine,ZANTAC,FALSE,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,7,11
2900,"Co-administration of oral DRUG1 200 mg twice daily increased DRUG2 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG2 ointment, 1% on the abraded skin of healthy adult males. ",ketoconazole,retapamulin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C,3,9
2901,"Co-administration of oral DRUG1 200 mg twice daily increased DRUG2 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG2 ointment, 1% on the abraded skin of healthy adult males. ",ketoconazole,retapamulin,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C,3,9
2902,"Co-administration of oral DRUGOTHER 200 mg twice daily increased DRUG1 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG1 ointment, 1% on the abraded skin of healthy adult males. ",retapamulin,retapamulin,FALSE,Neg,0,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C,9,-1
2906,"Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of DRUG1, DRUG2 is unlikely to affect the metabolism of other P450 substrates. ",ALTABAX,retapamulin,FALSE,Neg,0,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C,17,18
2907,"In addition to bleeding associated with DRUG1 and DRUG2, drugs that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",heparin,vitamin K antagonists,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,OC(=O)CCCCCCCC(O)=O,6,8
2908,"In addition to bleeding associated with DRUG1 and DRUGOTHER, drugs that alter platelet function (such as DRUG2, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",heparin,aspirin,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(=O)OC1=CC=CC=C1C(=O)O,6,16
2909,"In addition to bleeding associated with DRUG1 and DRUGOTHER, drugs that alter platelet function (such as DRUGOTHER, DRUG2, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",heparin,dipyridamole,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,6,17
2910,"In addition to bleeding associated with DRUG1 and DRUGOTHER, drugs that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",heparin,Retavase,TRUE,effect,2,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,C1CC(CCC1CN)C(=O)O,6,32
2911,"In addition to bleeding associated with DRUGOTHER and DRUG1, drugs that alter platelet function (such as DRUG2, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",vitamin K antagonists,aspirin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CC(=O)OC1=CC=CC=C1C(=O)O,8,16
2912,"In addition to bleeding associated with DRUGOTHER and DRUG1, drugs that alter platelet function (such as DRUGOTHER, DRUG2, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",vitamin K antagonists,dipyridamole,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,8,17
2913,"In addition to bleeding associated with DRUGOTHER and DRUG1, drugs that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",vitamin K antagonists,Retavase,TRUE,effect,2,OC(=O)CCCCCCCC(O)=O,C1CC(CCC1CN)C(=O)O,8,32
2917,Interactions for DRUG1 (DRUG2):  DRUGOTHER - impairs the intestinal absorption of DRUGOTHER,Vitamin B2,Riboflavin,FALSE,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,2,3
2918,Interactions for DRUG1 (DRUGOTHER):  DRUG2 - impairs the intestinal absorption of DRUGOTHER,Vitamin B2,Alcohol,FALSE,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CCO,2,5
2919,Interactions for DRUG1 (DRUGOTHER):  DRUGOTHER - impairs the intestinal absorption of DRUG2,Vitamin B2,riboflavin,FALSE,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,2,12
2920,Interactions for DRUGOTHER (DRUG1):  DRUG2 - impairs the intestinal absorption of DRUGOTHER,Riboflavin,Alcohol,FALSE,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CCO,3,5
2921,Interactions for DRUGOTHER (DRUG1):  DRUGOTHER - impairs the intestinal absorption of DRUG2,Riboflavin,riboflavin,FALSE,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,3,12
2922,Interactions for DRUGOTHER (DRUGOTHER):  DRUG1 - impairs the intestinal absorption of DRUG2,Alcohol,riboflavin,TRUE,mechanism,4,CCO,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,5,12
2923,DRUG1 - concurrent use decreases gastrointestinal absorption of DRUG2; ,Probenecid,riboflavin,TRUE,mechanism,4,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,0,8
2924,requirements for DRUG1 may be increased in patients receiving DRUG2.,riboflavin,probenecid,TRUE,effect,2,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,2,9
2925,DRUG1: The effects of chronic DRUG2 use on the metabolism of DRUGOTHER are not known. ,Cimetidine,cimetidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,0,5
2926,DRUG1: The effects of chronic DRUGOTHER use on the metabolism of DRUG2 are not known. ,Cimetidine,rimantadine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C12CC3CC(C1)CC(C3)C2)N,0,11
2927,DRUGOTHER: The effects of chronic DRUG1 use on the metabolism of DRUG2 are not known. ,cimetidine,rimantadine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C12CC3CC(C1)CC(C3)C2)N,5,11
2928,"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total DRUGOTHER clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUGOTHER clearance in the same subjects in the absence of DRUGOTHER). ",rimantadine HCl,Cimetidine,TRUE,mechanism,4,CC(C12CC3CC(C1)CC(C3)C2)N.Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,7,16
2929,"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUGOTHER). ",rimantadine HCl,rimantadine,FALSE,Neg,0,CC(C12CC3CC(C1)CC(C3)C2)N.Cl,CC(C12CC3CC(C1)CC(C3)C2)N,7,26
2930,"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUGOTHER). ",rimantadine HCl,rimantadine,FALSE,Neg,0,CC(C12CC3CC(C1)CC(C3)C2)N.Cl,CC(C12CC3CC(C1)CC(C3)C2)N,7,26
2931,"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUGOTHER clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUGOTHER clearance in the same subjects in the absence of DRUG2). ",rimantadine HCl,cimetidine,FALSE,Neg,0,CC(C12CC3CC(C1)CC(C3)C2)N.Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,7,55
2932,"When a single 100 mg dose of DRUG2 HCl was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUGOTHER). ",Cimetidine,rimantadine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C12CC3CC(C1)CC(C3)C2)N,17,7
2933,"When a single 100 mg dose of DRUG2 HCl was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUGOTHER). ",Cimetidine,rimantadine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C12CC3CC(C1)CC(C3)C2)N,17,7
2934,"When a single 100 mg dose of DRUGOTHER was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUGOTHER clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUGOTHER clearance in the same subjects in the absence of DRUG2). ",Cimetidine,cimetidine,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,16,55
2935,"When a single 100 mg dose of DRUG1 HCl was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUGOTHER). ",rimantadine,rimantadine,FALSE,Neg,0,CC(C12CC3CC(C1)CC(C3)C2)N,CC(C12CC3CC(C1)CC(C3)C2)N,7,-1
2936,"When a single 100 mg dose of DRUG1 HCl was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUG2). ",rimantadine,cimetidine,FALSE,Neg,0,CC(C12CC3CC(C1)CC(C3)C2)N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,7,56
2937,"When a single 100 mg dose of DRUG1 HCl was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUG2). ",rimantadine,cimetidine,FALSE,Neg,0,CC(C12CC3CC(C1)CC(C3)C2)N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,7,56
2938,"DRUG1: DRUG2, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. ",Acetaminophen,Rimantadine HCl,FALSE,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CC(C12CC3CC(C1)CC(C3)C2)N.Cl,0,1
2939,Coadministration with DRUG1 reduced the peak concentration and AUC values for DRUG2 by approximately 11%. ,acetaminophen,rimantadine,TRUE,mechanism,4,CC(=O)NC1=CC=C(C=C1)O,CC(C12CC3CC(C1)CC(C3)C2)N,2,11
2940,"DRUG1: DRUG2, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. ",Aspirin,Rimantadine HCl,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(C12CC3CC(C1)CC(C3)C2)N.Cl,0,1
2941,Peak plasma concentrations and AUC of DRUG1 were reduced approximately 10% in the presence of DRUG2.,rimantadine,aspirin,TRUE,mechanism,4,CC(C12CC3CC(C1)CC(C3)C2)N,CC(=O)OC1=CC=CC=C1C(=O)O,6,15
2942,Drug-Drug Interactions Effect of DRUG1    (DRUG2) on the Metabolism of Other Drugs: DRUGOTHER is primarily metabolized through hydrolysis by esterases. ,Exelon,rivastigmine tartrate,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,4,8
2943,Drug-Drug Interactions Effect of DRUG1    (DRUGOTHER) on the Metabolism of Other Drugs: DRUG2 is primarily metabolized through hydrolysis by esterases. ,Exelon,Rivastigmine,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,4,15
2944,Drug-Drug Interactions Effect of DRUGOTHER    (DRUG1) on the Metabolism of Other Drugs: DRUG2 is primarily metabolized through hydrolysis by esterases. ,rivastigmine tartrate,Rivastigmine,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,8,15
2945,"No pharmacokinetic interaction was observed between DRUG1 and DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER in studies in healthy volunteers. ",rivastigmine,digoxin,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,6,8
2946,"No pharmacokinetic interaction was observed between DRUG1 and DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER in studies in healthy volunteers. ",rivastigmine,warfarin,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,9
2947,"No pharmacokinetic interaction was observed between DRUG1 and DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER in studies in healthy volunteers. ",rivastigmine,diazepam,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,6,10
2948,"No pharmacokinetic interaction was observed between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 in studies in healthy volunteers. ",rivastigmine,fluoxetine,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,6,12
2949,"No pharmacokinetic interaction was observed between DRUGOTHER and DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER in studies in healthy volunteers. ",digoxin,warfarin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,9
2950,"No pharmacokinetic interaction was observed between DRUGOTHER and DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER in studies in healthy volunteers. ",digoxin,diazepam,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,8,10
2951,"No pharmacokinetic interaction was observed between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2 in studies in healthy volunteers. ",digoxin,fluoxetine,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,8,12
2952,"No pharmacokinetic interaction was observed between DRUGOTHER and DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER in studies in healthy volunteers. ",warfarin,diazepam,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,9,10
2953,"No pharmacokinetic interaction was observed between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2 in studies in healthy volunteers. ",warfarin,fluoxetine,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,9,12
2954,"No pharmacokinetic interaction was observed between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2 in studies in healthy volunteers. ",diazepam,fluoxetine,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,10,12
2955,The elevation of prothrombin time induced by DRUG1 is not affected by administration of DRUG2. ,warfarin,Exelon,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,7,14
2956,Effect of Other Drugs on the Metabolism of DRUG1: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of DRUG2. ,Exelon,rivastigmine,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,8,24
2957,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",rivastigmine,digoxin,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,9,18
2958,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",rivastigmine,warfarin,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,9,19
2959,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",rivastigmine,diazepam,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,9,20
2960,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",rivastigmine,fluoxetine,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,9,22
2961,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",digoxin,warfarin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,18,19
2962,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",digoxin,diazepam,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,18,20
2963,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",digoxin,fluoxetine,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,18,22
2964,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",warfarin,diazepam,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,19,20
2965,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",warfarin,fluoxetine,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,19,22
2966,"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",diazepam,fluoxetine,FALSE,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,20,22
2967,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER (n=75), DRUGOTHER (n=21), DRUG2 (n=79), DRUGOTHER (n=70), DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",rivastigmine,nonsteroidal anti-inflammatory drugs,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,14,32
2968,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG2 (n=70), DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",rivastigmine,estrogens,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],14,34
2969,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",rivastigmine,antihistamines,FALSE,Neg,0,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,NCCC1=CNC=N1,14,41
2970,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER (n=75), DRUGOTHER (n=21), DRUG1 (n=79), DRUG2 (n=70), DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",nonsteroidal anti-inflammatory drugs,estrogens,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],32,34
2971,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER (n=75), DRUGOTHER (n=21), DRUG1 (n=79), DRUGOTHER (n=70), DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",nonsteroidal anti-inflammatory drugs,antihistamines,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,NCCC1=CNC=N1,32,41
2972,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG1 (n=70), DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",estrogens,antihistamines,FALSE,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],NCCC1=CNC=N1,34,41
2973,"Use with DRUGOTHER and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUG1, similar DRUGOTHER or DRUGOTHER such as DRUG2.",succinylcholine,bethanechol,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,CC(C[N+](C)(C)C)OC(=O)N,18,25
2974,"Drug Interactions: The use of DRUG1    (DRUG2) Injection before DRUGOTHER, for the purpose of attenuating some of the side effects of DRUGOTHER, has not been studied. ",ZEMURON,rocuronium bromide,FALSE,Neg,0,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],5,9
2975,"Drug Interactions: The use of DRUG1    (DRUGOTHER) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",ZEMURON,succinylcholine,FALSE,Neg,0,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,5,12
2976,"Drug Interactions: The use of DRUG1    (DRUGOTHER) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",ZEMURON,succinylcholine,FALSE,Neg,0,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,5,12
2977,"Drug Interactions: The use of DRUGOTHER    (DRUG1) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",rocuronium bromide,succinylcholine,FALSE,Neg,0,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,9,12
2978,"Drug Interactions: The use of DRUGOTHER    (DRUG1) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",rocuronium bromide,succinylcholine,FALSE,Neg,0,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,9,12
2979,"Drug Interactions: The use of DRUGOTHER    (DRUGOTHER) Injection before DRUG1, for the purpose of attenuating some of the side effects of DRUG1, has not been studied. ",succinylcholine,succinylcholine,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,12,-1
2980,"If DRUG1    is administered following administration of DRUG2, it should not be given until recovery from DRUG2 has been observed. ",ZEMURON,succinylcholine,TRUE,advise,1,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,10
2981,"If DRUG1    is administered following administration of DRUG2, it should not be given until recovery from DRUG2 has been observed. ",ZEMURON,succinylcholine,FALSE,Neg,0,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,10
2982,"If DRUGOTHER    is administered following administration of DRUG1, it should not be given until recovery from DRUG1 has been observed. ",succinylcholine,succinylcholine,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,10,-1
2983,"The median duration of action of DRUG1    0.6 mg/kg administered after a 1 mg/kg dose of DRUG2 when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. ",ZEMURON,succinylcholine,FALSE,Neg,0,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,6,19
2984,"DRUG1 should be used with caution in patients receiving other local DRUG2 or agents structurally related to amide-type local DRUG2, since the toxic effects of these drugs are additive. ",Ropivacaine,anesthetics,TRUE,advise,1,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCOC(=O)C1=CC=C(N)C=C1,0,11
2985,"In vivo, the plasma clearance of DRUG1 was reduced by 70% during coadministration of DRUG2 (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",ropivacaine,fluvoxamine,TRUE,mechanism,4,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,6,14
2986,"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUGOTHER plasma levels. ",fluvoxamine,Ropivacaine,TRUE,int,3,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,8,14
2987,"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUGOTHER plasma levels. ",fluvoxamine,Ropivacaine,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,8,14
2988,"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUGOTHER, can interact with DRUGOTHER leading to increased DRUG2 plasma levels. ",fluvoxamine,ropivacaine,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,8,22
2989,"Thus strong inhibitors of cytochrome P4501A2, such as DRUGOTHER, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUGOTHER plasma levels. ",Ropivacaine,Ropivacaine,FALSE,Neg,0,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,14,-1
2990,"Thus strong inhibitors of cytochrome P4501A2, such as DRUGOTHER, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG2 plasma levels. ",Ropivacaine,ropivacaine,FALSE,Neg,0,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,14,22
2991,"Thus strong inhibitors of cytochrome P4501A2, such as DRUGOTHER, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG2 plasma levels. ",Ropivacaine,ropivacaine,FALSE,Neg,0,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,14,22
2992,Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as DRUG1 and DRUG2 may also occur. ,theophylline,imipramine,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,17
2993,"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",ketoconazole,ropivacaine,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,9,17
2994,"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with DRUGOTHER infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUGOTHER.",ketoconazole,ketoconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,9,-1
2995,"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",ketoconazole,ropivacaine,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,9,17
2996,"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG2 (100 mg bid for 2 days with DRUG1 infusion administered 1 hour after DRUG2) caused a 15% reduction in in-vivo plasma clearance of DRUG1.",ropivacaine,ketoconazole,FALSE,Neg,0,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,17,9
2997,"Coadministration of a selective and potent inhibitor of CYP3A4, DRUGOTHER (100 mg bid for 2 days with DRUG1 infusion administered 1 hour after DRUGOTHER) caused a 15% reduction in in-vivo plasma clearance of DRUG1.",ropivacaine,ropivacaine,FALSE,Neg,0,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,17,-1
2998,"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",ketoconazole,ropivacaine,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,9,17
2999,An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as DRUGOTHER) may decrease the AUC of DRUG2. ,gemfibrozil,rosiglitazone,TRUE,mechanism,4,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,6,12
3000,An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUGOTHER and an inducer of CYP2C8 (such as DRUG2) may decrease the AUC of DRUGOTHER. ,gemfibrozil,rifampin,FALSE,Neg,0,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,6,20
3001,An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as DRUGOTHER) may decrease the AUC of DRUG2. ,gemfibrozil,rosiglitazone,FALSE,Neg,0,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,6,12
3002,An inhibitor of CYP2C8 (such as DRUGOTHER) may increase the AUC of DRUG1 and an inducer of CYP2C8 (such as DRUG2) may decrease the AUC of DRUG1. ,rosiglitazone,rifampin,FALSE,Neg,0,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,12,20
3003,An inhibitor of CYP2C8 (such as DRUGOTHER) may increase the AUC of DRUG1 and an inducer of CYP2C8 (such as DRUGOTHER) may decrease the AUC of DRUG1. ,rosiglitazone,rosiglitazone,FALSE,Neg,0,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,12,-1
3004,An inhibitor of CYP2C8 (such as DRUGOTHER) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as DRUG1) may decrease the AUC of DRUG2. ,rifampin,rosiglitazone,TRUE,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,20,12
3005,Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain DRUGOTHER interact with DRUGOTHER and DRUG2 leading to increased serum concentrations of the latter. ,Terfenadine,astemizole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,6,8
3006,Concomitant administrations not recommended:  - DRUG1 and DRUGOTHER: Certain DRUGOTHER interact with DRUG2 and DRUGOTHER leading to increased serum concentrations of the latter. ,Terfenadine,terfenadine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,6,13
3007,Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain DRUGOTHER interact with DRUGOTHER and DRUG2 leading to increased serum concentrations of the latter. ,Terfenadine,astemizole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,6,8
3008,Concomitant administrations not recommended:  - DRUGOTHER and DRUG1: Certain DRUGOTHER interact with DRUG2 and DRUG1 leading to increased serum concentrations of the latter. ,astemizole,terfenadine,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,8,13
3009,Concomitant administrations not recommended:  - DRUGOTHER and DRUG1: Certain DRUGOTHER interact with DRUGOTHER and DRUG1 leading to increased serum concentrations of the latter. ,astemizole,astemizole,FALSE,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,8,-1
3010,Concomitant administrations not recommended:  - DRUGOTHER and DRUG2: Certain DRUGOTHER interact with DRUG1 and DRUG2 leading to increased serum concentrations of the latter. ,terfenadine,astemizole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,13,8
3011,"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUGOTHER or DRUGOTHER is not recommended. ",roxithromycin,roxithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,9,-1
3012,"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUG2 or DRUGOTHER is not recommended. ",roxithromycin,terfenadine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,9,15
3013,"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUGOTHER or DRUG2 is not recommended. ",roxithromycin,astemizole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,9,17
3014,"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUG2 or DRUGOTHER is not recommended. ",roxithromycin,terfenadine,TRUE,advise,1,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,9,15
3015,"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUGOTHER or DRUG2 is not recommended. ",roxithromycin,astemizole,TRUE,advise,1,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,9,17
3016,"Although such a reaction has not been demonstrated with DRUGOTHER, concomitant administration of DRUGOTHER with DRUG1 or DRUG2 is not recommended. ",terfenadine,astemizole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,15,17
3017,#NAME?,Cisapride,pimozide,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,1,2
3018,#NAME?,Cisapride,cisapride,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,1,7
3019,#NAME?,Cisapride,pimozide,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,1,2
3020,#NAME?,pimozide,cisapride,FALSE,Neg,0,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,2,7
3021,#NAME?,pimozide,pimozide,FALSE,Neg,0,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,2,-1
3022,#NAME?,cisapride,pimozide,FALSE,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,7,2
3023,"Although such a risk is not verified for DRUG1, combination of DRUG1 with such drugs is not recommended.",roxithromycin,roxithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,8,-1
3024,DRUG1 AND OTHER DRUGOTHER WILL BE ADDITIVE TO DRUG2 AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUGOTHER TO TOXIC LEVELS. ,ASPIRIN,DISALCID,TRUE,effect,2,CC(=O)OC1=CC=CC=C1C(=O)O,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,0,8
3025,DRUG1 AND OTHER DRUGOTHER WILL BE ADDITIVE TO DRUGOTHER AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,ASPIRIN,SALICYLIC ACID,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C1=CC=C(C(=C1)C(=O)O)O,0,15
3026,DRUGOTHER AND OTHER DRUGOTHER WILL BE ADDITIVE TO DRUG1 AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,DISALCID,SALICYLIC ACID,FALSE,Neg,0,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,C1=CC=C(C(=C1)C(=O)O)O,8,15
3027,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,penicillin,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,0,12
3028,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,thiopental,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,0,13
3029,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,thyroxine,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,0,14
3030,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,triiodothyronine,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,0,15
3031,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,phenytoin,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,16
3032,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,sulfinpyrazone,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,0,17
3033,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,naproxen,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,0,18
3034,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,warfarin,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,19
3035,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",Salicylate,methotrexate,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,20
3036,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",Salicylate,corticosteroids,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,23
3037,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,thiopental,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,12,13
3038,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,thyroxine,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,12,14
3039,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,triiodothyronine,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,12,15
3040,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,phenytoin,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,16
3041,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,sulfinpyrazone,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,12,17
3042,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,naproxen,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,12,18
3043,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,warfarin,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,12,19
3044,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",penicillin,methotrexate,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,12,20
3045,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",penicillin,corticosteroids,FALSE,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,12,23
3046,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thiopental,thyroxine,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,13,14
3047,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thiopental,triiodothyronine,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,13,15
3048,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thiopental,phenytoin,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,16
3049,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thiopental,sulfinpyrazone,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,13,17
3050,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thiopental,naproxen,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,13,18
3051,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",thiopental,warfarin,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,13,19
3052,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",thiopental,methotrexate,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,13,20
3053,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",thiopental,corticosteroids,FALSE,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,23
3054,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thyroxine,triiodothyronine,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,14,15
3055,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thyroxine,phenytoin,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,16
3056,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thyroxine,sulfinpyrazone,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,14,17
3057,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thyroxine,naproxen,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,14,18
3058,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",thyroxine,warfarin,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,14,19
3059,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",thyroxine,methotrexate,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,14,20
3060,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",thyroxine,corticosteroids,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,14,23
3061,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",triiodothyronine,phenytoin,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,16
3062,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",triiodothyronine,sulfinpyrazone,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,15,17
3063,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",triiodothyronine,naproxen,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,15,18
3064,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",triiodothyronine,warfarin,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,15,19
3065,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",triiodothyronine,methotrexate,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,15,20
3066,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",triiodothyronine,corticosteroids,FALSE,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,15,23
3067,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",phenytoin,sulfinpyrazone,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,16,17
3068,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",phenytoin,naproxen,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,16,18
3069,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",phenytoin,warfarin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,16,19
3070,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",phenytoin,methotrexate,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,16,20
3071,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",phenytoin,corticosteroids,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,16,23
3072,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",sulfinpyrazone,naproxen,FALSE,Neg,0,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,17,18
3073,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",sulfinpyrazone,warfarin,FALSE,Neg,0,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,17,19
3074,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",sulfinpyrazone,methotrexate,FALSE,Neg,0,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,17,20
3075,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",sulfinpyrazone,corticosteroids,FALSE,Neg,0,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,17,23
3076,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",naproxen,warfarin,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,18,19
3077,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",naproxen,methotrexate,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,18,20
3078,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",naproxen,corticosteroids,FALSE,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,18,23
3079,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and possibly DRUGOTHER. ",warfarin,methotrexate,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,19,20
3080,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and possibly DRUG2. ",warfarin,corticosteroids,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,19,23
3081,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and possibly DRUG2. ",methotrexate,corticosteroids,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,20,23
3082,"DRUG1 should be used with care in patients taking other drugs that are capable of causing CNS effects such as DRUGOTHER, DRUG2, or DRUGOTHER. ",Scopolamine,tranquilizers,TRUE,advise,1,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,0,21
3083,"DRUG1 should be used with care in patients taking other drugs that are capable of causing CNS effects such as DRUGOTHER, DRUGOTHER, or DRUG2. ",Scopolamine,alcohol,TRUE,advise,1,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,CCO,0,23
3084,"DRUGOTHER should be used with care in patients taking other drugs that are capable of causing CNS effects such as DRUGOTHER, DRUG1, or DRUG2. ",tranquilizers,alcohol,FALSE,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CCO,21,23
3085,"e.g., other DRUG1, DRUG2 (including DRUGOTHER), DRUGOTHER, and DRUGOTHER. ",belladonna alkaloids,antihistamines,FALSE,Neg,0,CN1C2CCC1CC(C2)OC(=O)C3CCC(C4=CC=CC=C34)(C5=CC=CC=C5)C(=O)OC6CC7CCC(C6)N7C,NCCC1=CNC=N1,2,3
3086,"e.g., other DRUG1, DRUGOTHER (including DRUG2), DRUGOTHER, and DRUGOTHER. ",belladonna alkaloids,meclizine,FALSE,Neg,0,CN1C2CCC1CC(C2)OC(=O)C3CCC(C4=CC=CC=C34)(C5=CC=CC=C5)C(=O)OC6CC7CCC(C6)N7C,CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,2,5
3087,"e.g., other DRUG1, DRUGOTHER (including DRUGOTHER), DRUG2, and DRUGOTHER. ",belladonna alkaloids,tricyclic antidepressants,FALSE,Neg,0,CN1C2CCC1CC(C2)OC(=O)C3CCC(C4=CC=CC=C34)(C5=CC=CC=C5)C(=O)OC6CC7CCC(C6)N7C,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,2,6
3088,"e.g., other DRUGOTHER, DRUG1 (including DRUG2), DRUGOTHER, and DRUGOTHER. ",antihistamines,meclizine,FALSE,Neg,0,NCCC1=CNC=N1,CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,3,5
3089,"e.g., other DRUGOTHER, DRUG1 (including DRUGOTHER), DRUG2, and DRUGOTHER. ",antihistamines,tricyclic antidepressants,FALSE,Neg,0,NCCC1=CNC=N1,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,3,6
3090,"e.g., other DRUGOTHER, DRUGOTHER (including DRUG1), DRUG2, and DRUGOTHER. ",meclizine,tricyclic antidepressants,FALSE,Neg,0,CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,5,6
3091,"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,antibiotics,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,7,9
3092,"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,quinidine,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,7,10
3093,"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,theophylline,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,11
3094,"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",contraceptives,corticosteroids,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,12
3095,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",antibiotics,quinidine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,9,10
3096,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",antibiotics,theophylline,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,11
3097,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",antibiotics,corticosteroids,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,9,12
3098,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",quinidine,theophylline,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,11
3099,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",quinidine,corticosteroids,FALSE,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,10,12
3100,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",theophylline,corticosteroids,FALSE,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,11,12
3101,"The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of DRUG1 and DRUG2. ",selegiline,meperidine,TRUE,effect,2,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,21,23
3102,Severe toxicity has also been reported in patients receiving the combination of DRUG1 and DRUG2 and DRUGOTHER and DRUG2. ,tricyclic antidepressants,ELDEPRYL,TRUE,effect,2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C[C@H](CC1=CC=CC=C1)N(C)CC#C,12,14
3103,Severe toxicity has also been reported in patients receiving the combination of DRUG1 and DRUGOTHER and DRUG2 and DRUGOTHER. ,tricyclic antidepressants,selective serotonin reuptake inhibitors,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,12,16
3104,Severe toxicity has also been reported in patients receiving the combination of DRUG1 and DRUG2 and DRUGOTHER and DRUG2. ,tricyclic antidepressants,ELDEPRYL,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C[C@H](CC1=CC=CC=C1)N(C)CC#C,12,14
3105,Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG1 and DRUG2 and DRUG1. ,ELDEPRYL,selective serotonin reuptake inhibitors,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,NCCC1=CNC2=CC=C(O)C=C12,14,16
3106,Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG1 and DRUGOTHER and DRUG1. ,ELDEPRYL,ELDEPRYL,FALSE,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C[C@H](CC1=CC=CC=C1)N(C)CC#C,14,-1
3107,Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG2 and DRUG1 and DRUG2. ,selective serotonin reuptake inhibitors,ELDEPRYL,TRUE,effect,2,NCCC1=CNC2=CC=C(O)C=C12,C[C@H](CC1=CC=CC=C1)N(C)CC#C,16,14
3108,One case of hypertensive crisis has been reported in a patient taking the recommended doses of DRUG1 and a DRUGOTHER (DRUG2).,selegiline,ephedrine,TRUE,effect,2,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,16,20
3109,"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of DRUG2 with the co-administration of 100 mg DRUGOTHER for 10 days. ",Digoxin,digoxin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,22
3110,"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of DRUGOTHER with the co-administration of 100 mg DRUG2 for 10 days. ",Digoxin,sitagliptin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N,0,29
3111,"DRUGOTHER: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of DRUG1 with the co-administration of 100 mg DRUG2 for 10 days. ",digoxin,sitagliptin,TRUE,mechanism,4,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N,22,29
3112,No dosage adjustment of DRUG1 or DRUG2 is recommended.,digoxin,JANUVIA,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N,4,6
3113,DRUG1 and DRUG2 are incompatible with DRUGOTHER solution. ,norepinephrine,dobutamine,FALSE,Neg,0,C1=CC(=C(C=C1[C@H](CN)O)O)O,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,0,2
3114,DRUG1 and DRUGOTHER are incompatible with DRUG2 solution. ,norepinephrine,sodium bicarbonate,TRUE,int,3,C1=CC(=C(C=C1[C@H](CN)O)O)O,C(=O)(O)[O-].[Na+],0,6
3115,DRUGOTHER and DRUG1 are incompatible with DRUG2 solution. ,dobutamine,sodium bicarbonate,TRUE,int,3,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,C(=O)(O)[O-].[Na+],2,6
3116,Do not exceed a 5 mg daily dose of DRUG1 when administered with therapeutic doses of DRUG2 or other potent CYP3A4 inhibitors. ,VESIcare,ketoconazole,TRUE,advise,1,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,9,16
3117,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUGOTHER at its therapeutic dose. ",solifenacin,solifenacin,FALSE,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,14,-1
3118,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUGOTHER at its therapeutic dose. ",solifenacin,solifenacin,FALSE,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,14,-1
3119,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",solifenacin,moxifloxacin,FALSE,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,14,61
3120,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUGOTHER at its therapeutic dose. ",solifenacin,solifenacin,FALSE,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,14,-1
3121,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",solifenacin,moxifloxacin,FALSE,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,14,61
3122,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",solifenacin,moxifloxacin,FALSE,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,14,61
3123,"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER). ",corticosteroids,anticonvulsants,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,21,23
3124,"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2). ",corticosteroids,cyclosporin,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,21,24
3125,"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2). ",anticonvulsants,cyclosporin,FALSE,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,23,24
3126,Caution is recommended when administering DRUG1 with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. DRUG2). ,NEXAVAR,irinotecan,TRUE,advise,1,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,5,17
3127,Concomitant treatment with DRUG1 resulted in a 21% increase in the AUC of DRUG2. ,NEXAVAR,doxorubicin,TRUE,mechanism,4,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,3,13
3128,Caution is recommended when administering DRUG1 with DRUG2. ,doxorubicin,NEXAVAR,TRUE,advise,1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,5,7
3129,DRUG1 competitively inhibits the intracellular phosphorylation of DRUG2. ,Zidovudine,stavudine,TRUE,effect,2,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,0,7
3130,"Therefore, use of DRUG1 in combination with DRUG2 should be avoided. ",zidovudine,ZERIT,TRUE,advise,1,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,3,7
3131,In vitro data indicate that the phosphorylation of DRUG1 is also inhibited at relevant concentrations by DRUG2 and DRUGOTHER. ,stavudine,doxorubicin,TRUE,effect,2,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,8,16
3132,In vitro data indicate that the phosphorylation of DRUG1 is also inhibited at relevant concentrations by DRUGOTHER and DRUG2. ,stavudine,ribavirin,TRUE,effect,2,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,8,18
3133,In vitro data indicate that the phosphorylation of DRUGOTHER is also inhibited at relevant concentrations by DRUG1 and DRUG2. ,doxorubicin,ribavirin,FALSE,Neg,0,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,16,18
3134,DRUG1 has been reported to prolong the elimination half-life of DRUG2 and may lead to severe bone marrow suppression; ,Streptozocin,doxorubicin,TRUE,mechanism,4,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,0,10
3135,a reduction of the DRUG1 dosage should be considered in patients receiving DRUG2 concurrently. ,doxorubicin,ZANOSAR,TRUE,advise,1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,4,12
3136,The concurrent use of DRUG1 and DRUG2 has been reported in one case to result in reduced DRUG1 cytotoxicity.    ,streptozocin,phenytoin,TRUE,effect,2,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,6
3137,The concurrent use of DRUG1 and DRUGOTHER has been reported in one case to result in reduced DRUG1 cytotoxicity.    ,streptozocin,streptozocin,FALSE,Neg,0,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,4,-1
3138,The concurrent use of DRUG2 and DRUG1 has been reported in one case to result in reduced DRUG2 cytotoxicity.    ,phenytoin,streptozocin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,6,4
3139,"DRUG1 may increase the effects of DRUGOTHER, DRUG2, and DRUGOTHER. ",Sulfamethizole,tolbutamide,TRUE,effect,2,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,0,7
3140,"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,cyclosporine,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,8
3141,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,warfarin,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,15
3142,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
3143,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
3144,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
3145,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
3146,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",cyclosporine,warfarin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,15
3147,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",cyclosporine,methotrexate,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,8,19
3148,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",cyclosporine,methotrexate,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,8,19
3149,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
3150,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
3151,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",warfarin,methotrexate,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,15,19
3152,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",warfarin,methotrexate,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,15,19
3153,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
3154,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
3155,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",methotrexate,methotrexate,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,19,-1
3156,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3157,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3158,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3159,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3160,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG1 (decreased hepatic clearance of DRUG1).",phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,-1
3161,"In elderly patients concurrently receiving certain DRUG1, primarily DRUG2, an increased incidence of thrombopenia with purpura has been reported. ",diuretics,thiazides,FALSE,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,6,8
3162,It has been reported that DRUG1 may prolong the prothrombin time in patients who are receiving the DRUG2 DRUGOTHER. ,sulfamethoxazole,anticoagulant,FALSE,Neg,0,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,5,17
3163,It has been reported that DRUG1 may prolong the prothrombin time in patients who are receiving the DRUGOTHER DRUG2. ,sulfamethoxazole,warfarin,TRUE,effect,2,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,18
3164,It has been reported that DRUGOTHER may prolong the prothrombin time in patients who are receiving the DRUG1 DRUG2. ,anticoagulant,warfarin,FALSE,Neg,0,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,17,18
3165,DRUG1 may inhibit the hepatic metabolism of DRUG2. ,Sulfamethoxazole,phenytoin,TRUE,mechanism,4,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
3166,"At a 1.6-g dose, DRUG1 produced a slight but significant increase in the half-life of DRUG2 but did not produce a corresponding decrease in the metabolic clearance rate. ",sulfamethoxazole,phenytoin,TRUE,mechanism,4,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,15
3167,"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",Sulfonamides,methotrexate,TRUE,mechanism,4,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,4
3168,"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",Sulfonamides,methotrexate,FALSE,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,4
3169,"DRUGOTHER can also displace DRUG1 from plasma protein-binding sites, thus increasing free DRUG1 concentrations. ",methotrexate,methotrexate,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,4,-1
3170,Reduced absorption of DRUG1 and DRUG2 have been reported when those agents were administered concomitantly with DRUGOTHER. ,folic acid,digoxin,FALSE,Neg,0,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,3,5
3171,Reduced absorption of DRUG1 and DRUGOTHER have been reported when those agents were administered concomitantly with DRUG2. ,folic acid,sulfasalazine,TRUE,mechanism,4,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,3,16
3172,Reduced absorption of DRUGOTHER and DRUG1 have been reported when those agents were administered concomitantly with DRUG2. ,digoxin,sulfasalazine,TRUE,mechanism,4,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,5,16
3173,"When daily doses of DRUG1 2 g and weekly doses of DRUG2 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. ",sulfasalazine,methotrexate,FALSE,Neg,0,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,4,11
3174,Daily doses of DRUG1 2 g (maximum 3 g) and weekly doses of DRUG2 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. ,sulfasalazine,methotrexate,FALSE,Neg,0,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,3,13
3175,"DRUG1 may increase the effects of DRUGOTHER, DRUG2, and DRUGOTHER. ",Sulfoxone,tolbutamide,TRUE,effect,2,C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,0,7
3176,"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,cyclosporine,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,8
3177,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,warfarin,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,15
3178,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
3179,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
3180,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
3181,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,FALSE,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
3182,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",cyclosporine,warfarin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,15
3183,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",cyclosporine,methotrexate,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,8,19
3184,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",cyclosporine,methotrexate,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,8,19
3185,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
3186,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
3187,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",warfarin,methotrexate,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,15,19
3188,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",warfarin,methotrexate,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,15,19
3189,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
3190,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
3191,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",methotrexate,methotrexate,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,19,-1
3192,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3193,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3194,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3195,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
3196,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG1 (decreased hepatic clearance of DRUG1).",phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,-1
3197,"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUGOTHER) and DRUGOTHER within 24 hours of each other should be avoided. ",ergotamine,dihydroergotamine,FALSE,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,14,-1
3198,"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided. ",ergotamine,methysergide,FALSE,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,14,20
3199,"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUGOTHER) and DRUG2 within 24 hours of each other should be avoided. ",ergotamine,sumatriptan,TRUE,advise,1,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,14,22
3200,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided. ",dihydroergotamine,methysergide,FALSE,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,18,20
3201,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUGOTHER) and DRUG2 within 24 hours of each other should be avoided. ",dihydroergotamine,sumatriptan,TRUE,advise,1,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,18,22
3202,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like dihydroDRUGOTHER or DRUG1) and DRUG2 within 24 hours of each other should be avoided. ",methysergide,sumatriptan,TRUE,advise,1,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,20,22
3203,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,fluoxetine,FALSE,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,4,16
3204,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,fluvoxamine,FALSE,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,4,17
3205,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,paroxetine,FALSE,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,4,18
3206,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,sertraline,FALSE,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4,19
3207,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",sumatriptan succinate,sumatriptan,FALSE,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,4,33
3208,"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",fluoxetine,fluvoxamine,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,16,17
3209,"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",fluoxetine,paroxetine,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,16,18
3210,"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",fluoxetine,sertraline,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,16,19
3211,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",fluoxetine,sumatriptan,TRUE,effect,2,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,17,4
3212,"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",fluvoxamine,paroxetine,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,17,18
3213,"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",fluvoxamine,sertraline,FALSE,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,17,19
3214,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",fluvoxamine,sumatriptan,TRUE,effect,2,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,18,4
3215,"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",paroxetine,sertraline,FALSE,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,18,19
3216,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",paroxetine,sumatriptan,TRUE,effect,2,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,19,4
3217,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",sertraline,sumatriptan,TRUE,effect,2,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,20,4
3218,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,ketoconazole,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,2,11
3219,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,itraconazole,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,2,12
3220,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,clarithromycin,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,2,13
3221,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,atazanavir,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,2,14
3222,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,indinavir,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,2,15
3223,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,nefazodone,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,2,16
3224,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,nelfinavir,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,2,17
3225,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,ritonavir,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,2,18
3226,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,saquinavir,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,2,19
3227,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,telithromycin,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,2,20
3228,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",SUTENT,sunitinib,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,2,24
3229,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,11,12
3230,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,clarithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,11,13
3231,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,atazanavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,11,14
3232,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,indinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,11,15
3233,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,nefazodone,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,16
3234,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,nelfinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,11,17
3235,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,ritonavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,18
3236,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,saquinavir,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,19
3237,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,telithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,20
3238,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",ketoconazole,sunitinib,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,11,24
3239,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,clarithromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,12,13
3240,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,atazanavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,12,14
3241,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,indinavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,12,15
3242,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,nefazodone,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,12,16
3243,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,nelfinavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,12,17
3244,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,ritonavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,12,18
3245,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,saquinavir,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,12,19
3246,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,telithromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,12,20
3247,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",itraconazole,sunitinib,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,12,24
3248,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,atazanavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,13,14
3249,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,indinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,13,15
3250,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,nefazodone,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,13,16
3251,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,nelfinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,13,17
3252,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,ritonavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,13,18
3253,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,saquinavir,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,13,19
3254,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,telithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,13,20
3255,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",clarithromycin,sunitinib,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,13,24
3256,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,indinavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,14,15
3257,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,nefazodone,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,14,16
3258,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,nelfinavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,14,17
3259,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,ritonavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,14,18
3260,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,saquinavir,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,14,19
3261,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,telithromycin,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,14,20
3262,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",atazanavir,sunitinib,FALSE,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,14,24
3263,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,nefazodone,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,15,16
3264,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,nelfinavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,15,17
3265,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,ritonavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,15,18
3266,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,saquinavir,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,15,19
3267,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,telithromycin,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,15,20
3268,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",indinavir,sunitinib,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,15,24
3269,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,nelfinavir,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,16,17
3270,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,ritonavir,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,16,18
3271,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,saquinavir,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,16,19
3272,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,telithromycin,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,16,20
3273,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",nefazodone,sunitinib,FALSE,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,16,24
3274,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nelfinavir,ritonavir,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,17,18
3275,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nelfinavir,saquinavir,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,17,19
3276,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",nelfinavir,telithromycin,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,17,20
3277,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",nelfinavir,sunitinib,FALSE,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,17,24
3278,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ritonavir,saquinavir,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,18,19
3279,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",ritonavir,telithromycin,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,18,20
3280,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",ritonavir,sunitinib,FALSE,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,18,24
3281,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",saquinavir,telithromycin,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,19,20
3282,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",saquinavir,sunitinib,FALSE,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,19,24
3283,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) may increases DRUG2 concentrations. ",telithromycin,sunitinib,FALSE,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,20,24
3284,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,dexamethasone,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,2,10
3285,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,phenytoin,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,11
3286,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,carbamazepine,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,2,12
3287,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,rifampin,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,2,13
3288,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,rifabutin,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,2,14
3289,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,rifapentin,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,2,15
3290,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,phenobarbital,TRUE,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,2,16
3291,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",SUTENT,sunitinib,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,2,22
3292,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",dexamethasone,phenytoin,FALSE,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,11
3293,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",dexamethasone,carbamazepine,FALSE,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,10,12
3294,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",dexamethasone,rifampin,FALSE,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,10,13
3295,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",dexamethasone,rifabutin,FALSE,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,10,14
3296,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",dexamethasone,rifapentin,FALSE,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,10,15
3297,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",dexamethasone,phenobarbital,FALSE,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,10,16
3298,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",dexamethasone,sunitinib,FALSE,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,10,22
3299,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,11,12
3300,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,rifampin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,11,13
3301,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,rifabutin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,11,14
3302,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,rifapentin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,11,15
3303,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,phenobarbital,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,11,16
3304,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",phenytoin,sunitinib,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,11,22
3305,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",carbamazepine,rifampin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,12,13
3306,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",carbamazepine,rifabutin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,12,14
3307,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",carbamazepine,rifapentin,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,12,15
3308,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",carbamazepine,phenobarbital,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,12,16
3309,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",carbamazepine,sunitinib,FALSE,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,12,22
3310,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",rifampin,rifabutin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,13,14
3311,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",rifampin,rifapentin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,13,15
3312,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",rifampin,phenobarbital,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,13,16
3313,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",rifampin,sunitinib,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,13,22
3314,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",rifabutin,rifapentin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,14,15
3315,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",rifabutin,phenobarbital,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,14,16
3316,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",rifabutin,sunitinib,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,14,22
3317,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",rifapentin,phenobarbital,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,15,16
3318,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",rifapentin,sunitinib,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,15,22
3319,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, St. Johns Wort) may decrease DRUG2 concentrations. ",phenobarbital,sunitinib,FALSE,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,16,22
3320,"Other eye drops or medications such as DRUG1 (DRUG2) and DRUGOTHER (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",acetylcholine chloride,Miochol,FALSE,Neg,0,CC(=O)OCC[N+](C)(C)C.[Cl-],CC(=O)OCC[N+](C)(C)C.[Cl-],7,8
3321,"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUG2 (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",acetylcholine chloride,carbachol,FALSE,Neg,0,CC(=O)OCC[N+](C)(C)C.[Cl-],C[N+](C)(C)CCOC(=O)N.[Cl-],7,10
3322,"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUGOTHER (DRUG2, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",acetylcholine chloride,Carboptic,FALSE,Neg,0,CC(=O)OCC[N+](C)(C)C.[Cl-],C[N+](C)(C)CCOC(=O)N,7,11
3323,"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUGOTHER (DRUGOTHER, DRUG2) may decrease the effects of DRUGOTHER ophthalmic.",acetylcholine chloride,Isopto Carbachol,FALSE,Neg,0,CC(=O)OCC[N+](C)(C)C.[Cl-],C[N+](C)(C)CCOC(=O)N.[Cl-],7,12
3324,"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUGOTHER (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",acetylcholine chloride,suprofen,TRUE,effect,2,CC(=O)OCC[N+](C)(C)C.[Cl-],CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,7,18
3325,"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUG2 (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",Miochol,carbachol,FALSE,Neg,0,CC(=O)OCC[N+](C)(C)C.[Cl-],C[N+](C)(C)CCOC(=O)N.[Cl-],8,10
3326,"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUGOTHER (DRUG2, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",Miochol,Carboptic,FALSE,Neg,0,CC(=O)OCC[N+](C)(C)C.[Cl-],C[N+](C)(C)CCOC(=O)N,8,11
3327,"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUGOTHER (DRUGOTHER, DRUG2) may decrease the effects of DRUGOTHER ophthalmic.",Miochol,Isopto Carbachol,FALSE,Neg,0,CC(=O)OCC[N+](C)(C)C.[Cl-],C[N+](C)(C)CCOC(=O)N.[Cl-],8,12
3328,"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUGOTHER (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",Miochol,suprofen,TRUE,effect,2,CC(=O)OCC[N+](C)(C)C.[Cl-],CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,8,18
3329,"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUG1 (DRUG2, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",carbachol,Carboptic,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)N.[Cl-],C[N+](C)(C)CCOC(=O)N,10,11
3330,"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUG1 (DRUGOTHER, DRUG2) may decrease the effects of DRUGOTHER ophthalmic.",carbachol,Isopto Carbachol,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)N.[Cl-],C[N+](C)(C)CCOC(=O)N.[Cl-],10,12
3331,"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUG1 (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",carbachol,suprofen,TRUE,effect,2,C[N+](C)(C)CCOC(=O)N.[Cl-],CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,10,18
3332,"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUGOTHER (DRUG1, DRUG2) may decrease the effects of DRUGOTHER ophthalmic.",Carboptic,Isopto Carbachol,FALSE,Neg,0,C[N+](C)(C)CCOC(=O)N,C[N+](C)(C)CCOC(=O)N.[Cl-],11,12
3333,"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUGOTHER (DRUG1, DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",Carboptic,suprofen,TRUE,effect,2,C[N+](C)(C)CCOC(=O)N,CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,11,18
3334,"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUGOTHER (DRUGOTHER, DRUG1) may decrease the effects of DRUG2 ophthalmic.",Isopto Carbachol,suprofen,TRUE,effect,2,C[N+](C)(C)CCOC(=O)N.[Cl-],CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,12,18
3335,The pharmacokinetic interaction between DRUG1 and DRUG2 capsules was investigated. ,cimetidine,FLOMAX,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.Cl,4,6
3336,"Therefore, DRUG1 capsules should be used with caution in combination with DRUG2, particularly at doses higher than 0.4 mg. ",FLOMAX,cimetidine,TRUE,advise,1,CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,1,11
3337,"Therefore, caution should be exercised with concomitant administration of DRUG1 and DRUG2 capsules.        ",warfarin,FLOMAX,TRUE,advise,1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.Cl,9,11
3338,Administration of DRUG1 decreases oral clearance of DRUG2 by about 5%. ,valproic acid,temozolomide,TRUE,mechanism,4,CCCC(CCC)C(=O)O,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,2,7
3339,Patients studied in clinical trials of DRUGOTHER were routinely treated with DRUG1 and DRUG2. ,heparin,aspirin,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(=O)OC1=CC=CC=C1C(=O)O,11,13
3340,"DRUGOTHER (such as DRUG1 and DRUG2) and drugs that alter platelet function (such as DRUGOTHER, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",heparin,vitamin K antagonists,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,OC(=O)CCCCCCCC(O)=O,3,5
3341,"DRUGOTHER (such as DRUG1 and DRUGOTHER) and drugs that alter platelet function (such as DRUG2, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",heparin,acetylsalicylic acid,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(=O)OC1=CC=CC=C1C(=O)O,3,14
3342,"DRUGOTHER (such as DRUG1 and DRUGOTHER) and drugs that alter platelet function (such as DRUGOTHER, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",heparin,dipyridamole,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,3,15
3343,"DRUGOTHER (such as DRUGOTHER and DRUG1) and drugs that alter platelet function (such as DRUG2, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",vitamin K antagonists,acetylsalicylic acid,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CC(=O)OC1=CC=CC=C1C(=O)O,5,14
3344,"DRUGOTHER (such as DRUGOTHER and DRUG1) and drugs that alter platelet function (such as DRUGOTHER, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",vitamin K antagonists,dipyridamole,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,5,15
3345,"DRUGOTHER (such as DRUGOTHER and DRUGOTHER) and drugs that alter platelet function (such as DRUG1, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",acetylsalicylic acid,dipyridamole,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,14,15
3346,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUG1, DRUG2 and DRUGOTHER displaced protein-bound DRUGOTHER in fresh human serum to a small but significant extent. ",tolbutamide,sodium salicylate,FALSE,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],14,15
3347,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUG1, DRUGOTHER and DRUG2 displaced protein-bound DRUGOTHER in fresh human serum to a small but significant extent. ",tolbutamide,sulfamethizole,FALSE,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,14,17
3348,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUG1, DRUGOTHER and DRUGOTHER displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",tolbutamide,teniposide,TRUE,mechanism,4,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,14,20
3349,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUGOTHER, DRUG1 and DRUG2 displaced protein-bound DRUGOTHER in fresh human serum to a small but significant extent. ",sodium salicylate,sulfamethizole,FALSE,Neg,0,C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,15,17
3350,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUGOTHER, DRUG1 and DRUGOTHER displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",sodium salicylate,teniposide,TRUE,mechanism,4,C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,15,20
3351,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUGOTHER, DRUGOTHER and DRUG1 displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",sulfamethizole,teniposide,TRUE,mechanism,4,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,17,20
3352,"Therefore, caution should be used in administering DRUG1 (DRUG2 injection) to patients receiving these other agents. ",VUMON,teniposide,FALSE,Neg,0,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,7,8
3353,There was no change in the plasma kinetics of DRUG1 when coadministered with DRUG2. ,teniposide,methotrexate,FALSE,Neg,0,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,9,13
3354,An increase in intracellular levels of DRUG1 was observed in vitro in the presence of DRUG2.,methotrexate,teniposide,TRUE,mechanism,4,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,6,15
3355,"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terbinafine,tolbutamide,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,9,16
3356,"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",terbinafine,ethinylestradiol,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,9,17
3357,"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",terbinafine,ethoxycoumarin,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CCOC1=CC2=CC=CC=C2OC1=O,9,18
3358,"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",terbinafine,cyclosporine,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,9,20
3359,"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",tolbutamide,ethinylestradiol,FALSE,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,16,17
3360,"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",tolbutamide,ethoxycoumarin,FALSE,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,CCOC1=CC2=CC=CC=C2OC1=O,16,18
3361,"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",tolbutamide,cyclosporine,FALSE,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,16,20
3362,"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",ethinylestradiol,ethoxycoumarin,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CCOC1=CC2=CC=CC=C2OC1=O,17,18
3363,"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",ethinylestradiol,cyclosporine,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,17,20
3364,"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",ethoxycoumarin,cyclosporine,FALSE,Neg,0,CCOC1=CC2=CC=CC=C2OC1=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,18,20
3365,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUG1,    -blockers, DRUG2 (DRUGOTHER), and DRUGOTHER, if they have a narrow therapeutic window. ",tricyclic antidepressants,selective serotonin reuptake inhibitors,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,15,20
3366,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that DRUG1 does not affect the clearance of DRUG2 or DRUGOTHER. ,terbinafine,antipyrine,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CC1=CC(=O)N(N1C)C2=CC=CC=C2,12,19
3367,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that DRUG1 does not affect the clearance of DRUGOTHER or DRUG2. ,terbinafine,digoxin,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,12,21
3368,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that DRUGOTHER does not affect the clearance of DRUG1 or DRUG2. ,antipyrine,digoxin,FALSE,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,19,21
3369,DRUG1 decreases the clearance of DRUG2 by 19%. ,Terbinafine,caffeine,TRUE,mechanism,4,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,5
3370,DRUG1 increases the clearance of DRUG2 by 15%. ,Terbinafine,cyclosporine,TRUE,mechanism,4,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,5
3371,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUG1 and DRUG2, however, a causal relationship between DRUGOTHER    Tablets and these changes has not been established. ",terbinafine,warfarin,TRUE,effect,2,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,17,19
3372,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUG1 and DRUGOTHER, however, a causal relationship between DRUG2    Tablets and these changes has not been established. ",terbinafine,LAMISIL,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,17,25
3373,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUGOTHER and DRUG1, however, a causal relationship between DRUG2    Tablets and these changes has not been established. ",warfarin,LAMISIL,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,19,25
3374,"DRUG1 clearance is increased 100% by DRUG2, a CyP450 enzyme inducer, and decreased 33% by DRUGOTHER, a CyP450 enzyme inhibitor. ",Terbinafine,rifampin,TRUE,mechanism,4,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,0,6
3375,"DRUG1 clearance is increased 100% by DRUGOTHER, a CyP450 enzyme inducer, and decreased 33% by DRUG2, a CyP450 enzyme inhibitor. ",Terbinafine,cimetidine,TRUE,mechanism,4,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CC1=C(N=CN1)CSCCNC(=NC)NC#N,0,15
3376,"DRUGOTHER clearance is increased 100% by DRUG1, a CyP450 enzyme inducer, and decreased 33% by DRUG2, a CyP450 enzyme inhibitor. ",rifampin,cimetidine,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC1=C(N=CN1)CSCCNC(=NC)NC#N,6,15
3377,DRUG1 clearance is unaffected by DRUG2. ,Terbinafine,cyclosporine,FALSE,Neg,0,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,5
3378,"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUG2 with recommended doses of DRUGOTHER demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",Ketoconazole,ketoconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,0,9
3379,"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUGOTHER with recommended doses of DRUG2 demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",Ketoconazole,terfenadine,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,0,14
3380,"DRUGOTHER: Spontaneous adverse reaction reports of patients taking concomitant DRUG1 with recommended doses of DRUG2 demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",ketoconazole,terfenadine,TRUE,effect,2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,9,14
3381,"Pharmacokinetic data indicate that DRUG1 markedly inhibits the metabolism of DRUG2, resulting in elevated plasma DRUG2 levels. ",ketoconazole,terfenadine,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,4,10
3382,"Pharmacokinetic data indicate that DRUG1 markedly inhibits the metabolism of DRUG2, resulting in elevated plasma DRUG2 levels. ",ketoconazole,terfenadine,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,4,10
3383,"Pharmacokinetic data indicate that DRUGOTHER markedly inhibits the metabolism of DRUG1, resulting in elevated plasma DRUG1 levels. ",terfenadine,terfenadine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,10,-1
3384,Concomitant administration of DRUG1 and DRUG2 is contraindicated. ,ketoconazole,terfenadine,TRUE,advise,1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,3,5
3385,DRUG1: Torsades de pointes and elevated parent DRUG2 levels have been reported during concomitant use of DRUG2 and DRUGOTHER in clinical trials of DRUGOTHER and from foreign post-marketing sources. ,Itraconazole,terfenadine,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,0,7
3386,DRUG1: Torsades de pointes and elevated parent DRUG2 levels have been reported during concomitant use of DRUG2 and DRUGOTHER in clinical trials of DRUGOTHER and from foreign post-marketing sources. ,Itraconazole,terfenadine,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,0,7
3387,DRUG1: Torsades de pointes and elevated parent DRUGOTHER levels have been reported during concomitant use of DRUGOTHER and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,Itraconazole,itraconazole,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,0,18
3388,DRUG1: Torsades de pointes and elevated parent DRUGOTHER levels have been reported during concomitant use of DRUGOTHER and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,Itraconazole,itraconazole,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,0,18
3389,DRUGOTHER: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUGOTHER in clinical trials of DRUGOTHER and from foreign post-marketing sources. ,terfenadine,terfenadine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,7,-1
3390,DRUGOTHER: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,terfenadine,itraconazole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,18
3391,DRUGOTHER: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,terfenadine,itraconazole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,18
3392,DRUGOTHER: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,terfenadine,itraconazole,TRUE,mechanism,4,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,18
3393,DRUGOTHER: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,terfenadine,itraconazole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,18
3394,DRUGOTHER: Torsades de pointes and elevated parent DRUGOTHER levels have been reported during concomitant use of DRUGOTHER and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,itraconazole,itraconazole,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,18,-1
3395,Concomitant administration of DRUG1 and DRUG2 is contraindicated. ,itraconazole,terfenadine,TRUE,advise,1,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,3,5
3396,"Due to the chemical similarity of other DRUGOTHER (including DRUG1, DRUG2, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",fluconazole,metronidazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC1=NC=C(N1CCO)[N+](=O)[O-],9,10
3397,"Due to the chemical similarity of other DRUGOTHER (including DRUG1, DRUGOTHER, and DRUG2) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",fluconazole,miconazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,9,12
3398,"Due to the chemical similarity of other DRUGOTHER (including DRUG1, DRUGOTHER, and DRUGOTHER) to DRUG2, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",fluconazole,ketoconazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,9,14
3399,"Due to the chemical similarity of other DRUGOTHER (including DRUG1, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",fluconazole,itraconazole,FALSE,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,9,16
3400,"Due to the chemical similarity of other DRUGOTHER (including DRUG1, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",fluconazole,terfenadine,TRUE,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,9,23
3401,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUG1, and DRUG2) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",metronidazole,miconazole,FALSE,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,10,12
3402,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUG1, and DRUGOTHER) to DRUG2, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",metronidazole,ketoconazole,FALSE,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,10,14
3403,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUG1, and DRUGOTHER) to DRUGOTHER, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",metronidazole,itraconazole,FALSE,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,10,16
3404,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUG1, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",metronidazole,terfenadine,TRUE,advise,1,CC1=NC=C(N1CCO)[N+](=O)[O-],CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,10,23
3405,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUG1) to DRUG2, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",miconazole,ketoconazole,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,12,14
3406,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUG1) to DRUGOTHER, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",miconazole,itraconazole,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,12,16
3407,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUG1) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",miconazole,terfenadine,TRUE,advise,1,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,12,23
3408,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUG1, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,14,16
3409,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUG1, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",ketoconazole,terfenadine,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,14,23
3410,"Due to the chemical similarity of other DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUG1, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",itraconazole,terfenadine,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,16,23
3411,"DRUGOTHER: Clinical drug interaction studies indicate that DRUG1 and DRUG2 can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",erythromycin,clarithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,7,9
3412,"DRUGOTHER: Clinical drug interaction studies indicate that DRUG1 and DRUGOTHER can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",erythromycin,terfenadine,TRUE,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,7,15
3413,"DRUGOTHER: Clinical drug interaction studies indicate that DRUG1 and DRUGOTHER can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",erythromycin,ketoconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7,27
3414,"DRUGOTHER: Clinical drug interaction studies indicate that DRUGOTHER and DRUG1 can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",clarithromycin,terfenadine,TRUE,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,9,15
3415,"DRUGOTHER: Clinical drug interaction studies indicate that DRUGOTHER and DRUG1 can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",clarithromycin,ketoconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,9,27
3416,"DRUGOTHER: Clinical drug interaction studies indicate that DRUGOTHER and DRUGOTHER can exert an effect on DRUG1 metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",terfenadine,ketoconazole,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,15,27
3417,"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving DRUG1 or DRUG2. ",erythromycin,troleandomycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,21,23
3418,"Concomitant administration of DRUG1 with DRUG2, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUGOTHER, including DRUGOTHER, is not recommended. ",terfenadine,clarithromycin,TRUE,advise,1,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,3,5
3419,"Concomitant administration of DRUG1 with DRUGOTHER, DRUG2, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUGOTHER, including DRUGOTHER, is not recommended. ",terfenadine,erythromycin,TRUE,advise,1,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,3,6
3420,"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUGOTHER, including DRUGOTHER, is not recommended. ",terfenadine,troleandomycin,TRUE,advise,1,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,3,8
3421,"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUGOTHER, including DRUGOTHER, is not recommended. ",terfenadine,terfenadine,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,3,-1
3422,"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUG2, including DRUGOTHER, is not recommended. ",terfenadine,macrolide antibiotics,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,3,23
3423,"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUGOTHER, including DRUG2, is not recommended. ",terfenadine,azithromycin,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,3,25
3424,"Concomitant administration of DRUGOTHER with DRUG1, DRUG2, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUGOTHER, including DRUGOTHER, is not recommended. ",clarithromycin,erythromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,5,6
3425,"Concomitant administration of DRUGOTHER with DRUG1, DRUGOTHER, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUGOTHER, including DRUGOTHER, is not recommended. ",clarithromycin,troleandomycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,5,8
3426,"Concomitant administration of DRUG2 with DRUG1, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other DRUGOTHER, including DRUGOTHER, is not recommended. ",clarithromycin,terfenadine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,5,3
3427,"Concomitant administration of DRUGOTHER with DRUG1, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUG2, including DRUGOTHER, is not recommended. ",clarithromycin,macrolide antibiotics,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,5,23
3428,"Concomitant administration of DRUGOTHER with DRUG1, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUGOTHER, including DRUG2, is not recommended. ",clarithromycin,azithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,5,25
3429,"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUG1, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUGOTHER, including DRUGOTHER, is not recommended. ",erythromycin,troleandomycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,6,8
3430,"Concomitant administration of DRUG2 with DRUGOTHER, DRUG1, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other DRUGOTHER, including DRUGOTHER, is not recommended. ",erythromycin,terfenadine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,6,3
3431,"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUG1, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUG2, including DRUGOTHER, is not recommended. ",erythromycin,macrolide antibiotics,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,6,23
3432,"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUG1, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUGOTHER, including DRUG2, is not recommended. ",erythromycin,azithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,6,25
3433,"Concomitant administration of DRUG2 with DRUGOTHER, DRUGOTHER, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other DRUGOTHER, including DRUGOTHER, is not recommended. ",troleandomycin,terfenadine,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,8,3
3434,"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUGOTHER, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUG2, including DRUGOTHER, is not recommended. ",troleandomycin,macrolide antibiotics,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,8,23
3435,"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUGOTHER, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUGOTHER, including DRUG2, is not recommended. ",troleandomycin,azithromycin,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,8,25
3436,"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUG2, including DRUGOTHER, is not recommended. ",terfenadine,macrolide antibiotics,TRUE,advise,1,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,3,23
3437,"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUGOTHER, including DRUG2, is not recommended. ",terfenadine,azithromycin,TRUE,advise,1,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,3,25
3438,"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other DRUG1, including DRUG2, is not recommended. ",macrolide antibiotics,azithromycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,23,25
3439,Studies to evaluate potential interactions of DRUG1 with DRUG2 are in progress.,terfenadine,azithromycin,FALSE,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,6,8
3443,"DRUGOTHER has been reported to enhance the sedative activity of DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",alcohol,chlorpromazine,FALSE,Neg,0,CCO,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,11,12
3444,"DRUGOTHER has been reported to enhance the sedative activity of DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",alcohol,reserpine,FALSE,Neg,0,CCO,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,11,14
3445,"DRUGOTHER has been reported to enhance the sedative activity of DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",chlorpromazine,reserpine,FALSE,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,12,14
3446,"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and DRUG2 following administration of a single dose containing 1.0 mg of DRUG1 acetate and 75    g of DRUG2 were studied. ",norethindrone,ethinyl estradiol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,10,12
3447,"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and DRUGOTHER following administration of a single dose containing 1.0 mg of DRUG1 acetate and 75    g of DRUGOTHER were studied. ",norethindrone,norethindrone acetate,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,10,-1
3448,"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and DRUG2 following administration of a single dose containing 1.0 mg of DRUG1 acetate and 75    g of DRUG2 were studied. ",norethindrone,ethinyl estradiol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,10,12
3449,"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and DRUG1 following administration of a single dose containing 1.0 mg of DRUG2 and 75    g of DRUG1 were studied. ",ethinyl estradiol,norethindrone acetate,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,12,23
3450,"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and DRUG1 following administration of a single dose containing 1.0 mg of DRUGOTHER acetate and 75    g of DRUG1 were studied. ",ethinyl estradiol,ethinyl estradiol,FALSE,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,12,-1
3451,"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and DRUG2 following administration of a single dose containing 1.0 mg of DRUG1 and 75    g of DRUG2 were studied. ",norethindrone acetate,ethinyl estradiol,FALSE,Neg,0,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,23,12
3452,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUG2: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Thalidomide,Hormonal Contraceptives,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,1,8
3453,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Thalidomide,griseofulvin,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,1,13
3454,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Thalidomide,modafinil,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,1,14
3455,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Thalidomide,penicillins,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,1,15
3456,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Thalidomide,rifampin,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,1,16
3457,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Thalidomide,rifabutin,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,1,17
3458,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",Thalidomide,phenytoin,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,18
3459,"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",Thalidomide,carbamazepine,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1,19
3460,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Hormonal Contraceptives,griseofulvin,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,8,13
3461,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Hormonal Contraceptives,modafinil,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,8,14
3462,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Hormonal Contraceptives,penicillins,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,8,15
3463,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Hormonal Contraceptives,rifampin,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,16
3464,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",Hormonal Contraceptives,rifabutin,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,8,17
3465,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",Hormonal Contraceptives,phenytoin,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,18
3466,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",Hormonal Contraceptives,carbamazepine,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,8,19
3467,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",griseofulvin,modafinil,FALSE,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,13,14
3468,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",griseofulvin,penicillins,FALSE,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,13,15
3469,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",griseofulvin,rifampin,FALSE,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,13,16
3470,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",griseofulvin,rifabutin,FALSE,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,13,17
3471,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",griseofulvin,phenytoin,FALSE,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,18
3472,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",griseofulvin,carbamazepine,FALSE,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,13,19
3473,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",modafinil,penicillins,FALSE,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,14,15
3474,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",modafinil,rifampin,FALSE,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,14,16
3475,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",modafinil,rifabutin,FALSE,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,14,17
3476,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",modafinil,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,18
3477,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",modafinil,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,14,19
3478,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",penicillins,rifampin,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,15,16
3479,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",penicillins,rifabutin,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,15,17
3480,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",penicillins,phenytoin,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,18
3481,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",penicillins,carbamazepine,FALSE,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,15,19
3482,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",rifampin,rifabutin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,16,17
3483,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",rifampin,phenytoin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,18
3484,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",rifampin,carbamazepine,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,16,19
3485,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",rifabutin,phenytoin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,18
3486,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",rifabutin,carbamazepine,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,17,19
3487,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or certain herbal supplements such as St. ",phenytoin,carbamazepine,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,18,19
3488,"DRUG1 may compete with other drugs, such as DRUG2, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",Thiabendazole,theophylline,TRUE,mechanism,4,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,8
3489,"Interactions for DRUG1 (DRUG2):  DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER",Vitamin B1,Thiamine,FALSE,Neg,0,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Cl-],CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO,2,3
3490,"Interactions for DRUG1 (DRUGOTHER):  DRUGOTHER, Oral DRUGOTHER, DRUG2, DRUGOTHER",Vitamin B1,Stavudine,TRUE,int,3,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Cl-],CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,2,8
3491,"Interactions for DRUGOTHER (DRUG1):  DRUGOTHER, Oral DRUGOTHER, DRUG2, DRUGOTHER",Thiamine,Stavudine,TRUE,int,3,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,3,8
3492,"DRUG1 are capable of potentiating DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) ",Phenothiazines,CNS depressants,TRUE,effect,2,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,5
3493,"DRUG1 are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, etc.) ",Phenothiazines,anesthetics,TRUE,effect,2,N1C2=CC=CC=C2SC2=CC=CC=C12,CCOC(=O)C1=CC=C(N)C=C1,0,8
3494,"DRUG1 are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.) ",Phenothiazines,alcohol,TRUE,effect,2,N1C2=CC=CC=C2SC2=CC=CC=C12,CCO,0,10
3495,"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, etc.) ",CNS depressants,anesthetics,FALSE,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,5,8
3496,"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.) ",CNS depressants,alcohol,FALSE,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,5,10
3497,"DRUGOTHER are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, etc.) ",anesthetics,alcohol,FALSE,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCO,8,10
3498,There is usually complete cross-resistance between DRUG1 (DRUG2) and DRUGOTHER brand DRUGOTHER. ,PURINETHOL,mercaptopurine,FALSE,Neg,0,C1=NC2=C(N1)C(=S)N=CN2,C1=NC2=C(N1)C(=S)N=CN2,6,7
3499,There is usually complete cross-resistance between DRUG1 (DRUGOTHER) and DRUG2 brand DRUGOTHER. ,PURINETHOL,TABLOID,TRUE,effect,2,C1=NC2=C(N1)C(=S)N=CN2,C1=NC2=C(N1)C(=S)N=C(N2)N,6,9
3500,There is usually complete cross-resistance between DRUG1 (DRUGOTHER) and DRUGOTHER brand DRUG2. ,PURINETHOL,Thioguanine,TRUE,effect,2,C1=NC2=C(N1)C(=S)N=CN2,C1=NC2=C(N1)C(=S)N=C(N2)N,6,11
3501,There is usually complete cross-resistance between DRUGOTHER (DRUG1) and DRUG2 brand DRUGOTHER. ,mercaptopurine,TABLOID,TRUE,effect,2,C1=NC2=C(N1)C(=S)N=CN2,C1=NC2=C(N1)C(=S)N=C(N2)N,7,9
3502,There is usually complete cross-resistance between DRUGOTHER (DRUG1) and DRUGOTHER brand DRUG2. ,mercaptopurine,Thioguanine,TRUE,effect,2,C1=NC2=C(N1)C(=S)N=CN2,C1=NC2=C(N1)C(=S)N=C(N2)N,7,11
3503,There is usually complete cross-resistance between DRUGOTHER (DRUGOTHER) and DRUG1 brand DRUG2. ,TABLOID,Thioguanine,FALSE,Neg,0,C1=NC2=C(N1)C(=S)N=C(N2)N,C1=NC2=C(N1)C(=S)N=C(N2)N,9,11
3504,"As there is in vitro evidence that DRUGOTHER (e.g., DRUG1, DRUG2, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",olsalazine,mesalazine,FALSE,Neg,0,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O,C1=CC(=C(C=C1N)C(=O)O)O,9,10
3505,"As there is in vitro evidence that DRUGOTHER (e.g., DRUG1, DRUGOTHER, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",olsalazine,sulphasalazine,FALSE,Neg,0,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,9,12
3506,"As there is in vitro evidence that DRUGOTHER (e.g., DRUG1, DRUGOTHER, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",olsalazine,thioguanine,TRUE,mechanism,4,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O,C1=NC2=C(N1)C(=S)N=C(N2)N,9,27
3507,"As there is in vitro evidence that DRUGOTHER (e.g., DRUGOTHER, DRUG1, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",mesalazine,sulphasalazine,FALSE,Neg,0,C1=CC(=C(C=C1N)C(=O)O)O,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,10,12
3508,"As there is in vitro evidence that DRUGOTHER (e.g., DRUGOTHER, DRUG1, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mesalazine,thioguanine,TRUE,mechanism,4,C1=CC(=C(C=C1N)C(=O)O)O,C1=NC2=C(N1)C(=S)N=C(N2)N,10,27
3509,"As there is in vitro evidence that DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, or DRUG1) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",sulphasalazine,thioguanine,TRUE,mechanism,4,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,C1=NC2=C(N1)C(=S)N=C(N2)N,12,27
3510,Prothrombin time or other suitable anticoagulation test should be monitored if DRUG1 is administered with DRUG2.   ,tigecycline,warfarin,TRUE,advise,1,CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,11,15
3511,Concurrent use of DRUGOTHER with oral DRUG1 may render oral DRUG1 less effective.  ,contraceptives,contraceptives,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,6,-1
3512,"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",SKELID,SKELID,FALSE,Neg,0,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,3,-1
3513,"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",SKELID,SKELID,FALSE,Neg,0,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,3,-1
3514,"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",SKELID,SKELID,FALSE,Neg,0,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,3,-1
3515,DRUG1 may decrease bioavailability of DRUG2 by up to 50% when taken 2 hours after DRUG2. ,Aspirin,SKELID,TRUE,mechanism,4,CC(=O)OC1=CC=CC=C1C(=O)O,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,0,5
3516,DRUG1 may decrease bioavailability of DRUG2 by up to 50% when taken 2 hours after DRUG2. ,Aspirin,SKELID,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,0,5
3517,DRUGOTHER may decrease bioavailability of DRUG1 by up to 50% when taken 2 hours after DRUG1. ,SKELID,SKELID,FALSE,Neg,0,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,5,-1
3518,The bioavailability of DRUG1 is increased 2-4 fold by DRUG2 but is not significantly altered by coadministration of DRUGOTHER. ,SKELID,indomethacin,TRUE,mechanism,4,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,3,9
3519,The bioavailability of DRUG1 is increased 2-4 fold by DRUGOTHER but is not significantly altered by coadministration of DRUG2. ,SKELID,diclofenac,FALSE,Neg,0,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,3,18
3520,The bioavailability of DRUGOTHER is increased 2-4 fold by DRUG1 but is not significantly altered by coadministration of DRUG2. ,indomethacin,diclofenac,FALSE,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,9,18
3521,The pharmacokinetic parameters of DRUG1 are not significantly modified by DRUG2 coadministration. ,digoxin,SKELID,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,4,10
3522,In vitro studies show that DRUG1 does not displace DRUG2 from its binding site on protein.,tiludronate,warfarin,FALSE,Neg,0,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,9
3523,"However, the co   administration of DRUG1 with other DRUG2   containing drugs (e.g., DRUGOTHER) has not been studied and is therefore not recommended.",SPIRIVA,anticholinergic,TRUE,advise,1,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-],C[N+](C)(C)CCO,7,10
3524,"However, the co   administration of DRUG1 with other DRUGOTHER   containing drugs (e.g., DRUG2) has not been studied and is therefore not recommended.",SPIRIVA,ipratropium,TRUE,advise,1,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-],CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,7,16
3525,"However, the co   administration of DRUGOTHER with other DRUG1   containing drugs (e.g., DRUG2) has not been studied and is therefore not recommended.",anticholinergic,ipratropium,FALSE,Neg,0,C[N+](C)(C)CCO,CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,10,16
3526,DRUG1 has been studied on a background of DRUG2 and DRUGOTHER. ,AGGRASTAT,aspirin,FALSE,Neg,0,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,CC(=O)OC1=CC=CC=C1C(=O)O,0,8
3527,DRUG1 has been studied on a background of DRUGOTHER and DRUG2. ,AGGRASTAT,heparin,FALSE,Neg,0,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,0,10
3528,DRUGOTHER has been studied on a background of DRUG1 and DRUG2. ,aspirin,heparin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,8,10
3529,"The use of DRUG1, in combination with DRUG2 and DRUGOTHER, has been associated with an increase in bleeding compared to DRUG2 and DRUGOTHER alone (see",AGGRASTAT,heparin,TRUE,effect,2,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,3,7
3530,"The use of DRUG1, in combination with DRUGOTHER and DRUG2, has been associated with an increase in bleeding compared to DRUGOTHER and DRUG2 alone (see",AGGRASTAT,aspirin,TRUE,effect,2,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,CC(=O)OC1=CC=CC=C1C(=O)O,3,9
3531,"The use of DRUG1, in combination with DRUG2 and DRUGOTHER, has been associated with an increase in bleeding compared to DRUG2 and DRUGOTHER alone (see",AGGRASTAT,heparin,FALSE,Neg,0,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,3,7
3532,"The use of DRUG1, in combination with DRUGOTHER and DRUG2, has been associated with an increase in bleeding compared to DRUGOTHER and DRUG2 alone (see",AGGRASTAT,aspirin,FALSE,Neg,0,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,CC(=O)OC1=CC=CC=C1C(=O)O,3,9
3533,"The use of DRUGOTHER, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",heparin,aspirin,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(=O)OC1=CC=CC=C1C(=O)O,7,9
3534,"The use of DRUGOTHER, in combination with DRUG1 and DRUGOTHER, has been associated with an increase in bleeding compared to DRUG1 and DRUGOTHER alone (see",heparin,heparin,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,7,-1
3535,"The use of DRUGOTHER, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",heparin,aspirin,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(=O)OC1=CC=CC=C1C(=O)O,7,9
3536,"The use of DRUGOTHER, in combination with DRUG2 and DRUG1, has been associated with an increase in bleeding compared to DRUG2 and DRUG1 alone (see",aspirin,heparin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,9,7
3537,"The use of DRUGOTHER, in combination with DRUGOTHER and DRUG1, has been associated with an increase in bleeding compared to DRUGOTHER and DRUG1 alone (see",aspirin,aspirin,FALSE,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)OC1=CC=CC=C1C(=O)O,9,-1
3538,"The use of DRUGOTHER, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",heparin,aspirin,FALSE,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(=O)OC1=CC=CC=C1C(=O)O,7,9
3539,"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), DRUGOTHER, inhaled DRUGOTHER, other DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,TOBI,FALSE,Neg,0,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,4,-1
3540,"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), DRUGOTHER, inhaled DRUG2, other DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,corticosteroids,FALSE,Neg,0,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,4,18
3541,"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), DRUGOTHER, inhaled DRUGOTHER, other DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,aminoglycosides,FALSE,Neg,0,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,OC(=O)CCCCCCCC(O)=O,4,23
3542,"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), DRUGOTHER, inhaled DRUG2, other DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,corticosteroids,TRUE,effect,2,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,4,18
3543,"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), DRUGOTHER, inhaled DRUGOTHER, other DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,aminoglycosides,TRUE,effect,2,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,OC(=O)CCCCCCCC(O)=O,4,23
3544,"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), DRUGOTHER, inhaled DRUG1, other DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",corticosteroids,aminoglycosides,FALSE,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,OC(=O)CCCCCCCC(O)=O,18,23
3545,Some DRUG1 can enhance DRUG2 toxicity by altering DRUGOTHER concentrations in serum and tissue. ,diuretics,aminoglycoside,TRUE,effect,2,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,OC(=O)CCCCCCCC(O)=O,1,4
3546,"DRUG1 should not be administered concomitantly with DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",TOBI,ethacrynic acid,TRUE,advise,1,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,0,7
3547,"DRUG1 should not be administered concomitantly with DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER.",TOBI,furosemide,TRUE,advise,1,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,8
3548,"DRUG1 should not be administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",TOBI,urea,TRUE,advise,1,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,C(=O)(N)N,0,9
3549,"DRUG1 should not be administered concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2.",TOBI,mannitol,TRUE,advise,1,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,0,11
3550,"DRUGOTHER should not be administered concomitantly with DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER.",ethacrynic acid,furosemide,FALSE,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,7,8
3551,"DRUGOTHER should not be administered concomitantly with DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER.",ethacrynic acid,urea,FALSE,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C(=O)(N)N,7,9
3552,"DRUGOTHER should not be administered concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2.",ethacrynic acid,mannitol,FALSE,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,7,11
3553,"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER.",furosemide,urea,FALSE,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C(=O)(N)N,8,9
3554,"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2.",furosemide,mannitol,FALSE,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,8,11
3555,"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2.",urea,mannitol,FALSE,Neg,0,C(=O)(N)N,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,9,11
3556,"The in vitro binding of DRUG1 to human plasma proteins is unaffected by DRUG2, and DRUG2 does not alter the prothrombin time of normal volunteers. ",warfarin,tolmetin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,5,13
3557,"The in vitro binding of DRUG1 to human plasma proteins is unaffected by DRUG2, and DRUG2 does not alter the prothrombin time of normal volunteers. ",warfarin,tolmetin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,5,13
3558,"The in vitro binding of DRUGOTHER to human plasma proteins is unaffected by DRUG1, and DRUG1 does not alter the prothrombin time of normal volunteers. ",tolmetin,tolmetin,FALSE,Neg,0,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,13,-1
3559,"However, increased prothrombin time and bleeding have been reported in patients on concomitant DRUG1 and DRUG2 therapy. ",TOLECTIN,warfarin,TRUE,effect,2,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,13,15
3560,In adult diabetic patients under treatment with either DRUG1 or DRUG2 there is no change in the clinical effects of either DRUGOTHER or the DRUGOTHER. ,sulfonylureas,insulin,FALSE,Neg,0,NC(N)=O,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,8,10
3561,In adult diabetic patients under treatment with either DRUG1 or DRUGOTHER there is no change in the clinical effects of either DRUG2 or the DRUGOTHER. ,sulfonylureas,TOLECTIN,FALSE,Neg,0,NC(N)=O,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,8,21
3562,In adult diabetic patients under treatment with either DRUG1 or DRUGOTHER there is no change in the clinical effects of either DRUGOTHER or the DRUG2. ,sulfonylureas,hypoglycemic agents,FALSE,Neg,0,NC(N)=O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,8,24
3563,In adult diabetic patients under treatment with either DRUGOTHER or DRUG1 there is no change in the clinical effects of either DRUG2 or the DRUGOTHER. ,insulin,TOLECTIN,FALSE,Neg,0,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,10,21
3564,In adult diabetic patients under treatment with either DRUGOTHER or DRUG1 there is no change in the clinical effects of either DRUGOTHER or the DRUG2. ,insulin,hypoglycemic agents,FALSE,Neg,0,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,10,24
3565,In adult diabetic patients under treatment with either DRUGOTHER or DRUGOTHER there is no change in the clinical effects of either DRUG1 or the DRUG2. ,TOLECTIN,hypoglycemic agents,FALSE,Neg,0,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,21,24
3566,Caution should be used if DRUG1 is administered concomitantly with DRUG2. ,TOLECTIN,methotrexate,TRUE,advise,1,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,10
3567,"DRUG1 and other DRUG2 have been reported to reduce the tubular secretion of DRUGOTHER in an animal model, possibly enhancing the toxicity of DRUGOTHER. ",TOLECTIN,nonsteroidal anti-inflammatory drugs,FALSE,Neg,0,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0,3
3568,"DRUG1 and other DRUGOTHER have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",TOLECTIN,methotrexate,TRUE,mechanism,4,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,13
3569,"DRUG1 and other DRUGOTHER have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",TOLECTIN,methotrexate,FALSE,Neg,0,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,13
3570,"DRUGOTHER and other DRUG1 have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",nonsteroidal anti-inflammatory drugs,methotrexate,TRUE,mechanism,4,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,3,13
3571,"DRUGOTHER and other DRUG1 have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",nonsteroidal anti-inflammatory drugs,methotrexate,FALSE,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,3,13
3572,"DRUGOTHER and other DRUGOTHER have been reported to reduce the tubular secretion of DRUG1 in an animal model, possibly enhancing the toxicity of DRUG1. ",methotrexate,methotrexate,FALSE,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,13,-1
3573,"CYP3A4 Inhibitors: DRUG1, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of DRUG2 when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",Ketoconazole,tolterodine,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2,2,16
3574,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUG2 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,azole antifungals,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,OC(=O)CCCCCCCCC=C,3,12
3575,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,itraconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,3,14
3576,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,miconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,3,15
3577,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,macrolide antibiotics,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,3,17
3578,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,erythromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,3,19
3579,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,clarithromycin,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,3,20
3580,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,cyclosporine,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,3,22
3581,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",ketoconazole,vinblastine,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,3,24
3582,"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",ketoconazole,DETROL LA,TRUE,advise,1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,3,29
3583,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUG2, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",azole antifungals,itraconazole,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,12,14
3584,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUGOTHER, DRUG2) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",azole antifungals,miconazole,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,12,15
3585,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUG2 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",azole antifungals,macrolide antibiotics,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,12,17
3586,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",azole antifungals,erythromycin,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,12,19
3587,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",azole antifungals,clarithromycin,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,12,20
3588,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",azole antifungals,cyclosporine,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,12,22
3589,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",azole antifungals,vinblastine,FALSE,Neg,0,OC(=O)CCCCCCCCC=C,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,12,24
3590,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",azole antifungals,DETROL LA,TRUE,advise,1,OC(=O)CCCCCCCCC=C,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,12,29
3591,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG1, DRUG2) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",itraconazole,miconazole,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,14,15
3592,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUG2 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",itraconazole,macrolide antibiotics,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,14,17
3593,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",itraconazole,erythromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,14,19
3594,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",itraconazole,clarithromycin,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,14,20
3595,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",itraconazole,cyclosporine,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,14,22
3596,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",itraconazole,vinblastine,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,14,24
3597,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",itraconazole,DETROL LA,TRUE,advise,1,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,14,29
3598,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUG2 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",miconazole,macrolide antibiotics,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,15,17
3599,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",miconazole,erythromycin,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,15,19
3600,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",miconazole,clarithromycin,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,15,20
3601,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",miconazole,cyclosporine,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,15,22
3602,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",miconazole,vinblastine,FALSE,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,15,24
3603,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",miconazole,DETROL LA,TRUE,advise,1,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,15,29
3604,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",macrolide antibiotics,erythromycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,17,19
3605,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",macrolide antibiotics,clarithromycin,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,17,20
3606,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",macrolide antibiotics,cyclosporine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,17,22
3607,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",macrolide antibiotics,vinblastine,FALSE,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,17,24
3608,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",macrolide antibiotics,DETROL LA,TRUE,advise,1,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,17,29
3609,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUG1, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",erythromycin,clarithromycin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,19,20
3610,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",erythromycin,cyclosporine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,19,22
3611,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",erythromycin,vinblastine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,19,24
3612,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",erythromycin,DETROL LA,TRUE,advise,1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,19,29
3613,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",clarithromycin,cyclosporine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,20,22
3614,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",clarithromycin,vinblastine,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,20,24
3615,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",clarithromycin,DETROL LA,TRUE,advise,1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,20,29
3616,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",cyclosporine,vinblastine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,22,24
3617,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",cyclosporine,DETROL LA,TRUE,advise,1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,22,29
3618,"For patients receiving DRUGOTHER or other potent CYP3A4 inhibitors such as other DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG1, the recommended dose of DRUG2 is 2 mg daily. ",vinblastine,DETROL LA,TRUE,advise,1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,24,29
3619,DRUG1 may interact with DRUG2 or DRUGOTHER (causing too great a decrease in adrenal function).,Trilostane,aminoglutethimide,TRUE,int,3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,0,4
3620,DRUG1 may interact with DRUGOTHER or DRUG2 (causing too great a decrease in adrenal function).,Trilostane,mitotane,TRUE,int,3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,0,6
3621,DRUGOTHER may interact with DRUG1 or DRUG2 (causing too great a decrease in adrenal function).,aminoglutethimide,mitotane,FALSE,Neg,0,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,4,6
3622,DRUG1 may inhibit the hepatic metabolism of DRUG2. ,Trimethoprim,phenytoin,TRUE,mechanism,4,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
3623,"DRUG1, given at a common clinical dosage, increased the DRUG2 half-life by 51% and decreased the DRUG2 metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,TRUE,mechanism,4,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,9
3624,"DRUG1, given at a common clinical dosage, increased the DRUG2 half-life by 51% and decreased the DRUG2 metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,TRUE,mechanism,4,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,9
3625,"DRUGOTHER, given at a common clinical dosage, increased the DRUG1 half-life by 51% and decreased the DRUG1 metabolic clearance rate by 30%. ",phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,-1
3626,"Since DRUG1 is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter DRUG1 plasma concentrations. ",trimetrexate,trimetrexate,FALSE,Neg,0,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1,-1
3627,"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",trimetrexate,erythromycin,TRUE,effect,2,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,6,19
3628,"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",trimetrexate,rifampin,TRUE,effect,2,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,6,20
3629,"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",trimetrexate,rifabutin,TRUE,effect,2,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,6,21
3630,"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",trimetrexate,ketoconazole,TRUE,effect,2,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6,22
3631,"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",trimetrexate,fluconazole,TRUE,effect,2,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,6,24
3632,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",erythromycin,rifampin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,19,20
3633,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",erythromycin,rifabutin,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,19,21
3634,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",erythromycin,ketoconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,19,22
3635,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",erythromycin,fluconazole,FALSE,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,19,24
3636,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",rifampin,rifabutin,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,20,21
3637,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",rifampin,ketoconazole,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,20,22
3638,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",rifampin,fluconazole,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,20,24
3639,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",rifabutin,ketoconazole,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,21,22
3640,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",rifabutin,fluconazole,FALSE,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,21,24
3641,"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",ketoconazole,fluconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,22,24
3642,In vitro perfusion of isolated rat liver has shown that DRUG1 caused a significant reduction in DRUG2 metabolism and that DRUGOTHER altered the relative concentration of DRUG2 metabolites possibly by competing for sulfate metabolites. ,cimetidine,trimetrexate,TRUE,mechanism,4,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,10,16
3643,In vitro perfusion of isolated rat liver has shown that DRUG1 caused a significant reduction in DRUGOTHER metabolism and that DRUG2 altered the relative concentration of DRUGOTHER metabolites possibly by competing for sulfate metabolites. ,cimetidine,acetaminophen,FALSE,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(=O)NC1=CC=C(C=C1)O,10,20
3644,In vitro perfusion of isolated rat liver has shown that DRUGOTHER caused a significant reduction in DRUG1 metabolism and that DRUG2 altered the relative concentration of DRUG1 metabolites possibly by competing for sulfate metabolites. ,trimetrexate,acetaminophen,FALSE,Neg,0,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,CC(=O)NC1=CC=C(C=C1)O,16,20
3645,"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",clotrimazole,ketoconazole,FALSE,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,12
3646,"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",clotrimazole,miconazole,FALSE,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,11,13
3647,"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) were potent, non-competitive inhibitors of DRUG2 metabolism. ",clotrimazole,trimetrexate,TRUE,mechanism,4,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,11,19
3648,"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER (DRUGOTHER, DRUG1, DRUG2) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",ketoconazole,miconazole,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,12,13
3649,"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) were potent, non-competitive inhibitors of DRUG2 metabolism. ",ketoconazole,trimetrexate,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,12,19
3650,"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) were potent, non-competitive inhibitors of DRUG2 metabolism. ",miconazole,trimetrexate,TRUE,mechanism,4,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,13,19
3651,"DRUG1 may enhance the sedative effects of DRUG2 including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",Triprolidine,central nervous system depressants,TRUE,effect,2,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,0,7
3652,"DRUG1 may enhance the sedative effects of DRUGOTHER including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",Triprolidine,alcohol,TRUE,effect,2,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,CCO,0,9
3653,"DRUG1 may enhance the sedative effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",Triprolidine,narcotic analgesics,TRUE,effect,2,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,0,12
3654,"DRUGOTHER may enhance the sedative effects of DRUG1 including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",central nervous system depressants,alcohol,FALSE,Neg,0,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,CCO,7,9
3655,"DRUGOTHER may enhance the sedative effects of DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",central nervous system depressants,narcotic analgesics,FALSE,Neg,0,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,7,12
3656,"DRUGOTHER may enhance the sedative effects of DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",alcohol,narcotic analgesics,FALSE,Neg,0,CCO,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,9,12
3657,"The effects of DRUGOTHER, such as DRUG1 and DRUG2 may be enhanced by the concomitant administration of DRUGOTHER. ",atropine,tricyclic antidepressants,FALSE,Neg,0,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,6,8
3658,"The effects of DRUGOTHER, such as DRUG1 and DRUGOTHER may be enhanced by the concomitant administration of DRUG2. ",atropine,triprolidine,TRUE,effect,2,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,6,17
3659,"The effects of DRUGOTHER, such as DRUGOTHER and DRUG1 may be enhanced by the concomitant administration of DRUG2. ",tricyclic antidepressants,triprolidine,TRUE,effect,2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,8,17
3660,"The concomitant use of DRUG1 with other DRUG2 that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",Sanctura,anticholinergic agents,TRUE,effect,2,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[N+](C)(C)CCO,4,7
3661,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,Sanctura,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],13,-1
3662,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,digoxin,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,13,36
3663,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,procainamide,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,13,37
3664,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,pancuronium,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,13,38
3665,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,morphine,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,13,39
3666,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",Sanctura,vancomycin,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,13,40
3667,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",Sanctura,metformin,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CN(C)C(=N)N=C(N)N,13,41
3668,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",Sanctura,tenofovir,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,13,43
3669,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,digoxin,TRUE,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,13,36
3670,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,procainamide,TRUE,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,13,37
3671,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,pancuronium,TRUE,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,13,38
3672,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",Sanctura,morphine,TRUE,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,13,39
3673,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",Sanctura,vancomycin,TRUE,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,13,40
3674,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",Sanctura,metformin,TRUE,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],CN(C)C(=N)N=C(N)N,13,41
3675,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",Sanctura,tenofovir,TRUE,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,13,43
3676,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",digoxin,procainamide,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,36,37
3677,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",digoxin,pancuronium,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,36,38
3678,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",digoxin,morphine,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,36,39
3679,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",digoxin,vancomycin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,36,40
3680,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",digoxin,metformin,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CN(C)C(=N)N=C(N)N,36,41
3681,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",digoxin,tenofovir,FALSE,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,36,43
3682,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",procainamide,pancuronium,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,37,38
3683,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",procainamide,morphine,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,37,39
3684,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",procainamide,vancomycin,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,37,40
3685,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",procainamide,metformin,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CN(C)C(=N)N=C(N)N,37,41
3686,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",procainamide,tenofovir,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,37,43
3687,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",pancuronium,morphine,FALSE,Neg,0,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,38,39
3688,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",pancuronium,vancomycin,FALSE,Neg,0,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,38,40
3689,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",pancuronium,metformin,FALSE,Neg,0,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,CN(C)C(=N)N=C(N)N,38,41
3690,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",pancuronium,tenofovir,FALSE,Neg,0,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,38,43
3691,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER). ",morphine,vancomycin,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,39,40
3692,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER). ",morphine,metformin,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CN(C)C(=N)N=C(N)N,39,41
3693,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2). ",morphine,tenofovir,FALSE,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,39,43
3694,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER). ",vancomycin,metformin,FALSE,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CN(C)C(=N)N=C(N)N,40,41
3695,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2). ",vancomycin,tenofovir,FALSE,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,40,43
3696,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2). ",metformin,tenofovir,FALSE,Neg,0,CN(C)C(=N)N=C(N)N,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,41,43
3697,Coadministration of DRUG1 with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of DRUG1 and/or the coadministered drug due to competition for this elimination pathway. ,Sanctura,Sanctura,FALSE,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],2,-1
3698,Concomitant administration of DRUG1 and DRUG2 has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,vancomycin,anesthetic agents,TRUE,effect,2,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CCOC(=O)C1=CC=C(N)C=C1,3,5
3699,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",amphotericin B,aminoglycosides,FALSE,Neg,0,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,OC(=O)CCCCCCCC(O)=O,16,17
3700,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",amphotericin B,polymyxin B,FALSE,Neg,0,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,16,19
3701,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",amphotericin B,colistin,FALSE,Neg,0,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,16,20
3702,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",amphotericin B,viomycin,FALSE,Neg,0,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N,16,21
3703,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",amphotericin B,cisplatin,FALSE,Neg,0,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,N.N.Cl[Pt]Cl,16,23
3704,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",aminoglycosides,polymyxin B,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,17,19
3705,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",aminoglycosides,colistin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,17,20
3706,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",aminoglycosides,viomycin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N,17,21
3707,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",aminoglycosides,cisplatin,FALSE,Neg,0,OC(=O)CCCCCCCC(O)=O,N.N.Cl[Pt]Cl,17,23
3708,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",polymyxin B,colistin,FALSE,Neg,0,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,19,20
3709,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",polymyxin B,viomycin,FALSE,Neg,0,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N,19,21
3710,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",polymyxin B,cisplatin,FALSE,Neg,0,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,N.N.Cl[Pt]Cl,19,23
3711,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",colistin,viomycin,FALSE,Neg,0,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N,20,21
3712,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",colistin,cisplatin,FALSE,Neg,0,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,N.N.Cl[Pt]Cl,20,23
3713,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2, when indicated, requires careful monitoring.",viomycin,cisplatin,FALSE,Neg,0,C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N,N.N.Cl[Pt]Cl,21,23
3714,A study published in 2002 found that DRUG1 causes a statistically significant increase in plasma clearance of DRUG2. ,vigabatrin,carbamazepine,TRUE,mechanism,4,C=CC(CCC(=O)O)N,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,7,17
3715,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,TRUE,mechanism,4,C=CC(CCC(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,16
3716,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,FALSE,Neg,0,C=CC(CCC(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,16
3717,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUGOTHER with DRUG1 lowered the serum DRUG1 concentration in patients with treatment-resistant epilepsy. ",phenytoin,phenytoin,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,-1
3720,"DRUGOTHER can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUG2: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHERs: may decrease patient's response to the DRUGOTHER",Phenytoin,Mitomycin-C,FALSE,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,43,74
3721,Drug Interactions: Women on oral DRUG1 have shown a significant increase in plasma DRUG2 levels.,contraceptives,vitamin A,TRUE,mechanism,4,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C,5,13
3722,Limited evidence suggests that DRUG1 may influence the intensity and duration of action of DRUG2.,ascorbic acid,bishydroxycoumarin,TRUE,mechanism,4,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O,4,14
3723,"Other DRUGOTHER Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUG1 and other DRUGOTHER (e.g., DRUG2). ",ZOLINZA,valproic acid,TRUE,effect,2,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,CCCC(CCC)C(=O)O,14,19
3724,"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,2,-1
3725,"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,2,-1
3726,"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,2,-1
3727,"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,4,-1
3728,"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,4,-1
3729,"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,4,-1
3730,"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG1/DRUGOTHER-treated animals than in DRUG1/vehicle-treated monkeys. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,43,-1
3731,"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/DRUGOTHER-treated monkeys. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",FALSE,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,1,-1
3732,"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG2 (DRUGOTHER), an orally active DRUGOTHER.
",ketoconazole,panobinostat,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,2,9
3733,"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGOTHER (DRUG2), an orally active DRUGOTHER.
",ketoconazole,LBH589,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,2,10
3734,"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGOTHER (DRUGOTHER), an orally active DRUG2.
",ketoconazole,histone deacetylase inhibitor,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO.Cl,2,14
3735,"Effect of DRUGOTHER-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG1 (DRUG2), an orally active DRUGOTHER.
",panobinostat,LBH589,FALSE,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,9,10
3736,"Effect of DRUGOTHER-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG1 (DRUGOTHER), an orally active DRUG2.
",panobinostat,histone deacetylase inhibitor,FALSE,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO.Cl,9,14
3737,"Effect of DRUGOTHER-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGOTHER (DRUG1), an orally active DRUG2.
",LBH589,histone deacetylase inhibitor,FALSE,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO.Cl,10,14
3738,"This study evaluated the effect of a potent CYP3A inhibitor, DRUG1, on the pharmacokinetics and safety of DRUG2.",ketoconazole,panobinostat,FALSE,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,10,17
3739,"On day 8, a single DRUG1 dose was co-administered with DRUG2. ",panobinostat,ketoconazole,FALSE,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,5,10
3740,"In the presence of DRUG1, there was 1.6- and 1.8-fold increase in C (max) and AUC of DRUG2, respectively. ",ketoconazole,panobinostat,TRUE,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,4,17
3741,Co-administration of DRUG1 with CYP3A inhibitors is feasible as the observed increase in DRUG1 PK parameters was not considered clinically relevant. ,panobinostat,panobinostat,FALSE,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,2,-1
3742,"Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of DRUG1 was not studied with CYP3A inhibitors, close monitoring of DRUG1-related adverse events is necessary.",panobinostat,panobinostat,FALSE,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,15,-1
3744,DRUG1 and DRUG2 are DRUGOTHER used in treating urinary and respiratory tract infections. ,Moxifloxacin,lomefloxacin,FALSE,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,0,2
3745,"Being DRUG1 and lomefloxacin DRUGOTHER the interaction study of was carried out with DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",moxifloxacin,sucralfate,FALSE,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],1,13
3746,"Being DRUG1 and lomefloxacin DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",moxifloxacin,erythromycin,FALSE,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1,15
3747,"Being DRUGOTHER and lomefloxacin DRUGOTHER the interaction study of was carried out with DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER. ",sucralfate,erythromycin,FALSE,Neg,0,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,13,15
3748,The response of DRUG1 and DRUG2 after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ,moxifloxacin,lomefloxacin,FALSE,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,3,5
3749,DRUG1 and DRUG2 reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,Moxifloxacin,Lomefloxacin,FALSE,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,0,2
3750,DRUG1 and DRUGOTHER reacts faster with DRUG2 and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,Moxifloxacin,sucralfate,TRUE,mechanism,4,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],0,6
3751,DRUG1 and DRUGOTHER reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,Moxifloxacin,erythromycin,TRUE,mechanism,4,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,0,14
3752,DRUGOTHER and DRUG1 reacts faster with DRUG2 and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,Lomefloxacin,sucralfate,TRUE,mechanism,4,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],2,6
3753,DRUGOTHER and DRUG1 reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,Lomefloxacin,erythromycin,TRUE,mechanism,4,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,2,14
3754,DRUGOTHER and DRUGOTHER reacts faster with DRUG1 and DRUGOTHER in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,sucralfate,erythromycin,FALSE,Neg,0,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,6,14
3755,"Exposure to oral DRUG1 is unaffected by DRUG2 but greatly increased by DRUGOTHER.
",S-ketamine,itraconazole,FALSE,Neg,0,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,3,7
3756,"Exposure to oral DRUG1 is unaffected by DRUGOTHER but greatly increased by DRUG2.
",S-ketamine,ticlopidine,TRUE,effect,2,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,3,12
3757,"Exposure to oral DRUGOTHER is unaffected by DRUG1 but greatly increased by DRUG2.
",itraconazole,ticlopidine,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,7,12
3758,This study examined drug-drug interactions of oral DRUG1 with the cytochrome P450 (CYP) 2B6 inhibitor DRUG2 and the CYP3A inhibitor DRUGOTHER. ,S-ketamine,ticlopidine,FALSE,Neg,0,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,7,15
3759,This study examined drug-drug interactions of oral DRUG1 with the cytochrome P450 (CYP) 2B6 inhibitor DRUGOTHER and the CYP3A inhibitor DRUG2. ,S-ketamine,itraconazole,FALSE,Neg,0,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,20
3760,This study examined drug-drug interactions of oral DRUGOTHER with the cytochrome P450 (CYP) 2B6 inhibitor DRUG1 and the CYP3A inhibitor DRUG2. ,ticlopidine,itraconazole,FALSE,Neg,0,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,15,20
3761,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg DRUG1 after pretreatments with oral DRUG2 (250 mg twice daily), DRUGOTHER (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",S-ketamine,ticlopidine,FALSE,Neg,0,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,12,17
3762,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg DRUG1 after pretreatments with oral DRUGOTHER (250 mg twice daily), DRUG2 (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",S-ketamine,itraconazole,FALSE,Neg,0,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,12,22
3763,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg DRUGOTHER after pretreatments with oral DRUG1 (250 mg twice daily), DRUG2 (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",ticlopidine,itraconazole,FALSE,Neg,0,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,17,22
3764,"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG2 by 2.4-fold, whereas DRUGOTHER treatment did not increase the exposure to S-DRUG2. ",Ticlopidine,ketamine,TRUE,mechanism,4,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,0,20
3765,"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUGOTHER by 2.4-fold, whereas DRUG2 treatment did not increase the exposure to S-DRUGOTHER. ",Ticlopidine,itraconazole,FALSE,Neg,0,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,0,24
3766,"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUGOTHER by 2.4-fold, whereas DRUGOTHER treatment did not increase the exposure to DRUG2. ",Ticlopidine,S-ketamine,FALSE,Neg,0,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,0,32
3767,"DRUGOTHER treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG1 by 2.4-fold, whereas DRUG2 treatment did not increase the exposure to S-DRUG1. ",ketamine,itraconazole,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,20,24
3768,"DRUGOTHER treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG1 by 2.4-fold, whereas DRUGOTHER treatment did not increase the exposure to S-DRUG1. ",ketamine,S-ketamine,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,20,-1
3769,"DRUGOTHER treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUGOTHER by 2.4-fold, whereas DRUG1 treatment did not increase the exposure to DRUG2. ",itraconazole,S-ketamine,FALSE,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,24,32
3770,The ratio of DRUG1 AUC(0-   ) to DRUG2 AUC(0-   ) was significantly decreased in the DRUGOTHER (P &lt; 0.001) and DRUGOTHER phases (P = 0.006) as compared to placebo. ,norketamine,ketamine,FALSE,Neg,0,C1CCC(C(=O)C1)(C2=CC=CC=C2Cl)N,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,3,9
3771,The ratio of DRUG1 AUC(0-   ) to DRUGOTHER AUC(0-   ) was significantly decreased in the DRUG2 (P &lt; 0.001) and DRUGOTHER phases (P = 0.006) as compared to placebo. ,norketamine,ticlopidine,FALSE,Neg,0,C1CCC(C(=O)C1)(C2=CC=CC=C2Cl)N,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,3,19
3772,The ratio of DRUG1 AUC(0-   ) to DRUGOTHER AUC(0-   ) was significantly decreased in the DRUGOTHER (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,norketamine,itraconazole,FALSE,Neg,0,C1CCC(C(=O)C1)(C2=CC=CC=C2Cl)N,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,3,24
3773,The ratio of norDRUG1 AUC(0-   ) to DRUG1 AUC(0-   ) was significantly decreased in the DRUG2 (P &lt; 0.001) and DRUGOTHER phases (P = 0.006) as compared to placebo. ,ketamine,ticlopidine,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,3,19
3774,The ratio of norDRUG1 AUC(0-   ) to DRUG1 AUC(0-   ) was significantly decreased in the DRUGOTHER (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,ketamine,itraconazole,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,3,24
3775,The ratio of DRUGOTHER AUC(0-   ) to DRUGOTHER AUC(0-   ) was significantly decreased in the DRUG1 (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,ticlopidine,itraconazole,FALSE,Neg,0,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,19,24
3776,"In the DRUG1 and DRUG2 phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ",ticlopidine,itraconazole,FALSE,Neg,0,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,2,4
3777,The findings suggest that the dosage of DRUG1 should be reduced in patients receiving DRUG2.,S-ketamine,ticlopidine,TRUE,advise,1,CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,7,14
3778,"The DRUG1 (DRUG2), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ",3-Deazaneplanocin A,DZNep,FALSE,Neg,0,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,1,2
3779,"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",DZNep,DZNep,FALSE,Neg,0,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,8,-1
3780,"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUG2, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",DZNep,ABT-737,FALSE,Neg,0,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-],8,16
3781,"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",DZNep,DZNep,FALSE,Neg,0,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,8,-1
3782,"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUG2, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",DZNep,ABT-737,TRUE,effect,2,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-],8,16
3783,"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",DZNep,DZNep,FALSE,Neg,0,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,8,-1
3784,"We also found that Bcl-2 was overexpressed in DRUG2 insensitive cells, and cotreatment with DRUG2 and DRUG1, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG2 insensitive MM cells. ",ABT-737,DZNep,FALSE,Neg,0,CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-],C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,16,8
3785,"In addition, DRUG1 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUG2 and DRUG1 could synergistically induced apoptosis. ",DZNep,ABT-737,FALSE,Neg,0,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-],2,15
3786,"In addition, DRUG1 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUGOTHER and DRUG1 could synergistically induced apoptosis. ",DZNep,DZNep,FALSE,Neg,0,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,2,-1
3787,"In addition, DRUG2 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUG1 and DRUG2 could synergistically induced apoptosis. ",ABT-737,DZNep,TRUE,effect,2,CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-],C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,15,2
3788,"In total, 430,455 DRUG1 users contributed 407,370 person-years of DRUG1 use. ",warfarin,warfarin,FALSE,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,-1
3789,"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG2 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,citalopram,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,0,13
3790,"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG2 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,fluoxetine,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,24
3791,"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,paroxetine,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,0,35
3792,"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,amitriptyline,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,0,46
3793,"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG2 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,fluoxetine,FALSE,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,13,24
3794,"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,paroxetine,FALSE,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,13,35
3795,"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,amitriptyline,FALSE,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,13,46
3796,"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG1 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",fluoxetine,paroxetine,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,24,35
3797,"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG1 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",fluoxetine,amitriptyline,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,24,46
3798,"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG1 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",paroxetine,amitriptyline,FALSE,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,35,46
3799,"Also DRUG1, which is not believed to interact with DRUG2, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",mirtazapine,warfarin,TRUE,effect,2,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,1,9
3800,"DRUG1 users who initiated DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,citalopram,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,0,4
3801,"DRUG1 users who initiated DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,fluoxetine,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,5
3802,"DRUG1 users who initiated DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,paroxetine,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,0,6
3803,"DRUG1 users who initiated DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,amitriptyline,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,0,7
3804,"DRUG1 users who initiated DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,mirtazapine,TRUE,effect,2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,0,9
3805,"DRUGOTHER users who initiated DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,fluoxetine,FALSE,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,4,5
3806,"DRUGOTHER users who initiated DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,paroxetine,FALSE,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,4,6
3807,"DRUGOTHER users who initiated DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,amitriptyline,FALSE,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,4,7
3808,"DRUGOTHER users who initiated DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,mirtazapine,FALSE,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,4,9
3809,"DRUGOTHER users who initiated DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,paroxetine,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,5,6
3810,"DRUGOTHER users who initiated DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,amitriptyline,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,5,7
3811,"DRUGOTHER users who initiated DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,mirtazapine,FALSE,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,5,9
3812,"DRUGOTHER users who initiated DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",paroxetine,amitriptyline,FALSE,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,6,7
3813,"DRUGOTHER users who initiated DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",paroxetine,mirtazapine,FALSE,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,6,9
3814,"DRUGOTHER users who initiated DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",amitriptyline,mirtazapine,FALSE,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,7,9
3815,"Of the isoform-specific CYP inhibitors tested for an effect on the DRUG1 metabolite profile, only DRUG2 was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ",precocene I,tranylcypromine,FALSE,Neg,0,CC1(C=CC2=C(O1)C=C(C=C2)OC)C,C1[C@H]([C@@H]1N)C2=CC=CC=C2,11,15
3816,"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUGOTHER>DRUG1~DRUG2>DRUGOTHER. ",diethyldithiocarbamate,tranylcypromine,FALSE,Neg,0,CCN(CC)C(=S)[S-],C1[C@H]([C@@H]1N)C2=CC=CC=C2,11,11
3817,"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUGOTHER>DRUG1~DRUGOTHER>DRUG2. ",diethyldithiocarbamate,ketoconazole,FALSE,Neg,0,CCN(CC)C(=S)[S-],CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,11
3818,"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUGOTHER>DRUGOTHER~DRUG1>DRUG2. ",tranylcypromine,ketoconazole,FALSE,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,11
3819,"DRUG1 and DRUG2 had no effect, while DRUGOTHER appeared to augment DRUGOTHER toxicity. ",Furafylline,sulfaphenazole,FALSE,Neg,0,CC1=NC2=C(N1)C(=O)N(C(=O)N2CC3=CC=CO3)C,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,0,2
3820,"DRUG1 and DRUGOTHER had no effect, while DRUG2 appeared to augment DRUGOTHER toxicity. ",Furafylline,quinidine,FALSE,Neg,0,CC1=NC2=C(N1)C(=O)N(C(=O)N2CC3=CC=CO3)C,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,0,7
3821,"DRUG1 and DRUGOTHER had no effect, while DRUGOTHER appeared to augment DRUG2 toxicity. ",Furafylline,precocene I,FALSE,Neg,0,CC1=NC2=C(N1)C(=O)N(C(=O)N2CC3=CC=CO3)C,CC1(C=CC2=C(O1)C=C(C=C2)OC)C,0,11
3822,"DRUGOTHER and DRUG1 had no effect, while DRUG2 appeared to augment DRUGOTHER toxicity. ",sulfaphenazole,quinidine,FALSE,Neg,0,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,2,7
3823,"DRUGOTHER and DRUG1 had no effect, while DRUGOTHER appeared to augment DRUG2 toxicity. ",sulfaphenazole,precocene I,FALSE,Neg,0,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,CC1(C=CC2=C(O1)C=C(C=C2)OC)C,2,11
3824,"DRUGOTHER and DRUGOTHER had no effect, while DRUG1 appeared to augment DRUG2 toxicity. ",quinidine,precocene I,TRUE,effect,2,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC1(C=CC2=C(O1)C=C(C=C2)OC)C,7,11
3825,These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of DRUG1 and therefore may not be an appropriate model for DRUG1 metabolism. ,precocene I,precocene I,FALSE,Neg,0,CC1(C=CC2=C(O1)C=C(C=C2)OC)C,CC1(C=CC2=C(O1)C=C(C=C2)OC)C,16,-1
3826,"Prevention of emergence agitation in seven children receiving low-dose DRUG1 and DRUG2 total intravenous anesthesia.
",ketamine,propofol,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,9,11
3827,We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose DRUG1 in conjunction with DRUG2 for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ,ketamine,propofol,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,13,17
3828,EA signs were observed in all 7 patients in association with DRUG1 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose DRUG2 was added to DRUG1. ,propofol,ketamine,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,11,27
3829,EA signs were observed in all 7 patients in association with DRUG1 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose DRUGOTHER was added to DRUG1. ,propofol,propofol,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,CC(C)C1=C(C(=CC=C1)C(C)C)O,11,-1
3830,EA signs were observed in all 7 patients in association with DRUG2 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose DRUG1 was added to DRUG2. ,ketamine,propofol,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,27,11
3831,"Based on this experience, we suggest that low-dose DRUG1 added to DRUG2 may be associated with prevention of EA in children with a history of EA with DRUG2 TIVA.",ketamine,propofol,TRUE,effect,2,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,8,11
3832,"Based on this experience, we suggest that low-dose DRUG1 added to DRUG2 may be associated with prevention of EA in children with a history of EA with DRUG2 TIVA.",ketamine,propofol,FALSE,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,8,11
3833,"Based on this experience, we suggest that low-dose DRUGOTHER added to DRUG1 may be associated with prevention of EA in children with a history of EA with DRUG1 TIVA.",propofol,propofol,FALSE,Neg,0,CC(C)C1=C(C(=CC=C1)C(C)C)O,CC(C)C1=C(C(=CC=C1)C(C)C)O,11,-1
3834,DRUG1 and DRUG2 reduce the plasma concentration of DRUGOTHER by about 50%. ,Paroxetine,fluoxetine,FALSE,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,2
3835,DRUG1 and DRUGOTHER reduce the plasma concentration of DRUG2 by about 50%. ,Paroxetine,endoxifen,TRUE,mechanism,4,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3,0,8
3836,DRUGOTHER and DRUG1 reduce the plasma concentration of DRUG2 by about 50%. ,fluoxetine,endoxifen,TRUE,mechanism,4,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3,2,8
3837,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially DRUGOTHER such as DRUG2 and DRUGOTHER. ",tamoxifen,paroxetine,TRUE,advise,1,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,14,22
3838,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially DRUGOTHER such as DRUGOTHER and DRUG2. ",tamoxifen,fluoxetine,TRUE,advise,1,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,14,24
3839,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUGOTHER for breast cancer, especially DRUGOTHER such as DRUG1 and DRUG2. ",paroxetine,fluoxetine,FALSE,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,22,24
3840,"If in certain cases, an DRUGOTHER is considered necessary, it may be advisable to replace DRUG1 with DRUG2.",tamoxifen,anastrozole,FALSE,Neg,0,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,15,17
3841,"DRUG1 locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with DRUG2.
",Amphetamine,quinpirole,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,0,16
3842,The objective was to analyze the effects of neonatal DRUG1 treatment on effects of DRUG2 in adolescent rats using locomotor sensitization and conditioned place preference procedures. ,quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,9,14
3843,"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",quinpirole,amphetamine,TRUE,effect,2,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,7
3844,"In female rats, neonatal DRUG1 treatment enhanced DRUGOTHER locomotor sensitization compared with DRUG1-free controls sensitized to DRUGOTHER. ",quinpirole,quinpirole,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,4,-1
3845,"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,7
3846,"In female rats, neonatal DRUG2 treatment enhanced DRUG1 locomotor sensitization compared with DRUG2-free controls sensitized to DRUG1. ",amphetamine,quinpirole,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,7,4
3847,"In female rats, neonatal DRUGOTHER treatment enhanced DRUG1 locomotor sensitization compared with DRUGOTHER-free controls sensitized to DRUG1. ",amphetamine,amphetamine,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CC(CC1=CC=CC=C1)N,7,-1
3848,"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,7
3849,"Male rats demonstrated sensitization to DRUG1, although this was muted compared with female rats, and were unaffected by neonatal DRUG2. ",amphetamine,quinpirole,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,5,19
3850,"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,10
3851,"Rats treated with neonatal DRUG1 enhanced time spent in the DRUGOTHER-paired context compared with DRUG1-free controls conditioned with DRUGOTHER, but only female controls conditioned with DRUGOTHER spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,quinpirole,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,4,-1
3852,"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,10
3853,"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,10
3854,"Rats treated with neonatal DRUG2 enhanced time spent in the DRUG1-paired context compared with DRUG2-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,quinpirole,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,10,4
3855,"Rats treated with neonatal DRUGOTHER enhanced time spent in the DRUG1-paired context compared with DRUGOTHER-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CC(CC1=CC=CC=C1)N,10,-1
3856,"Rats treated with neonatal DRUGOTHER enhanced time spent in the DRUG1-paired context compared with DRUGOTHER-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CC(CC1=CC=CC=C1)N,10,-1
3857,"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,10
3858,"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,FALSE,Neg,0,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,CC(CC1=CC=CC=C1)N,4,10
3859,"Rats treated with neonatal DRUGOTHER enhanced time spent in the DRUG1-paired context compared with DRUGOTHER-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,FALSE,Neg,0,CC(CC1=CC=CC=C1)N,CC(CC1=CC=CC=C1)N,10,-1
3860,"In vivo CYP3A activity is significantly lower in DRUG1-treated as compared with DRUG2-treated renal allograft recipients.
",cyclosporine,tacrolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,8,12
3861,In vitro studies have identified DRUG1 and DRUG2 as CYP3A inhibitors. ,cyclosporine,tacrolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,5,7
3862,"Systemic and apparent oral DRUG1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUG2-treated patients (n = 20) than in matched DRUGOTHER-treated patients (n = 20). ",midazolam,cyclosporine,TRUE,mechanism,4,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,4,45
3863,"Systemic and apparent oral DRUG1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUGOTHER-treated patients (n = 20) than in matched DRUG2-treated patients (n = 20). ",midazolam,tacrolimus,FALSE,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,4,53
3864,"Systemic and apparent oral DRUGOTHER clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUG1-treated patients (n = 20) than in matched DRUG2-treated patients (n = 20). ",cyclosporine,tacrolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,45,53
3865,The latter displayed DRUG1 clearances similar to those in two larger cohorts of nonmatched DRUG2-treated patients (n = 58 and n = 80) and to those receiving a DRUGOTHER-free regimen (n = 6). ,midazolam,tacrolimus,FALSE,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,3,14
3866,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG1 than in those receiving DRUG2, indicating that, at the doses generally used in clinical practice, DRUG1 is the stronger of the two with respect to CYP3A inhibition. ",cyclosporine,tacrolimus,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,16,21
3867,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG1 than in those receiving DRUGOTHER, indicating that, at the doses generally used in clinical practice, DRUG1 is the stronger of the two with respect to CYP3A inhibition. ",cyclosporine,cyclosporine,FALSE,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,16,-1
3868,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG2 than in those receiving DRUG1, indicating that, at the doses generally used in clinical practice, DRUG2 is the stronger of the two with respect to CYP3A inhibition. ",tacrolimus,cyclosporine,FALSE,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,21,16
3869,"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to DRUG1 (DRUG2) resistance. ",erythropoietin,EPO,FALSE,Neg,0,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],8,9
3870,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUG2, DRUGOTHER and DRUGOTHER   DRUGOTHER following different incubation schedules were analyzed.",5-FU,cisplatin,FALSE,Neg,0,C1=C(C(=O)NC(=O)N1)F,N.N.Cl[Pt]Cl,21,22
3871,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER   DRUGOTHER following different incubation schedules were analyzed.",5-FU,doxorubicin,FALSE,Neg,0,C1=C(C(=O)NC(=O)N1)F,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,21,23
3872,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUGOTHER, DRUGOTHER and DRUG2   DRUGOTHER following different incubation schedules were analyzed.",5-FU,etoposide,FALSE,Neg,0,C1=C(C(=O)NC(=O)N1)F,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,21,25
3873,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER   DRUG2 following different incubation schedules were analyzed.",5-FU,celecoxib,FALSE,Neg,0,C1=C(C(=O)NC(=O)N1)F,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,21,28
3874,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER   DRUGOTHER following different incubation schedules were analyzed.",cisplatin,doxorubicin,FALSE,Neg,0,N.N.Cl[Pt]Cl,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,22,23
3875,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUG1, DRUGOTHER and DRUG2   DRUGOTHER following different incubation schedules were analyzed.",cisplatin,etoposide,FALSE,Neg,0,N.N.Cl[Pt]Cl,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,22,25
3876,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER   DRUG2 following different incubation schedules were analyzed.",cisplatin,celecoxib,FALSE,Neg,0,N.N.Cl[Pt]Cl,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,22,28
3877,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2   DRUGOTHER following different incubation schedules were analyzed.",doxorubicin,etoposide,FALSE,Neg,0,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,23,25
3878,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUGOTHER, DRUG1 and DRUGOTHER   DRUG2 following different incubation schedules were analyzed.",doxorubicin,celecoxib,FALSE,Neg,0,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,23,28
3879,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1   DRUG2 following different incubation schedules were analyzed.",etoposide,celecoxib,FALSE,Neg,0,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,25,28
3880,We found antagonism between DRUG1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUGOTHER in all cell lines except for two combinations in HCT116 cells. ,celecoxib,celecoxib,FALSE,Neg,0,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,4,-1
3881,We found antagonism between DRUG1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUG2 in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,FALSE,Neg,0,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,4,23
3882,We found antagonism between DRUG1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUG2 in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,TRUE,effect,2,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,4,23
3883,"These results, if confirmed in-vivo, indicate that DRUG1 is not a suitable chemosensitizer for breast cancer or with DRUG2 for other cancers. ",celecoxib,doxorubicin,FALSE,Neg,0,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,7,18
3884,"Concomitant use of DRUG1 and DRUG2 was found to decrease the exposure (AUC) to DRUG2's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG1 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,clopidogrel,TRUE,mechanism,4,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,3,5
3885,"Concomitant use of DRUG1 and DRUGOTHER was found to decrease the exposure (AUC) to DRUGOTHER's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG1 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,omeprazole,FALSE,Neg,0,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,3,-1
3886,"Concomitant use of DRUG2 and DRUG1 was found to decrease the exposure (AUC) to DRUG1's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG2 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",clopidogrel,omeprazole,FALSE,Neg,0,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,5,3
3887,DRUG1 has a much weaker effect on DRUG2's pharmacokinetics and on platelet reactivity during concomitant use. ,Pantoprazole,clopidogrel,TRUE,mechanism,4,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,0,7
3888,Regulatory agencies state that the combination of DRUG1 and the CYP2C19 inhibitors DRUG2 and esDRUG2 should be avoided. ,clopidogrel,omeprazole,TRUE,advise,1,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,7,12
3889,Regulatory agencies state that the combination of DRUG1 and the CYP2C19 inhibitors DRUGOTHER and DRUG2 should be avoided. ,clopidogrel,esomeprazole,TRUE,advise,1,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC,7,14
3890,Regulatory agencies state that the combination of DRUGOTHER and the CYP2C19 inhibitors DRUG1 and esDRUG1 should be avoided. ,omeprazole,esomeprazole,FALSE,Neg,0,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC,12,-1
3891,"In vitro activity of DRUG1 combined with DRUG2 against clinical isolates of DRUGOTHER-resistant Staphylococcus aureus.
",minocycline,fosfomycin,FALSE,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,4,7
3892,"In vitro activity of DRUG1 combined with DRUGOTHER against clinical isolates of DRUG2-resistant Staphylococcus aureus.
",minocycline,methicillin,FALSE,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C,4,12
3893,"In vitro activity of DRUGOTHER combined with DRUG1 against clinical isolates of DRUG2-resistant Staphylococcus aureus.
",fosfomycin,methicillin,FALSE,Neg,0,C[C@H]1[C@H](O1)P(=O)(O)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C,7,12
3894,This study aimed to evaluate the in vitro activity of DRUG1 combined with DRUG2 against isolates of DRUGOTHER-resistant Staphylococcus aureus (MRSA). ,minocycline,fosfomycin,FALSE,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,10,13
3895,This study aimed to evaluate the in vitro activity of DRUG1 combined with DRUGOTHER against isolates of DRUG2-resistant Staphylococcus aureus (MRSA). ,minocycline,methicillin,FALSE,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C,10,17
3896,This study aimed to evaluate the in vitro activity of DRUGOTHER combined with DRUG1 against isolates of DRUG2-resistant Staphylococcus aureus (MRSA). ,fosfomycin,methicillin,FALSE,Neg,0,C[C@H]1[C@H](O1)P(=O)(O)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C,13,17
3897,The susceptibility results for DRUG1 and DRUG2 were interpreted according to the most relevant criteria. ,minocycline,fosfomycin,FALSE,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,4,6
3898,The combination of DRUG1 and DRUG2 can be synergistic against MRSA. ,minocycline,fosfomycin,TRUE,effect,2,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,3,5
3899,The authors report the case of an infant with confirmed congenital hypothyroidism on DRUG1 who experienced a possible drug interaction with DRUG2. ,levothyroxine,simeticone,TRUE,int,3,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,13,21
3900,Drug interaction of DRUG1 with DRUG2 has not been reported previously and is not listed in the British National Formulary for Children. ,thyroxine,simeticone,FALSE,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,3,5
3901,Synergistic interaction between DRUG1 and DRUG2 is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,sunitinib,docetaxel,TRUE,int,3,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,3,5
3902,This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUGOTHER in NSCLC cell lines that are resistant to EGFR TKIs.,sunitinib,sunitinib,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,12,-1
3903,This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUG2 in NSCLC cell lines that are resistant to EGFR TKIs.,sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,12,23
3904,This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUG2 in NSCLC cell lines that are resistant to EGFR TKIs.,sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,12,23
3905,NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either DRUG1 or DRUG2 or both based on various sequential administrations. ,sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,14,16
3906,"DRUG1 exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas DRUG2 arrested at S phase. ",Sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,0,17
3907,"Although single or concurrent use of DRUG1 and DRUG2 has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ",sunitinib,docetaxel,TRUE,effect,2,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,6,8
3908,"When cells were exposed to DRUG1 followed by DRUG2, synergism was observed. ",docetaxel,sunitinib,TRUE,effect,2,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,5,8
3909,The molecular basis of this synergism is that the signaling pathways that were initially activated by DRUG1 exposure were efficiently suppressed by the subsequent exposure to DRUG2. ,docetaxel,sunitinib,TRUE,effect,2,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,16,26
3910,DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUGOTHER is superior to DRUGOTHER followed by DRUG2 and concurrent administration.,Sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,0,25
3911,DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUGOTHER followed by DRUG2 is superior to DRUG2 followed by DRUGOTHER and concurrent administration.,Sunitinib,sunitinib,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,0,28
3912,DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUGOTHER followed by DRUG2 is superior to DRUG2 followed by DRUGOTHER and concurrent administration.,Sunitinib,sunitinib,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,0,28
3913,DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUGOTHER is superior to DRUGOTHER followed by DRUG2 and concurrent administration.,Sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,0,25
3914,DRUGOTHER as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUG2 is superior to DRUG2 followed by DRUG1 and concurrent administration.,docetaxel,sunitinib,TRUE,effect,2,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,25,28
3915,DRUGOTHER as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUG2 is superior to DRUG2 followed by DRUG1 and concurrent administration.,docetaxel,sunitinib,FALSE,Neg,0,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,25,28
3916,DRUGOTHER as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUGOTHER is superior to DRUGOTHER followed by DRUG1 and concurrent administration.,docetaxel,docetaxel,FALSE,Neg,0,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,25,-1
3917,DRUGOTHER as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUGOTHER followed by DRUG1 is superior to DRUG1 followed by DRUGOTHER and concurrent administration.,sunitinib,sunitinib,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,28,-1
3918,DRUGOTHER as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,28,25
3919,DRUGOTHER as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,sunitinib,docetaxel,FALSE,Neg,0,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,28,25
3920,"Distinct synergistic action of DRUG1 and DRUG2 against Pseudomonas aeruginosa.
",piperacillin,methylglyoxal,FALSE,Neg,0,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,CC(=O)C=O,4,6
3921,"Results revealed that the strains were resistant to many drugs at high levels, only DRUG1, DRUG2, DRUGOTHER and DRUGOTHER showed resistances at comparatively lower levels. ",piperacillin,carbenicillin,FALSE,Neg,0,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C,14,15
3922,"Results revealed that the strains were resistant to many drugs at high levels, only DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER showed resistances at comparatively lower levels. ",piperacillin,amikacin,FALSE,Neg,0,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,14,16
3923,"Results revealed that the strains were resistant to many drugs at high levels, only DRUG1, DRUGOTHER, DRUGOTHER and DRUG2 showed resistances at comparatively lower levels. ",piperacillin,ciprofloxacin,FALSE,Neg,0,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,14,18
3924,"Results revealed that the strains were resistant to many drugs at high levels, only DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER showed resistances at comparatively lower levels. ",carbenicillin,amikacin,FALSE,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,15,16
3925,"Results revealed that the strains were resistant to many drugs at high levels, only DRUGOTHER, DRUG1, DRUGOTHER and DRUG2 showed resistances at comparatively lower levels. ",carbenicillin,ciprofloxacin,FALSE,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,15,18
3926,"Results revealed that the strains were resistant to many drugs at high levels, only DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2 showed resistances at comparatively lower levels. ",amikacin,ciprofloxacin,FALSE,Neg,0,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,16,18
3927,Distinct and statistically significant synergism was observed between DRUG1 and DRUG2 by disc diffusion tests when compared with their individual effects. ,methylglyoxal,piperacillin,TRUE,effect,2,CC(=O)C=O,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,8,10
3928,Synergism was also noted when DRUG1 was combined with DRUG2 and DRUGOTHER.,methylglyoxal,carbenicillin,TRUE,effect,2,CC(=O)C=O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C,5,9
3929,Synergism was also noted when DRUG1 was combined with DRUGOTHER and DRUG2.,methylglyoxal,amikacin,TRUE,effect,2,CC(=O)C=O,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,5,11
3930,Synergism was also noted when DRUGOTHER was combined with DRUG1 and DRUG2.,carbenicillin,amikacin,FALSE,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,9,11
3931,Protective effect of DRUG1 and  DRUG2 against the acute toxicity of diepoxybutane to human lymphocytes.,acetyl-l-carnitine,alpha lipoic acid,FALSE,Neg,0,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,C1CSSC1CCCCC(=O)O,3,6
3932,"(ii) DRUG1 elicits a significant protective effect on DEB induced toxicity, which was potentiated by  DRUG2.",acetyl-l-carnitine,alpha-lipoic acid,TRUE,effect,2,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,C1CSSC1CCCCC(=O)O,1,16
3933,"and/or DRUGOTHER DRUG1 (100 mg/kg, p. o.), as well as that of neurotoxin DRUG2 (DRUGOTHER) (4 x 20 mg/kg, i. p.) ",doxycycline,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",FALSE,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CCC(C=C1)C2=CC=CC=C2,2,13
3934,"and/or DRUGOTHER DRUG1 (100 mg/kg, p. o.), as well as that of neurotoxin DRUGOTHER (DRUG2) (4 x 20 mg/kg, i. p.) ",doxycycline,MPTP,FALSE,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CCC(=CC1)C2=CC=CC=C2,2,14
3935,"and/or DRUGOTHER DRUGOTHER (100 mg/kg, p. o.), as well as that of neurotoxin DRUG1 (DRUG2) (4 x 20 mg/kg, i. p.) ","1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",MPTP,FALSE,Neg,0,CN1CCC(C=C1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,13,14
3936,"The role of p27(Kip1) in DRUG1-enhanced DRUG2 cytotoxicity in human ovarian cancer cells.
",dasatinib,paclitaxel,TRUE,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,5,6
3937,"The effect of DRUG1, an inhibitor of Src and Abl kinases, on DRUG2 sensitivity was measured in ovarian cancer cells and HEY xenografts. ",dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,3,12
3938,"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by DRUG1 and DRUG2 were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ",dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,11,13
3939,HEY cells treated with DRUG1 plus DRUG2 formed fewer colonies than did cells treated with either agent alone. ,dasatinib,paclitaxel,TRUE,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,4,6
3940,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,TRUE,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
3941,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUGOTHER inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUGOTHER vs DRUGOTHER: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,dasatinib,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,6,-1
3942,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
3943,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
3944,"Treatment of HEY xenograft-bearing mice with DRUG2 plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG2 + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,dasatinib,FALSE,Neg,0,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,8,6
3945,"Treatment of HEY xenograft-bearing mice with DRUGOTHER plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUGOTHER + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,paclitaxel,FALSE,Neg,0,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,8,-1
3946,"Treatment of HEY xenograft-bearing mice with DRUGOTHER plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUGOTHER + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,paclitaxel,FALSE,Neg,0,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,8,-1
3947,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
3948,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
3949,"Treatment of HEY xenograft-bearing mice with DRUGOTHER plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUGOTHER + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,paclitaxel,FALSE,Neg,0,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,8,-1
3950,DRUG1 + DRUG2 vs. ,dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,0,2
3951,"The siRNA knockdown of p27(Kip1) decreased DRUG1- and DRUG2-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ",dasatinib,paclitaxel,FALSE,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
3952,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that DRUG1-mediated induction of p27(Kip1) enhanced DRUG2-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,dasatinib,paclitaxel,TRUE,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,13,18
3953,Inhibition of Src family and Abl kinases with either siRNAs or DRUG1 enhances DRUG2 sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,dasatinib,paclitaxel,TRUE,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,11,13
3954,"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",lenalidomide,CCI-779,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,6
3955,"Phase I trial of DRUG1 and DRUGOTHER in patients with relapsed multiple myeloma: evidence for DRUG1-DRUGOTHER interaction via P-glycoprotein.
",lenalidomide,lenalidomide,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,4,-1
3956,"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",lenalidomide,CCI-779,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,6
3957,"Phase I trial of DRUG2 and DRUG1 in patients with relapsed multiple myeloma: evidence for DRUG2-DRUG1 interaction via P-glycoprotein.
",CCI-779,lenalidomide,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,6,4
3958,"Phase I trial of DRUGOTHER and DRUG1 in patients with relapsed multiple myeloma: evidence for DRUGOTHER-DRUG1 interaction via P-glycoprotein.
",CCI-779,CCI-779,FALSE,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,6,-1
3959,"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",lenalidomide,CCI-779,FALSE,Neg,0,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,6
3960,The preclinical combination of DRUG1 with the mTOR inhibitor DRUG2 has displayed synergy in vitro and represents a novel combination in MM.,lenalidomide,CCI-779,TRUE,effect,2,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,9
3962,"We evaluated mechanisms of interaction between the alkyating agent DRUG1 (DRUG2) and the pro-oxidant, DRUGOTHER, in the human A375 melanoma cell line.",dacarbazine,DTIC,FALSE,Neg,0,CN(C)/N=N/C1=C(NC=N1)C(=O)N,CN(C)/N=N/C1=C(NC=N1)C(=O)N,9,10
3963,"We evaluated mechanisms of interaction between the alkyating agent DRUG1 (DRUGOTHER) and the pro-oxidant, DRUG2, in the human A375 melanoma cell line.",dacarbazine,imexon,FALSE,Neg,0,CN(C)/N=N/C1=C(NC=N1)C(=O)N,C1C2N1C(=O)N=C2N,9,14
3964,"We evaluated mechanisms of interaction between the alkyating agent DRUGOTHER (DRUG1) and the pro-oxidant, DRUG2, in the human A375 melanoma cell line.",DTIC,imexon,FALSE,Neg,0,CN(C)/N=N/C1=C(NC=N1)C(=O)N,C1C2N1C(=O)N=C2N,10,14
3965,"The effect of DRUG1 and DRUG2, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). ",DTIC,imexon,FALSE,Neg,0,CN(C)/N=N/C1=C(NC=N1)C(=O)N,C1C2N1C(=O)N=C2N,3,5
3966,There was a >75% reduction in cellular glutathione and cysteine with DRUG1 but not DRUG2. ,imexon,DTIC,FALSE,Neg,0,C1C2N1C(=O)N=C2N,CN(C)/N=N/C1=C(NC=N1)C(=O)N,11,14
3967,DRUG1 and DRUG2 show additive effects in vitro but not in vivo in human A375 melanoma cells.,Imexon,dacarbazine,TRUE,effect,2,C1C2N1C(=O)N=C2N,CN(C)/N=N/C1=C(NC=N1)C(=O)N,0,2
3968,"Although it was previously reported that DRUG1 combined with DRUGOTHER improved the progression-free survival rate compared with DRUG1 alone for patients with DRUGOTHER-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",lapatinib,lapatinib,FALSE,Neg,0,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,6,-1
3969,"DRUG1 enhances the antinociceptive effect of DRUG2 in mice.
",Ephedrine,dexmedetomidine,TRUE,effect,2,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,0,6
3970,The purpose of this study was to evaluate whether the psychostimulant drug DRUG1 has any effect on DRUG2-induced antinociception and locomotor inhibitor activity in mice in acute application.,ephedrine,dexmedetomidine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,12,17
3971,"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,dexmedetomidine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,3,12
3972,"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUGOTHER (15     g/kg) and DRUG1 (10   mg/kg) + DRUGOTHER (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,ephedrine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,3,-1
3973,"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,dexmedetomidine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,3,12
3974,"saline + saline, DRUG2 (10   mg/kg) + saline, saline + DRUG1 (15     g/kg) and DRUG2 (10   mg/kg) + DRUG1 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",dexmedetomidine,ephedrine,FALSE,Neg,0,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,12,3
3975,"saline + saline, DRUGOTHER (10   mg/kg) + saline, saline + DRUG1 (15     g/kg) and DRUGOTHER (10   mg/kg) + DRUG1 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",dexmedetomidine,dexmedetomidine,FALSE,Neg,0,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,12,-1
3976,"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,dexmedetomidine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,3,12
3977,"In the hot plate test in mice, co-administration of 15     g/kg DRUG1 with 10   mg/kg DRUG2 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG1. ",dexmedetomidine,ephedrine,TRUE,effect,2,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,15,21
3978,"In the hot plate test in mice, co-administration of 15     g/kg DRUG1 with 10   mg/kg DRUGOTHER intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG1. ",dexmedetomidine,dexmedetomidine,FALSE,Neg,0,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,15,-1
3979,"In the hot plate test in mice, co-administration of 15     g/kg DRUG2 with 10   mg/kg DRUG1 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG2. ",ephedrine,dexmedetomidine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,21,15
3980,"At the same time, the locomotor inhibitory effect of DRUG1 was counteracted by DRUG2. ",dexmedetomidine,ephedrine,TRUE,effect,2,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,9,13
3981,"We concluded that the combined administration of DRUG1 with DRUG2 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUGOTHER in humans.",dexmedetomidine,ephedrine,TRUE,effect,2,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,7,9
3982,"We concluded that the combined administration of DRUG1 with DRUGOTHER may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUGOTHER in humans.",dexmedetomidine,dexmedetomidine,FALSE,Neg,0,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,7,-1
3983,"We concluded that the combined administration of DRUG2 with DRUG1 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG2 as an DRUGOTHER in humans.",ephedrine,dexmedetomidine,FALSE,Neg,0,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C,9,7
3984,[Efficacy of fixed combination DRUG1/DRUG2 in hospitalized patients with hypertensive disease],amlodipine,valsartan,FALSE,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,4,4
3985,Efficacy and tolerability of fixed DRUG1/DRUG2 combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. ,amlodipine,valsartan,FALSE,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,5,5
3986,All patients had indications for antihypertensive therapy and were randomized either to fixed combination DRUG1/DRUG2 (n=43) or to therapy which corresponded to the hospital formulary (n=43). ,amlodipine,valsartan,FALSE,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,14,14
3987,Rate of achievement of target BP with fixed combination DRUG1/DRUG2 (93%) was comparable with that on traditional therapy (90%). ,amlodipine,valsartan,FALSE,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,9,9
3988,"But the use of fixed combination DRUG1/DRUG2 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUGOTHER (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",amlodipine,valsartan,TRUE,effect,2,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,6,6
3989,"But the use of fixed combination DRUG1/DRUGOTHER compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUG2 (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",amlodipine,antihypertensive drugs,FALSE,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,6,34
3990,"But the use of fixed combination DRUGOTHER/DRUG1 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUG2 (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",valsartan,antihypertensive drugs,FALSE,Neg,0,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,6,34
3991,"We have demonstrated appropriateness of inhospital administration of fixed DRUG1/DRUG2 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUGOTHER, and diminishing concealed inefficacy of treatment.",amlodipine,valsartan,TRUE,effect,2,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,9,9
3992,"We have demonstrated appropriateness of inhospital administration of fixed DRUG1/DRUGOTHER combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUG2, and diminishing concealed inefficacy of treatment.",amlodipine,antihypertensive drugs,FALSE,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,9,27
3993,"We have demonstrated appropriateness of inhospital administration of fixed DRUGOTHER/DRUG1 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUG2, and diminishing concealed inefficacy of treatment.",valsartan,antihypertensive drugs,FALSE,Neg,0,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,9,27
3994,DRUG1 (DRUG2)--better than DRUGOTHER (DRUGOTHER),Ticagrelor,Brilinta,FALSE,Neg,0,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,0,1
3995,DRUG1 (DRUGOTHER)--better than DRUG2 (DRUGOTHER),Ticagrelor,clopidogrel,FALSE,Neg,0,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,0,3
3996,DRUG1 (DRUGOTHER)--better than DRUGOTHER (DRUG2),Ticagrelor,Plavix,FALSE,Neg,0,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.OS(=O)(=O)O,0,4
3997,DRUGOTHER (DRUG1)--better than DRUG2 (DRUGOTHER),Brilinta,clopidogrel,FALSE,Neg,0,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1,3
3998,DRUGOTHER (DRUG1)--better than DRUGOTHER (DRUG2),Brilinta,Plavix,FALSE,Neg,0,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.OS(=O)(=O)O,1,4
3999,DRUGOTHER (DRUGOTHER)--better than DRUG1 (DRUG2),clopidogrel,Plavix,FALSE,Neg,0,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.OS(=O)(=O)O,3,4
4000,"The FDA has approved DRUG1 (DRUG2-AstraZeneca), an oral DRUGOTHER, for use with low-dose DRUGOTHER to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,Brilinta,FALSE,Neg,0,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,4,5
4001,"The FDA has approved DRUG1 (DRUGOTHER-AstraZeneca), an oral DRUGOTHER, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,aspirin,TRUE,effect,2,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,CC(=O)OC1=CC=CC=C1C(=O)O,4,13
4002,"The FDA has approved DRUGOTHER (DRUG1-AstraZeneca), an oral DRUGOTHER, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",Brilinta,aspirin,TRUE,effect,2,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F,CC(=O)OC1=CC=CC=C1C(=O)O,5,13
4003,It will compete with DRUG1 (DRUG2) and DRUGOTHER (DRUGOTHER) for such use. ,clopidogrel,Plavix,FALSE,Neg,0,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.OS(=O)(=O)O,4,5
4004,It will compete with DRUG1 (DRUGOTHER) and DRUG2 (DRUGOTHER) for such use. ,clopidogrel,prasugrel,FALSE,Neg,0,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,4,7
4005,It will compete with DRUG1 (DRUGOTHER) and DRUGOTHER (DRUG2) for such use. ,clopidogrel,Effient,FALSE,Neg,0,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,4,8
4006,It will compete with DRUGOTHER (DRUG1) and DRUG2 (DRUGOTHER) for such use. ,Plavix,prasugrel,FALSE,Neg,0,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.OS(=O)(=O)O,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,5,7
4007,It will compete with DRUGOTHER (DRUG1) and DRUGOTHER (DRUG2) for such use. ,Plavix,Effient,FALSE,Neg,0,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.OS(=O)(=O)O,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,5,8
4008,It will compete with DRUGOTHER (DRUGOTHER) and DRUG1 (DRUG2) for such use. ,prasugrel,Effient,FALSE,Neg,0,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,7,8
4009,"Influence of DRUG1 on DRUG2 induced antinociception and its pharmacokinetics.
",piperine,ibuprofen,FALSE,Neg,0,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,2,4
4010,"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both DRUGOTHER writhing and formalin test, when it was administered with DRUG2. ",piperine,ibuprofen,TRUE,effect,2,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,4,14
4011,"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUGOTHER evaluated by both DRUG2 writhing and formalin test, when it was administered with DRUGOTHER. ",piperine,acetic acid,FALSE,Neg,0,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,CC(=O)O,4,18
4012,"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both DRUGOTHER writhing and formalin test, when it was administered with DRUG2. ",piperine,ibuprofen,FALSE,Neg,0,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,4,14
4013,"In the present study DRUGOTHER (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG1 evaluated by both DRUG2 writhing and formalin test, when it was administered with DRUG1. ",ibuprofen,acetic acid,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(=O)O,14,18
4014,"In the present study DRUGOTHER (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG1 evaluated by both DRUGOTHER writhing and formalin test, when it was administered with DRUG1. ",ibuprofen,ibuprofen,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,14,-1
4015,"In the present study DRUGOTHER (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both DRUG1 writhing and formalin test, when it was administered with DRUG2. ",acetic acid,ibuprofen,FALSE,Neg,0,CC(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,18,14
4016,DRUG1 plasma concentration was also increased when it was administered with DRUG2. ,Ibuprofen,piperine,TRUE,mechanism,4,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,0,11
4017,The synergistic antinociception activity of DRUG1 when administered with DRUG2 can be attributed to increased plasma concentration of DRUG1. ,ibuprofen,piperine,TRUE,mechanism,4,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,5,9
4018,The synergistic antinociception activity of DRUG1 when administered with DRUGOTHER can be attributed to increased plasma concentration of DRUG1. ,ibuprofen,ibuprofen,FALSE,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,5,-1
4019,The synergistic antinociception activity of DRUG2 when administered with DRUG1 can be attributed to increased plasma concentration of DRUG2. ,piperine,ibuprofen,FALSE,Neg,0,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,9,5
4020,From this study it can be concluded that DRUG1 can be used as a bioenhancer along with DRUG2.,piperine,ibuprofen,TRUE,effect,2,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,8,17
